FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Weitzman, JB Pujades, C Hemler, ME AF Weitzman, JB Pujades, C Hemler, ME TI Integrin alpha chain cytoplasmic tails regulate ''antibody-redirected'' cell adhesion, independently of ligand binding SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE integrin; CD32; cell-cell adhesion; Fc receptor; VCAM-1 ID FUNCTION-ASSOCIATED ANTIGEN-1; OUT SIGNAL-TRANSDUCTION; GLYCOPROTEIN-IIB-IIIA; MONOCLONAL-ANTIBODIES; AFFINITY STATES; BETA-SUBUNIT; FC RECEPTOR; MEDIATED ADHESION; HUMAN-NEUTROPHILS; FOCAL ADHESIONS AB Here we describe a novel ''antibody-redirected cell adhesion'' (ARCA) assay. This assay measures heterotypic cell-cell adhesion, resulting from antibody bridging between Fc gamma receptors type II (CD32) on leukocytes, and clustered intergrins on adherent cell monolayers. This ARCA activity, facilitated by integrins alpha(3) beta(1) or alpha(4) beta(1), required an intact cytoskeleton, but did not involve typical integrin ligand binding sites or divalent cations. Furthermore, deletion of the alpha(4) cytoplasmic tail almost completely abrogated integrin ARCA activity, suggesting an alteration of integrin recruitment into adhesive sites. If two or more tail residues were present after the conserved GFFKR motif, then ARCA activity was largely restored. Although alpha(4) tail deletion caused loss of ARCA activity, it had no effect on the binding of VCAM-1 to intact alpha(4)-transfected K562 cells. In conclusion, the integrin alpha chain tail can positively regulate integrin-dependent cell adhesion by a receptor recruitment/clustering mechanism independent of conventional integrin ligand-binding considerations. C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. RI Pujades, Cristina/F-7908-2014; OI Pujades, Cristina/0000-0001-6423-7451; Weitzman, Jonathan/0000-0001-8445-0102 FU NIGMS NIH HHS [GM46526] NR 70 TC 15 Z9 15 U1 0 U2 2 PU VCH PUBLISHERS INC PI DEERFIELD BEACH PA 303 NW 12TH AVE, DEERFIELD BEACH, FL 33442-1788 SN 0014-2980 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD JAN PY 1997 VL 27 IS 1 BP 78 EP 84 DI 10.1002/eji.1830270112 PG 7 WC Immunology SC Immunology GA WD562 UT WOS:A1997WD56200011 PM 9022001 ER PT J AU Cassatella, MA Gasperini, S Calzetti, F Bertagnin, A Luster, AD McDonald, PP AF Cassatella, MA Gasperini, S Calzetti, F Bertagnin, A Luster, AD McDonald, PP TI Regulated production of the interferon-gamma-inducible protein-10 (IP-10) chemokine by human neutrophils SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE neutrophil; interferon-gamma-inducible protein-10; interferon-gamma; lipopolysaccharide; tumor necrosis factor-alpha ID HUMAN POLYMORPHONUCLEAR LEUKOCYTES; MURINE PERITONEAL-MACROPHAGES; STIMULATED RESPONSE ELEMENT; GENE-EXPRESSION; IFN-GAMMA; LIPOPOLYSACCHARIDE; ALPHA; CHEMOATTRACTANT; INTERLEUKIN-8; TRANSCRIPTION AB Interferon-gamma (IFN-gamma)-inducible protein-10 (IP-10), a member of the C-X-C subfamily of chemokines, is known to be produced by monocytes, lymphocytes, keratinocytes and endothelial cells in response to IFN-gamma. Here, we show that human polymorphonuclear neutrophils (PMN) also have the ability to produce IP-10. IFN-gamma alone had a modest effect on IP-10 mRNA accumulation, whereas tumor necrosis factor-alpha (TNF-alpha), yeast particles opsonized with IgG (Y-IgG), lipopolysaccharide (LPS), and formyl-methionyl-leucyl-phenylalanine (fMLP) all failed to up-regulate IP-10 gene expression. However, stimulation of neutrophils with IFN-gamma in combination with either TNF-alpha or LPS (but not with Y-IgG or fMLP) resulted in a considerable induction of IP-10 mRNA transcripts, as well as in the extracellular release of the protein. In contrast, the best inducer of IP-10 release from peripheral blood mononuclear cells was IFN-gamma alone. Furthermore, mRNA stabilization analyses demonstrated that IP-10 mRNA isolated from PMN stimulated with IFN-gamma only, or with IFN-gamma plus either TNF-alpha or LPS, had similar half-lives. Finally, we found that interleukin-10, a known inhibitor of chemokine production in PMN, moderatley suppressed the extracellular production of IP-10 in neutrophils stimulated with IFN-gamma plus either LPS or TNF-alpha. Since IP-10 is a potent chemoattractant for activated T lymphocytes, the ability of neutrophils to produce IP-10 might contribute to the evolution and progression of the inflammatory response. C1 MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,CHARLESTOWN,MA. RP Cassatella, MA (reprint author), UNIV VERONA,IST PATOL GEN,DEPT GEN PATHOL,ST LE GRAZIE 4,I-37134 VERONA,ITALY. FU NCI NIH HHS [R01-CA69212] NR 30 TC 102 Z9 103 U1 0 U2 2 PU VCH PUBLISHERS INC PI DEERFIELD BEACH PA 303 NW 12TH AVE, DEERFIELD BEACH, FL 33442-1788 SN 0014-2980 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD JAN PY 1997 VL 27 IS 1 BP 111 EP 115 DI 10.1002/eji.1830270117 PG 5 WC Immunology SC Immunology GA WD562 UT WOS:A1997WD56200016 PM 9022006 ER PT J AU Witte, T Smolyar, A Spoerl, R Goyarts, EC Nathenson, SG Reinherz, EL Chang, HC AF Witte, T Smolyar, A Spoerl, R Goyarts, EC Nathenson, SG Reinherz, EL Chang, HC TI Major histocompatibility complex recognition by immune receptors: Differences among T cell receptor versus antibody interactions with the VSV8/H-2K(b) complex SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE VSV8; H-2K(b); T cell receptor; immune recognition ID CLASS-I MOLECULES; CRYSTAL-STRUCTURE; ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODIES; H-2K(B) MOLECULE; ALPHA-3 DOMAIN; BETA-CHAIN; HLA-A; MHC; PEPTIDE AB The surface residues of the VSV8/K-b complex important for recognition by N15 and N26 alpha beta T cell receptors (TCR) were mapped by mutational analysis and compared to each other and with epitopes of well-characterized K-b specific monoclonal antibodies (mAb). Three features of immune receptor recognition emerge. First, the footprints of the two TCR on VSV8/K-b are similar with more than 80% overlap between sites. Given that only 8 of 14 surface exposed VSV8/K-b residues identified as critical for TCR interaction are in common, the chemical basis of the N15 and N26 interactions is nevertheless distinct. Second, the cognate peptide is a major focus of TCR recognition: mutation at any of the three exposed side chains (at p1, p4 or p6) abrogates interaction of both TCR as measured by functional T cell activation. Third, in contrast to TCR, mAb bind to discrete segments on the periphery of the alpha 1 and/or alpha 2 helices without orientational restriction. These findings suggest that unlike soluble antibodies, surface membrane receptor-ligand interactions on opposing cells (i.e. TCR-peptide/MHC, CD8-MHC) limit the orientational freedom of the TCR in the immune recognition process. C1 DANA FARBER CANC INST,IMMUNOBIOL LAB,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA. ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10467. RI Witte, Torsten/B-5783-2016 FU NIAID NIH HHS [AI07289, AI19807, AI39098] NR 46 TC 9 Z9 9 U1 0 U2 2 PU VCH PUBLISHERS INC PI DEERFIELD BEACH PA 303 NW 12TH AVE, DEERFIELD BEACH, FL 33442-1788 SN 0014-2980 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD JAN PY 1997 VL 27 IS 1 BP 227 EP 233 DI 10.1002/eji.1830270134 PG 7 WC Immunology SC Immunology GA WD562 UT WOS:A1997WD56200033 PM 9022023 ER PT J AU Fidias, P Fan, CM McGovern, FJ Wright, CD Kaufman, J Grossbard, ML AF Fidias, P Fan, CM McGovern, FJ Wright, CD Kaufman, J Grossbard, ML TI Intracaval extension of germ cell carcinoma: Diagnosis via endovascular biopsy and a review of the literature SO EUROPEAN UROLOGY LA English DT Review DE Testicular carcinoma; germ cell tumor; Inferior vena cava ID INFERIOR VENA-CAVA; GREENFIELD FILTER; PULMONARY-EMBOLISM; TESTICULAR-TUMOR; DISTAL MIGRATION; COMPLICATION; THROMBOSIS; INVOLVEMENT; METASTASES; CANCER AB We report a case of testicular carcinoma invading the inferior vena cava. Tumor invasion was diagnosed via endovascular biopsy. This is the first known report of a diagnosis of this entity using endovascular biopsy. We also review the literature on diagnosis and management of inferior vena caval involvement by testicular cancer. C1 MASSACHUSETTS GEN HOSP,HEMATOL ONCOL UNIT,DEPT RADIOL,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT UROL,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DIV THORAC SURG,BOSTON,MA 02114. NR 32 TC 4 Z9 4 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0302-2838 J9 EUR UROL JI Eur. Urol. PY 1997 VL 31 IS 3 BP 376 EP 379 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA WU395 UT WOS:A1997WU39500023 PM 9129935 ER PT J AU Pichon, L Venditti, C Harris, J TenElshof, A Pinelli, M Chorney, M AF Pichon, L Venditti, C Harris, J TenElshof, A Pinelli, M Chorney, M TI Studies of the 6.7 family of dispersed genomic fragments within the MHC class I region SO EXPERIMENTAL AND CLINICAL IMMUNOGENETICS LA English DT Article ID MAJOR HISTOCOMPATIBILITY COMPLEX; HLA POLYMORPHISM; GENE; LOCALIZATION; SUSCEPTIBILITY; PSEUDOGENES; HAPLOTYPES; EVOLUTION; SUBREGION; SEQUENCES AB Searches for MHC-encoded disease susceptibility genes have led to considerable knowledge of the content of the class I region. In an effort to further understand the nature of the five 6.7 family members previously mapped to this region of the genome, we have further analyzed the cross-reactive members of the family and have observed additional genomic instability within the HLA-A subregion. Such genomic variation may underscore the slower evolutionary rates of the HLA-A allelic family and the extended linkage disequilibrium of markers distal to this locus. Moreover, one of the largest genes associated with a member of the 6.7 family, the 3.8-1 gene found proximal to HLA-B, was found to demonstrate limited, composite similarity to RAG2 and complement C4a gene sequences. A pancreas-specific transcript embedded in a 6.7 cross-reactive fragment was found distal to HLA-H and suggests that the fragments have remained linked to transcriptionally active chromatin comprised of both a major class I gene and a second novel coding sequence since the time of their dispersal. The absence of a 6.7 fragment in the HLA-B subregions of higher nonhuman primates lends credence to the possibility that the great apes have suffered a recent deletion event within this region following the emergence of Homo sapiens. C1 PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033. MASSACHUSETTS GEN HOSP,SERV PEDIAT,BOSTON,MA 02114. BECTON DICKINSON IMMUNOCYTOMETRY SYST,SPARKS,MD. ROYAL PERTH HOSP,DEPT IMMUNOGENET,PERTH,WA,AUSTRALIA. PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT PEDIAT,COLL MED,HERSHEY,PA 17033. FU NIDDK NIH HHS [1 R01 DK43734-01A2] NR 36 TC 3 Z9 3 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0254-9670 J9 EXP CLIN IMMUNOGENET JI Exp. Clin. Immunogenet. PY 1997 VL 14 IS 2 BP 131 EP 140 PG 10 WC Biochemistry & Molecular Biology; Genetics & Heredity; Immunology SC Biochemistry & Molecular Biology; Genetics & Heredity; Immunology GA YG606 UT WOS:A1997YG60600004 PM 9395889 ER PT J AU Manie, SN Sattler, M Astier, A Phifer, JS Canty, T Morimoto, C Druker, BJ Salgia, R Griffin, JD Freedman, AS AF Manie, SN Sattler, M Astier, A Phifer, JS Canty, T Morimoto, C Druker, BJ Salgia, R Griffin, JD Freedman, AS TI Tyrosine phosphorylation of the product of the c-cbl protooncogenesis induced after integrin stimulation SO EXPERIMENTAL HEMATOLOGY LA English DT Article DE cbl; integrin; B cells; tyrosine phosphorylation ID HUMAN-B-CELLS; BONE-MARROW STROMA; SIGNAL-TRANSDUCTION; PROTEIN PRODUCT; SH3 DOMAIN; T-CELLS; ADHESION MOLECULE-1; RECEPTOR COMPLEX; ANTIGEN RECEPTOR; V-CBL AB Integrin crosslinking on human B cells induces tyrosine phosphorylation of a set of proteins ranging from 105 to 130 kDa, among which is the focal adhesion kinase p125(FAK). Here we show that the c-CBL protooncogene product p120(c-CBL) is a component of these substrates. beta 1 integrin stimulation of p120(c-CBL) phosphorylation was observed in both transformed and normal human B cells, and was inhibited by prior treatment of cells with cytochalasin B, which disrupts the actin network. In contrast, tyrosine phosphorylation of p120(c-CBL) following crosslinking of the B cell antigen receptor (BCR) was not affected by cytochalasin B. Integrin stimulation of the promegakaryocytic cell line MO7e also led to a cytoskeleton-dependent tyrosine phosphorylation of p120(c-CBL). I, MO7e cells, this stimulation was induced by ligation of either beta 1 or beta 2 integrin, whereas only by Ligation of beta 1 integrin in B cells. Tyrosine phosphorylation of p120(c-CBL) links phosphatidylinositol-3 kinase (PI-3K) with the BCR signaling machinery. Although the p85 subunit of PI-3K was increased in p120(c-CBL) immunoprecipitates from BCR-stimulated B cells, this association was only minimally increased by beta 1 integrin ligation. The function of p120(c-CBL) remains unknown; however, its interactions in vitro and in vivo with Src homology 2 and 3 (SH2 and SH3) domain-containing proteins suggest that p120(c-CBL) has a significant function in signal transduction pathways, and therefore may play a role in integrin signaling in lymphoid and hematopoietic cells. C1 DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115. DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115. OREGON HLTH SCI UNIV,PORTLAND,OR 97201. HARVARD UNIV,SCH MED,DEPT MED,DIV HEMATOL & MED ONCOL,CAMBRIDGE,MA 02138. RI Astier, Anne/A-1641-2008 OI Astier, Anne/0000-0002-0144-3431 FU NCI NIH HHS [CA 36167, CA 55207, CA 60821] NR 43 TC 34 Z9 35 U1 0 U2 0 PU CARDEN JENNINGS PUBL CO LTD PI CHARLOTTESVILLE PA BLAKE CTR, STE 200, 1224 W MAIN ST, CHARLOTTESVILLE, VA 22903 SN 0301-472X J9 EXP HEMATOL JI Exp. Hematol. PD JAN PY 1997 VL 25 IS 1 BP 45 EP 50 PG 6 WC Hematology; Medicine, Research & Experimental SC Hematology; Research & Experimental Medicine GA WA667 UT WOS:A1997WA66700007 PM 8989906 ER PT J AU Zimmer, C Wright, SC Engelhardt, RT Johnson, GA Kramm, C Breakefield, XO Weissleder, R AF Zimmer, C Wright, SC Engelhardt, RT Johnson, GA Kramm, C Breakefield, XO Weissleder, R TI Tumor cell endocytosis imaging facilitates delineation of the glioma-brain interface SO EXPERIMENTAL NEUROLOGY LA English DT Article ID SOLID TUMORS; GLIAL-CELLS; IRON-OXIDE; PHAGOCYTOSIS; PINOCYTOSIS; MACROPHAGES; CULTURE; SYSTEM AB We describe a method for measuring tumor cell endocytosis in vivo and provide the anatomic correlate of this tumor cell function using a superparamagnetic and histologically detectable marker for cell uptake (MION). Rats (n = 22) were intrahemispherically implanted with a thymidine kinase (TK)-positive 9L gliosarcoma cell line, where TK served as the tumor marker. Twenty-four hours after intravenous injection of 10 mg Fe/kg of MION, rat brains were removed and underwent MR imaging ex vivo at near-microscopic resolution (isotropic voxel size of 86 mu m, 9.4 T) prior to histologic processing. The imaging probe accumulated within tumor cells adjacent to the hyperpermeable tumor-brain interface including microscopic deposits and along finger-like invasions of the tumor into brain, facilitating the demarcation of the true histologic tumor border in three dimensions by MR microscopy. The method has potential research and clinical implications for delineating the tumor-brain interface prior to therapy and/or for providing a rational basis for imaging nanocolloid drug delivery to solid tumors. (C) 1997 Academic Press C1 MASSACHUSETTS GEN HOSP,CTR NEUROSCI,MOL NEUROGENET UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02114. DUKE UNIV,MED CTR,DEPT RADIOL,CTR INVIVO MICROSCOPY,DURHAM,NC 27708. RP Zimmer, C (reprint author), MASSACHUSETTS GEN HOSP,DEPT RADIOL,CTR MOL IMAGING RES,BOSTON,MA 02114, USA. OI Johnson, G.Allan/0000-0002-7606-5447 FU NCI NIH HHS [2RO1 CA54886-04A1, R01CA59649-03]; NCRR NIH HHS [P41 RR05959] NR 35 TC 49 Z9 52 U1 0 U2 2 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD JAN PY 1997 VL 143 IS 1 BP 61 EP 69 DI 10.1006/exnr.1996.6350 PG 9 WC Neurosciences SC Neurosciences & Neurology GA WD333 UT WOS:A1997WD33300007 PM 9000446 ER PT J AU Merchant, A Fletcher, J Medina, CA Hemady, RK Foster, CS AF Merchant, A Fletcher, J Medina, CA Hemady, RK Foster, CS TI Pharmacomanipulation of HSV-1 induced chorioretinitis in mice SO EYE LA English DT Article DE acyclovir; anti-HSV-1 antibody; chorioretinitis; HSV-1; mouse; von Szily model ID HERPES-SIMPLEX VIRUS; ACUTE RETINAL NECROSIS; ANTERIOR-CHAMBER INOCULATION; INTRACAMERAL INOCULATION; GLYCOPROTEIN-D; RETINITIS; ENCEPHALITIS; ANTIBODY; TYPE-1; PATHOLOGY AB In the von Szily mouse model, intracameral inoculation of herpes simplex virus type-1 (HSV-1) results in inflammation of the ipsilateral anterior segment with relative chorioretinal sparing and destructive contralateral chorioretinitis. We studied the effect of the systemic antiviral agent acyclovir (ACV) and anti-HSV-1 antibody therapy in this model, Contralateral chorioretinitis developed in none of the 18 mice receiving ACV from post-inoculation day (pid) 1 (p<0.0001), in 6 of 10 (60%) mice when treatment was delayed until pid 7 (p = 0.40) and in 14 of 18 (77%) controls. Contralateral disease developed in 8 of 16 (50%) mice that received anti-HSV-1 antibody from pid 1 (p = 0.02), in 13 of 16 (81%) treated from pid 5 (p = 0.64), in 7 of 8 (87.5%) treated from pid 7 (p = 1.0) and in 17 of 20 (85%) controls. We conclude that early treatment with ACV or anti-HSV-1 antibody reduces the incidence of contralateral chorioretinitis in mice. C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HILLES IMMUNOL LAB,BOSTON,MA 02114. TUFTS UNIV,DEPT OTOLARYNGOL,BOSTON,MA 02111. UNIV MARYLAND,SCH MED,DEPT OPHTHALMOL,CORNEA & IMMUNOL SERV,BALTIMORE,MD 21201. NR 37 TC 0 Z9 4 U1 0 U2 0 PU ROYAL COLL OPHTHALMOLOGISTS PI LONDON PA 17 CORNWALL TERRACE, LONDON, ENGLAND NW1 4QW SN 0950-222X J9 EYE JI Eye PY 1997 VL 11 BP 504 EP 508 PN 4 PG 5 WC Ophthalmology SC Ophthalmology GA XY654 UT WOS:A1997XY65400014 PM 9425416 ER PT J AU Worcester, M Hedrick, S AF Worcester, M Hedrick, S TI Dilemmas in using respite for family caregivers of frail elders SO FAMILY & COMMUNITY HEALTH LA English DT Article DE aging; Alzheimer's disease; caregiving; cognitive impairment; grounded theory; help-seeking; physical impairment; respite; vulnerable ID DEMENTIA PATIENTS; RELIABILITY; SERVICES; BURDEN; ADULTS AB Respite use was explored with a group of vulnerable caregivers. Using a grounded theory approach, in-residence caregivers were interviewed about obtaining respite while caring for elders with severe cognitive or physical impairments. Respite use was influenced by caregivers' ways of knowing the receivers of care and concerns that potential helpers would not be aware of the complexities of care; feelings of imposing on helpers or feeling imposed on by helpers; and desire for matching the helper and the receiver for the greatest comfort of both. Caregivers' central concern was conservation of resources and energy. Processes involved in using respite more often depleted than conserved caregivers' resources and energy. Implications of the findings are applied to ways to reduce the vulnerability of caregivers to negative impacts of caregiving through facilitating acquisition of respite and improving the quality of respite experiences. C1 US DEPT VET AFFAIRS,HLTH SERV RES & DEV FIELD PROGRAM,SEATTLE,WA. UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195. RP Worcester, M (reprint author), SEATTLE PACIFIC UNIV,SCH HLTH SCI,SEATTLE,WA 98119, USA. NR 31 TC 10 Z9 9 U1 3 U2 6 PU ASPEN PUBL INC PI FREDERICK PA 7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 SN 0160-6379 J9 FAM COMMUNITY HEALTH JI Fam. Community Health PD JAN PY 1997 VL 19 IS 4 BP 31 EP 48 PG 18 WC Family Studies; Public, Environmental & Occupational Health SC Family Studies; Public, Environmental & Occupational Health GA VY345 UT WOS:A1997VY34500005 ER PT J AU Segal, S Isaacson, KB Chang, YC Leykin, L Pal, L Shifren, JL Toth, TL AF Segal, S Isaacson, KB Chang, YC Leykin, L Pal, L Shifren, JL Toth, TL TI The affect of baseline ovarian cyst on the outcome in IVF. SO FERTILITY AND STERILITY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,VINCENT MEM HOSP,DEPT OB GYN,VINCENT IVF UNIT,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC REPRODUCTIVE MEDICINE PI BIRMINGHAM PA 1209 MONTGOMERY HIGHWAY, BIRMINGHAM, AL 35216-2809 SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PY 1997 SU S BP P226 EP P226 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA XY160 UT WOS:A1997XY16000407 ER PT J AU Tao, XJ Shifren, J Tilly, JL Isaacson, K AF Tao, XJ Shifren, J Tilly, JL Isaacson, K TI Expression of members of the Bcl-2 gene family and the relationship with apoptosis in endometriosis. SO FERTILITY AND STERILITY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT OBSTET & GYNECOL,VINCENT CTR REPROD BIOL,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC REPRODUCTIVE MEDICINE PI BIRMINGHAM PA 1209 MONTGOMERY HIGHWAY, BIRMINGHAM, AL 35216-2809 SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PY 1997 SU S BP P071 EP P071 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA XY160 UT WOS:A1997XY16000254 ER PT J AU Polidori, MC Frei, B Rordorf, G Ogilvy, CS Koroshetz, WJ Beal, MF AF Polidori, MC Frei, B Rordorf, G Ogilvy, CS Koroshetz, WJ Beal, MF TI Increased levels of plasma cholesteryl ester hydroperoxides in patients with subarachnoid hemorrhage SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE oxidative stress; subarachnoid hemorrhage; free radicals; lipid peroxides; cerebral vasospasm ID HUMAN-BLOOD-PLASMA; CHELATING AGENT DEFEROXAMINE; CENTRAL-NERVOUS-SYSTEM; CEREBRAL VASOSPASM; LIPID-PEROXIDATION; RADICAL FORMATION; VITAMIN-E; ANTIOXIDANT; BRAIN; TRIAL AB The pathophysiology of subarachnoid hemorrhage (SAH) may involve free radical production and lipid peroxidation. We examined plasma levels of cholesteryl ester hydroperoxides (CEOOH) and antioxidants in 25 patients with SAH, and 10 neurologic controls with lacunar stroke. Patients with SAH had significantly increased plasma levels of CEOOH, which peaked on day 5 after the ictus. Concentrations of CEOOH were significantly increased, and ascorbic acid concentrations were significantly decreased in patients who developed vasospasm compared with patients without vasospasm. Increased levels of CEOOH were associated with increased mortality and correlated with clinical outcome scales. These results implicate oxidative stress in the pathogenesis of SAH and suggest that measurements of CEOOH in plasma may be useful both prognostically as well as in monitoring therapeutic interventions. (C) 1997 Elsevier Science Inc. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,NEUROL SERV,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROSURG,BOSTON,MA 02114. BOSTON UNIV,SCH MED,WHITAKER CARDIOVASC INST,BOSTON,MA 02114. FU NHLBI NIH HHS [HL49954, HL56170]; NIA NIH HHS [P01 AG12922] NR 46 TC 27 Z9 27 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 1997 VL 23 IS 5 BP 762 EP 767 DI 10.1016/S0891-5849(97)00053-1 PG 6 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA XT312 UT WOS:A1997XT31200009 PM 9296453 ER PT J AU Pahan, K Smith, BT Singh, AK Singh, I AF Pahan, K Smith, BT Singh, AK Singh, I TI Cytochrome P-450 2E1 in rat liver peroxisomes: Downregulation by ischemia/reperfusion-induced oxidative stress SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE cytochrome P-450 2E1; NADPH cytochrome P-450 reductase; aniline hydroxylation; peroxisomes; ischemia/reperfusion ID ISCHEMIA-REPERFUSION INJURY; ACID ALPHA-OXIDATION; ANTIPEPTIDE ANTIBODIES; CHOLESTEROL; EXPRESSION; KIDNEY; MICROSOMES; BINDING AB Cytochrome P-450 containing enzymes, known to be present in the endoplasmic reticulum and mitochondria, catalyze the oxidation of various compounds. In this study Eve have used highly purified peroxisomes (>95%) to provide evidence by analytical cell fractionation, enzyme activity, Western blot, and immunocytochemical analysis that cytochrome P-450 2E1 (Cyp 2E1) is present in peroxisomes. Similar specific activities of aniline hydroxylase, a Cyp 2E1-dependent enzyme, in purified peroxisomes (0.72 +/- 0.03 nmol/min/mg protein) and microsomes (0.58 +/- 0.03 nmol/min/mg protein) supports the conclusion that peroxisomes contain significant amount of Cyp 2E1. This peroxisomal Cyp 2E1 was also induced in acetone-treated rat liver. The status of microsomal and peroxisomal Cyp 2E1 was also examined following ischemia/reperfusion-induced oxidative stress. Ischemia alone had no effect; however, reperfusion following ischemia resulted in decrease in Cyp 2E1 both in microsomes and peroxisomes. This demonstration of cytochrome P-450 2E1 in peroxisomes and its downregulation during ischemia/reperfusion describes a new role for this organelle in cytochrome P-450 related cellular metabolism and in oxidative stress induced disease conditions. (C) 1997 Elsevier Science Inc. C1 MED UNIV S CAROLINA,DEPT PEDIAT,CHARLESTON,SC 29425. MED UNIV S CAROLINA,DEPT PATHOL,CHARLESTON,SC 29425. RALPH H JOHNSON VA MED CTR,DEPT PATHOL & LAB MED,CHARLESTON,SC. FU NINDS NIH HHS [NS 34741, NS 22576] NR 36 TC 41 Z9 45 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 1997 VL 23 IS 7 BP 963 EP 971 DI 10.1016/S0891-5849(97)00017-8 PG 9 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA YB606 UT WOS:A1997YB60600001 PM 9358238 ER PT J AU Biaglow, JE Manevich, Y Uckun, F Held, KD AF Biaglow, JE Manevich, Y Uckun, F Held, KD TI Quantitation of hydroxyl radicals produced by radiation and copper-linked oxidation of ascorbate by 2-deoxy-D-ribose method SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE hydroxyl radical; 2-deoxy-D-ribose; malondialdehyde; dithiothreitol; ascorbate; copper; fluorescence; radiation; oxygen consumption ID CONTAINING RADIOPROTECTOR DITHIOTHREITOL; MEDIATED TOXICITY; MAMMALIAN-CELLS; FENTON REACTION; IRON; DEOXYRIBOSE; DEGRADATION; RADIOLYSIS; MECHANISMS; DAMAGE AB We have established controlled conditions for studying the reaction of chemically and radiolytically produced hydroxyl radical ((OH)-O-.) with 2-deoxy-D-ribose (2-DR). Ascorbate (ASC) or dithiothreitol (DTT) and cuprous or cupric ions were used to generate the OH-radical. The OH-radical was detected using the classical method of measuring the amount of thiobarbituric acid reactive products (TBARP) formed by (OH)-O-.-mediated 2-DR degradation, but using sensitive fluorescent detection of the TBARP production to quantify the OH-radical. All experiments were performed with adequate O-2 concentrations. The copper reaction with ASC consumes O-2 in a manner that is strongly dependent on copper concentration, and less dependent on ascorbate concentration, For an independent check of the Cu2+ catalyzed ASC oxidation kinetics, the decay of ASC absorbency at 265 nm, as well as the increase of H2O2 absorbency at similar to 240 nm, were also monitored. These spectral changes agree well with the O-2 consumption data. TBARP production from 2-DR incubated with a Cu2+-ASC mixture or gamma-irradiated were also compared. gamma-Irradiation of 2-DR solutions shows a dose and 2-DR concentration dependent increase of TBARP generation. Other electron donors, such as DTT, are more complicated in their mechanism of OH-radical production. Incubation of 2-DR with Cu2+-DTT mixtures shows a delay (similar to 50 min) before OH-radical generation is detected. Our results suggest that the Cu2+-ASC reaction can be used to mimic the effects of ionizing radiation with respect to OH-radical generation. The good reproducibility and relative simplicity of the 2-DR method with fluorescence detection indicates its usefulness for the quantitation of the OH-radical generated radiolytically or chemically in carefully controlled model systems. (C) 1997 Elsevier Science Inc. C1 UNIV PENN,DEPT BIOCHEM & BIOPHYS,DIV ONCOL RES,PHILADELPHIA,PA 19104. MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02114. UNIV MINNESOTA,DEPT THERAPEUT RADIOL RADIAT ONCOL,MINNEAPOLIS,MN 55113. RP Biaglow, JE (reprint author), UNIV PENN,DEPT RADIAT ONCOL,DIV ONCOL RES,195 JOHN MORGAN BLDG,37TH & HAMILTON WALK,PHILADELPHIA,PA 19104, USA. FU NCI NIH HHS [CA 44982] NR 39 TC 50 Z9 52 U1 2 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 1997 VL 22 IS 7 BP 1129 EP 1138 DI 10.1016/S0891-5849(96)00527-8 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA WT377 UT WOS:A1997WT37700001 PM 9098085 ER PT J AU Munakata, J Naliboff, B Harraf, F Kodner, A Lembo, T Chang, L Silverman, DHS Mayer, EA AF Munakata, J Naliboff, B Harraf, F Kodner, A Lembo, T Chang, L Silverman, DHS Mayer, EA TI Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome SO GASTROENTEROLOGY LA English DT Article ID INTESTINAL MOTILITY; IBS PATIENTS; COLON MOTOR; DISTENSION; PERCEPTION; SENSITIVITY; THRESHOLDS; DEFINITION; DISORDER; HUMANS AB Background & Aims: Only a fraction of patients with irritable bowel syndrome (IBS) show hypersensitivity to rectal distention, The current study sought to determine if repetitive high-pressure stimulation of sigmoid mechanoreceptors modulates perception of rectal pain and discomfort. Methods: In 14 patients with IBS and 11 healthy controls, perception thresholds for discomfort and pain during rectal sensory tracking and verbal descriptor ratings of the perceived intensity of a rectal tonic stimulus were obtained before and after repetitive high-pressure mechanical sigmoid stimulation, Gastrointestinal and psychological symptoms were assessed by questionnaires, Results: Despite heterogeneity in baseline rectal sensitivity in patients with IBS, after sigmoid stimulation, 100% of patients, regardless of baseline sensitivity, developed rectal hyperalgesia manifested by at least two of the following three criteria: lowered thresholds for pain and discomfort and increased viscerosomatic referral and lower abdominal discomfort outlasting the experimental stimulation. This pattern of responses was not observed in any of the healthy controls, Conclusions: In patients with IBS, repetitive stimulation of sigmoid splanchnic afferents results in the development of central sensitization manifested as hyperalgesia and increased viscerosomatic referral during rectal distention and as spontaneous rectosigmoid hyperalgesia in the absence of applied stimuli, Repetitive sigmoid contractions may induce rectosigmoid hyperalgesia in patients with IBS. C1 UNIV CALIF LOS ANGELES, DEPT MED, CURE DIGEST DIS RES CTR, NEUROENTER BIOL GRP, LOS ANGELES, CA 90073 USA. UNIV CALIF LOS ANGELES, DEPT PHYSIOL, W LOS ANGELES VET AFFAIRS MED CTR, LOS ANGELES, CA 90073 USA. UNIV CALIF LOS ANGELES, DEPT PSYCHIAT, W LOS ANGELES VET AFFAIRS MED CTR, LOS ANGELES, CA 90073 USA. FU NIDDK NIH HHS [DK 40919] NR 31 TC 282 Z9 285 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JAN PY 1997 VL 112 IS 1 BP 55 EP 63 DI 10.1016/S0016-5085(97)70219-1 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA WA905 UT WOS:A1997WA90500011 PM 8978343 ER PT J AU Silverman, DHS Munakata, JA Ennes, H Mandelkern, MA Hoh, CK Mayer, EA AF Silverman, DHS Munakata, JA Ennes, H Mandelkern, MA Hoh, CK Mayer, EA TI Regional cerebral activity in normal and pathological perception of visceral pain SO GASTROENTEROLOGY LA English DT Article ID IRRITABLE-BOWEL-SYNDROME; POSITRON EMISSION TOMOGRAPHY; CORTEX; FIBROMYALGIA; HYPERALGESIA; LOCALIZATION; PROJECTIONS; PREVALENCE; TOLERANCE; RESPONSES AB Background & Aims: To characterize the cerebral processing of noxious visceral events, changes in regional cerebral blood flow associated with perception of intestinal pain were examined, Methods: The effects of rectal pressure stimuli on regional cerebral blood flow were assessed with O-15-water positron emission tomography (PET) in 12 subjects, half with irritable bowel syndrome (IBS), PET scans were obtained at baseline and during both actual and simulated delivery of anticipated stimuli, Changes in regional cerebral blood flow were interpreted using statistical parametric mapping and region of interest methods of analysis, Results: in healthy subjects, perception of pain during actual or simulated delivery of painful stimuli was significantly associated (P < 0.01) with activity of the anterior cingulate cortex (ACC; Brodmann's areas 24 and 32), whereas no ACC response to perception of nonpainful stimuli was observed, In patients with IBS, the ACC failed to respond to the same stimuli, whereas significant activation (P < 0.01) of the left prefrontal cortex (maximal in Brodmann's area 10) was seen, Conclusions: The perception of acute rectal pain is associated with activation of the ACC in healthy subjects, and patients with IBS show an aberrant brain activation pattern both during noxious rectal distention and during the anticipation of rectal pain. C1 W LOS ANGELES VET AFFAIRS MED CTR, NUCL MED SERV, LOS ANGELES, CA 90073 USA. UNIV CALIF LOS ANGELES, DEPT MED, CURE NEUROENTER BIOL GRP, LOS ANGELES, CA 90024 USA. UNIV CALIF LOS ANGELES, DEPT MOL & MED PHARMACOL, LOS ANGELES, CA 90024 USA. UNIV CALIF LOS ANGELES, DEPT PHYSIOL, LOS ANGELES, CA 90024 USA. UNIV CALIF IRVINE, DEPT PHYS, IRVINE, CA 92717 USA. FU NIDDK NIH HHS [DK 40919] NR 57 TC 393 Z9 397 U1 1 U2 11 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JAN PY 1997 VL 112 IS 1 BP 64 EP 72 DI 10.1016/S0016-5085(97)70220-8 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA WA905 UT WOS:A1997WA90500012 PM 8978344 ER PT J AU Jensen, DM Machicado, GA Cheng, S Jensen, ME Jutabha, R AF Jensen, DM Machicado, GA Cheng, S Jensen, ME Jutabha, R TI A randomized prospective study of endoscopic bipolar electrocoagulation and heater probe treatment of chronic rectal bleeding from radiation telangiectasia SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID LASER PHOTO-COAGULATION; YAG LASER; GASTROINTESTINAL-TRACT; CANINE COLON; PROCTITIS; FORMALIN; HEMOSTASIS; THERAPY; INJURY AB Background: Our purposes were to (1) evaluate efficacy and safety of bipolar or heater probe endoscopic coagulation compared to prior medical therapy for bleeding radiation telangiectasia, and (2) consider the impact of treatments on patients' impression of their overall health and activity. Methods: Twelve months of medical management had failed in 18 men and 3 women with chronic, recurrent hematochezia and anemia after radiation treatment of pelvic malignancies. Patients had multiple rectal telangiectasias coagulated with bipolar or heater probes in a randomized, prospective study. Results: Rectal bleeding stopped within four treatment sessions. During 12 months of endoscopic versus medical therapy, severe breeding episodes diminished significantly for bipolar probe versus 12 months of prior medical therapy (75% vs 33%) and heater probe (67% vs 11%); mean hematocrits rose significantly for patients undergoing bipolar (38.2 vs 31.9) and heater probe (37.6 vs 28.4) treatments, and their impression of overall health improved. During long-term follow-up, new telangiectasias or rectal bleeding were easily controlled. No major complications resulted. Conclusions: (1) Bipolar or heater probes were safe and effective relative to medical therapy for palliation of patients with lower gastrointestinal breeding from radiation telangiectasias, and (2) ail patients improved in ability to travel and exercise and in their overall impression of their health. C1 UNIV CALIF LOS ANGELES,CTR HLTH SCI,W LOS ANGELES VET ADM MED CTR,LOS ANGELES,CA 90024. NORTHRIDGE HOSP MED CTR,VAN NUYS,CA. RP Jensen, DM (reprint author), UNIV CALIF LOS ANGELES,CTR HLTH SCI,HEMOSTASIS RES UNIT,DIGEST DIS RES CTR,44-133 CHS,LOS ANGELES,CA 90095, USA. FU NIDDK NIH HHS [NIDDK 41301]; PHS HHS [R0I 33273] NR 29 TC 71 Z9 75 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 1997 VL 45 IS 1 BP 20 EP 25 DI 10.1016/S0016-5107(97)70298-0 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA WF734 UT WOS:A1997WF73400004 PM 9013165 ER PT J AU Reinertsen, KK Bronson, RT Stiles, CD Wang, CY AF Reinertsen, KK Bronson, RT Stiles, CD Wang, CY TI Temporal and spatial specificity of PDGF alpha receptor promoter in transgenic mice SO GENE EXPRESSION LA English DT Article DE PDGF alpha receptor; gene expression; transgenic mice; lacZ staining ID GROWTH-FACTOR PDGF; CENTRAL-NERVOUS-SYSTEM; IDIOPATHIC PULMONARY FIBROSIS; SIMIAN SARCOMA-VIRUS; GLIOMA CELL-LINES; FACTOR-A-CHAIN; DEVELOPMENTAL EXPRESSION; OLIGODENDROCYTE LINEAGE; UP-REGULATION; MUTANT MICE AB Aberrant expression of the platelet-derived growth factor alpha receptor (PDGF alpha R) has been linked to developmental abnormalities in vertebrate models, and has been implicated in multiple disease states in humans. To identify cis-acting regulatory elements that dictate expression of this receptor, we generated transgenic mice bearing the reporter gene beta-galactosidase (lacZ) under the control of a 6-kb promoter sequence. Expression of lacZ was monitored throughout embryonic development, with special focus on nervous tissue, skeleton, and several organ systems wherein PDGF alpha R expression is thought to play a pivotal role. In several independent transgenic mouse strains, lacZ expression recapitulated predominant features of PDGF alpha R gene expression during mouse development. These results demonstrate that critical tissue-specific regulatory elements for PDGF alpha R expression are located within a 6-kb upstream region of the PDGF alpha R gene. C1 UNIV ILLINOIS,CTR MOL BIOL ORAL DIS,CHICAGO,IL 60612. HARVARD UNIV,SCH MED,DEPT MOL GENET & MICROBIOL,BOSTON,MA 02115. DANA FARBER CANC INST,BOSTON,MA 02115. TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111. TUFTS UNIV,SCH VET MED,BOSTON,MA 02111. FU NCI NIH HHS [CA 74907]; NICHD NIH HHS [HD 24926] NR 62 TC 12 Z9 13 U1 0 U2 0 PU COGNIZANT COMMUNICATION CORP PI ELMSFORD PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 SN 1052-2166 J9 GENE EXPRESSION JI Gene Expr. PY 1997 VL 6 IS 5 BP 301 EP 314 PG 14 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA YE807 UT WOS:A1997YE80700004 PM 9368101 ER PT J AU Marasco, WA AF Marasco, WA TI Intrabodies: Turning the humoral immune system outside in for intracellular immunization SO GENE THERAPY LA English DT Review DE antibody engineering; intracellular antibodies; gene therapy; AIDS; oncogenes ID SINGLE-CHAIN ANTIBODY; HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODIES; OVARIAN-CANCER; FILAMENTOUS PHAGE; HIV-INFECTION; HIGH-AFFINITY; EXPRESSION; FRAGMENTS; ANTIGEN AB Antibodies have long been used in biomedical science as in vitro tools for the identification, purification and functional manipulation of target antigens; they have been exploited in vivo for diagnostic and therapeutic applications as well. Recent advances in antibody engineering have now Allowed the genes encoding antibodies to be manipulated so that the antigen binding domain can be expressed intracellularly. The specific and high-affinity binding properties of antibodies, combined with their ability to be stably expressed in precise intracellular locations inside mammalian cells, has provided a powerful new family of molecules for gene therapy applications. These intracellular antibodies are termed 'intrabodies'. Two clinical protocols have been approved by the RAC for the use of intrabodies bodies in the treatment of an oncologic and an infectious disease. Their clinical use will in all likelihood become widespread if these initial studies show 'proof in principle'. In this article, the studies from laboratories that have used intrabodies as molecular reagents for cancer therapy and for the control of infectious diseases will be reviewed and future directions of this technology will be discussed. C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV INFECT DIS,BOSTON,MA 02115. RP Marasco, WA (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HUMAN RETROVIROL,44 BINNEY ST,BOSTON,MA 02115, USA. NR 61 TC 72 Z9 73 U1 0 U2 0 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS SN 0969-7128 J9 GENE THER JI Gene Ther. PD JAN PY 1997 VL 4 IS 1 BP 11 EP 15 DI 10.1038/sj.gt.3300346 PG 5 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA WE183 UT WOS:A1997WE18300003 PM 9068790 ER PT J AU Scott, WK Yamaoka, LH Locke, PA Rosi, BL Gaskell, PC Saunders, AM Conneally, PM Small, GW Farrer, LA Growdon, JH Roses, AD PericakVance, MA Haines, JL AF Scott, WK Yamaoka, LH Locke, PA Rosi, BL Gaskell, PC Saunders, AM Conneally, PM Small, GW Farrer, LA Growdon, JH Roses, AD PericakVance, MA Haines, JL TI No association or linkage between an intronic polymorphism of presenilin-1 and sporadic or late-onset familial Alzheimer disease SO GENETIC EPIDEMIOLOGY LA English DT Article DE dementia; genetics; linkage analysis; PSEN1; APOE ID APOLIPOPROTEIN-E; MISSENSE MUTATIONS; TYPE-4 ALLELE; GENE; RISK AB Recent reports have shown an association between an intronic polymorphism of the presenilin-1 (PSEN1) gene and late-onset (age at onset > 65) familial and sporadic (no family history) Alzheimer disease (AD). The reported association was independent of the effect of the only previously identified gene associated with late-onset AD, APOE. Blood samples were obtained from members of 122 multiplex AD families, 42 unrelated cases of AD with positive family histories of dementia, 456 sporadic cases of AD, and 317 controls of similar ages at examination to the cases. These samples were genotyped for an intronic polymorphism of the PSEN1 gene, located 3' to exon 8, and the data analyzed for evidence of association or linkage. The samples were also genotyped for APOE and the data analyzed to see if the association or linkage changed when controlling fur APOE genotype. There was no statistically significant increase (at alpha = .01) in allele 1 (199 bp) or genotype 1/1 in the sporadic AD cases, or in a random sample of one affected from each multiplex family, compared to controls. When examining the effect of the PSEN1 polymorphism while controlling for APOE genotype, APOE genotype was strongly associated with AD, but the PSEN1 polymorphism genotype was not. Model-trait dependent (lod score) and independent (Sim1BD) methods detected no evidence of linkage between PSEN1 and AD. In this independent dataset, the previously reported association between the intronic PSEN1 polymorphism and AD cannot be confirmed, and the conclusion that PSEN1 is a major susceptibility gene for late-onset AD is not supported. (C) 1997 Wiley-Liss, Inc. C1 DUKE UNIV,MED CTR,DEPT MED,DIV NEUROL,SECT MED GENET,DURHAM,NC 27710. MASSACHUSETTS GEN HOSP,MOL NEUROGENET UNIT,CHARLESTOWN,MA. INDIANA UNIV,MED CTR,DEPT MED & MOL GENET,INDIANAPOLIS,IN. UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024. BOSTON UNIV,MED CTR,DEPT NEUROL,BOSTON,MA. RI Scott, William/A-7593-2009; Haines, Jonathan/C-3374-2012; OI Farrer, Lindsay/0000-0001-5533-4225 FU NIA NIH HHS [AG05128, U24 AG021886]; NINDS NIH HHS [NS26630, NS531153] NR 27 TC 24 Z9 24 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0741-0395 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PY 1997 VL 14 IS 3 BP 307 EP 315 PG 9 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA XC842 UT WOS:A1997XC84200008 PM 9181359 ER PT J AU Neas, BR Moser, KL Harley, JB AF Neas, BR Moser, KL Harley, JB TI Logistic transmission modeling for the simulated data of GAW10 problem 2 SO GENETIC EPIDEMIOLOGY LA English DT Article; Proceedings Paper CT Genetic Analysis Workshop 10 (GAW10) CY OCT 26-29, 1996 CL WATSONVILLE, CALIFORNIA DE association; conditional logistic; disequilibrium; genetic markers; linkage AB A recently developed nonparametric method is a generalization of the transmission disequilibrium test across all alleles of a locus. This approach has been applied to Problem 2 of GAW10 and has been extended to explore the combined contribution of neighboring loci for chromosomes 1, 5, and 8. When applied to the chromosome 5 data of the first replicate of the nuclear pedigrees from Problem 2 of GAW10, the data show that four of the 25 loci obtain a probability less than 0.05. However, when combined models composed of each potentially significant marker (p < 0.05) and its nearest neighbors are considered, the combined contributions of G14 and G15 are the most significant (p = 0.007). Consequently, the region near G14 and G15 is identified as the best candidate region in chromosome 5 for linkage to the common disease. (C) 1997 Wiley-Liss, Inc. C1 Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Dept Biostat & Epidemiol, Oklahoma City, OK 73190 USA. Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. US Dept Vet Affairs, Oklahoma City, OK USA. RP Neas, BR (reprint author), Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Dept Biostat & Epidemiol, POB 26901,CHB-309, Oklahoma City, OK 73190 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0741-0395 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PY 1997 VL 14 IS 6 BP 857 EP 860 DI 10.1002/(SICI)1098-2272(1997)14:6<857::AID-GEPI49>3.0.CO;2-M PG 4 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA YM987 UT WOS:000071121800050 PM 9433590 ER PT J AU Rogus, JJ Harrington, DP Jorgenson, E Xu, XP AF Rogus, JJ Harrington, DP Jorgenson, E Xu, XP TI Effectiveness of extreme discordant sib pairs to detect oligogenic disease loci SO GENETIC EPIDEMIOLOGY LA English DT Article; Proceedings Paper CT Genetic Analysis Workshop 10 (GAW10) CY OCT 26-29, 1996 CL WATSONVILLE, CALIFORNIA DE extreme discordant sib pair; genomic screening; linkage analysis ID QUANTITATIVE TRAIT LOCI AB A method for the genomic screening of quantitative traits using extreme discordant sib pairs (EDSPs) has recently been described by Risch and Zhang [1995; 1996]. For many models relevant to common, genetically complex diseases, EDSPs are the most powerful siblings for detecting linkage. Thus, if such siblings can be identified and collected, powerful studies with reasonable genotyping budgets can be conducted. Using a subset of the GAW10 data, we have simulated a genomic screen using EDSPs. From the 4,780 total families in the first 20 replicates of 239 families, there were 100, 104, 155, 107, and 180 EDSP families for Q1, Q2, Q3, Q4, and Q5, respectively. EDSP data were analyzed for each trait using a modified version of MAPMAKER/SIBS capable of handling extreme discordant sib pairs. Four regions, one for Q1, one for Q2, and two for Q4, were able to exceed a threshold for linkage corresponding to a 0.001 pointwise significance level. In three cases, maximum lod score (MLS) peaks occurred within 3.8 cM of a major gene. In the fourth case, the MLS peak occurred 28.4 cM from a major gene. Omission of parents and an alternative definition of EDSP were also investigated. (C) 1997 Wiley-Liss, Inc. C1 Harvard Univ, Sch Publ Hlth, Program Populat Genet, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. Stanford Univ, Dept Genet, Palo Alto, CA 94304 USA. RP Rogus, JJ (reprint author), Harvard Univ, Sch Publ Hlth, Program Populat Genet, 665 Huntington Ave, Boston, MA 02115 USA. NR 5 TC 5 Z9 5 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0741-0395 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PY 1997 VL 14 IS 6 BP 879 EP 884 DI 10.1002/(SICI)1098-2272(1997)14:6<879::AID-GEPI53>3.0.CO;2-J PG 6 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA YM987 UT WOS:000071121800054 PM 9433594 ER PT J AU Schneider, KA AF Schneider, KA TI Genetic counseling for BRCA1/BRCA2 testing SO GENETIC TESTING LA English DT Article ID BREAST-OVARIAN-CANCER; HUNTINGTON DISEASE; PSYCHOLOGICAL CONSEQUENCES; INHERITED PREDISPOSITION; GERMLINE MUTATIONS; FAMILY HISTORY; BRCA1; SUSCEPTIBILITY; RISK; CARRIERS AB Genetic counseling plays a key role in the BRCA1/BRCA2 testing process. The initial genetic counseling encounter will determine the appropriateness of the test by collecting a detailed family history and determining the likelihood that the family has a BRCA1 or BRCA2 mutation, Once the test is offered, then genetic counseling discussions center around the possible test results, implications of the results to the patient and other relatives, and risks and benefits of testing. The goal of this pre-test genetic counseling session is to ensure that patients have sufficient information with which to make a decision about being tested. At results disclosure, individuals can learn their results along with information about cancer risks and medical management options, Follow-up genetic counseling services can provide continued support and help arrange consultations with other medical care providers as needed. All clinical BRCA1/BRCA2 testing programs should include pre- and post-test genetic counseling. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. RP Schneider, KA (reprint author), Dana Farber Canc Inst, 44 Binney St,Mayer 3A, Boston, MA 02115 USA. NR 37 TC 21 Z9 21 U1 0 U2 0 PU MARY ANN LIEBERT INC PUBL PI LARCHMONT PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA SN 1090-6576 J9 GENET TEST JI Genet. Test. PY 1997 VL 1 IS 2 BP 91 EP 98 DI 10.1089/gte.1997.1.91 PG 8 WC Genetics & Heredity; Medicine, Research & Experimental SC Genetics & Heredity; Research & Experimental Medicine GA 161UU UT WOS:000078308700004 PM 10464632 ER PT J AU Larson, GP Zhang, GX Ding, SF Foldenauer, K Udar, N Gatti, RA Neuberg, D Lunetta, KL Ruckdeschel, JC Longmate, J Flanagan, S Krontiris, TG AF Larson, GP Zhang, GX Ding, SF Foldenauer, K Udar, N Gatti, RA Neuberg, D Lunetta, KL Ruckdeschel, JC Longmate, J Flanagan, S Krontiris, TG TI An allelic variant at the ATM locus is implicated in breast cancer susceptibility SO GENETIC TESTING LA English DT Article ID ATAXIA-TELANGIECTASIA; MUTATIONS; ASSOCIATION; FAMILIES; BRCA1; RAD51; RISK; GENE; DNA AB We have tested a simple procedure, disease association by locus stratification, for identifying breast cancer patients with pathogenetic allelic variants at several candidate loci. The strategy was based on the assumption of epistatic interactions of the candidates. We analyzed 66 independent cases from sib pairs affected with breast cancer that had previously been collected during an investigation of pathogenetic-allele-sharing at the HRAS1 mini-satellite locus, An exon 24 polymorphism of ATM, substituting arginine for proline was associated with breast cancer in these cases with an overall odds ratio of 4.5 (95% confidence interval, 1.2-20.5, nominal p = 0.02, 2-tail Fisher exact test). In the presence of a rare HRAS1 allele, the odds ratio increased to 6.9 (95% CI, 1.2-38.3, p = 0.03). Thus, our procedure identified at least one allelic variant of ATM associated with breast cancer, and indicated that the ATM locus may interact with HRAS1. C1 City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Med, Duarte, CA 91010 USA. Univ Calif Los Angeles, Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA. Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA. City Hope Natl Med Ctr, Div Informat Sci, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, Duarte, CA 91010 USA. RP Krontiris, TG (reprint author), City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Med, 1450 E Duarte Rd, Duarte, CA 91010 USA. FU NCI NIH HHS [CA45052] NR 15 TC 32 Z9 32 U1 0 U2 0 PU MARY ANN LIEBERT INC PUBL PI LARCHMONT PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA SN 1090-6576 J9 GENET TEST JI Genet. Test. PY 1997 VL 1 IS 3 BP 165 EP 170 DI 10.1089/gte.1997.1.165 PG 6 WC Genetics & Heredity; Medicine, Research & Experimental SC Genetics & Heredity; Research & Experimental Medicine GA 161UV UT WOS:000078308800003 PM 10464642 ER PT B AU Hofmann, F Livingston, DM AF Hofmann, F Livingston, DM BE Mihich, E Hartwell, L TI E2F-1 degradation by the ubiquitin-proteasome pathway SO GENOMIC INSTABILITY AND IMMORTALITY IN CANCER SE PEZCOLLER FOUNDATION SYMPOSIA LA English DT Proceedings Paper CT 8th Annual Pezcoller Symposium on Genomic Instability and Immortality in Cancer CY JUN 17-19, 1996 CL TRENT, ITALY SP Pezcoller Fdn C1 Childrens Hosp, Dana Farber Canc Inst, Div Neoplast Dis Mechanisms, Boston, MA 02115 USA. RP Hofmann, F (reprint author), Childrens Hosp, Dana Farber Canc Inst, Div Neoplast Dis Mechanisms, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA BN 0-306-45700-8 J9 PEZ FDN SYM PY 1997 VL 8 BP 215 EP 227 PG 13 WC Biochemistry & Molecular Biology; Oncology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Genetics & Heredity GA BK19N UT WOS:000071461800015 ER PT J AU Hall, RD Massengill, JL AF Hall, RD Massengill, JL TI The number of primary auditory afferents in the rat SO HEARING RESEARCH LA English DT Article DE spiral ganglion cell; cochlear nerve fiber; strain difference ID SPIRAL GANGLION-CELLS; COCHLEA; MORPHOLOGY; ORGAN; CORTI; MICE; AGE AB Published estimates of the number of primary auditory afferents in the rat differ by as much as 30%. We undertook to determine if the widely Varying estimates were related to methodological differences, especially the difference between counting cells in Rosenthal's canal and fibers in the cochlear nerve. Type I ganglion cells and myelinated cochlear nerve fibers in the same ears were counted in Long-Evans and Sprague-Dawley strains. Type II spiral ganglion cells were also counted. In each strain the numbers of myelinated fibers and type I ganglion cells were essentially the same. Means for the Long-Evans were 18,036 fibers and 17,749 cells. Means for Sprague-Dawleys were higher: 19,444 fibers and 19,229 cells. The mean number of type II ganglion cells was also greater in Sprague-Dawley than in Long-Evans rats: 1,388 and 1,170, respectively. Cell and fiber counts from the two ears of the same animal differed on average by only 1%. The number of auditory afferents did not change with age over the range (2-10 months) studied here. Several methodological differences have probably contributed to the varying estimates of type I primary auditory afferents, but the discrepancies are not inherent in counts of fibers and spiral ganglion cells. RP Hall, RD (reprint author), MASSACHUSETTS EYE & EAR INFIRM,DEPT OTOLARYNGOL,AUDITORY PROSTHESIS RES LAB,243 CHARLES ST,BOSTON,MA 02114, USA. FU NIDCD NIH HHS [DC00361] NR 16 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-5955 J9 HEARING RES JI Hear. Res. PD JAN PY 1997 VL 103 IS 1-2 BP 75 EP 84 DI 10.1016/S0378-5955(96)00166-9 PG 10 WC Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology GA WD588 UT WOS:A1997WD58800008 PM 9007576 ER PT S AU Wucherpfennig, KW AF Wucherpfennig, KW BE Svejgaard, A Buus, S Fugger, L TI Activation of myelin basic protein-specific T cells by viral peptides SO HLA AND DISEASE - THE MOLECULAR BASIS SE ALFRED BENZON SYMPOSIUM SERIES LA English DT Proceedings Paper CT 40th Symposium of the Alfred-Benzon-Foundation on HLA and Disease - the Molecular Basis CY AUG 04-08, 1996 CL ROYAL DANISH ACAD SCI & LETT, COPENHAGEN, DENMARK SP Alfred Benzon Fdn HO ROYAL DANISH ACAD SCI & LETT RP Wucherpfennig, KW (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MUNKSGAARD PI COPENHAGEN K PA 35 NORRE SOGADE POSTBOX 2148, DK-1016 COPENHAGEN K, DENMARK SN 0105-3639 BN 87-16-11942-8 J9 ALFRED BENZON SYMP S PY 1997 VL 40 BP 409 EP 422 PG 14 WC Immunology SC Immunology GA BJ08M UT WOS:A1997BJ08M00030 ER PT B AU Saidman, SL Fitzpatrick, D Mann, M Comerford, C Drew, L Marrari, M Duquesnoy, R AF Saidman, SL Fitzpatrick, D Mann, M Comerford, C Drew, L Marrari, M Duquesnoy, R BE Charron, D TI HLA class II antibodies in highly sensitized patients awaiting renal transplantation SO HLA - GENETIC DIVERSITY OF HLA FUNCTIONAL AND MEDICAL IMPLICATION, PROCEEDINGS OF THE TWELFTH INTERNATIONAL HISTOCOMPATIBILITY WORKSHOP AND CONFERENCE (12TH IHWC), VOL II: CONFERENCE LA English DT Proceedings Paper CT 12th International Histocompatibility Conference - HLA CY JUN, 1996 CL ST MALO, FRANCE SP Agence Francaise Sang, European Community, Biomed, Ligue Natl Francaise Contre Canc, HLA & Med, European Sci Fdn, Etablissement Francaise Greffes, Fdn St Louis, LNFCC, Comite Paris, Fac Med St Louis Lariboisiere, Inst Biomed Cordeliers, Inst Univ Hematol, Assoc France Transplant, Imperial Canc Res Fund, Soc Francophone Histocompatib & Immunogenet, CREG, Perkin Elmer, Pharmacia Biotech, IUnnogenet & Murex, ALK, Chugai Pharm, One Lambda, Prod Roche Roche Diagnost, Sandoz, France Biochem, Genset, Biotest AG C1 Massachusetts Gen Hosp, Histocompatib Lab, Boston, MA 02114 USA. RP Saidman, SL (reprint author), Massachusetts Gen Hosp, Histocompatib Lab, 32 Fruit St, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU EDITIONS EDK PI SEVRES PA 10, RUE CHAMPFLEURY, 92310 SEVRES, FRANCE BN 2-84254-003-4 PY 1997 BP 545 EP 547 PG 3 WC Anthropology; Genetics & Heredity; Immunology; Medical Laboratory Technology SC Anthropology; Genetics & Heredity; Immunology; Medical Laboratory Technology GA BK29Z UT WOS:000071717200159 ER PT J AU Shenker, Y Wesly, J Meranda, D Kosolcharoen, P AF Shenker, Y Wesly, J Meranda, D Kosolcharoen, P TI Effect of rapid intra-atrial saline infusion on atrial pressures and atrial natriuretic hormone secretion SO HORMONE AND METABOLIC RESEARCH LA English DT Article DE atrial natriuretic hormone; atrial pressure ID HEMODYNAMIC FUNCTION; CARDIAC-TAMPONADE; PLASMA-LEVELS; PEPTIDE; RELEASE; RESPONSES; STRETCH; DISEASE AB To evaluate the relationship between the right atrial pressure and atrial natriuretic hormone secretion, we studied 16 healthy mates, ages 18-24, after five days on a low-salt diet (mean 24-h urinary sodium excretion: 17 +/- 3 mEq). After 90 min of equilibration to the supine position, a multilumen catheter was inserted into the right atrium, and 1I of isotonic saline was infused intra-atrially over 15 min through this catheter. Blood pressure, heart rate, and right atrial pressure were recorded just before (0 min), immediately after completion of the infusion (15 min), and every 15 min for 45 min thereafter. Two blood samples were drawn at each time point for atrial natriuretic hormone assay: one from the right atrium (central) and the other from a peripheral vein. Blood pressure did not change significantly during the entire study. Heart rate increased by 5 beats/min on average at 15 min (p < 0.005) and returned to baseline at 60 min. Good correlation occurred between central and peripheral atrial natriuretic hormone levels at times 0, 30, 45 and 60 min (r(2) = 0.,66, 0.45, 0.76 and 0.70, respectively; p less than or equal to 0.02). An increase in right atrial pressure and an increase in central atrial natriuretic hormone levels correlated well at times 30, 45 and 60 min, but there was no such correlation between an increase in right atrial pressure and an increase in peripheral atrial natriuretic hormone levels at any time point. Similarly, a maximum increase in right atrial pressure correlated with a maximum increase in central atrial natriuretic hormone levels (r(2) = 0.48; p < 0.02), but not with a maximum increase in peripheral levels of this hormone. We concluded that an increase in right atrial pressure caused by a rapid infusion of isotonic saline induces secretion of atrial natriuretic hormone in the right atrium. The observed discrepant course of change in central and peripheral atrial natriuretic hormone levels suggests the additional contribution of secretion beyond the level of the coronary sinus. C1 UNIV WISCONSIN,DEPT MED,MADISON,WI. RP Shenker, Y (reprint author), WILLIAM S MIDDLETON MEM VET ADM MED CTR,MED SERV,2500 OVERLOOK TERRACE,MADISON,WI 53705, USA. FU NCRR NIH HHS [RR-03186] NR 21 TC 0 Z9 0 U1 0 U2 0 PU GEORG THIEME VERLAG PI STUTTGART PA P O BOX 30 11 20, D-70451 STUTTGART, GERMANY SN 0018-5043 J9 HORM METAB RES JI Horm. Metab. Res. PD JAN PY 1997 VL 29 IS 1 BP 33 EP 37 DI 10.1055/s-2007-978977 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA WF738 UT WOS:A1997WF73800008 PM 9049652 ER PT J AU Marsh, DJ Mulligan, LM Eng, C AF Marsh, DJ Mulligan, LM Eng, C TI RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma SO HORMONE RESEARCH LA English DT Article; Proceedings Paper CT 39th International Henri-Pierre Klotz Symposium on Clinical Endocrinology - Recent Progress on the Molecular Aspects on Endocrine Tumors CY MAY 30-31, 1996 CL PARIS, FRANCE DE RET; multiple endocrine neoplasia type 2; medullary thyroid carcinoma, familial; mutations; receptor tyrosine kinase; inherited cancer syndrome ID TYROSINE KINASE DOMAIN; SINGLE MISSENSE MUTATION; MEN 2A; PROTOONCOGENE MUTATIONS; HIRSCHSPRUNGS-DISEASE; TRANSFORMING GENE; POINT MUTATION; MESSENGER-RNA; FAMILIES; EXPRESSION AB Multiple endocrine neoplasia type 2 (MEN-2) is a familial cancer syndrome inherited in an autosomal dominant fashion with age-related penetrance. The main tumour type present in all manifestations of this syndrome, MEN-2A, MEN-2B and familial medullary thyroid carcinoma (FMTC), is medullary thyroid carcinoma (MTC). MTC arises from the parafollicular or C cells of the thyroid, MEN-2A is characterised by the triad of MTC, phaeochromocytoma, and parathyroid hyperplasia, MEN-2B is characterised by features similar to those of MEN-2A, except for the absence of clinically apparent parathyroid hyperplasia, and additional stigmata including a marfanoid habitus, mucosal neuromas and ganglioneuromatosis of the gastrointestinal tract, FIL ITC families have MTC as their only phenotype, Missense mutations affecting conserved cysteine codons adjacent to the transmembrane domain of the RET proto-oncogene have been identified in the germline DNA of patients with MEN-2A and FMTC, A single mutation at codon 918 in the tyrosine kinase domain of the RET receptor has been associated with the MEN-2B phenotype, In a small number of FMTC families, missense point mutations have also been identified in the intracellular domain of the RET protein, RET mutation analysis of MEN-2 families has allowed the identification of genotype-phenotype correlations. While 25% of all MTCs are hereditary, the great majority of MTCs, 75% are sporadic. Various somatic RET mutations have been identified in sporadic MTCs, In a small number of hereditary MTCs with germline mutations in RET, an additional somatic missense RET mutation has been identified, The discovery of RET mutations in MEN-2 has made possible accurate DNA-based diagnosis and predictive testing, The clinical significance of somatic RET mutations has yet to be determined. C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,DIV CANC EPIDEMIOL & CONTROL,BOSTON,MA 02115. QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON,CANADA. UNIV CAMBRIDGE,ADDENBROOKES HOSP,CANC RES CAMPAIGN,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND. RI Marsh, Deborah/I-1491-2014; OI Marsh, Deborah/0000-0001-5899-4931; Eng, Charis/0000-0002-3693-5145 NR 105 TC 38 Z9 41 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 1997 VL 47 IS 4-6 BP 168 EP 178 DI 10.1159/000185461 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA WY292 UT WOS:A1997WY29200006 PM 9167949 ER PT J AU Bandettini, PA Kwong, KK Davis, TL Tootell, RBH Wong, EC Fox, PT Belliveau, JW Weisskoff, RM Rosen, BR AF Bandettini, PA Kwong, KK Davis, TL Tootell, RBH Wong, EC Fox, PT Belliveau, JW Weisskoff, RM Rosen, BR TI Characterization of cerebral blood oxygenation and flow changes during prolonged brain activation SO HUMAN BRAIN MAPPING LA English DT Article DE BOLD contrast; fMRI; PET; deoxyhemoglobin; neuronal habituation; human brain mapping; neuronal metabolism; brain function; photic stimulation; visual cortex ID HUMAN VISUAL-CORTEX; FUNCTIONAL MRI; SENSORY STIMULATION; PHOTIC-STIMULATION; INTRINSIC SIGNALS; CONTRAST; RESOLUTION; EPI; ARCHITECTURE; SPECTROSCOPY AB The behavior of cerebral blood flow and oxygenation during prolonged brain activation was studied using magnetic resonance imaging (MRI) sensitized to flow and oxygenation changes, as well as positron emission tomography sensitized to flow. Neuronal habituation effects and hemodynamic changes were evaluated across tasks and cortical regions. Nine types of activation stimuli or tasks, including motor activation, vibrotactile stimulation, and several types of visual stimulation, were used. Both flow and oxygenation were evaluated in separate time course series as well as simultaneously using two different MRI methods. In most cases, the activation-induced increase in flow and oxygenation remained elevated for the entire stimulation duration. These results suggest that both flow rate and oxygenation consumption rate remain constant during the entire time that primary cortical neurons are activated by a task or a stimulus. (C) 1997 Wiley-Liss, Inc. C1 MASSACHUSETTS GEN HOSP,DEPT RADIOL,NMR CTR,CHARLESTOWN,MA. HARVARD UNIV,MIT,DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139. UNIV CALIF SAN DIEGO,DEPT RADIOL,SAN DIEGO,CA 92103. UNIV CALIF SAN DIEGO,DEPT PSYCHIAT,SAN DIEGO,CA 92103. UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX. RI Bandettini, Peter/F-5871-2012; Fox, Peter/B-4725-2010 OI Fox, Peter/0000-0002-0465-2028 NR 68 TC 113 Z9 115 U1 1 U2 6 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 1065-9471 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PY 1997 VL 5 IS 2 BP 93 EP 109 PG 17 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA XC645 UT WOS:A1997XC64500003 PM 10096414 ER PT J AU Rauch, SL Whalen, PJ Savage, CR Curran, T Kendrick, A Brown, HD Bush, G Breiter, HC Rosen, BR AF Rauch, SL Whalen, PJ Savage, CR Curran, T Kendrick, A Brown, HD Bush, G Breiter, HC Rosen, BR TI Striatal recruitment during an implicit sequence learning task as measured by functional magnetic resonance imaging SO HUMAN BRAIN MAPPING LA English DT Article DE putamen; caudate nucleus; procedural learning; memory ID HUNTINGTONS-DISEASE; SENSORY STIMULATION; KNOWLEDGE; MOTOR AB Prior research has repeatedly implicated the striatum in implicit sequence learning; however, imaging findings have been inconclusive with respect to the sub-territories and laterality involved. Using functional magnetic resonance imaging (fMRI), we studied brain activation profiles associated with performance of the serial reaction time task (SRT) in 10 normal right-handed males. Behavioral results indicate that significant implicit learning occurred, uncontaminated by significant explicit knowledge. Concatenated fMRI data from the entire cohort revealed significant right-lateralized activation in both the caudate and putamen. Analysis of fMRI data from individual subjects showed inter-individual variability as to the precise territories involved, including right as well as left caudate and putamen. Interestingly, all seven subjects who manifested robust learning effects exhibited significant activation within the putamen. Moreover, among those seven subjects, the magnitude of signal intensity change within the putamen correlated significantly with the magnitude of reaction time advantage achieved. These findings demonstrate right-sided striatal activation across subjects during implicit sequence learning, but also highlight interindividual variability with respect to the laterality and striatal subterritories involved. In particular, results from individual subjects suggest that, during the SRT, the reaction time advantage garnered via implicit sequence learning might be predominantly associated with activity within the putamen. (C) 1997 Wiley-Liss, Inc. C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02114. CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106. UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143. FU NIMH NIH HHS [MH01215, MH01230] NR 30 TC 229 Z9 229 U1 4 U2 20 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 1065-9471 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PY 1997 VL 5 IS 2 BP 124 EP 132 DI 10.1002/(SICI)1097-0193(1997)5:2<124::AID-HBM6>3.0.CO;2-5 PG 9 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA XC645 UT WOS:A1997XC64500006 PM 10096417 ER PT J AU Dale, AM Buckner, RL AF Dale, AM Buckner, RL TI Selective averaging of rapidly presented individual trials using fMRI SO HUMAN BRAIN MAPPING LA English DT Article DE single trial; neuroimaging; visual cortex; ERP; MRI; imaging ID HUMAN BRAIN; MRI AB A major limitation in conducting functional neuroimaging studies, particularly for cognitive experiments, has been the use of blocked task paradigms. Here we explored whether selective averaging techniques similar to those applied in event-related potential (ERP) experiments could be used to demonstrate functional magnetic resonance imaging (fMRI) responses to rapidly intermixed trials. In the first two experiments, we observed that for 1-sec trials of full-field visual checkerboard stimulation, the fMRI blood oxygenation level-dependent (BOLD) signal summated in a roughly linear fashion across successive trials even at very short (2 sec and 5 sec) intertrial intervals, although subtle departures from linearity were observed. In experiments 3 and 4, we observed that it is possible to obtain robust activation maps for rapidly presented randomly mixed trial types (left-and right-hemifield visual checkerboard stimulation) spaced as little as 2 sec apart. Taken collectively, these results suggest that selective averaging may enable fMRI experimental designs identical to those used in typical behavioral and ERP studies. The ability to analyze closely spaced single-trial, or event-related, signals provides for a class of experiments which cannot be conducted using blocked designs. Trial types can be randomly intermixed, and selective averaging based upon trial type and/or subject performance is possible. (C) 1997 Wiley-Liss, Inc. C1 HARVARD UNIV, SCH MED, DEPT RADIOL, BOSTON, MA 02129 USA. RP Dale, AM (reprint author), MASSACHUSETTS GEN HOSP, NUCL MAGNET RESONANCE CTR, BLDG 149, 13TH ST, BOSTON, MA 02129 USA. RI Dale, Anders/A-5180-2010; Frank, David/E-8213-2012 NR 30 TC 678 Z9 691 U1 8 U2 30 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1065-9471 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PY 1997 VL 5 IS 5 BP 329 EP 340 PG 12 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA YE097 UT WOS:A1997YE09700001 PM 20408237 ER PT J AU Dranoff, G Soiffer, R Lynch, T Mihm, M Jung, K Kolesar, K Liebster, L Duda, R Mentzer, S Singer, S Tanabe, K Johnson, R Sober, A Bhan, A Clift, S Cohen, L Parry, G Rokovich, J Richards, L Drayer, J Berns, A Mulligan, RC AF Dranoff, G Soiffer, R Lynch, T Mihm, M Jung, K Kolesar, K Liebster, L Duda, R Mentzer, S Singer, S Tanabe, K Johnson, R Sober, A Bhan, A Clift, S Cohen, L Parry, G Rokovich, J Richards, L Drayer, J Berns, A Mulligan, RC TI A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor SO HUMAN GENE THERAPY LA English DT Article ID TUMOR-INFILTRATING LYMPHOCYTES; ACTIVE-SPECIFIC IMMUNOTHERAPY; HUMAN REGRESSIVE MELANOMA; CYTOLYTIC T-LYMPHOCYTES; LASTING ANTITUMOR IMMUNITY; HIGH-DOSE INTERLEUKIN-2; METASTATIC MELANOMA; MALIGNANT-MELANOMA; GENE-TRANSFER; REDUCED TUMORIGENICITY C1 ALBANY MED COLL,ALBANY,NY 12208. WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA. SOMATIX THERAPY CORP,ALAMEDA,CA. RP Dranoff, G (reprint author), MASSACHUSETTS GEN HOSP,DANA FARBER CANC INST,BOSTON,MA 02114, USA. NR 61 TC 47 Z9 50 U1 0 U2 0 PU MARY ANN LIEBERT INC PUBL PI LARCHMONT PA 2 MADISON AVENUE, LARCHMONT, NY 10538 SN 1043-0342 J9 HUM GENE THER JI Hum. Gene Ther. PD JAN 1 PY 1997 VL 8 IS 1 BP 111 EP 123 DI 10.1089/hum.1997.8.1-111 PG 13 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA WD330 UT WOS:A1997WD33000011 PM 8990000 ER PT J AU Clavijo, OP Castro, JE Delgado, JC Yunis, EJ AF Clavijo, OP Castro, JE Delgado, JC Yunis, EJ TI Induction of apoptosis correlates with down regulations of CD16 in NK cells and neutrophils. SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV IMMUNOGENET,BOSTON,MA 02115. HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV PULM,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1997 VL 55 SU 1 BP 46 EP 46 PG 1 WC Immunology SC Immunology GA YA772 UT WOS:A1997YA77200084 ER PT J AU Uko, G Lu, LY Mahan, S Ding, W Fici, D Udim, E Asuquo, MA Fraser, PA AF Uko, G Lu, LY Mahan, S Ding, W Fici, D Udim, E Asuquo, MA Fraser, PA TI Risk of leprosy is associated with different DRB1 alleles in different Nigerian ethnic groups. SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 NIGERIAN INST MED RES,LAGOS,NIGERIA. HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1997 VL 55 SU 1 BP 56 EP 56 PG 1 WC Immunology SC Immunology GA YA772 UT WOS:A1997YA77200103 ER PT J AU Delgado, JC Hameed, A Yunis, JJ Bhol, K Rojas, AI Rehman, SB Kham, AA Alper, CA Ahmed, AR Yunis, EJ AF Delgado, JC Hameed, A Yunis, JJ Bhol, K Rojas, AI Rehman, SB Kham, AA Alper, CA Ahmed, AR Yunis, EJ TI HLA-DQB1*0503 is a common marker for pemphigus vulgaris in non-Jewish patients from Pakistan and Boston. SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV IMMUNOGENET,BOSTON,MA 02115. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1997 VL 55 SU 1 BP 57 EP 57 PG 1 WC Immunology SC Immunology GA YA772 UT WOS:A1997YA77200106 ER PT J AU Delgado, JC Goldfeld, AE Thim, S Bozon, MV Uglialoro, AM Turbay, D Cohen, C Yunis, EJ AF Delgado, JC Goldfeld, AE Thim, S Bozon, MV Uglialoro, AM Turbay, D Cohen, C Yunis, EJ TI A negatively charged P9 peptide binding pocket of the HLA-DQ molecule is associated with progressive tuberculosis. SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV INFECT DIS,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV IMMUNOGENET,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1997 VL 55 SU 1 BP 59 EP 59 PG 1 WC Immunology SC Immunology GA YA772 UT WOS:A1997YA77200109 ER PT J AU Saidman, SL Duan, JM Pascual, M Delmonico, FL TolkoffRubin, N Cosimi, AB AF Saidman, SL Duan, JM Pascual, M Delmonico, FL TolkoffRubin, N Cosimi, AB TI Successful treatment of antibody mediated rejection after renal transplantation: Monitoring of donor specific antibodies during plasma exchange. SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT SURG,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1997 VL 55 SU 1 BP 70 EP 70 PG 1 WC Immunology SC Immunology GA YA772 UT WOS:A1997YA77200132 ER PT J AU Fitzpatrick, DM Comerford, CA Saidman, SL AF Fitzpatrick, DM Comerford, CA Saidman, SL TI Significant differences in crossmatch results when testing with donor lymph node versus spleen cells. SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,HISTOCOMPATIBIL LAB,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1997 VL 55 SU 1 BP 84 EP 84 PG 1 WC Immunology SC Immunology GA YA772 UT WOS:A1997YA77200160 ER PT J AU Gonzalez, CM Ding, WZ Lu, LY Muhlradt, PF Fraser, PA AF Gonzalez, CM Ding, WZ Lu, LY Muhlradt, PF Fraser, PA TI Gene polymorphism and TNF alpha synthesis. SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract C1 BRIGHAM & WOMENS HOSP,CTR BLOOD RES,BOSTON,MA 02115. BRIGHAM & WOMENS HOSP,DIV RHEUMATOL & IMMUNOL,BOSTON,MA 02115. GESELL BIOTECHNOL FORSCH MBH,IMMUNOBIOL RES GRP,BRAUNSCHWEIG,GERMANY. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0198-8859 J9 HUM IMMUNOL JI Hum. Immunol. PY 1997 VL 55 SU 1 BP 97 EP 97 PG 1 WC Immunology SC Immunology GA YA772 UT WOS:A1997YA77200185 ER PT J AU Eng, C Mulligan, LM AF Eng, C Mulligan, LM TI Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease SO HUMAN MUTATION LA English DT Review ID MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; PROTOONCOGENE POINT MUTATIONS; CUTANEOUS LICHEN AMYLOIDOSIS; MEN 2A; GERMLINE MUTATIONS; TRANSFORMING GENE; FAMILIES; FMTC; PHEOCHROMOCYTOMAS AB The RET proto-oncogene codes for a receptor tyrosine kinase thought to play a role in the development of neural crest and its derivatives. Mutations in the RET proto-oncogene have been found in patients with the multiple endocrine neoplasia type 2 syndromes (MEN 2), the related sporadic tumours medullary thyroid carcinoma and pheochromocytoma, and familial and sporadic Hirschsprung disease, a syndrome of congenital absence of enteric innervation. Germline mutations in one of eight codons within RET cause the three subtypes of MEN 2, namely, MEN 2A, MEN 2B, and familial medullary thyroid carcinoma. Somatic mutation in an overlapping group of nine codons have been found in a proportion of sporadic medullary thyroid carcinoma and pheochromocytoma. In contrast to MEN 2, approximately 25% of patients with Hirschsprung disease have germline mutations scattered throughout the length of RET. (C) 1997 Wiley-Liss, Inc. C1 UNIV CAMBRIDGE,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND. QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA. QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON K7L 3N6,CANADA. RP Eng, C (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,DIV CANC EPIDEMIOL & CONTROL,44 BINNEY ST,BOSTON,MA 02115, USA. OI Eng, Charis/0000-0002-3693-5145 NR 102 TC 165 Z9 169 U1 0 U2 2 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 1059-7794 J9 HUM MUTAT JI Hum. Mutat. PY 1997 VL 9 IS 2 BP 97 EP 109 DI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.0.CO;2-M PG 13 WC Genetics & Heredity SC Genetics & Heredity GA WK785 UT WOS:A1997WK78500001 PM 9067749 ER PT J AU Rehm, HL GutierrezEspeleta, GA Garcia, R Jimenez, G Khetarpal, U Priest, JM Sims, KB Keats, BJB Morton, CC AF Rehm, HL GutierrezEspeleta, GA Garcia, R Jimenez, G Khetarpal, U Priest, JM Sims, KB Keats, BJB Morton, CC TI Norrie disease gene mutation in a large Costa Rican kindred with a novel phenotype including venous insufficiency SO HUMAN MUTATION LA English DT Article DE Norrie disease; venous insufficiency; blindness; deafness; point mutation ID CANDIDATE GENE; FAMILIES AB A large Costa Rican kindred has been identified with 15 males affected with congenital blindness, progressive hearing loss, and venous insufficiency, Due to ophthalmological and audio-otological findings, including bilateral retinal dysplasia and detachment, progressive bilateral sensorineural hearing loss, and an X-linked pattern of inheritance, a tentative diagnosis of Norrie disease was considered, However, venous insufficiency is a clinical finding nor reportedly associated with Norrie disease. Genetic linkage analysis using microsatellite repeat markers demonstrated linkage to Xp11.23-11.4 (z = 2.723 at theta = 0.0). A candidate gene approach using the Norrie disease gene (NDP), which maps to Xp11.3, revealed a point mutation in the third exon resulting in substitution of phenylalanine for leucine at position 61. The precise function of the gene product, norrin, has yet to be elucidated; however, it has been postulated to be involved in the regulation of neural cell differentiation and proliferation, although hypotheses have been considered for its role in vascular development in the eye The finding of a mutation in NDP in association with peripheral vascular disease may provide valuable insight into the potential role of this gene in cellular processes. (C) 1997 Wiley-Liss, Inc. C1 HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT NEUROL,MASSACHUSETTS GEN HOSP,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115. UNIV COSTA RICA,ESCUELA BIOL,INST INVEST SALUD,SAN JOSE,COSTA RICA. HOSP MEXICO,CCSS,SAN JOSE,COSTA RICA. LOUISIANA STATE UNIV,MED CTR,DEPT BIOMETRY & GENET,NEW ORLEANS,LA 70112. FU NHLBI NIH HHS [T32 HL07627]; NIDCD NIH HHS [DC00871] NR 23 TC 20 Z9 22 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 1059-7794 J9 HUM MUTAT JI Hum. Mutat. PY 1997 VL 9 IS 5 BP 402 EP 408 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA WW877 UT WOS:A1997WW87700004 PM 9143918 ER PT J AU Hornstein, MD Thomas, PP Sober, AJ Wyshak, G Albright, NL Frisch, RE AF Hornstein, MD Thomas, PP Sober, AJ Wyshak, G Albright, NL Frisch, RE TI Association between endometriosis, dysplastic naevi and history of melanoma in women of reproductive age SO HUMAN REPRODUCTION LA English DT Article DE dysplastic naevi; endometriosis; gynaecological disorders; melanoma ID MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; NEVI; RISK AB Women with melanoma and its precursor lesions, dysplastic naevi, have a higher prevalence of reproductive disorders than women without melanotic lesions. This association appears strongest among young women with dysplastic naevi and endometriosis. The purpose of this study was to evaluate patients with laparoscopy-confirmed endometriosis for the presence of dysplastic naevi. A total of 66 endometriosis patients and 35 controls completed a detailed questionnaire and underwent an extensive dermatological examination for the presence of dysplastic naevi. In all, 41% of patients aged less than or equal to 32 years had dysplastic naevi, compared with 8% of controls (P = 0.038). In addition, 29% of patients with endometriosis reported a family history of melanoma compared with 10% of controls (P = 0.039). This study demonstrated an association between endometriosis and dysplastic naevi in younger women of reproductive age and found an associated family history of melanoma among endometriosis patients. These observations may be useful in the evaluation and care of young women by both gynaecologists and dermatologists. C1 MASSACHUSETTS GEN HOSP,DEPT DERMATOL,BOSTON,MA 02114. HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115. HARVARD UNIV,SCH PUBL HLTH,DEPT POPULAT & INT HLTH,BOSTON,MA 02115. ADV MED RES FDN,BOSTON,MA 02115. HARVARD CTR POPULAT & DEV STUDIES,CAMBRIDGE,MA 02138. RP Hornstein, MD (reprint author), BRIGHAM & WOMENS HOSP,DEPT OBSTET & GYNECOL,75 FRANCIS ST,BOSTON,MA 02115, USA. NR 18 TC 28 Z9 28 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP SN 0268-1161 J9 HUM REPROD JI Hum. Reprod. PD JAN PY 1997 VL 12 IS 1 BP 143 EP 145 DI 10.1093/humrep/12.1.143 PG 3 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA WG754 UT WOS:A1997WG75400035 PM 9043919 ER PT J AU Harding, P Sigmon, DH Alfie, ME Huang, PL Fishman, MC Beierwaltes, WH Carretero, OA AF Harding, P Sigmon, DH Alfie, ME Huang, PL Fishman, MC Beierwaltes, WH Carretero, OA TI Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet SO HYPERTENSION LA English DT Article DE renin; cyclooxygenase; nitric oxide; mice ID NITRIC-OXIDE SYNTHASE; SUB-MAXILLARY GLAND; RELAXING FACTOR; MESSENGER-RNA; MACULA DENSA; RAT-KIDNEY; RELEASE; SECRETION; PRESSURE; PROSTAGLANDINS AB We hypothesized that neuronal nitric oxide synthase and cyclooxygenase-2, which both exist in the renal cortex, predominantly in the macula densa, play a role in the control of renal renin tissue content. We studied the possible role of neuronal nitric oxide synthase in regulating renal renin content by using mice in which the neuronal nitric oxide synthase gene has been disrupted (nNOS -/-) compared with its two progenitor strains, the 129/SvEv and the C57BL/6, to determine if the absence of neuronal nitric oxide synthase would result in decreased renal renin content or blunt the increase observed during low sodium intake. Renal renin content from cortical slices was determined in adult mice from all three strains maintained on a normal sodium diet. Renal renin content was significantly reduced in the nNOS -/- mice compared with the 129/SvEv and the C57BL/6 mice (3.11+/-0.23 versus 5.66+/-0.50 and 7.55+/-1.17 mu g angiotensin I/mg dry weight, respectively; P<.005), suggesting that neuronal nitric oxide synthase may stimulate renal renin content under basal conditions. Neither selective pharmacological inhibition of neuronal nitric oxide synthase using 7-nitroindazole or disruption of the neuronal nitric oxide synthase gene affected the increase in renal renin content observed during dietary sodium restriction. The influence of cyclooxygenase-2 on renal renin content through a macula densa-mediated pathway was studied using a selective cyclooxygenase-2 inhibitor, NS398, in 129/SvEv mice. A low-sodium diet increased renal renin content from 6.97+/-0.52 to 11.59+/-0.79 mu g angiotensin I/mg dry weight (P<.005); but this increase was blocked by NS398. In addition, treatment with NS398 reduced renin mRNA in response to a low-sodium diet. Thus, increased renal renin content in response to dietary sodium restriction appears to require the induction of cyclooxygenase-2, while neuronal nitric oxide synthase appears to affect basal but not stimulated renal renin content. C1 HENRY FORD HOSP,HYPERTENS & VASC RES DIV,DETROIT,MI 48202. MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,CHARLESTOWN,MA. NR 34 TC 146 Z9 153 U1 0 U2 1 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0194-911X J9 HYPERTENSION JI Hypertension PD JAN PY 1997 VL 29 IS 1 BP 297 EP 302 PN 2 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA WH716 UT WOS:A1997WH71600026 PM 9039118 ER PT J AU Guan, L Anderson, JA Sutton, JP AF Guan, L Anderson, JA Sutton, JP TI A network of networks processing model for image regularization SO IEEE TRANSACTIONS ON NEURAL NETWORKS LA English DT Article DE network of networks; image regularization; image and pattern analysis; adaptive control parameters; learning ID NEURAL NETWORK; ALGORITHM AB We introduce a network of networks (NoN) model to solve image regularization problems. The method is motivated by the fact that natural image formation involves both local processing and globally coordinated parallel processes. Both forms are readily implemented using an NoN architecture. The modeling is very powerful in that it achieves high-quality adaptive processing, and it reduces the computational difference between inhomogeneous and homogeneous conditions. This method is able to provide fast, quality imaging in early vision, and its replicating structure and sparse connectivity readily lend themselves to hardware implementations. C1 BROWN UNIV,DEPT COGNIT & LINGUIST SCI,PROVIDENCE,RI 02912. MASSACHUSETTS GEN HOSP,NEURAL SYST GRP,BOSTON,MA 02129. HARVARD UNIV,SCH MED,BOSTON,MA 02129. RP Guan, L (reprint author), UNIV SYDNEY,DEPT ELECT ENGN,SYDNEY,NSW 2006,AUSTRALIA. NR 16 TC 21 Z9 21 U1 1 U2 1 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017-2394 SN 1045-9227 J9 IEEE T NEURAL NETWOR JI IEEE Trans. Neural Netw. PD JAN PY 1997 VL 8 IS 1 BP 169 EP 174 DI 10.1109/72.554202 PG 6 WC Computer Science, Artificial Intelligence; Computer Science, Hardware & Architecture; Computer Science, Theory & Methods; Engineering, Electrical & Electronic SC Computer Science; Engineering GA WA612 UT WOS:A1997WA61200017 PM 18255621 ER PT J AU Young, F Mizoguchi, E Bhan, AK Alt, FW AF Young, F Mizoguchi, E Bhan, AK Alt, FW TI Constitutive Bcl-2 expression during immunoglobulin heavy chain promoted B cell differentiation expands novel precursor B cells SO IMMUNITY LA English DT Article ID SURROGATE LIGHT-CHAIN; MOUSE BONE-MARROW; PRE-B; LYMPHOCYTES-B; RAG-1-DEFICIENT MICE; TARGETED DISRUPTION; DEFICIENT MICE; MEMBRANE EXON; MUTANT MICE; SURFACE AB To test for effects on B cell differentiation, we introduced immunoglobulin mu heavy chain (HC) and Bcl-2 transgenes, separately or together, into recombination-activating gene 2 (RAG-2)-deficient mice. Transgenic Bcl-2 expression led to increased numbers of RAG-deficient pro-B cells, but did not promote their further differentiation. Expression of the mu HC transgene promoted the differentiation of RAG-deficient pro-B cells into pre-B cells that also expressed certain differentiation markers characteristic of even more mature B cell stages. However, the extent of the mu HC-dependent differentiation effects was greatly enhanced by coexpression of the transgenic Bcl-2 gene, and a subset of pre-B cells from both HC and HC, Bcl-2-transgenic RAG-2-deficient animals expressed surface mu HCs that were functional as judged by crosslinking experiments. These experiments demonstrate that the pro-B to pre-B transition in vivo cannot be effected by the expression of Bcl-2 alone, and that nontransformed immature B-lineage cells are competent to receive signals through a surface mu complex. C1 HOWARD HUGHES MED INST,BOSTON,MA 02115. CHILDRENS HOSP,DWPT GENET & PEDIAT,BOSTON,MA 02115. HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115. HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115. FU NCI NIH HHS [CA42335]; NIAID NIH HHS [UO1 AI31541, AI20047] NR 64 TC 49 Z9 49 U1 1 U2 1 PU CELL PRESS PI CAMBRIDGE PA 1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 SN 1074-7613 J9 IMMUNITY JI Immunity PD JAN PY 1997 VL 6 IS 1 BP 23 EP 33 DI 10.1016/S1074-7613(00)80239-3 PG 11 WC Immunology SC Immunology GA XB161 UT WOS:A1997XB16100003 PM 9052834 ER PT S AU Rauch, SD AF Rauch, SD BE Bernstein, JM Faden, HS Henderson, D Ryan, AF Barbara, M Quaranta, A TI Clinical management of immune-mediated inner-ear disease SO IMMUNOLOGIC DISEASES OF THE EAR SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Immunological Diseases of the Ear CY OCT 24-26, 1996 CL POSITANO, ITALY SP AMPLIFON SpA, Milan, Italy, ASTA MEDICA, Milan, AUDIOMEDICAL, Pompei, BRISTOL MYERS SQUIBB CO, CTR HEARING & DEAFNESS, State Univ New York Buffalo, CONNAUGHT LAB INC, ELI LILLY CO, PFIZER INC, SMITHKLINE BEECHAM, UPJOHN CO, WYETH AYERST LABS ID SENSORINEURAL HEARING-LOSS; THERAPY C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol, Boston, MA 02114 USA. RP Rauch, SD (reprint author), 243 Charles St, Boston, MA 02114 USA. EM sdr@epl.meei.harvard.edu NR 11 TC 16 Z9 18 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-100-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1997 VL 830 BP 203 EP 210 DI 10.1111/j.1749-6632.1997.tb51891.x PG 8 WC Immunology; Multidisciplinary Sciences; Otorhinolaryngology SC Immunology; Science & Technology - Other Topics; Otorhinolaryngology GA BK36A UT WOS:000071899400017 PM 9616679 ER PT S AU McKenna, MJ AF McKenna, MJ BE Bernstein, JM Faden, HS Henderson, D Ryan, AF Barbara, M Quaranta, A TI Measles, mumps, and sensorineural hearing loss SO IMMUNOLOGIC DISEASES OF THE EAR SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Immunological Diseases of the Ear CY OCT 24-26, 1996 CL POSITANO, ITALY SP AMPLIFON SpA, Milan, Italy, ASTA MEDICA, Milan, AUDIOMEDICAL, Pompei, BRISTOL MYERS SQUIBB CO, CTR HEARING & DEAFNESS, State Univ New York Buffalo, CONNAUGHT LAB INC, ELI LILLY CO, PFIZER INC, SMITHKLINE BEECHAM, UPJOHN CO, WYETH AYERST LABS ID RESPONSES C1 Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. RP McKenna, MJ (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. FU NIDCD NIH HHS [KO8 DC00065] NR 21 TC 13 Z9 13 U1 0 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-100-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1997 VL 830 BP 291 EP 298 DI 10.1111/j.1749-6632.1997.tb51899.x PG 8 WC Immunology; Multidisciplinary Sciences; Otorhinolaryngology SC Immunology; Science & Technology - Other Topics; Otorhinolaryngology GA BK36A UT WOS:000071899400025 PM 9616687 ER PT J AU Pahlavani, MA Harris, MD AF Pahlavani, MA Harris, MD TI In vitro effects of melatonin on mitogen-induced lymphocyte proliferation and cytokine expression in young and old rats SO IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY LA English DT Article ID AGE-RELATED DECLINE; CD4+ T-CELLS; INTERLEUKIN-2 PRODUCTION; OPIATERGIC MECHANISM; INTERFERON-GAMMA; IMMUNE FUNCTION; IL-2 PRODUCTION; PINEAL-GLAND; AGING MICE; F344 RATS AB Melatonin (MLT) treatment in vivo has been shown to have immunomodulatory and anti-immunosenescent effects in the mouse model. In the present report, the in vitro effect of MLT on mitogen-induced lymphocyte proliferation and cytokine expression was evaluated in a rat model. Splenic lymphocytes were isolated from young (6 months) and old (24 months) F344 rats and were incubated with MLT in the presence or absence of mitogens. The proliferative response to concanavalin A (ConA) or PMA plus ionomycin was measured in splenocytes or T cells isolated from young and old rats. In addition, the induction of interteukin-2 (IL-2) and interferon-gamma (IFN-gamma) production was measured in MLT-treated and untreated lymphocytes isolated from young and old rats. The ConA-induced lymphocyte proliferation and IL-2 expression were significantly lower and induction of IFN-gamma production was significantly higher in splenocytes and purified T cells isolated from old rats compared to splenocytes and T cells isolated from young rats. Treatment of lymphocytes with MLT did not significantly alter ConA-induced lymphocyte proliferation or IL-2 or IFN gamma expression in lymphocytes isolated from either young or old rats. On the basis of these data, we conclude that in vitro MLT treatment had no immunomodulatory effect on lymphocytes from rats. C1 AUDIE L MURPHY MEM VET ADM MED CTR, CTR GERIATR RES EDUC & CLIN, SAN ANTONIO, TX 78284 USA. RP Pahlavani, MA (reprint author), UNIV TEXAS, HLTH SCI CTR, DEPT PHYSIOL, SAN ANTONIO, TX 78284 USA. FU NIA NIH HHS [AG00165, AG00677] NR 50 TC 20 Z9 22 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0892-3973 J9 IMMUNOPHARM IMMUNOT JI Immunopharmacol. Immunotoxicol. PY 1997 VL 19 IS 3 BP 327 EP 337 DI 10.3109/08923979709046979 PG 11 WC Immunology; Pharmacology & Pharmacy; Toxicology SC Immunology; Pharmacology & Pharmacy; Toxicology GA XM952 UT WOS:A1997XM95200003 PM 9248861 ER PT J AU Syngal, S Wolfe, MM Friedman, LS VanDam, J AF Syngal, S Wolfe, MM Friedman, LS VanDam, J TI Helicobacter pylori: Pathogenic factor in the etiology of gastric diseases SO INFECTIOUS DISEASES IN CLINICAL PRACTICE LA English DT Review ID PEPTIC-ULCER DISEASE; RANDOMIZED CONTROLLED TRIAL; LONG-TERM MANAGEMENT; DUODENAL-ULCER; CAMPYLOBACTER-PYLORI; TRIPLE THERAPY; LYMPHOID-TISSUE; BREATH TEST; ANTIBIOTIC-THERAPY; INTESTINAL-TYPE C1 BRIGHAM & WOMENS HOSP,DIV GASTROENTEROL,BOSTON,MA 02115. HARVARD UNIV,MASSACHUSETTS GEN HOSP,GASTROENTEROL UNIT,BOSTON,MA. NR 109 TC 1 Z9 1 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 1056-9103 J9 INFECT DIS CLIN PRAC JI Infect. Dis. Clin. Pract. PD JAN PY 1997 VL 6 IS 1 BP 17 EP 27 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA WF582 UT WOS:A1997WF58200008 ER PT S AU Worth, AJ Makris, N Meyer, JW Caviness, VS Kennedy, DN AF Worth, AJ Makris, N Meyer, JW Caviness, VS Kennedy, DN BE Duncan, J Gindi, G TI Automated segmentation of brain exterior in MR images driven by empirical procedures and anatomical knowledge SO INFORMATION PROCESSING IN MEDICAL IMAGING SE Lecture Notes in Computer Science LA English DT Article; Proceedings Paper CT 15th International Conference on Information Processing in Medical Imaging CY JUN 09-13, 1997 CL GREEN MT COLL, POULTNEY, VT HO GREEN MT COLL ID MAGNETIC-RESONANCE IMAGES; VOLUME MEASUREMENT; SCHIZOPHRENIA; DISORDER; DISEASE; ATROPHY; HYPERACTIVITY; MORPHOMETRY AB This work demonstrates encouraging initial results for increasing the automation of a practical and precise MR brain image segmentation method. The intensity threshold for segmenting the brain exterior is automatically determined by locating the choroid plexus. This is done by finding peaks in a series of histograms taken over regions specified using anatomical knowledge. Intensity inhomogeneities are accounted for by adjusting the global intensity to match the white matter peak intensity in local regions. The results from 20 different brain scans (over 1000 images) obtained under different conditions are presented to validate the method which was able to determine the appropriate threshold in approximately 80% of the data. C1 Massachusetts Gen Hosp, Ctr Neurosci, Ctr Morphometr Anal, Charlestown, MA 02129 USA. RP Massachusetts Gen Hosp, Ctr Neurosci, Ctr Morphometr Anal, CNY-6,Bldg 149,13th St, Charlestown, MA 02129 USA. EM andy@cma.mgh.harvard.edu RI Kennedy, David/H-3627-2012 NR 44 TC 3 Z9 3 U1 0 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 3-540-63046-5 J9 LECT NOTES COMPUT SC PY 1997 VL 1230 BP 99 EP 112 PG 14 WC Computer Science, Theory & Methods; Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Engineering; Radiology, Nuclear Medicine & Medical Imaging GA BK96M UT WOS:000073946600008 ER PT S AU Morch, N Hansen, LK Strother, SC Svarer, C Rottenberg, DA Lautrup, B Savoy, R Paulson, OB AF Morch, N Hansen, LK Strother, SC Svarer, C Rottenberg, DA Lautrup, B Savoy, R Paulson, OB BE Duncan, J Gindi, G TI Nonlinear versus linear models in functional neuroimaging: Learning curves and generalization crossover SO INFORMATION PROCESSING IN MEDICAL IMAGING SE Lecture Notes in Computer Science LA English DT Article; Proceedings Paper CT 15th International Conference on Information Processing in Medical Imaging CY JUN 09-13, 1997 CL GREEN MT COLL, POULTNEY, VT HO GREEN MT COLL DE multivariate brain modeling; ill-posed learning; generalization; learning curves ID SCALED SUBPROFILE MODEL; PET AB We introduce the concept of generalization for models of functional neuroactivation, and show how it is affected by the number, N, of neuroimaging scans available. By plotting generalization as a function of N (i.e. a "learning curve") we demonstrate that while simple, linear models may generalize better for small N's, more flexible, low-biased nonlinear models, based on artificial neural networks (ANN's), generalize better for larger N's. We demonstrate that for sets of scans of two simple motor tasks-one set acquired with [O-15]water using PET, and the other using fMRI-practical N's exist for which "generalization crossover" occurs. This observation supports the application of highly flexible, ANN models to sufficiently large functional activation datasets. C1 Copenhagen Univ Hosp, Neurobiol Res Unit, Rigshosp, DK-2100 Copenhagen O, Denmark. Tech Univ Denmark, Dept Math Modelling, DK-2800 Lyngby, Denmark. Univ Minnesota, Dept Radiol, Minneapolis, MN 55417 USA. Univ Minnesota, Dept Nephrol, Minneapolis, MN 55417 USA. Minneapolis VA Med Ctr, PET Imaging Serv, Minneapolis, MN 55417 USA. Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen O, Denmark. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Copenhagen Univ Hosp, Neurobiol Res Unit, Rigshosp, DK-2100 Copenhagen O, Denmark. RI Hansen, Lars/E-3174-2013; Paulson, Olaf/N-6924-2016 OI Paulson, Olaf/0000-0001-7712-8596 NR 28 TC 32 Z9 32 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0302-9743 BN 3-540-63046-5 J9 LECT NOTES COMPUT SC PY 1997 VL 1230 BP 259 EP 270 PG 12 WC Computer Science, Theory & Methods; Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Engineering; Radiology, Nuclear Medicine & Medical Imaging GA BK96M UT WOS:000073946600020 ER PT J AU Tziortziotis, DV Bouros, AC Ziogas, VS Young, RH AF Tziortziotis, DV Bouros, AC Ziogas, VS Young, RH TI Clear cell hyperplasia of the fallopian tube epithelium associated with ectopic pregnancy: Report of a case SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY LA English DT Article DE fallopian tube; clear cell hyperplasia; ectopic pregnancy ID LIGHT AB A case of clear cell hyperplasia of the fallopian tube epithelium associated with ectopic pregnancy is described. The lesion was encountered in a 31-year-old woman who presented with abdominal pain and had a positive pregnancy test. Ultrasound examination disclosed an enlarged right fallopian tube. The patient underwent laparotomy, at which time the right fallopian tube was excised. On gross examination, a firm 1.2 x 1 x 1-cm nodule almost obliterating the lumen of the tube and an abundant blood clot were present. On histologic examination, chorionic villi were found in the blood clot. The nodule was composed of epithelial cells that formed solid and glandular structures. The cells had clear cytoplasm and nuclei without atypia. The differential diagnosis included clear cell adenocarcinoma, but clear cell hyperplasia associated with pregnancy was diagnosed because of the absence of cytologic atypia and mitotic figures. The patient has had an uneventful postoperative follow-up period of 1 year. C1 LITO HOSP,DEPT PATHOL,ATHENS,GREECE. LITO HOSP,DEPT OBSTET & GYNECOL,ATHENS,GREECE. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,JAMES HOMER WRIGHT PATHOL LABS,BOSTON,MA. NR 5 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0277-1691 J9 INT J GYNECOL PATHOL JI Int. J. Gynecol. Pathol. PD JAN PY 1997 VL 16 IS 1 BP 79 EP 80 DI 10.1097/00004347-199701000-00013 PG 2 WC Obstetrics & Gynecology; Pathology SC Obstetrics & Gynecology; Pathology GA VZ913 UT WOS:A1997VZ91300013 PM 8986537 ER PT J AU Leunig, M Yuan, F Gerweck, LE Jain, RK AF Leunig, M Yuan, F Gerweck, LE Jain, RK TI Effect of basic fibroblast growth factor on angiogenesis and growth of isografted bone: Quantitative in vitro in vivo analysis in mice SO INTERNATIONAL JOURNAL OF MICROCIRCULATION-CLINICAL AND EXPERIMENTAL LA English DT Article DE basic fibroblast growth factor; cartilage; bone; skin fold chamber; angiogenesis ID EXTRACELLULAR-MATRIX; TUMOR-GROWTH; BIOLOGY; CELLS; ACHONDROPLASIA; CHONDROCYTES; PERMEABILITY; MUTATIONS; CULTURES; INVIVO AB Basic fibroblast growth factor (bFGF), a constituent of bone and cartilage matrix, has been shown to be a potent mitogen for osteoblasts and chondrocytes and yet an inhibitor of chondrocyte terminal differentiation in cell culture. To characterize the effect of bFGF on bone formation, whole neonatal murine femora were cultured in the presence or absence of bFGF and a neutralizing antibody against bFGF. In vitro, femoral elongation was provided by cartilage growth only; the calcified diaphyseal zone stained by oxytetracycline did not increase. When bFGF was added to the culture medium, longitudinal growth of the proximal and distal cartilage was inhibited in a dose-dependent manner (p < 0.05), and the number of hypertrophic chondrocytes in the growth plate was reduced. This phenomenon was absent in the presence of a neutralizing antibody, which when given alone significantly promoted femoral elongation. In contrast, in vivo after transplantation into adult mice bearing dorsal skin fold chambers, femora rapidly calcified after revascularization. This observation supports the notion that bone formation largely depends on angiogenesis-mediated events. To verify this hypothesis, angiogenesis and bone formation were quantified using bFGF known to be a stimulator of angiogenesis. Calcification of grafted femora was accelerated by bFGF given intraperitoneally. The neutralizing antibody slightly suppressed angiogenesis and femoral elongation (not statistically significant), whereas intravenous injections of both substances did not reveal a significant modulatory effect. In vivo the effect of systemically administered bFGF was inhomogeneous, but there was a strong correlation between angiogenesis and endochondral calcification (p < 0.001). These results suggest that exogenous bFGF modulates bone formation in vitro by inhibition of terminal differentiation of chondrocytes in the growth plate, and angiogenesis and concomitant in vivo events are pivotal in the promotion of rapid bone formation. C1 MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,STEELE LAB,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA. RI Yuan, Fan/A-1287-2011; Leunig, Michael/E-7951-2017 OI Leunig, Michael/0000-0002-2036-5416 FU NCI NIH HHS [CA22860, R35-CA56591] NR 34 TC 8 Z9 8 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0167-6865 J9 INT J MICROCIRC JI Int. J. Microcirc.-Clin. Exp. PD JAN-FEB PY 1997 VL 17 IS 1 BP 1 EP 9 DI 10.1159/000179199 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA XA115 UT WOS:A1997XA11500001 PM 9176719 ER PT J AU Salcetti, JM Moriarty, JD Cooper, LF Smith, FW Collins, JG Socransky, SS Offenbacher, S AF Salcetti, JM Moriarty, JD Cooper, LF Smith, FW Collins, JG Socransky, SS Offenbacher, S TI The clinical, microbial, and host response characteristics of the failing implant SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS LA English DT Article DE bacterial pathogen; failing implant; growth factor; inflammatory mediator; peri-implantitis ID OSSEOINTEGRATED ORAL IMPLANTS; PARTIALLY EDENTULOUS PATIENTS; MARGINAL TISSUE-REACTIONS; PERIODONTAL-DISEASE; TITANIUM IMPLANTS; CREVICULAR FLUID; DENTAL IMPLANTS; GINGIVAL TISSUE; INTERLEUKIN-1-BETA; FIXTURES AB The goal of this study was to provide new data regarding levels of inflammatory and growth factor mediators and bacterial pathogens associated with failing implants, as compared to healthy implants. Twenty-one patients with failing implant sites (group 1) and 8 patients with only healthy implants (group 2) were included. Fifteen of the 21 failing implant patients (group 1) also presented with at least one stable nondiseased implant. Plaque samples were examined, using DNA oligonucleotide probes for 40 different microbes. Gingival crevicular fluid samples were collected for the analyses of catabolic bone resorbing agonists prostaglandin E-2 (PGE(2)), interleukin-1 beta (IL-1 beta) and IE-Ci and anabolic bone-forming growth factors transforming growth factor beta (TGF-beta) and platelet-derived growth factor (PDGF). Although positive trends were noted, there were no significant differences in any of the microbial, inflammatory, or growth factors mediators comparing failing to stable implants in group 1. This study found greater detection frequencies of P. nigrescens, P. micros, F. nucleatum ss vincentii, and F. nucleatum ss nucleatum, as well as significant elevations in GCF levels of PGE(2), IL-1 beta, and PDGF in mouths with failing implant sites as compared to mouths with healthy control implants. Risk appears to be primarily at a patient level and secondarily at a site or. implant level from a clinical, microbial (P. micros and P. nigrescens), and biochemical (PGE(2) and IL-1 beta) perspective. Furthermore, the counts of P. nigrescens and P. micros were found to correlate with concentrations of PGE(2) at a site level. C1 UNIV N CAROLINA,SCH DENT,DENT RES CTR,DEPT PERIODONT,CHAPEL HILL,NC 27599. FORSYTH DENT CTR,DEPT PERIODONTOL,BOSTON,MA 02115. FU NIDCR NIH HHS [K15-DE00325, 2P01DEO8917-0681, R01DE10519] NR 45 TC 143 Z9 148 U1 0 U2 5 PU QUINTESSENCE PUBL CO INC PI CAROL STREAM PA 551 KIMBERLY DR, CAROL STREAM, IL 60188-1881 SN 0882-2786 J9 INT J ORAL MAX IMPL JI Int. J. Oral Maxillofac. Implants PD JAN-FEB PY 1997 VL 12 IS 1 BP 32 EP 42 PG 11 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA XT372 UT WOS:A1997XT37200004 PM 9048452 ER PT J AU Hays, DM Dolgin, M Steele, LL Patenaude, AF Hewett, KD Ruymann, F Ruccione, K Sallan, S Siegel, SE AF Hays, DM Dolgin, M Steele, LL Patenaude, AF Hewett, KD Ruymann, F Ruccione, K Sallan, S Siegel, SE TI Educational achievement, employment and workplace experience of adult survivors of childhood cancer SO INTERNATIONAL JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY LA English DT Article DE educational achievement; employment; workplace experience; adult survivors of childhood cancer ID LONG-TERM SURVIVORS; ADOLESCENT CANCER; HODGKINS-DISEASE; ADJUSTMENT; CHILDREN; TUMORS; IRRADIATION; GLIOMA; LIFE AB Survivors of childhood cancer will comprise a progressively larger proportion of the adult population of all developed countries in the next decade. In this study the educational achievement, employment status and workplace experience of 969 such survivors treated in three U.S. pediatric cancer centers are examined and compared with the experience in the same areas of individual-matched control subjects. included were survivors who are now 20 or more years of age and are disease-free 2 or more years from the end of therapy. Pertinent medical and psychosocial areas were included in a 356-item instrument, administered during an hour-long telephone interview. This report concentrates on the subject's educational, occupational and workplace experience. Cancer survivors had completed fewer years of education with an ultimate lower educational achievement status, had higher rates of unemployment, had lower overall occupational status and had lower annual incomes than control subjects. Survivors of central nervous system (CNS) tumors had significantly reduced levels of both educational and employment achievement when compared with non-CNS tumor survivors. Relative to their workplace records, i.e., absenteeism disciplinary actions, requests for special provisions at work, etc., the records of survivors and control subjects were similar. Accomplishments of the adult survivors of childhood cancer remain significantly lower than those of control subjects in educational and economic areas. These differences are of much greater magnitude among the survivors of CNS tumors. C1 CHILDRENS HOSP LOS ANGELES, DEPT PEDIAT, LOS ANGELES, CA 90027 USA. UNIV SO CALIF, SCH MED, LOS ANGELES, CA USA. OHIO STATE UNIV, COLL MED, COLUMBUS, OH 43210 USA. CHILDRENS HOSP, DEPT PEDIAT, COLUMBUS, OH 43205 USA. CHILDRENS HOSP, DEPT PREVENT MED, COLUMBUS, OH 43205 USA. DANA FARBER CANC INST, DEPT PEDIAT ONCOL, BOSTON, MA 02115 USA. HARVARD UNIV, SCH MED, BOSTON, MA USA. RP Hays, DM (reprint author), CHILDRENS HOSP LOS ANGELES, DEPT SURG, 4650 SUNSET BLVD, MAILSTOP 54, LOS ANGELES, CA 90027 USA. NR 42 TC 2 Z9 2 U1 1 U2 4 PU HARWOOD ACAD PUBL GMBH, TAYLOR & FRANCIS GROUP PI PHILADELPHIA PA 325 CHESTNUT ST, 8TH FL, PHILADELPHIA, PA 19106 USA SN 1070-2903 J9 INT J PEDIAT HEM ONC JI Int. J. Pediatr. Hematol-Oncol. PY 1997 VL 4 IS 4 BP 327 EP 337 PG 11 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA YE853 UT WOS:A1997YE85300003 ER PT J AU Spillmann, M Borus, JS Davidson, KG Worthington, JJ Tedlow, JR Fava, M AF Spillmann, M Borus, JS Davidson, KG Worthington, JJ Tedlow, JR Fava, M TI Sociodemographic predictors of response to antidepressant treatment SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article; Proceedings Paper CT 149th Annual Meeting of the American-Psychiatric-Association CY MAY 04-09, 1996 CL NEW YORK, NY SP Amer Psychiat Assoc DE sociodemographic variables; depression; predictor; psychosocial functioning; SAS-SR ID MAJOR DEPRESSION; SOCIAL-ADJUSTMENT; RISK-FACTORS; COMMUNITY; PREVALENCE; SAMPLE AB Objective: Our goal was to assess whether sociodemographic variables such as gender, marital status, level of education, and employment status are related to the changes in social functioning that have been reported after drug treatment in outpatients with major depressive disorder. Method: Eligible subjects were 166 depressed outpatients participating in a study involving open treatment with fluoxetine 20 mg/day for eight weeks. Diagnosis of major depressive disorder was made with the use of the Structured Clinical Interview for DSM-III-R-Patient Edition (SCID-P), and patients were required to have a seventeen-item Hamilton Rating Scale for Depression (HAM-D-17) score greater than or equal to 16 at study entry. All subjects were administered the HAM-D-17 and the Social Adjustment Scale-Self-Report (SAS-SR) before and after treatment with fluoxetine. Results: We found that SAS-SR scores decreased significantly following treatment with fluoxetine from a mean score at baseline of 2.6 +/- 0.7 to a mean score at endpoint of 2.3 +/- 0.6. After adjusting for the degree of change in HAM-D-17 scores, we found a significant relationship between degree of change in SAS-SR and level of education. No statistically significant relationships were observed between SAS-SR change and age, gender, marital status, and employment status. Conclusion: The degree of improvement in psychosocial functioning observed in depressed outpatients following antidepressant treatment appears to be related to the level of education at study entry, but not to other sociodemographic variables. Further studies need to investigate the nature of this relationship. RP Spillmann, M (reprint author), MASSACHUSETTS GEN HOSP,DEPRESS CLIN & RES PROGRAM,CLIN PSYCHOPHARMACOL UNIT,WAC 812,BOSTON,MA 02114, USA. FU NIMH NIH HHS [R01 MH 48483-01] NR 13 TC 22 Z9 23 U1 0 U2 2 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, AMITYVILLE, NY 11701 SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 1997 VL 27 IS 2 BP 129 EP 136 PG 8 WC Psychiatry SC Psychiatry GA XX220 UT WOS:A1997XX22000004 PM 9565719 ER PT J AU Spiro, IJ Suit, HD AF Spiro, IJ Suit, HD TI Role of radiation therapy in management of patients with sarcoma of soft tissue SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,CTR CANC,DEPT RADIAT ONCOL,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 113 EP 113 DI 10.1016/S0360-3016(97)80493-2 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000019 ER PT J AU Shipley, WU Zietman, AL AF Shipley, WU Zietman, AL TI Bladder cancer: The combination of chemotherapy and irradiation in the treatment of patients with muscle-invading tumors SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,GENITOURINARY ONCOL UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 118 EP 118 DI 10.1016/S0360-3016(97)80506-8 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000032 ER PT J AU Gunderson, LL Willett, CG Harrison, LB AF Gunderson, LL Willett, CG Harrison, LB TI Intraoperative radiotherapy - Current status SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 MAYO CLIN,ROCHESTER,MN. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 121 EP 121 DI 10.1016/S0360-3016(97)80514-7 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000039 ER PT J AU Chabner, E Nixon, AJ Garber, J Gelman, R Bornstein, B Connolly, J Hetelekidis, S Recht, A Schnitt, S Silver, B Harris, JR AF Chabner, E Nixon, AJ Garber, J Gelman, R Bornstein, B Connolly, J Hetelekidis, S Recht, A Schnitt, S Silver, B Harris, JR TI Family history suggestive of an inherited susceptibility to breast cancer and treatment outcome in young women after breast-conserving therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA. HARVARD UNIV,SCH MED,BETH ISRAEL DEACONESS MED CTR,BOSTON,MA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 137 EP 137 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000087 ER PT J AU Fitzek, M Thornton, A Rabenow, J Lev, M Pardo, F Bussiere, M Braun, I Finklestein, D Hochberg, F Cosgrove, GR Okunieff, P Munzenrider, J Liebsch, N Harsh, G AF Fitzek, M Thornton, A Rabenow, J Lev, M Pardo, F Bussiere, M Braun, I Finklestein, D Hochberg, F Cosgrove, GR Okunieff, P Munzenrider, J Liebsch, N Harsh, G TI Results of 90 Gy proton/photon radiation therapy for glioblastoma multiforme SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA. HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT NEUROSURG,BOSTON,MA. HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT DIAGNOST RADIOL,BOSTON,MA. HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT BIOSTAT,BOSTON,MA. HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA. NATL CANC INST,RADIAT ONCOL BRANCH,BETHESDA,MD. NR 0 TC 1 Z9 1 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 139 EP 139 DI 10.1016/S0360-3016(97)80566-4 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000092 ER PT J AU Niemierko, A Terahara, A Goitein, M AF Niemierko, A Terahara, A Goitein, M TI Skull base chordomas: Analysis of dose-response characteristics SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 141 EP 141 DI 10.1016/S0360-3016(97)80570-6 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000095 ER PT J AU Stevenson, MA Yao, J AF Stevenson, MA Yao, J TI Stimulation of P38 (HOG1) kinase pathway by ionizing radiation results in downstream modulation of ATF/CREB transcription factor activity in NIH-3T3 cells SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 146 EP 146 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000106 ER PT J AU Shipley, WU Winter, KA Lee, R Kaufman, DS Heney, NM Tester, WJ Venner, PM Perez, CA Murray, KA Doggett, RLS AF Shipley, WU Winter, KA Lee, R Kaufman, DS Heney, NM Tester, WJ Venner, PM Perez, CA Murray, KA Doggett, RLS TI Initial results of RTOG 89-03: A Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy. SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. RTOG HEADQUARTERS,PHILADELPHIA,PA. WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC. ALBERT EINSTEIN CANC CTR,PHILADELPHIA,PA. UNIV ALBERTA,EDMONTON,AB,CANADA. WASHINGTON UNIV,SCH MED,ST LOUIS,MO. MED COLL WISCONSIN,MILWAUKEE,WI 53226. RADIAT ONCOL CTR,SACRAMENTO,CA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 155 EP 155 DI 10.1016/S0360-3016(97)80599-8 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000123 ER PT J AU Zietman, AL Kaufman, DS Shipley, WU Park, JJ Althausen, AF Gomery, P Young, HH McGovern, FV Heney, NM AF Zietman, AL Kaufman, DS Shipley, WU Park, JJ Althausen, AF Gomery, P Young, HH McGovern, FV Heney, NM TI A phase I/II trial of transurethral surgery plus cisplatin and radiation therapy followed by either selective bladder preservation or radical cystectomy for patients with muscle-invading bladder cancer but without hydronephrosis. SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT MED ONCOL,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT UROL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 1 Z9 1 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 155 EP 155 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000124 ER PT J AU Douglas, RM Mankin, HJ Jennings, LC Gebhardt, MC Harmon, D Ancukiewicz, M Suit, HD Spiro, IJ AF Douglas, RM Mankin, HJ Jennings, LC Gebhardt, MC Harmon, D Ancukiewicz, M Suit, HD Spiro, IJ TI Management strategies of sarcomas of the ankle and foot SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT ORTHOPED ONCOL,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT MED ONCOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 157 EP 157 DI 10.1016/S0360-3016(97)80602-5 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000128 ER PT J AU Powell, SN DeFrank, J Wu, B Wunsch, H Tang, W AF Powell, SN DeFrank, J Wu, B Wunsch, H Tang, W TI A role for p53-p21 (WAF1/CIP1) in the G2/M transition following exposure to ionizing radiation. SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 161 EP 161 DI 10.1016/S0360-3016(97)80610-4 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000135 ER PT J AU Chakravarti, A Willett, CG Shellito, P Kaufman, D Daley, WJ AF Chakravarti, A Willett, CG Shellito, P Kaufman, D Daley, WJ TI Adjuvant irradiation improves the outcome of patients with rectal cancer following local excision SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 167 EP 167 DI 10.1016/S0360-3016(97)80622-0 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000148 ER PT J AU Chmura, SJ Mauceri, H Quintans, J Kufe, DW Weichselbaum, RR AF Chmura, SJ Mauceri, H Quintans, J Kufe, DW Weichselbaum, RR TI Decreasing the apoptotic threshold with chelerythrine chloride enhances radiation cures in vivo SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 UNIV CHICAGO HOSP,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,PHARMACOL LAB,BOSTON,MA 02115. NR 0 TC 1 Z9 1 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 179 EP 179 DI 10.1016/S0360-3016(97)80647-5 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000170 ER PT J AU Hadenbergh, PH Hahnfeldt, P Hlatky, L Takemoto, C Shimamura, A McGill, G Fung, CY Bodis, S Fisher, DE AF Hadenbergh, PH Hahnfeldt, P Hlatky, L Takemoto, C Shimamura, A McGill, G Fung, CY Bodis, S Fisher, DE TI Distinct mathematical behavior of apoptotic vs. non-apoptotic tumor cell death SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 DANA FARBER CANC INST,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115. DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115. CHILDRENS HOSP,BOSTON,MA 02115. HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,CAMBRIDGE,MA 02138. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 180 EP 180 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000172 ER PT J AU Su, CK Wang, CC Park, J AF Su, CK Wang, CC Park, J TI The role of neck surgery in conjunction with radiation therapy in regional control of clinically node positive cancer of the oropharynx SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 190 EP 190 DI 10.1016/S0360-3016(97)80669-4 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000192 ER PT J AU Kumar, P Herndon, J Elias, AD Sugarbaker, DJ Green, MR AF Kumar, P Herndon, J Elias, AD Sugarbaker, DJ Green, MR TI Comparison of pre-operative thoracic radiation therapy (TRT) to pre-operative chemotherapy (CT) in surgically staged IIIA(N-2) non-small cell lung cancer (NSCLC): Initial results of cancer and leukemia group B (CALGB) phase III protocol 9134 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 VET ADM MED CTR,MEMPHIS,TN 38104. UNIV TENNESSEE,MEMPHIS,TN. DUKE UNIV,DURHAM,NC 27706. DANA FARBER CANC INST,BOSTON,MA. MED UNIV S CAROLINA,CHARLESTON,SC 29425. BRIGHAM & WOMENS HOSP,HARVARD MED SCH,BOSTON,MA 02115. NR 0 TC 4 Z9 4 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 195 EP 195 DI 10.1016/S0360-3016(97)80678-5 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000203 ER PT J AU Mitsumori, M Shrieve, DC Alexander, E Kaiser, UB Richardson, GE Black, PM Loeffler, JS AF Mitsumori, M Shrieve, DC Alexander, E Kaiser, UB Richardson, GE Black, PM Loeffler, JS TI Initial clinical results of LINAC stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) for pituitary adenomas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 BRIGHAM & WOMENS HOSP,BRAIN TUMOR CTR,BOSTON,MA 02115. CHILDRENS HOSP,BOSTON,MA 02115. DANA FARBER CANC INST,BOSTON,MA 02115. JOINT CTR RADIAT THERAPY,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT RADIAT ONCOL,BOSTON,MA. HARVARD UNIV,SCH MED,DEPT NEUROSURG,BOSTON,MA. HARVARD UNIV,SCH MED,DEPT ENDOCRINOL,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 201 EP 201 DI 10.1016/S0360-3016(97)80691-8 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000214 ER PT J AU Noah, C Thomas, L Douglas, M John, W Cameron, W Robert, C Michael, G Hermes, G AF Noah, C Thomas, L Douglas, M John, W Cameron, W Robert, C Michael, G Hermes, G TI Phase I/II study of preoperative chemo-radiotherapy (CT-RT) using twice daily radiation as concomitant boost during two cycles of Taxol (T), cisplatin (C), 5-Fu (F) in esophageal cancer: Normal tissue tolerance and early results SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT RADIAT ONCOL,BOSTON,MA. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,BOSTON,MA. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT SURG,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 203 EP 203 DI 10.1016/S0360-3016(97)80695-5 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000219 ER PT J AU Taghian, A Huang, P Griffon, G Hartford, A Allam, A DaCosta, A Kozin, S Suit, HD AF Taghian, A Huang, P Griffon, G Hartford, A Allam, A DaCosta, A Kozin, S Suit, HD TI Radiobiological hypoxic fraction does not correlate with pO2 measurements in eight human tumor xenografts into nude mice SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,EL STEELE LAB RADIOBIOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 210 EP 210 DI 10.1016/S0360-3016(97)80709-2 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000233 ER PT J AU Doppke, KP Wang, CC AF Doppke, KP Wang, CC TI The variation in dose at the interface due to the location of a small air cavity for low and medium energy X-rays SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CTR CANC,DEPT RADIAT ONCOL,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 213 EP 213 DI 10.1016/S0360-3016(97)80714-6 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000238 ER PT J AU Morris, AD Zietman, AL Althausen, AF Heney, NM Kaufman, DS Shipley, WU AF Morris, AD Zietman, AL Althausen, AF Heney, NM Kaufman, DS Shipley, WU TI The value of external beam radiation in pathologic node positive prostate cancer: A multivariate analysis SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT RADIAT ONCOL,BOSTON,MA. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT UROL,BOSTON,MA. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED ONCOL,BOSTON,MA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 217 EP 217 DI 10.1016/S0360-3016(97)80722-5 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000247 ER PT J AU Mahajan, A Thornton, A Cascio, E Koehler, A Harsh, G Chapman, P Munzenrider, J AF Mahajan, A Thornton, A Cascio, E Koehler, A Harsh, G Chapman, P Munzenrider, J TI Long-term results of proton radiosurgery and fractionated proton irradiation for vestibular schwannomas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT NEUROSURG,BOSTON,MA 02114. HARVARD UNIV,CYCLOTRON LAB,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 224 EP 224 DI 10.1016/S0360-3016(97)80736-5 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000261 ER PT J AU Spear, MA Sakamoto, KM Herrlinger, U Pechan, P Breakefield, XO AF Spear, MA Sakamoto, KM Herrlinger, U Pechan, P Breakefield, XO TI Function of the EGR-1/T1S8 radiation inducible promoter in a minimal HSV-1 amplicon system SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT NEUROGENET,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02114. UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,DEPT HEMATOL ONCOL,LOS ANGELES,CA 90054. NR 0 TC 1 Z9 1 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 250 EP 250 DI 10.1016/S0360-3016(97)80789-4 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000313 ER PT J AU Kim, J Munzenrider, J Maas, A Finkelstein, D Liebsch, N Hug, E Suit, H Smith, A Goitein, M AF Kim, J Munzenrider, J Maas, A Finkelstein, D Liebsch, N Hug, E Suit, H Smith, A Goitein, M TI Optic neuropathy following combined and photon radiotherapy for base of skull tumors SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DEPT RADIAT ONCOL & BIOPHYS,BOSTON,MA. HARVARD UNIV,SCH MED,DEPT BIOSTAT,BOSTON,MA. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 10 Z9 10 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 272 EP 272 DI 10.1016/S0360-3016(97)80832-2 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000357 ER PT J AU Liu, MCC Munzenrider, JE Finkelstein, D Leibsch, N Adams, J Hug, EB AF Liu, MCC Munzenrider, JE Finkelstein, D Leibsch, N Adams, J Hug, EB TI Radiation tolerance of the cervical spinal cord: Incidence and dose-volume relationship of symptomatic and asymptomatic late effects following high dose irradiation of paraspinal tumors SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA. LOMA LINDA UNIV,MED CTR,DEPT RADIAT MED,LOMA LINDA,CA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 273 EP 273 DI 10.1016/S0360-3016(97)80835-8 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000359 ER PT J AU Morris, MM Willett, CG AF Morris, MM Willett, CG TI Late renal function after upper abdominal irradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 284 EP 284 DI 10.1016/S0360-3016(97)80854-1 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000379 ER PT J AU Chan, WFA Wang, CC Park, J AF Chan, WFA Wang, CC Park, J TI Treatment outcome of cervical metastases with definitive radiotherapy in supraglottic carcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 305 EP 305 DI 10.1016/S0360-3016(97)80896-6 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000421 ER PT J AU Reinacher, PC Morris, MM Choi, NC AF Reinacher, PC Morris, MM Choi, NC TI Anaplastic thyroid carcinoma: Outcome and prognostic factors SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 UNIV HEIDELBERG,D-6900 HEIDELBERG,GERMANY. HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 309 EP 309 DI 10.1016/S0360-3016(97)80905-4 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000429 ER PT J AU Proulx, GM Park, J Wang, CC AF Proulx, GM Park, J Wang, CC TI Treatment of non-Hodgkin's lymphoma of the nasal cavity and paranasal sinuses with radiation alone or in combination with chemotherapy or surgery. SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 324 EP 324 DI 10.1016/S0360-3016(97)80934-0 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000459 ER PT J AU Dutton, SC Pomeroy, SL Billett, AL Barnes, P Kuhlman, C Riese, NE Goumnerova, L Scott, RM Coleman, CN Tarbell, NJ AF Dutton, SC Pomeroy, SL Billett, AL Barnes, P Kuhlman, C Riese, NE Goumnerova, L Scott, RM Coleman, CN Tarbell, NJ TI A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brain stem glioma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,CHILDRENS HOSP,JOINT CTR RADIAT THERAPY,BOSTON,MA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 1997 VL 39 IS 2 SU S BP 333 EP 333 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA XW280 UT WOS:A1997XW28000477 ER PT S AU Willett, CG Nakfoor, BK Daley, W Shellito, PC AF Willett, CG Nakfoor, BK Daley, W Shellito, PC BE Vaeth, JM TI Pathological downstaging does not guide the need for IORT in primary locally advanced rectal cancer SO INTRAOPERATIVE RADIATION THERAPY IN THE TREATMENT OF CANCER SE Frontiers of Radiation Therapy and Oncology LA English DT Article; Proceedings Paper CT 6th International IORT Symposium / 31st San Francisco Cancer Symposium CY SEP 22-25, 1996 CL SAN FRANCISCO, CA C1 MASSACHUSETTS GEN HOSP, DEPT GEN SURG, BOSTON, MA 02114 USA. RP Willett, CG (reprint author), MASSACHUSETTS GEN HOSP, DEPT RADIAT ONCOL, 100 BLOSSOM ST, BOSTON, MA 02114 USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0071-9676 BN 3-8055-6456-2 J9 FRONT RADIAT THER ON JI Front.Radiat.Ther.Oncol. PY 1997 VL 31 BP 245 EP 246 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BJ32X UT WOS:A1997BJ32X00056 PM 9263832 ER PT J AU Kakeji, Y Teicher, BA AF Kakeji, Y Teicher, BA TI Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents SO INVESTIGATIONAL NEW DRUGS LA English DT Article DE TNP-470; minocycline; suramin; genistein; antiangiogenic agents; combination anticancer therapies ID FIBROBLAST GROWTH-FACTOR; INVASIVE BREAST-CARCINOMA; ENDOTHELIAL-CELL GROWTH; LEWIS-LUNG-CARCINOMA; TUMOR-GROWTH; CANCER THERAPIES; TNP-470 AGM-1470; TOPOISOMERASE-II; IN-VITRO; INVITRO DIFFERENTIATION AB TNP-740, minocycline, suramin and genistein have demonstrated antiangiogenic activity in various experimental systems. The effect of these agents alone and in two agent combinations on the number of intratumoral vessels and response to cytotoxic anticancer therapies was assessed in animals bearing the Lewis lung carcinoma. Treatment with each of the antiangiogenic agents alone and in two agent combinations decreased the number of intratumoral vessels visualized by CD31 or Factor VIII staining to 30% to 50% of the number in the untreated control tumors. In general, the antiangiogenic agents are more effective adjuvants to cytotoxic therapies when used as two agent combinations than as single agents. The most effective antiangiogenic combinations were: TNP-470/minocycline > TNP-470/genistein > TNP-470/suramin. The increases in the response of the primary tumor to cyclophosphamide, adriamycin, CDDP, BCNU, x-rays or 5-fluorouracil and the lung metastases occur to about the same level with the addition of antiangiogenic agents to the therapies. With the treatment combination TNP-470/minocycline/cyclophosphamide 40% of the animals were cured. The results of these studies indicate that antiangiogenic agents can be very useful additions to treatment regimens for solid tumors. C1 DANA FARBER CANC INST, BOSTON, MA 02115 USA. NR 58 TC 103 Z9 103 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0167-6997 J9 INVEST NEW DRUG JI Invest. New Drugs PY 1997 VL 15 IS 1 BP 39 EP 48 DI 10.1023/A:1005718628223 PG 10 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA XD971 UT WOS:A1997XD97100005 PM 9195288 ER PT J AU Leaf, AN Neuberg, D Schwartz, EL Wadler, S Ritch, PS Dutcher, JP Adams, GL AF Leaf, AN Neuberg, D Schwartz, EL Wadler, S Ritch, PS Dutcher, JP Adams, GL TI An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390) SO INVESTIGATIONAL NEW DRUGS LA English DT Article DE head and neck neoplasms; amonafide ID SOUTHWEST-ONCOLOGY-GROUP; ACETYLATOR PHENOTYPE; CAFFEINE METABOLITES; NSC-308847; CANCER; TRIAL; PHARMACOKINETICS; NAFIDIMIDE; LEUKEMIA AB The purpose of this study was to determine the efficacy and toxicity of amonafide in unresectable or recurrent head and neck cancer and to determine if the degree of toxicity with amonafide correlated with the acetylator phenotype of the patient. Thirty patients were registered on the study and received amonafide, 300 mg/m(2), over two hours each day for five consecutive days every 21 days. There was one partial response (3%) which lasted four months. The dose-limiting toxicity was myelosuppression. Acetylator phenotype was determined prior to treatment using HPLC to quantitate caffeine metabolites in urine samples after administration of caffeine. This pharmacokinetic evaluation was performed in 21 patients and revealed that (17/21) 81% of the patients were slow acetylators and 19% of the patients were rapid acetylators. No association was found between acetylator phenotype and toxicity in our patient population. Based on this study, it appears that amonafide given at 300 mg/m(2) for 5 consecutive days every 21 days is not active in squamous cell carcinoma of the head and neck, and that acetylator status does not correlate with toxicity. C1 ALBERT EINSTEIN COLL MED,BRONX,NY 10467. DANA FARBER CANC INST,BOSTON,MA 02115. MONTEFIORE MED CTR,BRONX,NY 10467. MED COLL WISCONSIN,MILWAUKEE,WI 53226. UNIV MINNESOTA,MINNEAPOLIS,MN. FU NCI NIH HHS [CA14958, CA21076, CA23318] NR 19 TC 7 Z9 8 U1 0 U2 0 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0167-6997 J9 INVEST NEW DRUG JI Invest. New Drugs PY 1997 VL 15 IS 2 BP 165 EP 172 DI 10.1023/A:1005823703909 PG 8 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA XH808 UT WOS:A1997XH80800011 PM 9220297 ER PT J AU Schiller, JH Neuberg, D Burns, D Ritch, P Larson, M Levitt, M Dutcher, J AF Schiller, JH Neuberg, D Burns, D Ritch, P Larson, M Levitt, M Dutcher, J TI An Eastern Cooperative Oncology Group phase I trial of all-trans-retinoic acid and interferon-alpha: E2Y92 SO INVESTIGATIONAL NEW DRUGS LA English DT Article DE interferon-alpha; trans-retinoic acid; Phase I trial ID CANCER CELL-LINES; ACUTE PROMYELOCYTIC LEUKEMIA; MOUSE EPIDERMAL-CELLS; VITAMIN-A; 13-CIS-RETINOIC ACID; LUNG-CANCER; TERMINAL DIFFERENTIATION; ENVELOPE COMPETENCE; TRACHEAL EPITHELIUM; HUMAN KERATINOCYTES AB The Eastern Cooperative Oncology Group conducted a Phase I trial to determine the maximally tolerated doses of combination therapy with alpha interferon (IFN-alpha) and all-trans-retinoic acid (tRA). Fifty patients with incurable malignancies received IFN-alpha administered subcutaneously three times weekly, and tRA administered by mouth at bedtime. Doses were escalated between patient groups, starting at tRA dose level of 45 mg/m(2) and 3 million units of IFN-alpha. Major, dose-limiting toxicities were attributable to either the tRA (rash, chelitis) or IFN (constitutional symptoms), and were observed only at tRA dose levels of 224 mg/m(2) and 291 mg/m(2), or 6 million units of IFN-alpha. The maximally tolerated dose level of 172.5 mg/m(2) of tRA and 3 million units of IFN alpha was well-tolerated, with no grade 3 or 4 toxicities attributable to therapy. One patient at the third dose level (75 mg/m(2) of tRA and 3 million units of IFN-alpha) developed acute hepatic and renal failure and a metabolic encephalopathy of unclear etiology. We conclude that tRA and IFN-alpha may be safely administered together at the maximally tolerated dose of tRA as a single agent without unexpected side effects. The recommended doses of IFN-alpha and tRA for Phase II trials are 3 million units of IFN-alpha and 172.5 mg/m(2) of tRA. C1 Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA. Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Allegheny Singer Res Inst, Pittsburgh, PA 15212 USA. Albert Einstein Coll Med, Bronx, NY 10467 USA. RP Schiller, JH (reprint author), K4636 Clin Sci Ctr, Dept Med, Med Oncol Sect, 600 Highland Ave, Madison, WI 53792 USA. FU NCI NIH HHS [CA18653, CA23318, CA21076] NR 58 TC 2 Z9 2 U1 0 U2 1 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0167-6997 J9 INVEST NEW DRUG JI Invest. New Drugs PY 1997 VL 15 IS 4 BP 319 EP 324 DI 10.1023/A:1005985418441 PG 6 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA ZC471 UT WOS:000072582600006 PM 9547674 ER PT J AU Buchner, DM AF Buchner, DM TI Physical activity and quality of life in older adults SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 VET AFFAIRS PUGET SOUND HLTH CARE SYST,NW CTR OUTCOMES RES OLDER ADULTS,SEATTLE,WA. RP Buchner, DM (reprint author), UNIV WASHINGTON,DEPT HLTH SERV,POB 357660,SC-37,SEATTLE,WA 98195, USA. NR 7 TC 28 Z9 30 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 1 PY 1997 VL 277 IS 1 BP 64 EP 66 DI 10.1001/jama.277.1.64 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA VZ767 UT WOS:A1997VZ76700032 PM 8980213 ER PT J AU Suzuki, R Karageuzian, LN Crean, EV Anderson, PJ AF Suzuki, R Karageuzian, LN Crean, EV Anderson, PJ TI Effects of adrenergic agents and phosphodiesterase inhibitors on outflow facility and cell shape of bovine trabecular meshwork SO JAPANESE JOURNAL OF OPHTHALMOLOGY LA English DT Article DE adrenergic agents; cGMP; cyclic AMP; cytoskeleton; epinephrine; glaucoma; outflow facility; phosphodiesterase inhibitors; sulfhydryl agent; trabecular meshwork ID INTRAOCULAR-PRESSURE; ETHACRYNIC-ACID; ENUCLEATED EYES; AQUEOUS-HUMOR; GLYCOSAMINOGLYCANS; DYNAMICS; MONKEYS; CULTURE AB Changes in the outflow facility of perfused calf eyes and in the shape of cells in cultured trabecular meshwork (TM) have been studied, following exposure to adrenergic agents and phosphodiesterase inhibitors (PDE). Dobutamine caused confluent TM cells to change their usual polygonal shape to a characteristic stellate shape. Salbutamol had no effect, but PDE: inhibitors, isobutylmethylxanthine (IBMX), theophylline, and caffeine were very effective in producing this shape change. Epinephrine, isoproterenol, dobutamine, and salbutamol did not increase the outflow facility, either at 22 degrees C or 36 degrees C, while theophylline, caffeine, and IBMX did increase it in a dose-dependent manner. On the other hand, the high concentrations of beta-adrenergic agents required to produce even a small change in outflow facility and cell shape argue against the involvement of adrenergic-receptor mediation and may suggest another mechanism; on the other, the enhancement of epinephrine effects by PDE inhibitors and the similar effect produced by cyclic adenosine 3',5'-cyclic phosphate (cAMP) and purines suggest that changes in the cell shape are produced by beta-receptor activation. The beta-adrenergic agents were not effective in changing outflow facility, but the PDE inhibitors were remarkably effective both in changing the shape and in increasing facility. (C) 1997 Japanese Ophthalmological Society. C1 MASSACHUSETTS EYE & EAR INFIRM,HOWE LAB OPHTHALMOL,BOSTON,MA 02114. RP Suzuki, R (reprint author), YAMAGUCHI UNIV,SCH MED,DEPT OPHTHALMOL,UBE,YAMAGUCHI 755,JAPAN. FU PHS HHS [R01-3921] NR 30 TC 3 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0021-5155 J9 JPN J OPHTHALMOL JI Jpn. J. Ophthalmol. PD JAN-FEB PY 1997 VL 41 IS 1 BP 31 EP 37 DI 10.1016/S0021-5155(96)00002-0 PG 7 WC Ophthalmology SC Ophthalmology GA WT372 UT WOS:A1997WT37200007 PM 9147186 ER PT J AU Sorensen, AG Tievsky, AL Ostergaard, L Weisskoff, RM Rosen, BR AF Sorensen, AG Tievsky, AL Ostergaard, L Weisskoff, RM Rosen, BR TI Contrast agents in functional MR imaging SO JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Review DE perfusion; functional MR imaging (MRI); cerebral blood volume; paramagnetic contrast agents ID BRAIN; GLIOMAS AB Contrast agents have greatly expanded the role of MR imaging (MRI) to allow assessment of physiologic, or ''functional,'' parameters, Although activation mapping generally does not require contrast agents, other forms of functional MRI, including mapping of cerebral hemodynamics (eg, perfusion imaging), are best done with the use of contrast agents, Serial echo planar images are obtained after bolus injection of lanthanide chelates. Application of susceptibility contrast physics and standard tracer kinetic principles permits generation of relative cerebral blood volume maps, Deconvolution of cerebral blood flow and mean transit time parameters is also possible within technical limitations, By using diffusion and perfusion pulse sequences, an imaging correlate to the ischemic penumbra can be identified. Functional MRI perfusion imaging of intraaxial tumors is analogous to positron emission tomography for delineation of metabolic activity, yet may be even more sensitive to neo-vascularity and possesses improved image quality, Clinical applications include biopsy site selection and postirradiation follow-up, Further improvements in data analysis and map generation techniques may improve diagnostic accuracy and utility. RP Sorensen, AG (reprint author), MASSACHUSETTS GEN HOSP,NUCL MAGNET RESONANCE CTR,DEPT RADIOL,CHARLESTOWN,MA 02129, USA. RI Ostergaard, Leif/A-9281-2008 OI Ostergaard, Leif/0000-0003-2930-6997 NR 25 TC 72 Z9 77 U1 0 U2 4 PU SOC MAGNETIC RESONANCE IMAGING PI EASTON PA 1991 NORTHAMPTON ST, EASTON, PA 18042-3189 SN 1053-1807 J9 JMRI-J MAGN RESON IM JI JMRI-J. Magn. Reson. Imaging PD JAN-FEB PY 1997 VL 7 IS 1 BP 47 EP 55 DI 10.1002/jmri.1880070108 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA WG331 UT WOS:A1997WG33100007 PM 9039593 ER PT J AU Schima, W Petersein, J Hahn, PF Harisinghani, M Halpern, E Saini, S AF Schima, W Petersein, J Hahn, PF Harisinghani, M Halpern, E Saini, S TI Contrast-enhanced MR imaging of the liver: Comparison between Gd-BOPTA and Mangafodipir SO JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE contrast media, effects; liver, MR; contrast enhancement; gadolinium; manganese ID FOCAL HEPATIC-LESIONS; SUPERPARAMAGNETIC IRON-OXIDE; MN-DPDP; GADOBENATE DIMEGLUMINE; SAFETY; IMAGES; NOISE; AGENT; DTPA AB The purpose of the study was to evaluate the MR contrast agents gadolinium benzyloxypropionictetro-acetate (Gd-BOPTA) and Mangafodipir for liver enhancement and the lesion-liver contrast on T1W spin-echo (SE) and gradient-recalled-echo (GRE) images, Fifty-one patients (three groups of 17 patients each) with known or suspected liver lesions were evaluated with T1W SE (300/12) and GRE (77-80/2.3-2.5/80 degrees) images before and after intravenous (IV) Gd-BOPTA (0.1 or 0.05 mmol/kg) or Mangafodipir (5 mu mol/kg) in phase II to III clinical trials. Quantitative analysis by calculating liver signal-to-noise ratio (SNR), lesion-liver contrast-to-noise ratio (CNR), and spleen-liver CNR was performed, Liver SNR and spleen-liver CNR were always significantly increased postcontrast. SNR was highest after application of 0.1 mmol/kg Gd-BOPTA (51.3 +/- 3.6, P < .05). CNR was highest after Mangafodipir (-22.6 +/- 2.7), but this was not significantly different from others (P = .07). Overall, GRE images were superior to SE images for SNR and CNR, Mangafodipir and Gd-BOPTA (0.1 mmol/kg) provide equal liver enhancement and lesion conspicuity postcontrast. By all criteria, contrast-enhanced T1-weighted GRE were comparable to SE images. C1 MASSACHUSETTS GEN HOSP,DEPT RADIOL,BOSTON,MA 02114. NR 21 TC 21 Z9 22 U1 0 U2 0 PU SOC MAGNETIC RESONANCE IMAGING PI EASTON PA 1991 NORTHAMPTON ST, EASTON, PA 18042-3189 SN 1053-1807 J9 JMRI-J MAGN RESON IM JI JMRI-J. Magn. Reson. Imaging PD JAN-FEB PY 1997 VL 7 IS 1 BP 130 EP 135 DI 10.1002/jmri.1880070118 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA WG331 UT WOS:A1997WG33100017 PM 9039603 ER PT J AU Harisinghani, MG Saini, S Slater, GJ Schnall, MD Rifkin, MD AF Harisinghani, MG Saini, S Slater, GJ Schnall, MD Rifkin, MD TI MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (Combidex): Preliminary observations SO JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE MRI; contrast; USPIO; lymph node ID HODGKIN DISEASE; CONTRAST AGENT; LYMPHOGRAPHY; METASTASIS; HEAD; NECK AB The potential of ultrasmall superparamagnetic iron oxide (Combidex)-enhanced MRI of pelvic lymph nodes in patients with primary pelvic carcinoma is evaluated, Fifteen histologically classified lymph nodes in six patients with known primary pelvic cancer (four prostate; one rectum; one uterus) were evaluated with T2-weighted fast spin-echo (FSE) and T2*-weighted gradient-echo (GRE) MRI at 1.5T 12 to 48 hours after intravenous administration of Combidex at a dose of 1.7 mg Fe/kg. Quantitative image evaluation was performed by comparing signal intensity of individual nodes on pre- and postcontrast images. All patients proceeded to pelvic lymph-node biopsy or surgical dissection, where six were found to be benign and nine were malignant. Of the 15 lymph nodes, four nodes showed a decrease in signal intensity, Of these, three, in which signal loss was homogenous were benign, and one, in which the signal-intensity decrease was heterogeneous, was malignant (micrometastases). No signal change was noted in 11 of 15 lymph nodes of which three were benign (inflammatory) and eight were malignant. Combidex is a promising MR contrast agent for evaluating pelvic lymph nodes. Our preliminary observations suggest that the agent is most useful for classifying normal lymph nodes. C1 MASSACHUSETTS GEN HOSP,DEPT RADIOL,BOSTON,MA 02114. RI Schnall, Mitchell/D-1149-2009 NR 19 TC 63 Z9 66 U1 1 U2 2 PU SOC MAGNETIC RESONANCE IMAGING PI EASTON PA 1991 NORTHAMPTON ST, EASTON, PA 18042-3189 SN 1053-1807 J9 JMRI-J MAGN RESON IM JI JMRI-J. Magn. Reson. Imaging PD JAN-FEB PY 1997 VL 7 IS 1 BP 161 EP 163 DI 10.1002/jmri.1880070124 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA WG331 UT WOS:A1997WG33100023 PM 9039609 ER PT J AU Weissleder, R Cheng, HC Bogdanova, A Bogdanov, A AF Weissleder, R Cheng, HC Bogdanova, A Bogdanov, A TI Magnetically labeled cells can be detected by MR imaging SO JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE MR imaging; cell labeling; cancer ID IRON-OXIDE PARTICLES; PERITONEAL-MACROPHAGES; T-CELLS; PHAGOCYTOSIS; PINOCYTOSIS; AGENT; MION AB To determine the feasibility of MR imaging of magnetically labeled cells, different cell lines were labeled with monocrystalline iron oxide (MION) particles. Phantoms containing MION labeled cells were then assembled and imaged by MR at 1.5 T using T1-weighted and T2-weighted pulse sequences. MION uptake ranged from 8.5 x 10(4) to 2.9 x 10(5) particles/cell for tumor cells (9L and LX1, respectively) to 1.5 x 10(6) to 4.8 x 10(8) particles/cell for ''professional phagocytes'' (J774 and peritoneal macrophages, respectively). On the T1-weighted images, cell-internalized MION appeared hyperintense relative to agar and similar to MION in aqueous solution. On T2-weighted images, signal intensity varied according to concentration of MION within cells. Cell-internalized MION caused similar MR signal changes of cells as did free MION; however, at a dose that was an order of magnitude lower, depending on the pulse sequence used. The detectability of MION within cells was approximately 2 ng Fe, which corresponded to 10(5) tumor cells/well or 5 x 10(3) macrophages/well. We conclude that a variety of cells can be efficiently labeled with MION by simple incubation. Intracellular labeling may be used for MR imaging of in vivo cell tracking. RP Weissleder, R (reprint author), MASSACHUSETTS GEN HOSP,DEPT RADIOL,CTR MOL IMAGING RES,32 FRUIT ST,BOSTON,MA 02114, USA. FU NCI NIH HHS [R01 CA 59649-03] NR 34 TC 262 Z9 267 U1 0 U2 14 PU SOC MAGNETIC RESONANCE IMAGING PI EASTON PA 1991 NORTHAMPTON ST, EASTON, PA 18042-3189 SN 1053-1807 J9 JMRI-J MAGN RESON IM JI JMRI-J. Magn. Reson. Imaging PD JAN-FEB PY 1997 VL 7 IS 1 BP 258 EP 263 DI 10.1002/jmri.1880070140 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA WG331 UT WOS:A1997WG33100039 PM 9039625 ER PT J AU Scadden, DT AF Scadden, DT TI Cytokine use in the management of HIV disease SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY LA English DT Article DE cytokines; growth factors; HIV; erythropoietin; G-CSF; GM-CSF; anemia; neutropenia ID COLONY-STIMULATING FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT-HUMAN-ERYTHROPOIETIN; AIDS-RELATED COMPLEX; CLINICAL-APPLICATIONS; MYELOID CELLS; ZIDOVUDINE; ANEMIA; INFECTION; IMMUNE AB Multilineage hematopoietic defects occur in patients with human immunodeficiency virus (HIV) infection and affect therapy of the disease and of associated opportunistic infections and neoplasms. Anemia and neutropenia are common in HIV patients, and can occur as a result of HIV-related myelosuppression or complications or may be secondary effects of antiretroviral or other agents used in management of the disease. With the advent of combination drug therapy for the treatment of HIV infection and prophylaxis and treatment of infectious complications, myelosuppression is frequently encountered and may be treated with synthetic hematopoietic growth factors. Erythropoietin has been shown to increase mean hematocrit levels and to reduce transfusion requirements in anemic HIV-infected patients receiving zidovudine. Granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor have been shown to increase neutrophil counts in patients with AIDS-related bone marrow failure and those receiving zidovudine, interferon-alpha, or ganciclovir. Although recent research using interleukin-2 (IL-2) has shown that use of this cytokine in AIDS patients can lead to increases in CD4 cell counts that appear to be functional, further study is needed to determine whether cytokines can play a role other than palliation in HIV-infected patients. C1 HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA. RP Scadden, DT (reprint author), MASSACHUSETTS GEN HOSP,AIDS RES CTR,ROOM 5212D,149 13TH ST,BOSTON,MA 02129, USA. NR 42 TC 6 Z9 6 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 1077-9450 J9 J ACQ IMMUN DEF SYND JI J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. PY 1997 VL 16 SU 1 BP S23 EP S29 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA YJ610 UT WOS:A1997YJ61000004 PM 9389312 ER PT J AU Dezube, BJ Ahlers, CM Lawrence, JP Teng, EI Silberman, SL Pardee, AB Finberg, RW AF Dezube, BJ Ahlers, CM Lawrence, JP Teng, EI Silberman, SL Pardee, AB Finberg, RW TI Tenidap inhibits replication of the human immunodeficiency virus-1 in cultured cells SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY LA English DT Article; Proceedings Paper CT 2nd International Cytokine Conference CY OCT 01-05, 1994 CL BANFF, CANADA DE HIV; interleukin-6; tenidap; UK5099; piroxicam ID INTERLEUKIN-6; INFECTION; TRANSPORT; PH AB Interleukin-6 (IL-6) may be important in the pathogenesis of HIV-1 because of its ability to induce HIV-1 expression in infected cells in vitro. Tenidap, a structurally and functionally novel antirheumatic drug affecting diverse biologic processes, has been shown to reduce IL-6 production by peripheral blood mononuclear cells stimulated with lipopolysaccharide. Tenidap also inhibits the activity of chloride-bicarbonate exchangers and causes acidification of the cytoplasmic compartment that is similar to the effect of the anion transport inhibitor UK5099. Furthermore, tenidap inhibits the cyclooxygenase-mediated pathway of arachidonic acid metabolism as do the nonsteroidal antiinflammatory drugs (NSAIDs). Here we show that tenidap decreased HIV-1 replication as measured by p24 core antigen in the acutely infected CD4(+) T-lymphocyte lines H9 and Jurkat, in the acutely infected monocyte line U937, and in its chronically infected subclone U1.8/HIV. These effects were seen at concentrations in the range of 3 to 15 mu M, well below those toxic to cells. The antiviral effects of tenidap may be independent of its ability to reduce IL-6 production based on the observations that these effects were as prominent in IL-6 nonresponsive lines as in IL-6 responsive lines and that the inhibition of p24 production was not reversed by exogenous IL-6. C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELL GROWTH & REGULAT,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV INFECT DIS,BOSTON,MA 02115. PFIZER INC,DIV CENT RES,GROTON,CT 06340. RI Finberg, Robert/E-3323-2010 NR 16 TC 3 Z9 3 U1 0 U2 1 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 1077-9450 J9 J ACQ IMMUN DEF SYND JI J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. PD JAN 1 PY 1997 VL 14 IS 1 BP 13 EP 17 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA WA979 UT WOS:A1997WA97900003 PM 8989205 ER PT J AU Huber, A Ling, W Shoptaw, S Gulati, V Brethen, P Rawson, R AF Huber, A Ling, W Shoptaw, S Gulati, V Brethen, P Rawson, R TI Integrating treatments for methamphetamine abuse: A psychosocial perspective SO JOURNAL OF ADDICTIVE DISEASES LA English DT Article ID COCAINE AB The recent West Coast experience with increased methamphetamine use is showing signs of spreading to other parts of the US. The risk of corresponding medical and psychosocial problems has led to a call to action at the highest levels of government. The next few years will likely witness a substantial increase in treatment research on methamphetamine abuse/dependence, with particular emphasis on the development and application of novel pharmacotherapies. The evaluation of these agents presupposes that we understand the clinical syndrome resulting from chronic methamphetamine use. To establish a clear picture of the biological and psychological sequellae of methamphetamine use, we compare two cohorts (500 methamphetamine and 224 cocaine users) treated at the same outpatient clinic over the past nine years, using identical manualized treatments. The results suggest that while there are important differences in group characteristics and drug effects, the total response to treatment was quite comparable. C1 LOS ANGELES ADDICT TREATMENT RES CTR,LOS ANGELES,CA 90025. W LOS ANGELES VET ADM MEDICAT DEV RES UNIT,LOS ANGELES,CA. UNIV CALIF LOS ANGELES,ALCOHOLISM & ADDICT MED SERV,LOS ANGELES,CA 90024. OI Shoptaw, Steven/0000-0002-3583-0026 FU NIDA NIH HHS [DA 06185, DA 09260, DA 50038] NR 12 TC 72 Z9 73 U1 1 U2 2 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 SN 1055-0887 J9 J ADDICT DIS JI J. Addict. Dis. PY 1997 VL 16 IS 4 BP 41 EP 50 DI 10.1300/J069v16n04_04 PG 10 WC Substance Abuse SC Substance Abuse GA XZ092 UT WOS:A1997XZ09200004 PM 9328808 ER PT J AU Ling, W Shoptaw, S AF Ling, W Shoptaw, S TI Integration of research in pharmacotherapy for addictive disease: Where are we? Where are we going? SO JOURNAL OF ADDICTIVE DISEASES LA English DT Article ID METHADONE-MAINTENANCE PATIENTS; SMOKING CESSATION; CONTINGENCY MANAGEMENT; ALCOHOL DEPENDENCE; COCAINE ABSTINENCE; NICOTINE PATCH; REINFORCEMENT; INTERVENTION; PHARMACOLOGY; ACAMPROSATE AB Systematic efforts by NIDA and NIAAA to develop new medications for drug and alcohol dependence have resulted in recent FDA approval of LAAM for opiate dependence, naltrexone for alcohol dependence and, more recently, a nasal spray for nicotine dependence. This article reviews the current strategies that guide these development efforts, including further examination of the interactions between potential pharmacotherapeutic agents and the drugs of abuse, the enhancement of pharmacotherapeutic efficacy with non-pharmacological interventions, and the development of more precise and meaningful measures of research outcome. C1 FRIENDS MED SCI RES CTR INC,W LOS ANGELES VET ADM MED CTR,MATRIX CTR,LOS ANGELES,CA. UNIV CALIF LOS ANGELES,DEPT PSYCHIAT,LOS ANGELES,CA 90024. FU NIDA NIH HHS [R18 DA6082]; PHS HHS [R4408786] NR 42 TC 15 Z9 15 U1 2 U2 4 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 SN 1055-0887 J9 J ADDICT DIS JI J. Addict. Dis. PY 1997 VL 16 IS 4 BP 83 EP 102 DI 10.1300/J069v16n04_07 PG 20 WC Substance Abuse SC Substance Abuse GA XZ092 UT WOS:A1997XZ09200007 PM 9328811 ER PT J AU Dahl, AM York, IA Grant, E Rock, KL AF Dahl, AM York, IA Grant, E Rock, KL TI Characterization of COS mutant cells with novel defects in the class I antigen presentation pathway. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 DANA FARBER CANC INST,DIV LYMPHOCYTE BIOL,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 45 EP 45 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14200045 ER PT J AU Boyle, LA Durda, PJ Pandolfi, F Kurnick, JT AF Boyle, LA Durda, PJ Pandolfi, F Kurnick, JT TI Human T cell responses to E-coli opposing effects of IL-4 and IL-15 on responding alpha beta and gamma delta T cells. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CHARLESTOWN,MA 02129. GENZYME CORP,CAMBRIDGE,MA 02139. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 61 EP 61 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14200061 ER PT J AU Virella, G Mironova, M Virella, I LopesVirella, MF AF Virella, G Mironova, M Virella, I LopesVirella, MF TI The atherogenic potential of anti-LDL antibodies. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 MED UNIV S CAROLINA,CHARLESTON,SC 29425. RALPH H JOHNSON VA MED CTR,CHARLESTON,SC. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 92 EP 92 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14200091 ER PT J AU Durda, PJ Boyle, LA Kersten, CM Kurnick, JT AF Durda, PJ Boyle, LA Kersten, CM Kurnick, JT TI Comparison of in vitro cytokine production by E-coli stimulated human T cells. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CHARLESTOWN,MA 02129. GENZYME CORP,CAMBRIDGE,MA 02139. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 213 EP 213 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14200212 ER PT J AU Geisler, D Sanchez, H Bush, R AF Geisler, D Sanchez, H Bush, R TI Detection of Alternaria antigen by dot-immunoblot PCR. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 UNIV WISCONSIN,MADISON,WI. WILLIAM S MIDDLETON MEM VET ADM MED CTR,MADISON,WI 53705. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 343 EP 343 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14200342 ER PT J AU Issekutz, AC Springer, TA AF Issekutz, AC Springer, TA TI LFA-1 mediates neutrophil transendothelial migration via engagement of ICAM-1 and ICAM-2, but Mac-1 mediated migration is not ICAM-1 or -2 dependent. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 CTR BLOOD RES,BOSTON,MA 02115. DALHOUSIE UNIV,HALIFAX,NS,CANADA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 482 EP 482 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14200480 ER PT J AU Crawford, WW Klaustermeyer, WB AF Crawford, WW Klaustermeyer, WB TI Age effects on total serum IgE, atopy, prevalence of asthma, and prevalence of rhinitis. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90073. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 560 EP 560 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14200558 ER PT J AU Stahl, JL Cook, EB Sanchez, H Luster, AD Barney, NP Graziano, FM AF Stahl, JL Cook, EB Sanchez, H Luster, AD Barney, NP Graziano, FM TI Eotaxin is produced and released by human conjunctival epithelial cells. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 UNIV WISCONSIN HOSP & CLIN,MADISON,WI 53792. MASSACHUSETTS GEN HOSP,CHARLESTOWN,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 677 EP 677 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14200675 ER PT J AU Zhao, Y Sergio, JJ Swenson, K Arn, JS Sachs, DH Sykes, M AF Zhao, Y Sergio, JJ Swenson, K Arn, JS Sachs, DH Sykes, M TI Role of host and donor MHC in development of mouse CD4(+) T cells in porcine thymus grafts. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 809 EP 809 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14200807 ER PT J AU Rudd, CE Hu, H Raab, M Cefai, D Schneider, H AF Rudd, CE Hu, H Raab, M Cefai, D Schneider, H TI CD28 and CTLA-4 regulation of interleukin-2 production in T-cells. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 DANA FARBER CANC INST,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 832 EP 832 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14200830 ER PT J AU Beland, JL Sobel, RA Adler, H DelPan, N Rimm, IJ AF Beland, JL Sobel, RA Adler, H DelPan, N Rimm, IJ TI B cell-deficient mice hare increased susceptibility to HSV-1 encephalitis and mortality. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,CHILDRENS HOSP,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. VET ADM MED CTR,PALO ALTO,CA 94304. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 913 EP 913 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14200910 ER PT J AU Fernandes, DM Vidard, L Rock, KL AF Fernandes, DM Vidard, L Rock, KL TI Effects of targeting endogenously synthesized antigens to endocytic compartments on presentation in association with MHC class II molecules. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 DANA FARBER CANC INST,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 934 EP 934 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14200931 ER PT J AU daSilva, AJ Li, ZW deVera, C Canto, E Findell, P Rudd, CE AF daSilva, AJ Li, ZW deVera, C Canto, E Findell, P Rudd, CE TI T-cell signaling molecule FYB binds SLP-76 and regulates interleukin 2 production. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1024 EP 1024 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201021 ER PT J AU Adler, H Beland, JL Kozlow, W DelPan, NC Kobzik, L Rimm, IJ AF Adler, H Beland, JL Kozlow, W DelPan, NC Kobzik, L Rimm, IJ TI Suppression of Herpes simplex virus type 1 (HSV-1) induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS2). SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1036 EP 1036 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201033 ER PT J AU Nikolic, B Sykes, M AF Nikolic, B Sykes, M TI Pre-treatment with cyclosporin A (CYA) facilitates induction of mixed chimerism and central tolerance. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1119 EP 1119 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201116 ER PT J AU Bloch, DB Gutierrez, JE Guerriero, V Bloch, KJ AF Bloch, DB Gutierrez, JE Guerriero, V Bloch, KJ TI Localization in bovine HSP70 of an epitope which is target of antibodies in idiopathic, progressive, sensorineural hearing loss (IPBSNHL). SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. UNIV ARIZONA,TUCSON,AZ. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1139 EP 1139 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201136 ER PT J AU Pahlavani, MA Harris, MD AF Pahlavani, MA Harris, MD TI Age-related changes in MAP kinase and LCK, FYN, and ZAP-70 activities in mitogen-stimulated rat T cells. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 AUDIE L MURPHY MEM VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,DEPT PHYSIOL,SAN ANTONIO,TX. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1180 EP 1180 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201177 ER PT J AU Theze, J Bani, L David, D Moreau, JL Cayota, A Nakarai, T Ritz, J AF Theze, J Bani, L David, D Moreau, JL Cayota, A Nakarai, T Ritz, J TI Expression of the IL-2 receptor gamma subunit in human CD4 T lymphocytes. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 INST PASTEUR,PARIS,FRANCE. DANA FARBER CANC INST,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1182 EP 1182 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201179 ER PT J AU Manilay, JO Sykes, M AF Manilay, JO Sykes, M TI Education of natural killer cells for self/non-self recognition. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1197 EP 1197 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201194 ER PT J AU Shen, J Andrews, DM Boyle, LA Leary, CP Kersten, CM vandenElsen, PJ Pandolfi, F Kurnick, JT AF Shen, J Andrews, DM Boyle, LA Leary, CP Kersten, CM vandenElsen, PJ Pandolfi, F Kurnick, JT TI Oligoclonality of V delta 1 and V delta d2 cells in PBMC is a reflection of selection drier to environmental stimuli. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 BOSTON UNIV,SCH MED,BOSTON,MA 02118. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1210 EP 1210 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201207 ER PT J AU Trimble, LA Lieberman, J AF Trimble, LA Lieberman, J TI A survival factor in serum is required for clonal expansion of antigen specific CD8+ cytotoxic T lymphocytes. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,CTR BLOOD RES,CAMBRIDGE,MA 02138. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1225 EP 1225 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201222 ER PT J AU Bush, R Sanchez, H Geisler, D AF Bush, R Sanchez, H Geisler, D TI Recombinant Alt a 2 is a significant Alternaria allergen. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 WILLIAM S MIDDLETON MEM VET ADM MED CTR,MADISON,WI 53705. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1429 EP 1429 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201424 ER PT J AU Sanchez, H Geisler, D Bush, R AF Sanchez, H Geisler, D Bush, R TI IgE-binding epitopes of the recombinant Alternaria allergen, Alt a 2. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 UNIV WISCONSIN,MADISON,WI. WILLIAM S MIDDLETON MEM VET ADM MED CTR,MADISON,WI 53705. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1594 EP 1594 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201590 ER PT J AU Kivens, WJ Hunt, SW Bierer, BE Shimizu, Y AF Kivens, WJ Hunt, SW Bierer, BE Shimizu, Y TI Dissection of CD2 cytoplasmic domains essential for upregulation of beta 1 integrin function. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455. UNIV MINNESOTA,CTR IMMUNOL,MINNEAPOLIS,MN 55455. WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT IMMUNOPATHOL,ANN ARBOR,MI 48105. DANA FARBER CANC INST,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1858 EP 1858 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201852 ER PT J AU Sykes, M Pearson, DA Szot, GL AF Sykes, M Pearson, DA Szot, GL TI Achievement of high levels of mixed allogeneic chimerism without whole body irradiation or myelosuppressive drugs. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1898 EP 1898 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201892 ER PT J AU Yang, YG Dey, B Sergio, JJ Sykes, M AF Yang, YG Dey, B Sergio, JJ Sykes, M TI IL-12 prevents GVHD and GVHD-associated immune dysfunction in a full MHC haplotype-mismatched murine BMT model. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1901 EP 1901 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201895 ER PT J AU Anderson, DE Ausubel, L Hollsberg, P Freeman, G Hafler, DA AF Anderson, DE Ausubel, L Hollsberg, P Freeman, G Hafler, DA TI B7-1 and B7-2 provide different costimulatory signals for altered peptide ligands stimulating human MBPp85-99 reactive T cell clones. SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 BRIGHAM & WOMENS HOSP,DANA FARBER CANC INST,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 1997 VL 99 IS 1 SU S BP 1914 EP 1914 PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA WH142 UT WOS:A1997WH14201908 ER PT J AU Hausdorff, JM Mitchell, SL Firtion, R Peng, CK Cudkowicz, ME Wei, JY Goldberger, AL AF Hausdorff, JM Mitchell, SL Firtion, R Peng, CK Cudkowicz, ME Wei, JY Goldberger, AL TI Altered fractal dynamics of gait: Reduced stride-interval correlations with aging and Huntington's disease SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE nonlinear dynamics; human locomotion; long-range correlations; power-law scaling ID LONG-RANGE CORRELATIONS; MOBILITY; WALKING; STATE AB Fluctuations in the duration of the gait cycle (the stride interval) display fractal dynamics and long-range correlations in healthy young adults. We hypothesized that these stride-interval correlations would be altered by changes in neurological function associated with aging and certain disease states. To test this hypothesis, we compared the stride-interval time series of 1) healthy elderly subjects and young controls and of 2) subjects with Huntington's disease and healthy controls. Using detrended fluctuation analysis, we computed alpha, a measure of the degree to which one stride interval is correlated with previous and subsequent intervals over different time scales. The scaling exponent a was significantly lower in elderly subjects compared with young subjects (elderly: 0.68 +/- 0.14; young: 0.87 +/- 0.15; P < 0.003). The scaling exponent a was also smaller in the subjects with Huntington's disease compared with disease-free controls (Huntington's disease: 0.60 +/- 0.24; controls: 0.88 +/- 0.17; P < 0.005). Moreover, a was Linearly related to degree of functional impairment in subjects with Huntington's disease (r = 0.78, P < 0.0005). These findings demonstrate that stride-interval fluctuations are more random (i.e., less correlated) in elderly subjects and in subjects with Huntington's disease. Abnormal alterations in the fractal properties of gait dynamics are apparently associated with changes in central nervous system control. C1 HARVARD UNIV, SCH MED, DIV AGING, BOSTON, MA 02115 USA. HEBREW REHABIL CTR AGED, BOSTON, MA 02131 USA. BOSTON UNIV, DEPT BIOMED ENGN, BOSTON, MA 02215 USA. HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV CARDIOVASC, BOSTON, MA 02215 USA. HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02114 USA. RP Hausdorff, JM (reprint author), BETH ISRAEL HOSP, GERONTOL DIV, 330 BROOKLINE AVE, ROOM KB-26, BOSTON, MA 02215 USA. RI Peng, Chung-Kang/E-1489-2011 OI Peng, Chung-Kang/0000-0003-3666-9833 FU NIA NIH HHS [AG-10829, AG-00294, AG-08812] NR 44 TC 370 Z9 378 U1 3 U2 15 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD JAN PY 1997 VL 82 IS 1 BP 262 EP 269 PG 8 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA WG328 UT WOS:A1997WG32800035 PM 9029225 ER PT J AU Estok, DM Orr, TE Harris, WH AF Estok, DM Orr, TE Harris, WH TI Factors affecting cement strains near the tip of a cemented femoral component SO JOURNAL OF ARTHROPLASTY LA English DT Article DE cement strains; cemented femoral prosthesis; total hip arthroplasty ID TOTAL HIP-ARTHROPLASTY; FINITE-ELEMENT; REPLACEMENT; INITIATION; FAILURE; DESIGN AB A generic three-dimensional finite-element model of the upper half of the femur containing a cemented femoral stem of a total hip arthroplasty was developed to study those factors influencing cement strains near the tip of a cemented femoral component. This generic model was verified through another three-dimensional finite-element model that had been created based on the precise geometry of a cadaver femur implanted with a contemporary cemented femoral component. This cadaveric femoral reconstruction had been created with strain gauges embedded in the cement mantle and was then loaded under conditions simulating single leg stance and stairclimbing. By use of the cement strains measured experimentally in the cadaver femur, and comparison of them with those obtained from the finite-element model of that cadaver femur, it was possible to establish proper material properties, boundary conditions, and loading conditions for the generic model. The generic model was then modified parametrically to determine those factors that influence the strains occurring within the cement mantle near the tip of a cemented femoral component. These models suggest that the single factor that most adversely influenced peak strains at or near the tip of the prosthesis was a thin cement mantle. This effect was present both when the cement mantle was reduced in thickness and when a similar effect occurred by virtue of a varus or valgus placement of the stem. Factors that decreased the peak cement strains near the tip of the femoral stem included a more flexible stem and thicker cement mantles. This effect of a more flexible stem could be obtained by changing the modulus of the metal implant, by uniformly reducing the thickness of the stem, or by tapering the stem within the same bone geometry. Thicker cement mantles reduced both the axial and the shear strains occurring at the tip of the prosthesis. The presence or absence of a hole in the tip of the prosthesis per se, as for a centralizer had no significant effect on the peak cement strains seen around the tip of the prosthesis; however, truncating the tip of the prosthesis from a hemisphere to a flat profile, which resulted in a sharp corner at the tip of the prosthesis, produced a 35% increase in cement strains at the tip as a result of a stress concentration effect. Thus, the common way of modifying the rip to have a hole for a centralizer, which involved truncating the tip, increased the cement strains occurring near the tip of the prosthesis. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT ORTHOPAED SURG,HIP & IMPLANT UNIT,BOSTON,MA 02114. NR 26 TC 54 Z9 54 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 SN 0883-5403 J9 J ARTHROPLASTY JI J. Arthroplast. PD JAN PY 1997 VL 12 IS 1 BP 40 EP 48 DI 10.1016/S0883-5403(97)90045-0 PG 9 WC Orthopedics SC Orthopedics GA WE871 UT WOS:A1997WE87100006 PM 9021500 ER PT J AU Jasty, M Bragdon, CR Zalenski, E OConnor, D Page, A Harris, WH AF Jasty, M Bragdon, CR Zalenski, E OConnor, D Page, A Harris, WH TI Enhanced stability of uncemented canine femoral components by bone ingrowth into the porous coatings SO JOURNAL OF ARTHROPLASTY LA English DT Article DE hip; stability; porous coatings; bone ingrowth AB The following questions were answered in this study: (1) What is the initial stability of proximally porous-coated canine femoral components? (2) Does bone ingrowth occur under these conditions? (3) Is the stability enhanced by tissue ingrowth in vivo? The stability of proximally porous-coated femoral components of canine total hip arthroplasties after 6 months to 2 years of in vivo service in dogs was measured in vitro using displacement transducers under loads simulating canine midstance. This was compared with the stability of identical components under the same loading conditions immediately after implantation in vitro in the contralateral femurs. The femurs were then sectioned and bone ingrowth into the porous coatings was quantified. The results showed that immediately after implantation the implants can move as much as 50 mu m, but that the bone ingrowth into porous coatings of canine femoral components can occur even under such conditions. These data also suggested that the relative motion existing at the time of insertion can be reduced to very small amounts (< 10 mu m) by bone ingrowth. RP Jasty, M (reprint author), MASSACHUSETTS GEN HOSP,DEPT ORTHOPAED,ORTHOPAED BIOMECH LAB,HIP & IMPLANT SURG UNIT,BOSTON,MA 02114, USA. FU NIAMS NIH HHS [AR-35828] NR 16 TC 27 Z9 27 U1 1 U2 3 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 SN 0883-5403 J9 J ARTHROPLASTY JI J. Arthroplast. PD JAN PY 1997 VL 12 IS 1 BP 106 EP 113 DI 10.1016/S0883-5403(97)90055-3 PG 8 WC Orthopedics SC Orthopedics GA WE871 UT WOS:A1997WE87100016 PM 9021510 ER PT J AU Watnick, PI Eto, T Takahashi, H Calderwood, SB AF Watnick, PI Eto, T Takahashi, H Calderwood, SB TI Purification of Vibrio cholerae Fur and estimation of its intracellular abundance by antibody sandwich enzyme-linked immunosorbent assay SO JOURNAL OF BACTERIOLOGY LA English DT Article ID ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATION; COORDINATE REGULATION; NUCLEOTIDE-SEQUENCE; VIRULENCE GENE; RNA-POLYMERASE; IRON; CLONING; EXPRESSION; REPRESSOR AB The Vibrio cholerae fur gene was previously cloned and sequenced. A putative Fur box was identified in the divergent promoters of irgA, a virulence factor of V. cholerae, and irgB, a transcriptional activator of irgA. In this work, V. cholerae Fur was overexpressed in Escherichia coli and purified to approximately 95% homogeneity. The purified protein bound a DNA fragment containing the irgA-irgB promoter in a gel shift assay. The purified protein was used to raise monoclonal and polyclonal antibodies to V. cholerae Fur, and a Fur sandwich enzyme-linked immunosorbent assay was developed to estimate the intracellular abundance of Fur under a variety of grow-th conditions. The number of Fur molecules per cell during exponential growth was approximately 2,500, which is higher than most measurements for other bacterial repressors but comparable to the intracellular concentration of the leucine responsive regulatory protein, The number of Fur molecules per cell increased in the late logarithmic and stationary phases, Growth of V. cholerae in low-iron medium did not alter the intracellular abundance of Fur significantly. Growth under microaerophilic conditions resulted in a significant, approximately twofold decrease in the intracellular levels of Fur, The measurements of intracellular Fur abundance indicate that a large amount of this repressor is produced constitutively and that the concentration of Fur in the cell varies by less than a factor of 2 under the conditions studied. We hypothesize that the high constitutive expression of Fur is necessary for its role as an iron-responsive regulator. C1 MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115. FU NIAID NIH HHS [AI34968]; NIDDK NIH HHS [NIDDK 43351] NR 34 TC 37 Z9 37 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD JAN PY 1997 VL 179 IS 1 BP 243 EP 247 PG 5 WC Microbiology SC Microbiology GA VZ792 UT WOS:A1997VZ79200032 PM 8982004 ER PT J AU Carroll, PA Zhao, GS Boyko, SA Winkler, ME Calderwood, SB AF Carroll, PA Zhao, GS Boyko, SA Winkler, ME Calderwood, SB TI Identification, sequencing, and enzymatic activity of the erythrose-4-phosphate dehydrogenase gene of Vibrio cholerae SO JOURNAL OF BACTERIOLOGY LA English DT Article ID ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; SUICIDE VECTOR; VIRULENCE GENE; CLONING; CONSTRUCTION; IRON; PROTEINS AB We have identified a gene in vibrio choler ne (epd) which encodes an erythrose-4-phosphate dehydrogenase activity and is located immediately downstream of an iron-regulated virulence gene, irgA, and immediately upstream of a gene encoding phosphoglycerate kinase (pgk). Expression of epd in V. cholerae is not regulated by iron, nor is it required for virulence in an infant mouse model. C1 MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114. UNIV TEXAS,SCH MED,DEPT MICROBIOL & MOL GENET,HOUSTON,TX 77030. HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115. FU NIAID NIH HHS [AI34968]; NIGMS NIH HHS [GM37561] NR 20 TC 6 Z9 8 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD JAN PY 1997 VL 179 IS 1 BP 293 EP 296 PG 4 WC Microbiology SC Microbiology GA VZ792 UT WOS:A1997VZ79200042 PM 8982014 ER PT J AU OrtizCruz, E Gebhardt, MC Jennings, LC Springfield, DS Mankin, HJ AF OrtizCruz, E Gebhardt, MC Jennings, LC Springfield, DS Mankin, HJ TI The results of transplantation of intercalary allografts after resection of tumors - A long-term follow-up study SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID BONE-TUMORS; RADIOGRAPHIC EVALUATION; FEMORAL ALLOGRAFTS; OSTEO-SARCOMA; REPLACEMENT; PROSTHESES; MANAGEMENT AB We reviewed the results of 104 intercalary allograft procedures that had been performed, between April 1974 and August 1992, in 100 patients, usually after resection of a segment of bone because of an osseous neoplasm, The median duration of follow-up was 5.6 years, Retention of the graft and return to essentially normal function were the measures of success and, on that basis, eighty-seven (84 per cent) of the 104 reconstructions were successful, Of the fifteen limbs in which the reconstruction failed, four were salvaged with insertion of a second allograft and three, with use of some other technique. Of the 104 allograft procedures, eight (including two in patients who had a recurrent tumor) were followed by an amputation; thus, the ultimate rate of salvage was 92 per cent for the entire series, Thirty-one grafts failed to unite at one junction with the host or both, within one year after the operation, and this necessitated eighty-one additional operative procedures to achieve a good result. Life-table regression analysis showed that age, gender, anatomical site, and length of the graft were not associated with significant differences in the over-all outcome. Infection (p = 0.0001); fracture (p = 0.002); stage of the lesion (p = 0.007); and use of adjuvant chemotherapy or radiation, or both (p = 0.008), all had an adverse effect on the survival of the allograft. Despite the relatively high rate of non-union that necessitated additional operations, these data indicate that transplantation of allografts for the treatment of intercalary defects has a high rate of success and usually results in a functional limb. C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. MT SINAI HOSP,NEW YORK,NY 10029. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,ORTHOPAED ONCOL UNIT,BOSTON,MA. HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115. OI ORTIZ CRUZ, EDUARDO J./0000-0002-1405-0688 NR 54 TC 140 Z9 155 U1 0 U2 2 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD JAN PY 1997 VL 79A IS 1 BP 97 EP 106 PG 10 WC Orthopedics; Surgery SC Orthopedics; Surgery GA WF033 UT WOS:A1997WF03300010 PM 9010190 ER PT J AU Osswald, S Wilber, DJ Lin, JL Du, D Holden, HB Ruskin, JN Garan, H AF Osswald, S Wilber, DJ Lin, JL Du, D Holden, HB Ruskin, JN Garan, H TI Mechanisms underlying different surface ECG morphologies of recurrent monomorphic ventricular tachycardia and their modification by procainamide SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE ventricular tachycardia; ECG polymorphism; canine model; ventricular mapping; procainamide ID CORONARY-ARTERY DISEASE; MYOCARDIAL-INFARCTION PERIOD; RADIOFREQUENCY CATHETER ABLATION; REENTRANT CIRCUITS; CANINE MODEL; ACTIVATION; ARRHYTHMIAS; ORIGIN; SITE; LOCALIZATION AB ECG Pleomorphism of Ventricular Tachycardia, Introduction: Distinct surface ECG morphologies (ECGMs), from one episode to the next, of recurrent monomorphic ventricular tachycardia (VT) in the same patient complicate endocardial catheter mapping and the success of ablative therapy, This study investigates the incidence and mechanisms of multiple ECGMs during recurrent monomorphic VTs in a canine model of experimental myocardial infarction (MI), Methods and Results: Computerized ECG analysis and simultaneous endocardial and epicardial activation mapping with a 64 bipolar electrode array were used to analyze the relation between site of VT origin, local activation sequence, and surface ECGM in 72 VT episodes induced in 9 of 17 dogs with experimental MI, Pairwise comparisons of all VTs induced in the same animal were done in drug-free state (47 VTs) and after intravenous procainamide (25 VTs), In drug-free state, VT pairs with similar surface ECGMs manifested endocardial breakthrough sites (BSs) within a distance < 10 mm in 46 (100%) of 46 VT pairs compared to 43 (45%) of 95 VT pairs with different surface ECGMs (P < 0.0001), Of all 89 VT pairs with endocardial BSs within < 10 mm, similar endocardial activation patterns were found in 34 (74%) of 46 pairs with similar ECGMs in contrast to 6 (14%) of 43 pairs with different ECGMs (P < 0.001), Similar comparisons of VT pairs induced after intravenous procainamide administration showed that the endocardial BSs were located within < 10 mm in 9 (75%) of 12 VT pairs with similar and in 17 (49%) of 95 with different surface ECGMs, respectively (P = NS), Conclusions: In the same heart, similar surface ECGMs of recurrent VT are highly predictive of closely spaced endocardial BSs in drug-free state, but not after procainamide administration, Nearly half of the VTs with different surface ECGMs still originate from closely spaced endocardial BSs but commonly manifest a change in the endocardial activation spread from this site, Thus, assumptions about different mechanisms and sites of VT origin based on different surface ECGMs should be made with caution. C1 MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA. FU NHLBI NIH HHS [R0L-HL-26215-07] NR 32 TC 5 Z9 5 U1 0 U2 1 PU FUTURA PUBL CO PI ARMONK PA 135 BEDFORD RD, PO BOX 418, ARMONK, NY 10504-0418 SN 1045-3873 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD JAN PY 1997 VL 8 IS 1 BP 11 EP 23 DI 10.1111/j.1540-8167.1997.tb00604.x PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA WE850 UT WOS:A1997WE85000003 PM 9116962 ER PT J AU Kanellopoulos, AJ Pallikaris, IG Donnenfeld, ED Detorakis, S Koufala, K Perry, HD AF Kanellopoulos, AJ Pallikaris, IG Donnenfeld, ED Detorakis, S Koufala, K Perry, HD TI Comparison of corneal sensation following photorefractive keratectomy and laser in situ keratomileusis SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY LA English DT Article; Proceedings Paper CT International-Society-of-Refractive-Surgery Meeting CY OCT 28, 1995 CL ATLANTA, GA SP Int Soc Refract Surg ID INSITU KERATOMILEUSIS; SENSITIVITY; RECOVERY AB Purpose: To evaluate the effect of photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK) on corneal sensation. Setting: Eye Institute, Medical School of the University of Crete, Heraklion, Greece, and Orasis, Hellenic Eye Center of Athens, Greece. Methods: In a masked study, corneal sensation was measured with the Cochet-Bonnet aesthesiometer in 40 consecutive patients 6 to 12 months following PRK and LASIK (60 mm constitutes normal reading and <40 mm, abnormal). Results: After 6 to 12 months, the mean corneal sensation following PRK was 39.2 mm (range 30 to 55 mm) (mean 9.5 months) and after LASIK, 53.6 mm (range 40 to 60 mm) (mean 9.3 months). The mean correction attempted for PRK was 7.05 diopters (D) (range 2.5 to 12.0 D) and for LASIK, 11.71 D (range 6.0 to 20.0 D). Conclusion: in this group of patients, with correction of primarily severe myopia, corneal sensation was significantly greater after LASIK than after PRK. C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA. NR 19 TC 77 Z9 82 U1 0 U2 1 PU AMER SOC CATARACT REFRACTIVE SURGERY PI FAIRFAX PA 4000 LEGATO RD, SUITE 850, FAIRFAX, VA 22030 SN 0886-3350 J9 J CATARACT REFR SURG JI J. Cataract. Refract. Surg. PD JAN-FEB PY 1997 VL 23 IS 1 BP 34 EP 38 PG 5 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA WR071 UT WOS:A1997WR07100017 PM 9100105 ER PT J AU Vamvakas, EC Pineda, AA AF Vamvakas, EC Pineda, AA TI Determinants of the efficacy of prophylactic granulocyte transfusions: A meta-analysis SO JOURNAL OF CLINICAL APHERESIS LA English DT Article DE granulocytes; leukocytes; neutrophils; transfusion; sepsis; septicemia; infection; granulocytopenia; leukopenia; neutropenia; fungal ID COLONY-STIMULATING FACTOR; BONE-MARROW TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; CONTROLLED TRIAL; INDIUM-111-LABELED GRANULOCYTES; LEUKOCYTE ANTIBODIES; THERAPY; INFECTION; LEUKAPHERESIS; COMPLICATIONS AB BACKGROUND: Cytokines that improve granulocyte collection yields have recently become available, and may lend to a new series of trials of granulocyte transfusion (GTX) therapy. We conducted a meta-analysis of studies of prophylactic GTX in order to identify the determinants of efficacy of this intervention, and to assist in thr design of future trials of GTX for the treatment of patients with overwhelming infection. METHODS: Randomized controlled trials of the efficacy of prophylactic GTX published in English in 1970-1995 were retrieved, and eight studies were eligible for analysis. Summary relative odds (RR) of bacterial or fungal infection, death, or death from infection in transfused patients vs. controls were computed for patient subsets defined on the basis of dose of granulocytes transfused, assessment of leukocyte compatibility, duration of neutropenia, and infection rate of controls. The random-effects method was used for all analyses. RESULTS: Assessment of leukocyte compatibility prior to the transfusion, dose of granulocytes transfused, and duration of neutropenia in enrolled patients could account. respectively, for the variation in findings across published reports in terms of all three, two, and one of the outcome measures studied. Transfusion of adequate doses of compatible leukocytes significantly reduced the relative risk (RR) of infection, death, and death from infection in transfused patients vs, controls (RR) - 0.075, RR = 0.224, and RR = 0.168, respectively; P < 0.05). CONCLUSION: Two necessary elements in the design of future trials of therapeutic GTX should be the transfusion of high doses of granulocytes and the provision of leukocytes that are crossmatch-compatible with the recipient's serum. (C) 1997 Wiley-Liss, Inc. C1 MAYO CLIN,DIV TRANSFUS MED,ROCHESTER,MN. RP Vamvakas, EC (reprint author), MASSACHUSETTS GEN HOSP,BLOOD TRANSFUS SERV,GRJ-224,BOSTON,MA 02114, USA. NR 49 TC 49 Z9 51 U1 0 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0733-2459 J9 J CLIN APHERESIS JI J. Clin. Apheresis PY 1997 VL 12 IS 2 BP 74 EP 81 DI 10.1002/(SICI)1098-1101(1997)12:2<74::AID-JCA4>3.0.CO;2-6 PG 8 WC Hematology SC Hematology GA XP429 UT WOS:A1997XP42900004 PM 9263114 ER PT J AU Vamvakas, EC AF Vamvakas, EC TI Rationale, objectives, and interpretation of randomized controlled trials SO JOURNAL OF CLINICAL APHERESIS LA English DT Article; Proceedings Paper CT 18th Annual Meeting of the American-Society-for-Apheresis CY MAR 20-22, 1997 CL WASHINGTON, DC SP Amer Soc Apheresis DE methods; design; conduct; analysis; quality; evaluation; reporting ID DESIGN AFFECTS OUTCOMES; CLINICAL-TRIALS; SCIENTIFIC MISCONDUCT; CONSORT STATEMENT; MEDICAL JOURNALS; META-ANALYSIS; PHASE-II; QUALITY; CANCER; MULTICENTER AB A randomized controlled trial (RCT) is the most definitive tool for evaluation of the effectiveness of an intervention and can establish a cause-and-effect relationship between an intervention and an improved disease outcome. However, the undertaking of an RCT does not guarantee valid results, and the findings of RCTs of the same intervention are often discrepant. While many reported trials are of high quality, a significant number have deficiencies in design, conduct, analysis, or interpretation of results. Medical practitioners must become familiar with the methodology of RCTs in order to assess the validity of the reported findings and the relevance of the results to their own patients. Trialists must report sufficient information about the methods used se that readers can judge for themselves if the trial worked as planned. (C) 1997 Wiley-Liss, Inc. RP Vamvakas, EC (reprint author), HARVARD UNIV,BLOOD TRANSFUS SERV,GRJ 224,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA 02114, USA. NR 83 TC 4 Z9 4 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0733-2459 J9 J CLIN APHERESIS JI J. Clin. Apheresis PY 1997 VL 12 IS 3 BP 130 EP 139 DI 10.1002/(SICI)1098-1101(1997)12:3<130::AID-JCA6>3.0.CO;2-B PG 10 WC Hematology SC Hematology GA YE216 UT WOS:A1997YE21600006 PM 9365866 ER PT J AU Ho, HP Niederman, R AF Ho, HP Niederman, R TI Effectiveness of the Sonicare(R) sonic toothbrush on reduction of plaque, gingivitis, probing pocket depth and subgingival bacteria in adolescent orthodontic patients SO JOURNAL OF CLINICAL DENTISTRY LA English DT Article ID CLINICAL-EVALUATION; REMOVAL; BANDS AB The Sonicare(R) sonic toothbrush and a traditional manual toothbrush were compared for efficacy in improving periodontal health in young orthodontic patients with existing gingival inflammation. A 4-week, single-blind clinical trial was employed. Twenty-four subjects, ages 11-17 years, who were fully bonded and banded with fixed orthodontic appliances were selected. Subjects were randomly assigned to use either the manual or the Sonicare toothbrush, instructed in its use, and asked to brush each morning and evening for 2 minutes. Plaque index, gingival index, percentage of sites which bled on probing, pocket depth, and total gram-negative bacteria in a subgingival plaque sample were assessed at baseline and 4 weeks around the banded teeth. The results demonstrate that the Sonicare brush was significantly more effective than the manual brush in all clinical parameters. Sonicare was statistically superior to the manual brush in supragingival plaque reduction (57% vs. 10%, respectively; p < 0.001). Gingival Index scores fell by 29 percent in the Sonicare group, but only 3 percent in the manual group. Reduction of bleeding on probing was significantly greater in the Sonicare group than in the manual group (p < 0.001). The Sonicare group decreased from 78% bleeding sites at baseline to 24.5% after 1 month. In the manual group there was only a slight reduction in bleeding on probing (70% of sites at baseline and 64.6% sites after 1 month). Mean pocket depths were significantly reduced compared to baseline values in both the Sonicare and the manual groups (p < 0.001). Pocket depth reduction in the Sonicare group was, however, significantly greater than in the manual group (28% vs. 6%, respectively; p < 0.001). Total gram-negative bacteria in subgingival plaque samples from banded test teeth of a subset of patients were reduced in the Sonicare group (p less than or equal to 0.05), but increased in the manual group. These results clearly demonstrate that the Sonicare sonic toothbrush is superior to a manual toothbrush in improving periodontal health in adolescent orthodontic patients with existing gingivitis. C1 HARVARD UNIV,SCH DENT MED,DEPT PERIODONT,BOSTON,MA 02115. FORSYTH DENT CTR,DEPT CYTOKINE BIOL,BOSTON,MA 02115. RP Ho, HP (reprint author), HARVARD UNIV,SCH DENT MED,DEPT ORTHODONT,188 LONGWOOD AVE,BOSTON,MA 02115, USA. NR 23 TC 28 Z9 28 U1 0 U2 1 PU PROFESSIONAL AUDIENCE COMMUNICATIONS, INC PI YARDLEY PA PO BOX 243, YARDLEY, PA 19067 SN 0895-8831 J9 J CLIN DENT JI J. Clin. Dent. PY 1997 VL 8 IS 1 BP 15 EP 19 PG 5 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA XB999 UT WOS:A1997XB99900004 PM 9487840 ER PT J AU Georgopoulos, NA Pralong, FP Seidman, CE Seidman, JG Crowley, WF Vallejo, M AF Georgopoulos, NA Pralong, FP Seidman, CE Seidman, JG Crowley, WF Vallejo, M TI Genetic heterogeneity evidenced by low incidence of KAL-1 gene mutations in sporadic cases of gonadotropin-releasing hormone deficiency SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID LINKED KALLMANN SYNDROME; NEURAL CELL-ADHESION; SECONDARY SEX CHARACTERISTICS; HEALTH-EXAMINATION-SURVEY; HYPOGONADOTROPIC HYPOGONADISM; X-CHROMOSOME; CANDIDATE GENE; DELETION; XP22.3; INHERITANCE AB Isolated GnRH deficiency is a heritable condition characterized by a functional deficit in GnRH secretion. Familial cases with different modes of inheritance have been described, and the gene responsible for the X-linked form (KAL-1) has been identified. However, sporadic cases with no documented family history of GnRH deficiency account for the majority of the affected patients. For this reason, we sought to determine the frequency with which KAL-1 gene mutations occur in patients with sporadic GnRH deficiency. Only 1 of 21 patients with sporadic GnRH deficiency was found to bear a defect in the KAL-1 gene (a deletion of 14 bases starting at codon 464). Three types of polymorphic single base substitutions with no apparent correlation with GnRH deficiency were also detected in several patients. In each of 3 different patients with an X-linked mode of inheritance, 3 genetic defects, 2 point mutations and a small intragenic deletion, were detected. These defects consist of a single base mutation introducing a stop codon at position 328, a single base mutation resulting in a phenylalanine to leucine substitution at position 517, and a 9-base deletion at the 3'-exon-intron splice site of exon 8, respectively. All identified genetic defects occur within the fibronectin type III repeats of the predicted protein encoded by the KAL-1 gene. In conclusion, our study indicates that the incidence of genetic defects within the coding region of the KAL-1 gene in patients with sporadic GnRH deficiency is low (5-8%), thus supporting the idea that the X-linked form of inheritance represents the least common form of the disease. C1 MASSACHUSETTS GEN HOSP, REPROD ENDOCRINE UNIT, BOSTON, MA 02114 USA. MASSACHUSETTS GEN HOSP, NATL CTR INFERTIL RES, BOSTON, MA 02114 USA. HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02114 USA. HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA. FU NICHD NIH HHS [P30-HD-28138, R01 HD015788, U54 HD028138, U54-HD-29164] NR 40 TC 84 Z9 87 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 1997 VL 82 IS 1 BP 213 EP 217 DI 10.1210/jc.82.1.213 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA WA943 UT WOS:A1997WA94300042 PM 8989261 ER PT J AU Takahashi, M Ikeda, U Kasahara, T Kitagawa, S Takahashi, Y Shimada, K Kano, S Morimoto, C Masuyama, J AF Takahashi, M Ikeda, U Kasahara, T Kitagawa, S Takahashi, Y Shimada, K Kano, S Morimoto, C Masuyama, J TI Activation of human monocytes for enhanced production of interleukin 8 during transendothelial migration in vitro SO JOURNAL OF CLINICAL IMMUNOLOGY LA English DT Article DE endothelium; macrophage; inflammation; chemokine; adhesion molecule ID ENDOTHELIAL-CELL INTERACTIONS; MESSENGER-RNA EXPRESSION; CHEMOATTRACTANT PROTEIN-1; IN-VITRO; B-CELLS; NEUTROPHIL; INDUCTION; ADHERENCE; ADHESION; CYTOKINE AB Interleukin-8 (IL-8) is a chemokine for polymorphonuclear leukocytes (PMNs) and lymphocytes, which promotes the extravasation of these inflammatory cells. In this study, we investigated IL-8 synthesis induced by the adhesive interaction between monocytes and endothelial cells during transmigration and the capacity of transmigrated monocytes to produce IL-8 Cocultured human monocytes and human umbilical vein endothelial cell (HUVEC) monolayers induced the synergistic production of IL-8, compared with cultures of either monocytes or HUVEC monolayers alone. Coculture-induced IL-8 production almost doubled after HUVECs were stimulated with IL-1 beta. The induced IL-8 mRNA expression was consistent with the protein data, indicating the de novo synthesis of IL-8 by the coculture. Monoclonal antibodies (mAbs) against IL-8 inhibited the transendothelial chemotactic activity of the supernatants for PMNs by 55%. Immunohistochemistry revealed that both adherent and transmigrated monocytes and unstimulated HUVECs expressed IL-8 protein, whereas nonadherent monocytes did little. Transmigrated monocytes spontaneously secreted a 3.8-fold greater amount of IL-8 than the initial monocytes. Coculture-induced IL-8 production was inhibited about 30% by polyclonal Abs against IL-alpha, IL-1 beta, or tumor necrosis factor alpha, while it was not affected by mAbs against intercellular adhesion molecule 1 or vascular cell adhesion molecule 1. The results suggested that adhesive interaction during the transmigration of monocytes through HUVEC monolayers activates both cell types to produce IL-8 and that transmigrated monocytes are capable of producing ample IL-8. C1 JICHI MED SCH,DEPT CLIN IMMUNOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN. JICHI MED SCH,DIV HEMOPOIESIS,INST HEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN. KYORITSU COLL PHARMACEUT SCI,DEPT CARDIOL,TOKYO,JAPAN. KYORITSU COLL PHARMACEUT SCI,BIOCHEM SECT,TOKYO,JAPAN. TOHOKU UNIV,SCH MED,DEPT CLIN LAB & MED,SENDAI,MIYAGI 980,JAPAN. DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115. NR 35 TC 18 Z9 18 U1 1 U2 4 PU PLENUM PUBL CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0271-9142 J9 J CLIN IMMUNOL JI J. Clin. Immunol. PD JAN PY 1997 VL 17 IS 1 BP 53 EP 62 DI 10.1023/A:1027388412806 PG 10 WC Immunology SC Immunology GA WJ841 UT WOS:A1997WJ84100007 PM 9049786 ER PT J AU EspinelIngroff, A Bartlett, M Bowden, R Chin, NX Cooper, C Fothergill, A McGinnis, MR Menezes, P Messer, SA Nelson, PW Odds, FC Pasarell, L Peter, J Pfaller, MA Rex, JH Rinaldi, MG Shankland, GS Walsh, TJ Weitzman, I AF EspinelIngroff, A Bartlett, M Bowden, R Chin, NX Cooper, C Fothergill, A McGinnis, MR Menezes, P Messer, SA Nelson, PW Odds, FC Pasarell, L Peter, J Pfaller, MA Rex, JH Rinaldi, MG Shankland, GS Walsh, TJ Weitzman, I TI Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID AMPHOTERICIN-B; BROTH MACRODILUTION; CANDIDA-ALBICANS; FLUCONAZOLE; INFECTIONS; THERAPY AB A multicenter study was conducted to expand the generation and analysis of data that supports the proposal of a reference method for the antifungal susceptibility testing of filamentous fungi. Broth microdilution MICs of amphotericin B and itraconazole were determined in 11 centers against 30 coded duplicate pairs of Aspergillus spp., Fusarium spp., Pseudallescheria boydii, and Rhizopus arrhizus. The effect of inoculum density (approximately 10(3) and 10(4) CFU/ml), incubation time (24, 48, and 72 h), and procedure of MIC determination (conventional and colorimetric [Alamar Blue] evaluation of growth inhibition) on intra- and interlaboratory agreement was analyzed. Based on intra- (97 to 100%) and interlaboratory (94 to 95%) agreement for both drugs, the overall optimal testing conditions identified were determination of colorimetric MICs after 48 to 72 h of incubation with an inoculum density of approximately 10(4) CFU/ml. These testing conditions are proposed as guidelines for a reference broth microdilution method. C1 INDIANA UNIV,SCH MED,INDIANAPOLIS,IN 46202. FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104. COLUMBIA PRESBYTERIAN MED CTR,NEW YORK,NY 10032. UNIV TEXAS,MED BRANCH,GALVESTON,TX 77555. UNIV TEXAS,HLTH SCI CTR,AUDIE L MURPHY MEM VET HOSP,LAB SERV,SAN ANTONIO,TX 78284. UNIV IOWA,COLL MED,DEPT PATHOL,IOWA CITY,IA 52242. UNIV TEXAS,SCH MED,CTR STUDY EMERGING & REEMERGING PATHOGENS,DEPT INTERNAL MED,DIV INFECT DIS,HOUSTON,TX 77030. JANSSEN RES FDN,B-2340 BEERSE,BELGIUM. NCI,MYCOL UNIT,BETHESDA,MD 20892. NCI,IMMUNOCOMPROMISED HOST SECT,PEDIAT BRANCH,BETHESDA,MD 20892. REG MYCOL REFERENCE LAB,GLASGOW,LANARK,SCOTLAND. RP EspinelIngroff, A (reprint author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV INFECT DIS,BOX 980049,1101 E MARSHALL ST,RICHMOND,VA 23298, USA. NR 20 TC 198 Z9 206 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JAN PY 1997 VL 35 IS 1 BP 139 EP 143 PG 5 WC Microbiology SC Microbiology GA VY566 UT WOS:A1997VY56600024 PM 8968895 ER PT J AU Purtz, EP Hess, D Kacmarek, RM AF Purtz, EP Hess, D Kacmarek, RM TI Evaluation of electrochemical nitric oxide and nitrogen dioxide analyzers suitable for use during mechanical ventilation SO JOURNAL OF CLINICAL MONITORING LA English DT Article DE chemiluminescence analyzer; electrochemical analyzer; inhaled nitric oxide; mechanical ventilation; nitrogen dioxide ID RESPIRATORY-DISTRESS-SYNDROME; PULMONARY-HYPERTENSION; OXYGENATION; INHALATION; EXPOSURE; HUMANS AB Objective. Inhaled nitric oxide (NO) is increasingly being used in the treatment of diseases characterized by hypoxemia and pulmonary hypertension. To avoid complications, accurate quantitative analysis of NO and NO2 is necessary during this therapy. We evaluated the accuracy of electrochemical NC) and nitrogen dioxide (NO2) analyzers suitable for use during mechanical ventilation. Methods. We evaluated six electrochemical NO analyzer brands (Bedfont, B & W, Drager, EIT, Pulmonox, Saan). All were calibrated and used per manufacturer's specifications. An adult mechanical ventilator was used to produce serial dilutions of NO with Or for [NO] of 0-80 ppm. FIO2 settings of 0.90, 0.70, 0.50, 0.30, and 0.21 were used. Settings of low, moderate, and high ventilation pressures were evaluated. Gas was sampled from the inspiratory limb of the ventilator circuit using either a sidestream or mainstream technique. [NO] was also measured using a calibrated chemiluminescence analyzer. For the analyzers that measured NO2, serial dilutions of 8.5 ppm NO2 with O-2 were analyzed using chemiluminescence and the electrochemical analyzers, Results, Bias +/- precision for [NO] by individual devices ranged from 1.8 +/- 1.9 ppm to -1.0 +/- 0.7 ppm. There were significant differences in the bias between analyzers (P < 0.001), pressure settings (P < 0.001), and NO level (P < 0.017). The difference in bias between levels of FIO2 was not significant (P = 0.062). Bias +/- precision for NO2 ranged from 0.18 +/- 0.12 ppm to -0.14 +/- 0.13 ppm, with a significant difference between analyzers (P < 0.001). Conclusions. The bias and precision of these analyzers was acceptable for clinical use. The devices tended to be most accurate at [NO] less than or equal to 20 ppm - the clinical conditions at which NO is most commonly used. C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 26 TC 3 Z9 3 U1 1 U2 2 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0748-1977 J9 J CLIN MONITOR JI J. Clin. Monit. PD JAN PY 1997 VL 13 IS 1 BP 25 EP 34 DI 10.1023/A:1007301912697 PG 10 WC Anesthesiology SC Anesthesiology GA XC948 UT WOS:A1997XC94800004 PM 9058250 ER PT J AU Beard, CJ Propert, KJ Rieker, PP Clark, JA Kaplan, I Kantoff, PW Talcott, JA AF Beard, CJ Propert, KJ Rieker, PP Clark, JA Kaplan, I Kantoff, PW Talcott, JA TI Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: A prospective multiinstitutional outcomes study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID QUALITY-OF-LIFE; CARCINOMA; EXPERIENCE; RADIATION; PATTERNS; CARE; MEN AB Purpose: To use data from a prospective quality-of-life study to assess differences in disease-specific and general health-related quality-of-life changes after treatment with different external-beam irradiation techniques for prostate cancer, Patients and Methods: Patients were divided into three groups based on their pretreatment field size and planning technique: whole pelvis, small field, or conformal. Measures of bowel, urinary, and sexual function and of global health-related quality-of-life parameters (from the Health Survey Short Form [SF-36] and the Profile of Mood Stares [POMS]) were obtained from self-report questionnaires completed before initiation of therapy and at 3 and 12 months after therapy, Results: Irritative gastrointestinal and genitourinary side effects were frequent 3 months after treatment, but were substantially improved at 12 months. Sexual dysfunction increased steadily over the study period. The POMS and the SF-36 did not demonstrate significant changes over time. Despite small patient numbers, we found trends in favor of conformal therapy across several symptom measures, including sexual function, In the fatigue, energy, and vigor subscales, patients who received whole-pelvis treatment fared significantly worse than those in the other two groups, Conclusion: Prospective, detailed data from a feasibility study allowed us to assess the effect of technique on quality of life following external-beam irradiation. Although limited by the small planned sample size, these results suggest that smaller radiation fields limit treatment-related complications, including, unexpectedly, sexual dysfunction. However, confirmation in a larger study is necessary. (C) 1997 by American Society of Clinical Oncology. C1 DANA FARBER CANC INST,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BOSTON,MA. RP Beard, CJ (reprint author), JOINT CTR RADIAT THERAPY,330 BROOKLINE AVE,BOSTON,MA 02115, USA. FU AHRQ HHS [HS-06824] NR 20 TC 126 Z9 128 U1 0 U2 3 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN PY 1997 VL 15 IS 1 BP 223 EP 229 PG 7 WC Oncology SC Oncology GA WB907 UT WOS:A1997WB90700031 PM 8996146 ER PT J AU Takvorian, T Skarin, A Johnson, R AF Takvorian, T Skarin, A Johnson, R TI Pyoderma gangrenosum SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article RP Takvorian, T (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA. NR 3 TC 7 Z9 7 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN PY 1997 VL 15 IS 1 BP 407 EP 407 PG 1 WC Oncology SC Oncology GA WB907 UT WOS:A1997WB90700053 PM 8996168 ER PT J AU Rosenbaum, JF AF Rosenbaum, JF TI Treatment of panic disorder: The state of the art - Introduction SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Editorial Material C1 MASSACHUSETTS GEN HOSP,CLIN PSYCHOPHARMACOL UNIT,BOSTON,MA 02114. RP Rosenbaum, JF (reprint author), HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115, USA. NR 0 TC 1 Z9 2 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1997 VL 58 SU 2 BP 3 EP 3 PG 1 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA WN600 UT WOS:A1997WN60000001 ER PT J AU Schatzberg, AF Haddad, P Kaplan, EM Lejoyeux, M Rosenbaum, JF Young, AH Zajecka, J AF Schatzberg, AF Haddad, P Kaplan, EM Lejoyeux, M Rosenbaum, JF Young, AH Zajecka, J TI Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Symposium on Antidepressant Discontinuation Syndrome: Update on Serotonin Reuptake Inhibitors CY DEC 17, 1996 CL TUCSON, AZ SP Eli Lilly & Co ID PAROXETINE WITHDRAWAL; ANTIDEPRESSANT WITHDRAWAL; ABRUPT DISCONTINUATION; SYMPTOMS; DISORDER; MEDICATION AB Adverse events following discontinuation from serotonin reuptake inhibitors (SRIs) are being reported in the literature with increasing frequency; the frequency and severity of these symptoms appear to vary according to the half-life of the SRI, e.g., the incidence appears higher with the shorter half-life agents than with fluoxetine, which has an extended half-life. Yet, there have been no systematic studies of the phenomenon to date. Therefore, a group of experts convened in Phoenix, Arizona, to develop a clear description or definition of the phenomenon based on these reports. The SRI discontinuation syndrome, referred to as ''withdrawal symptoms'' in many anecdotal case reports, is distinctly different from the classic withdrawal syndrome associated with alcohol and barbiturates. Antidepressants are not associated with dependence or drug-seeking behavior. SRI discontinuation symptoms tend to be short-lived and self-limiting, but can be troublesome. They may emerge when an SRI is abruptly discontinued, when doses are missed, and less frequently, during dosage reduction. In addition, the symptoms are not attributable to any other cause and can be reversed when the original agent is reinstituted, or one that is pharmacologically similar is substituted. SRI discontinuation symptoms, in most cases, may be minimized by slowly tapering antidepressant therapy, but there have been several case reports where symptoms occurred consistently even through repeated attempts to taper therapy. Physical symptoms include problems with balance, gastrointestinal and flu-like symptoms, and sensory and sleep disturbances. Psychological symptoms include anxiety and/or agitation, crying spells, and irritability. Further analyses of data bases and clinical studies are needed to define this proposed syndrome more clearly. C1 PRESTWICH HOSP,MANCHESTER,LANCS,ENGLAND. UNIV S FLORIDA,SCH MED,DEPT PSYCHIAT,TAMPA,FL 33620. HOSP BICHAT CLAUDE BERNARD,PARIS,FRANCE. MASSACHUSETTS GEN HOSP,CLIN PSYCHOPHARMACOL UNIT,BOSTON,MA 02114. NEWCASTLE GEN HOSP,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND. RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612. RP Schatzberg, AF (reprint author), STANFORD UNIV,SCH MED,DEPT PSYCHIAT TD114 5490,STANFORD,CA 94305, USA. NR 32 TC 102 Z9 106 U1 1 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1997 VL 58 SU 7 BP 5 EP 10 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA XK602 UT WOS:A1997XK60200002 PM 9219487 ER PT J AU Frazer, A AF Frazer, A TI Antidepressants SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Symposium on Advances in Antidepressant Pharmacotherapy CY FEB 02, 1996 CL NEW ORLEANS, LA ID MONOAMINE-OXIDASE INHIBITORS; SEROTONIN REUPTAKE INHIBITORS; LOCUS-CERULEUS NEURONS; LONG-TERM TREATMENT; MAJOR DEPRESSION; ATYPICAL DEPRESSION; PHARMACOKINETIC PROPERTIES; PLASMA TRYPTOPHAN; LIMBIC FOREBRAIN; DORSAL RAPHE AB This review covers the chemical structures, efficacy, side effects, toxicity, and mechanisms of action of various classes of antidepressants: tricyclic antidepressants, monoamine oxidase inhibitors, and second generation antidepressants including the serotonin selective reuptake inhibitors, and novel drugs such as mirtazapine, nefazodone, and venlafaxine. C1 AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. RP Frazer, A (reprint author), UNIV TEXAS,HLTH SCI CTR,DEPT PHARMACOL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA. FU NIMH NIH HHS [MH 29094] NR 155 TC 119 Z9 121 U1 3 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1997 VL 58 SU 6 BP 9 EP 25 PG 17 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA XL060 UT WOS:A1997XL06000002 PM 9227669 ER PT J AU Glazer, WM AF Glazer, WM TI Olanzapine and the new generation of antipsychotic agents: Patterns of use SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Symposium on Practical Issues in Using Olanzapine CY AUG 01-03, 1996 CL BOSTON, MA SP Eli Lilly & Co, Physicians Postgrad Press Inc ID POST-PSYCHOTIC DEPRESSION; NEGATIVE SYMPTOMS; SCHIZOPHRENIA; DISORDERS; RISPERIDONE; CLOZAPINE; THERAPY; ABUSE AB As the new generation of atypical antipsychotics becomes available, the limitations of the older typical agents become apparent. The new medications, which have benefits other than the alleviation of positive symptoms of schizophrenia, may also be beneficial for psychotic disorders that have responded poorly to conventional neuroleptics. This article will describe the potential use of the atypical antipsychotics, especially olanzapine, for affective mood disturbances in schizophrenia, psychotic depression and mania, first-break schizophrenia, comorbid schizophrenia and substance abuse disorders, dementia in the elderly and those with late-onset schizophrenia, and behavioral problems in patients with mental retardation or developmental delays. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 30 TC 39 Z9 41 U1 3 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1997 VL 58 SU 10 BP 18 EP 21 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA XP738 UT WOS:A1997XP73800004 PM 9265912 ER PT J AU Pollack, MH Worthington, JJ Manfro, GG Otto, MW Zucker, BG AF Pollack, MH Worthington, JJ Manfro, GG Otto, MW Zucker, BG TI Abecarnil for the treatment of generalized anxiety disorder: A placebo-controlled comparison of two dosage ranges of abecarnil and buspirone SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 20th Collegium-Internationale-Neuropsychopharmacologicum Symposium on a New Concept in the Treatment of Anxiety CY JUN 23-27, 1996 CL MELBOURNE, AUSTRALIA SP Collegium Int Neuropsychopharm, Schering AG ID OUTPATIENTS; IMIPRAMINE; WITHDRAWAL AB Background: The development of effective and well-tolerated anxiolytic agents is an area of critical clinical importance. Abecarnil, a beta carboline, is a partial benzodiazepine-receptor agonist that has demonstrated promise as an anxiolytic agent. In this study, we examine the efficacy, safety, and discontinuation-related effects of abecarnil, buspirone, and placebo in the acute and long-term treatment of patients who have generalized anxiety disorder. Method: This is a double-blind, placebo-controlled study of two dosages of abecarnil and buspirone. In total, 464 patients were randomized. After a placebo run-in week, patients entered a 6-week double-blind treatment period, followed by an optional 18-week maintenance period for treatment responders; After abrupt discontinuation of the acute or maintenance treatment, patients entered a 3-week placebo-substitution follow-up period. Treatment response was assessed with the Hamilton Raring Scale for Anxiety and the Clinical Global Impressions (CGI) Scale. Results: Compared with placebo, abecarnil showed significant anxiolytic activity early in the treatment period, particularly in the high-dosage group, though these differences did not maintain statistical significance at the end of the trial. Buspirone was associated with a slower onset of action and better symptom relief than placebo after 6 weeks of therapy. Withdrawal symptoms emerged in patients who abruptly discontinued abecarnil (particularly at the higher dosage) only in those receiving a longer duration of treatment. Conclusion: The results of this study need to be understood in the context of a high placebo-response rate, which hampers the ability to demonstrate significant drug-placebo differences. This study suggests that abecarnil may be an effective anxiolytic agent; further attention is warranted to assess its spectrum of clinical effectiveness. C1 HARVARD UNIV,SCH MED,BOSTON,MA. RP Pollack, MH (reprint author), MASSACHUSETTS GEN HOSP,15 PARKMANN ST,WACC-815,BOSTON,MA 02114, USA. RI Manfro, Gisele/B-7020-2009 NR 16 TC 46 Z9 47 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1997 VL 58 SU 11 BP 19 EP 23 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA YE167 UT WOS:A1997YE16700004 PM 9363044 ER PT J AU Leuchter, AF Cook, IA Uijtdehaage, SHJ Dunkin, J Lufkin, RB Anderson-Hanley, C Abrams, M Rosenberg-Thompson, S O'Hara, R Simon, SL Osato, S Babaie, A AF Leuchter, AF Cook, IA Uijtdehaage, SHJ Dunkin, J Lufkin, RB Anderson-Hanley, C Abrams, M Rosenberg-Thompson, S O'Hara, R Simon, SL Osato, S Babaie, A TI Brain structure and function and the outcomes of treatment for depression SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Symposium on Functional Brain Alterations in Depression and Anxiety, at the Xth World Congress of Psychiatry CY AUG 24, 1996 CL MADRID, SPAIN SP Wyeth Ayerst Labs ID CEREBRAL BLOOD-FLOW; HIGH-INTENSITY SIGNALS; LATE-LIFE DEPRESSION; MOOD DISORDERS; ALZHEIMERS-DISEASE; COMPUTED-TOMOGRAPHY; GLUCOSE-METABOLISM; FOLLOW-UP; OLD-AGE; SUBCORTICAL HYPERINTENSITIES AB Depressed patients have a variety of brain structural alterations, the most common being atrophy and deep white-matter lesions. Alterations in brain function also are common, particularly regional decreases in cerebral metabolism and perfusion. Method: We review here the evidence that alterations in brain structure and function may explain some of the heterogeneity in outcomes of depression. We also report initial results suggesting that measurement of brain structure and function may help to predict outcomes of treatment for depression. Brain structure was examined using three-dimensional reconstruction and volumetric analysis of magnetic resonance imaging (MRT) scans. Brain function was examined using quantitative electroencephalography (QEEG), performed at baseline and serially during the course of treatment. QEEG measures included coherence (a measure of synchronized activity between brain regions) and cordance (a measure strongly associated with regional cerebral perfusion). Results: Depressed patients have been reported to have larger volumes of white-matter lesions than controls. We have found that some types of white-matter lesions are associated with lower coherence and that subjects with low coherence had significantly poorer outcomes of treatment for depression at 2-year follow-up. Depressed subjects had low cordance at baseline, which decreased further during the course of effective treatment. Subjects who did not improve had little or no change in cordance. Changes in cordance were detected prior to the onset of clinical response, with decreases seen as early as 48 hours after the initiation of treatment in subjects who showed eventual response. Conclusion: These preliminary results suggest that functional imaging using QEEG may be useful for assessing, and possibly predicting, outcomes of treatment for depression. C1 Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Quantitat EEG Lab, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Psychiat Serv, Los Angeles, CA 90073 USA. RP Leuchter, AF (reprint author), Univ Calif Los Angeles, Inst Neuropsychiat, 760 Westwood Plaza,Room 37-452, Los Angeles, CA 90024 USA. OI Uijtdehaage, Sebastian/0000-0001-8598-4683 FU NIDA NIH HHS [1 Y01 DA 50038]; NIMH NIH HHS [1 KO2 MH 01165]; PHS HHS [1RO1 40705-09] NR 57 TC 49 Z9 53 U1 3 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1997 VL 58 SU 16 BP 22 EP 31 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA YQ022 UT WOS:000071339600005 PM 9430506 ER PT J AU Zarate, CA Weinstock, L Cukor, P Morabito, C Leahy, L Burns, C Baer, L AF Zarate, CA Weinstock, L Cukor, P Morabito, C Leahy, L Burns, C Baer, L TI Applicability of telemedicine for assessing patients with schizophrenia: Acceptance and reliability SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article AB Background: Telemedicine holds promise for providing expert psychiatric consultation to underserved populations, but has not been quantitatively studied in schizophrenia or any other major mental disorder. This study was conducted to assess the reliability and acceptance of videoconferencing equipment in the assessment of patients with schizophrenia. Method: We assessed reliability of the Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Positive Symptoms (SAPS), and Scale for the Assessment of Negative Symptoms (SANS) under three conditions: (1) in person, (2) by videoconferencing at low (128 kilobits per second [kbs]) bandwidth, (3) by videoconferencing at high (384 kbs) bandwidth. All 45 patients met DSM-IV criteria for schizophrenia. All patients and the two interviewers rated various aspects of the study interviews against previous live psychiatric interviews. Results: Total scores on both the BPRS and SAPS were assessed equally reliably by the three media. Total score on the SANS was less reliably assessed at the low bandwidth, as were several specific negative symptoms of schizophrenia that depend heavily on nonverbal cues. Video interviews were well accepted by patients in both groups, although patients in the high bandwidth group were more likely to prefer the video interview to a live interview. Conclusion: Global severity of schizophrenia and overall severity of positive symptoms were reliably assessed by videoconferencing technology, Higher bandwidth resulted in more reliable assessment of negative symptoms and was preferred over low bandwidth, although patients' and raters' acceptance of video was good in both conditions, Videoconsultation appears to be a reliable method of assessing schizophrenic patients in remote locations who have limited access to expert consultation. C1 MASSACHUSETTS GEN HOSP,DEPT PSYCHIAT,CHARLESTOWN,MA 02129. HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115. MCLEAN HOSP,MAILMAN RES CTR,BIPOLAR & PSYCHOT DISORDERS PROGRAM,BELMONT,MA 02178. MCLEAN HOSP,MAILMAN RES CTR,PHARMACOEPIDEMIOL CTR,BELMONT,MA 02178. HARVARD UNIV,SCH MED,CONSOLIDATED DEPT PSYCHIAT,BOSTON,MA 02115. FU NIMH NIH HHS [MH-19126] NR 12 TC 122 Z9 122 U1 0 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 1997 VL 58 IS 1 BP 22 EP 25 DI 10.4088/JCP.v58n0104 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA WH696 UT WOS:A1997WH69600004 PM 9055833 ER PT J AU Schatzberg, AF Haddad, P Kaplan, EM Lejoyeux, M Rosenbaum, JF Young, AH Zajecka, J AF Schatzberg, AF Haddad, P Kaplan, EM Lejoyeux, M Rosenbaum, JF Young, AH Zajecka, J TI Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Symposium on Antidepressant Discontinuation Syndrome: Update on Serotonin Reuptake Inhibitors CY DEC 17, 1996 CL TUCSON, AZ SP Eli Lilly & Co ID PAROXETINE WITHDRAWAL SYNDROME; SERTRALINE DISCONTINUATION; SYMPTOMS AB Although the number of documented serotonin reuptake inhibitor (SRI) discontinuation reactions is increasing, to date no systematic studies have been completed; therefore the mechanism of action for these reactions is not clearly understood. However, several hypotheses have been proposed. Researchers have postulated that discontinuation events result from a sudden decrease in the availability of synaptic serotonin in the face of down-regulated serotonin receptors. In addition, other neurotransmitters, such as dopamine, norepinephrine, or gamma-aminobutyric acid (GABA), may also be involved, although little research in this area has been published. Individual patient sensitivity, i.e., genetics or cognitive mindset, may also be a factor in SRI discontinuation phenomena. Finally, experts have hypothesized that since some symptoms associated with paroxetine withdrawal are similar to those of tricyclic antidepressant discontinuation, they may be caused by cholinergic rebound. C1 PRESTWICH HOSP,MANCHESTER,LANCS,ENGLAND. UNIV S FLORIDA,SCH MED,DEPT PSYCHIAT,TAMPA,FL 33620. HOSP BICHAT,PARIS,FRANCE. MASSACHUSETTS GEN HOSP,CLIN PSYCHOPHARMACOL UNIT,BOSTON,MA 02114. NEWCASTLE GEN HOSP,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND. RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612. RP Schatzberg, AF (reprint author), STANFORD UNIV,SCH MED,DEPT PSYCHIAT TD114 5490,STANFORD,CA 94305, USA. NR 28 TC 58 Z9 59 U1 1 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1997 VL 58 SU 7 BP 23 EP 27 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA XK602 UT WOS:A1997XK60200005 PM 9219490 ER PT J AU Small, GW Bystritsky, A AF Small, GW Bystritsky, A TI Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 20th Collegium-Internationale-Neuropsychopharmacologicum Symposium on a New Concept in the Treatment of Anxiety CY JUN 23-27, 1996 CL MELBOURNE, AUSTRALIA SP Collegium Int Neuropsychopharm, Schering AG ID BENZODIAZEPINES; COMORBIDITY; PREVALENCE; DEPRESSION; COMMUNITY AB We studied the tolerability and efficacy of abecarnil, a new partial benzodiazepine agonist, for short-term relief of anxiety in geriatric patients. After a 1-week placebo lead-in, 182 outpatients (mean +/- SD age = 68.3 +/- 5.8; range, 59-85 years) were randomly assigned in a double-blind, parallel-group design to high-dosage abecarnil (7.5-17.5 mg daily), low-dosage abecarnil (3.0-7.0 mg daily), or placebo far 6 weeks of acute treatment followed by abrupt discontinuation and a 2-week follow-up. During the acute treatment period, the discontinuation rate from adverse events was greater for the group treated with high-dosage abecarnil (44%) than for the groups treated with low-dosage abecarnil (14%) or placebo (12%). The most frequently reported side effects associated with abecarnil were drowsiness and insomnia. For the acute treatment period, low-dosage abecarnil was superior to placebo in reducing anxiety at Weeks 2-4 and 6, and was statistically significantly superior to high-dosage abecarnil at Weeks 4-6. More than half of the placebo group showed at least moderate global improvement al Weeks 3 and 6, One week after abrupt discontinuation of abecarnil, the placebo-treated group had less anxiety than did both groups treated with high-dosage and low-dosage abecarnil. The most commonly reported symptoms of withdrawal were headache and insomnia. These data indicate that abecarnil, at dosages ranging from 3.0 to 7.0 mg daily, is better tolerated and more efficacious for the short-term treatment of anxiety in geriatric patients than are higher dosages of 7.5 to 17.5 mg daily. Abrupt discontinuation of abecarnil at tither dosage range causes definite rebound symptoms within the first week after withdrawal. These data also suggest that treatment with placebo offers at least moderate relief of anxiety in many elderly patients. C1 UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024. UNIV CALIF LOS ANGELES,SCH MED,CTR AGING,LOS ANGELES,CA 90024. W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90073. RP Small, GW (reprint author), UNIV CALIF LOS ANGELES,SCH MED,INST NEUROPSYCHIAT,760 WESTWOOD PLAZA,LOS ANGELES,CA 90024, USA. NR 17 TC 10 Z9 10 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1997 VL 58 SU 11 BP 24 EP 29 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA YE167 UT WOS:A1997YE16700005 PM 9363045 ER PT J AU Rosenbaum, JF Zajecka, J AF Rosenbaum, JF Zajecka, J TI Clinical management of antidepressant discontinuation SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Symposium on Antidepressant Discontinuation Syndrome: Update on Serotonin Reuptake Inhibitors CY DEC 17, 1996 CL TUCSON, AZ SP Eli Lilly & Co ID PANIC DISORDER; PAROXETINE; WITHDRAWAL; SYMPTOMS AB To minimize the symptoms of antidepressant discontinuation, gradual tapering is necessary for all serotonin reuptake inhibitors (SRIs) except fluoxetine, which has an extended half-life. Agents with shorter half-lives such as venlafaxine, fluvoxamine, and paroxetine should be tapered gradually. Discontinuation symptoms, which frequently emerge after abrupt discontinuation or intermittent non-compliance and, less frequently, during dose reduction, are generally mild, short-lived, and self-limiting but can be distressing and may lead to missed work days and decreased productivity. The symptoms may be somatic (e.g., dizziness and light-headedness; nausea and vomiting; fatigue, lethargy, myalgia, chills, and other flu-like symptoms; sensory and sleep disturbances) or psychological (anxiety and/or agitation, crying spells, irritability). Mild symptoms dan often be treated by simply reassuring the patient that they are usually transient, but for more severe symptoms, it may be necessary to reinstitute the dosage of the original antidepressant and slow the rate of taper. Symptoms of discontinuation may be mistaken for physical illness or relapse into depression; misdiagnosing the symptoms may lead to unnecessary, costly tests and treatment. Thus, health care professionals need to be educated about the potential adverse effects of SRI discontinuation. C1 RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612. RP Rosenbaum, JF (reprint author), MASSACHUSETTS GEN HOSP,CLIN PSYCHOPHARMACOL UNIT,WACC 715,15 PARKMAN ST,BOSTON,MA 02114, USA. NR 13 TC 56 Z9 58 U1 1 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1997 VL 58 SU 7 BP 37 EP 40 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA XK602 UT WOS:A1997XK60200008 PM 9219493 ER PT J AU Glazer, WM Johnstone, BM AF Glazer, WM Johnstone, BM TI Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Symposium on Practical Issues in Using Olanzapine CY AUG 01-03, 1996 CL BOSTON, MA SP Eli Lilly & Co, Physicians Postgrad Press Inc ID COST-EFFECTIVENESS; CLOZAPINE; TRIALS AB Medications comprise a minor portion of the costs of schizophrenia, but may have a major impact on the likelihood of successful outcome of care. Novel antipsychotic medications which demonstrate superior symptom control, an improved safety profile, and benefits to quality-of-life may also reduce patients' need for medical services and the associated costs of these treatments. This report first considers key experimental design elements involved in integrating pharmacoeconomic and clinical objectives in studies of new drug therapies for schizophrenia. We briefly discuss the choice of therapies for comparison, randomization and blinding, sample size and composition, data collection, selection of the time frame for economic evaluation, and the importance of an intent-to-treat perspective. Second, as an example we present the design and selected results from a new economic clinical trial of the novel antipsychotic olanzapine. This trial utilized a randomized, double-blind design to compare the use of medical services and the cost of treatment for 817 schizophrenic patients from the United Slates treated with olanzapine or haloperidol. In comprehensive health care cost comparisons that incorporated the expenditures for study medications, the total cost of health care for olanzapine-treated patients was reduced by an average of $431 per month in comparison with haloperidol-treated patients during the initial 6 weeks of treatment. Among treatment responders receiving double-blind therapy for a maximum of 1 year, the total cost of care among olanzapine responders was reduced by an average of $345 per month in comparison with haloperidol responders. The results of this economic evaluation suggest that olanzapine's superior treatment profile may lead to reductions in the overall costs of medical care for patients with schizophrenia. C1 HARVARD UNIV,SCH MED,BOSTON,MA. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. ELI LILLY & CO,DIV HLTH SERV RES & POLICY,US MED OPERAT,INDIANAPOLIS,IN 46285. NR 29 TC 74 Z9 74 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1997 VL 58 SU 10 BP 50 EP 54 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA XP738 UT WOS:A1997XP73800009 PM 9265917 ER PT J AU Pollack, MH Otto, MW AF Pollack, MH Otto, MW TI Long-term course and outcome of panic disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Symposium on Treatment of Panic Disorder: The State of the Art CY JAN 12, 1996 CL W PALM BEACH, FL ID NATURALISTIC FOLLOW-UP; BEHAVIORAL-INHIBITION; AGORAPHOBIA; ALPRAZOLAM; DISCONTINUATION; CHILDHOOD; CHILDREN; PARENTS; ANXIETY; THERAPY AB The longitudinal course of panic disorder is an issue of critical clinical and research importance. For many patients, panic disorder may be a manifestation of an underlying, lifelong predisposition to anxiety with a chronic course, often requiring ongoing maintenance therapy. In this paper, we review some of the pertinent follow-up studies of patients with panic disorder treated with antidepressants, high-potency benzodiazepines, and cognitive behavior therapy, as well as data from longitudinal studies. RP Pollack, MH (reprint author), MASSACHUSETTS GEN HOSP,CLIN PSYCHOPHARMACOL UNIT,ANXIETY DISORDERS PROGRAM,15 PARKMAN ST,WAC 815,BOSTON,MA 02114, USA. NR 23 TC 18 Z9 18 U1 1 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1997 VL 58 SU 2 BP 57 EP 60 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA WN600 UT WOS:A1997WN60000010 PM 9078996 ER PT J AU Rosenbaum, JF AF Rosenbaum, JF TI Treatment-resistant panic disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Symposium on Treatment of Panic Disorder: The State of the Art CY JAN 12, 1996 CL W PALM BEACH, FL ID BEHAVIORAL-INHIBITION; BENZODIAZEPINE TREATMENT; ANXIETY DISORDERS; AGORAPHOBIA; CHILDREN; ASSOCIATION; COMORBIDITY; DEPRESSION; IMIPRAMINE; ATTACKS AB Although effective pharmacologic and psychosocial treatments are available for panic disorder, many patients continue to experience residual anxiety symptoms, recurrent panic attacks, or continuing impairment and distress. Selecting the appropriate treatment for such patients can be confounded by factors such as comorbid disorders (both psychiatric and medical), psychosocial complications, and physiologic provocations. The clinician must assess these factors before an optimal therapeutic strategy can be designed. C1 HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115. RP Rosenbaum, JF (reprint author), MASSACHUSETTS GEN HOSP,CLIN PSYCHOPHARMACOL UNIT,WAC 815,15 PARKMAN ST,BOSTON,MA 02114, USA. NR 20 TC 9 Z9 9 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 1997 VL 58 SU 2 BP 61 EP 65 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA WN600 UT WOS:A1997WN60000011 PM 9078997 ER PT J AU VanDijk, S Dean, DD Liu, Y Zhao, Y Schwartz, Z Boyan, BD AF VanDijk, S Dean, DD Liu, Y Zhao, Y Schwartz, Z Boyan, BD TI Immunological detection of bacterial proteolipids involved in microbial calcification. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX. HEBREW UNIV JERUSALEM,JERUSALEM,ISRAEL. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 102 EP 102 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000103 ER PT J AU Xue, J Margolis, HC Prostak, KS Bartlett, JD AF Xue, J Margolis, HC Prostak, KS Bartlett, JD TI Proteinase and inhibitor mRNA expression in the developing enamel organ. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 105 EP 105 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000105 ER PT J AU Bartlett, JD Xue, J Margolis, HC AF Bartlett, JD Xue, J Margolis, HC TI A novel serine proteinase mRNA isolated from porcine enamel organ. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 106 EP 106 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000109 ER PT J AU Fan, Y Davis, JJ Stultz, JD Margolis, HC AF Fan, Y Davis, JJ Stultz, JD Margolis, HC TI Buffer capacity of plaque fluids from caries-free and caries-active subjects SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 175 EP 175 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000170 ER PT J AU Yaskell, T Kashket, S AF Yaskell, T Kashket, S TI Enamel-protective effects of soluble calcium additives in foods. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 176 EP 176 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000174 ER PT J AU Socransky, SS Haffajee, AD Cugini, MA Smith, C Kent, RL AF Socransky, SS Haffajee, AD Cugini, MA Smith, C Kent, RL TI Microbial complexes in subgingival plaque. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 1 U2 7 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 302 EP 302 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000301 ER PT J AU Haffajee, AD Cugini, MA Tanner, A Pollack, RP Smith, C Kent, RL Socransky, SS AF Haffajee, AD Cugini, MA Tanner, A Pollack, RP Smith, C Kent, RL Socransky, SS TI Subgingival microbiota in healthy, elder and periodontitis subjects. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 303 EP 303 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000298 ER PT J AU Cugini, MA Haffajee, AD Smith, C Kent, RL Socransky, SS AF Cugini, MA Haffajee, AD Smith, C Kent, RL Socransky, SS TI 12 month effects of scaling and root planing on clinical and microbiological parameters. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 322 EP 322 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000323 ER PT J AU Gatti, JJ Skobe, Z Dobeck, JM Smith, C Socransky, SS AF Gatti, JJ Skobe, Z Dobeck, JM Smith, C Socransky, SS TI Bacterial DNA in periapical lesions using two surgical techniques. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,SCH DENT MED,BOSTON,MA 02115. FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 358 EP 358 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000357 ER PT J AU Kawashima, N Stashenko, P AF Kawashima, N Stashenko, P TI Cytokine network gene expression in experimentally-induced murine periapical lesions. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 361 EP 361 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000359 ER PT J AU Maseki, T Okuyama, C Ishizaka, C Nara, Y Tanaka, H Dogon, JL AF Maseki, T Okuyama, C Ishizaka, C Nara, Y Tanaka, H Dogon, JL TI Effect of the procedure following etching treatment on dentin bond strength. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,SCH DENT MED,FORSYTH DENT CTR,CAMBRIDGE,MA 02138. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 419 EP 419 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000416 ER PT J AU Niederman, R BuyleBodin, Y Lu, BY Robinson, P Naleway, C AF Niederman, R BuyleBodin, Y Lu, BY Robinson, P Naleway, C TI Short-chain carboxylic acid concentration in human gingival crevicular fluid SO JOURNAL OF DENTAL RESEARCH LA English DT Article DE short-chain carboxylic acids; periodontal disease; propionic acid; butyric acid ID ANAEROBIC-BACTERIA; BY-PRODUCT; HUMAN-NEUTROPHILS; INTRACELLULAR PH; SUCCINIC ACID; HL-60 CELLS; BUTYRATE; PROPIONATE; EXPRESSION; DIFFERENTIATION AB Short-chain carboxylic acids (e.g., lactic acid, propionic acid, butyric acid) are metabolic by-products of bacterial metabolism which can accumulate in the gingival crevice. It is of no small consequence, therefore, that 1- to 5-mM concentrations of these acids exhibit significant biological activity, including the ability to alter cell proliferation and gene expression in cells of importance to the periodontium. This communication reports on the in vivo concentrations of propionic and butyric acid in the gingival crevices of periodontal subjects with severe and mild disease. The results indicated that severely diseased subjects exhibited a > 10-fold increase in the mM concentration of these acids when compared with mildly diseased subjects (mean propionic acid - severe = 9.5 +/- 1.8 mM, and mild = 0.8 +/- 0.3 mM; mean butyric acid - severe = 2.6 +/- 0.4 mM, and mild = 0.2 +/- 0.04 mM). These differences (mean +/- SE) were significant (p < 0.0001). The propionic and butyric acid concentrations were below detection limits in healthy sites of mildly diseased subjects. The propionic and butyric acid concentrations also associated significantly with clinical measures of disease severity (e.g., pocket depth, attachment level) and inflammation (e.g., subgingival temperature, % of sites bleeding when probed), and with the total microbial load (all p < 0.05). Taken together, these data suggest that short-chain carboxylic acids play a mediating role in periodontal disease pathogenesis. C1 HARVARD UNIV,SCH DENT MED,DEPT PERIODONTOL,BOSTON,MA 02115. NORTHWESTERN UNIV,DEPT STOMATOL,CHICAGO,IL 60611. AMER DENT ASSOC HLTH FDN,CHICAGO,IL. RP Niederman, R (reprint author), FORSYTH DENT CTR,BOSTON,MA 02115, USA. FU NIDCR NIH HHS [DE08415] NR 38 TC 66 Z9 70 U1 0 U2 6 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PD JAN PY 1997 VL 76 IS 1 BP 575 EP 579 PG 5 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WH344 UT WOS:A1997WH34400008 PM 9042080 ER PT J AU Galvis, DLM Cruz, GD Tavares, M Kim, M LeGeros, RZ AF Galvis, DLM Cruz, GD Tavares, M Kim, M LeGeros, RZ TI Oral health practices of Asian-American adults residing in New York City SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NYU,COLL DENT,NEW YORK,NY 10012. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 609 EP 609 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000607 ER PT J AU Prostak, K Skobe, Z AF Prostak, K Skobe, Z TI Characterization of developing fluorotic enamel induced by fluoride and furosemide. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 673 EP 673 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000670 ER PT J AU Loo, CY Ganeshkumar, N AF Loo, CY Ganeshkumar, N TI Molecular cloning of a sialic acid-binding lectin from Streptococcus sanguis 12. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 727 EP 727 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000721 ER PT J AU Gasbarro, M Ahern, J Ganeshkumar, N Schluckebier, S Hay, DI AF Gasbarro, M Ahern, J Ganeshkumar, N Schluckebier, S Hay, DI TI Bacterial adhesion to hydroxyapatite surfaces in vivo. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 743 EP 743 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68000737 ER PT J AU Tanner, A Maiden, MFJ Taubman, MA Macuch, PJ Murray, LL AF Tanner, A Maiden, MFJ Taubman, MA Macuch, PJ Murray, LL TI Serum antibodies from initial periodontitis, gingivitis, and healthy subjects. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1103 EP 1103 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001097 ER PT J AU Colombo, AP Haffajee, AD Dewhirst, FE Paster, BJ Smith, CM Cugini, MA Socransky, SS AF Colombo, AP Haffajee, AD Dewhirst, FE Paster, BJ Smith, CM Cugini, MA Socransky, SS TI Subgingival microbiota of refractory periodontitis subjects. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1106 EP 1106 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001106 ER PT J AU XimenezFyvie, L Martin, L Haffajee, AD Tanner, A Macuch, P Socransky, SS AF XimenezFyvie, L Martin, L Haffajee, AD Tanner, A Macuch, P Socransky, SS TI DNA probes for oral Actinomyces. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1107 EP 1107 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001103 ER PT J AU Mobley, CC Romeu, J Cornell, JE Saudners, MJ AF Mobley, CC Romeu, J Cornell, JE Saudners, MJ TI Nutrient profile analysis for elders with removable dental prostheses. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX. GRECC,AUDIE L MURPHY MEM VET HOSP,SAN ANTONIO,TX. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1266 EP 1266 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001266 ER PT J AU Nagasawa, T Taubman, MA Kawai, T Smith, DJ Ishikawa, I AF Nagasawa, T Taubman, MA Kawai, T Smith, DJ Ishikawa, I TI Potential for regulatory effects of IL-10 on IL-12 function in periodontal disease. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,DEPT IMMUNOL,BOSTON,MA 02115. TOKYO MED & DENT UNIV,DEPT PERIODONTOL,TOKYO 113,JAPAN. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1288 EP 1288 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001285 ER PT J AU Niederman, R Lee, C Hynes, R AF Niederman, R Lee, C Hynes, R TI Early onset peridontal disease in P/E selectin-deficient mice. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 MIT,CAMBRIDGE,MA 02139. HARVARD UNIV,SCH DENT MED,FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1300 EP 1300 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001299 ER PT J AU Niederman, R Kelderman, H Ostroff, G Stashenko, P AF Niederman, R Kelderman, H Ostroff, G Stashenko, P TI PGG-glucan enhances the host response to periodontal pathogens. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,SCH DENT MED,FORSYTH DENT CTR,BOSTON,MA 02115. ALPHA BETA TECHNOL,WORCESTER,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1301 EP 1301 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001296 ER PT J AU Uematsu, T Truong, D Ostroff, G Stashenko, P Niederman, R AF Uematsu, T Truong, D Ostroff, G Stashenko, P Niederman, R TI Increased infection resistance in PGG-glucan-treated ICAM-1 deficient mice. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,SCH DENT MED,FORSYTH DENT CTR,BOSTON,MA 02115. ALPHA BETA TECHNOL,WORCESTER,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1302 EP 1302 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001300 ER PT J AU Sakellari, D Goodson, JM Socransky, SS Kolokotronis, A Konstantinidis, A AF Sakellari, D Goodson, JM Socransky, SS Kolokotronis, A Konstantinidis, A TI Concentration of 3 Tetracyclines in plasma, GCF and saliva. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. ARISTOTELIAN UNIV THESSALONIKI,GR-54006 THESSALONIKI,GREECE. RI SAKELLARI, DIMITRA/F-3299-2011 NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1304 EP 1304 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001301 ER PT J AU Burgess, JO Douglas, AS Norling, BK AF Burgess, JO Douglas, AS Norling, BK TI Post retention in root filled teeth. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78285. S TEXAS VET HLTH CARE SYST,SAN ANTONIO,TX. RI Norling, Barry/I-4119-2013 OI Norling, Barry/0000-0001-6655-8750 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1357 EP 1357 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001352 ER PT J AU Kimishima, T Enomoto, H Shibaoka, N Nara, Y Tanaka, H Dogon, IL AF Kimishima, T Enomoto, H Shibaoka, N Nara, Y Tanaka, H Dogon, IL TI In vivo and in vitro bond strength of light cure glass ionomer cement to cervical abrasion. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,SCH DENT MED,FORSYTH DENT CTR,CAMBRIDGE,MA 02138. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1374 EP 1374 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001372 ER PT J AU Chen, W Stashenko, P Li, YP AF Chen, W Stashenko, P Li, YP TI Identification of rat osteoblast-related genes by differential screening SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1638 EP 1638 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001636 ER PT J AU Akintoye, SO Dasso, M Ganeshkumar, N Hay, DI Bivona, P Spielman, AI AF Akintoye, SO Dasso, M Ganeshkumar, N Hay, DI Bivona, P Spielman, AI TI Further characterization of salivary adhesion promoting protein. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NYU,COLL DENT,NEW YORK,NY 10012. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1651 EP 1651 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001647 ER PT J AU Choi, YJ Troxler, RF Schluckebier, SK Hay, DJ Oppenheim, FG AF Choi, YJ Troxler, RF Schluckebier, SK Hay, DJ Oppenheim, FG TI Production of recombinant and mutant human statherin. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. GOLDMAN SCH DENT MED,DEPT ORAL BIOL,BOSTON,MA 02118. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1657 EP 1657 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001654 ER PT J AU Ali, R Johannessen, AC Dahlen, G Socransky, SS Skaug, N AF Ali, R Johannessen, AC Dahlen, G Socransky, SS Skaug, N TI Subgingival microbiota of adults with periodontitis or healthy periodontium in Cameroon. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 UNIV BERGEN,N-5020 BERGEN,NORWAY. GOTHENBURG UNIV,GOTHENBURG,SWEDEN. FORSYTH DENT CTR,BOSTON,MA 02115. RI Johannessen, Anne Christine/B-8929-2017 OI Johannessen, Anne Christine/0000-0001-5403-2380 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1713 EP 1713 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001710 ER PT J AU Kawai, T Wilson, ME Nagasawa, T Watanabe, H Eastcott, JW Smith, DJ Taubman, MA AF Kawai, T Wilson, ME Nagasawa, T Watanabe, H Eastcott, JW Smith, DJ Taubman, MA TI Adoptive transfer of cloned antigen-specific Th1 lymphocytes produces periodontal bone loss. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,DEPT IMMUNOL,BOSTON,MA 02115. TOKYO MED & DENT UNIV,DEPT PERIODONT,TOKYO 113,JAPAN. SUNY BUFFALO,DEPT ORAL BIOL,BUFFALO,NY 14260. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1738 EP 1738 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001738 ER PT J AU Esch, TR Taubman, MA AF Esch, TR Taubman, MA TI Cytokine profiles of gingival mononuclear cells measured by intracellular fluorescent staining SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,DEPT IMMUNOL,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1739 EP 1739 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001735 ER PT J AU Skobe, Z Dobeck, JM Prostak, KS AF Skobe, Z Dobeck, JM Prostak, KS TI Immunohistochemistry of bacteria in periodontium and lesions on human teeth. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 1930 EP 1930 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68001929 ER PT J AU Lingstrom, P Kashket, S VanHoute, J AF Lingstrom, P Kashket, S VanHoute, J TI The cariogenic potential of foods with various starch and sugar contents. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 2029 EP 2029 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68002023 ER PT J AU Maiden, MFJ Tanner, A Macuch, PJ Murray, LL AF Maiden, MFJ Tanner, A Macuch, PJ Murray, LL TI Subgingival temperature and microbiotas in health, gingivitis, & initial periodontitis. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 2038 EP 2038 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68002035 ER PT J AU Giannobile, WV Socransky, SS Palys, MD Haffajee, AD AF Giannobile, WV Socransky, SS Palys, MD Haffajee, AD TI Relationship between crevicular fluid ICTP levels of putative periodontal pathogens. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,SCH DENT MED,BOSTON,MA 02115. FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 2039 EP 2039 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68002032 ER PT J AU Dodds, MWJ Johnson, DA Yeh, CK AF Dodds, MWJ Johnson, DA Yeh, CK TI Effect of diabetes on saliva output and composition. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX. AUDIE L MURPHY MEM VET ADM MED CTR,GRECC,SAN ANTONIO,TX 78284. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 2080 EP 2080 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68002076 ER PT J AU Johansson, I Jarvholm, M Li, T Stromberg, N Hay, D AF Johansson, I Jarvholm, M Li, T Stromberg, N Hay, D TI Acidic proline-rich protein and statherin binding properties among microorganisms colonizing the oral cavity. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 UMEA UNIV,DEPT CARIOL,S-90187 UMEA,SWEDEN. FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 2256 EP 2256 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68002252 ER PT J AU Teles, R Wang, CY Alt, F Stashenko, P AF Teles, R Wang, CY Alt, F Stashenko, P TI Role of specific immunity in the pathogenesis of periapical lesions. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 CHILDRENS HOSP MED CTR,HSDM,FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 2268 EP 2268 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68002266 ER PT J AU Shoushtari, B Smith, DJ Heschel, RL King, WF Taubman, MA AF Shoushtari, B Smith, DJ Heschel, RL King, WF Taubman, MA TI Immunogenicity of peptides derived from a hypothetical second GTF catalytic domain. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,DEPT IMMUNOL,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 2269 EP 2269 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68002263 ER PT J AU Zhang, J Kashket, S AF Zhang, J Kashket, S TI Short chain carboxylic acids regulate cytokines of gingival epithelial cells. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 2275 EP 2275 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68002270 ER PT J AU Taubman, MA Holmberg, CJ Smith, DJ AF Taubman, MA Holmberg, CJ Smith, DJ TI Diepitopic construct of functionally relevant peptides enhances immunogenicity and reactivity with glucosyltransferase. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,DEPT IMMUNOL,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 2666 EP 2666 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68002664 ER PT J AU Smith, DJ Gupta, RK Chang, A Melvin, JL Heschel, RL Pereira, MBB King, WF Taubman, MA AF Smith, DJ Gupta, RK Chang, A Melvin, JL Heschel, RL Pereira, MBB King, WF Taubman, MA TI Effect of systemic priming on intragastric induction of mucosal immunity. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. MASS PUBL HLTH BIOL LABS,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 2667 EP 2667 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68002661 ER PT J AU Smith, DJ Heschel, RL Taubman, MA Thomas, WD AF Smith, DJ Heschel, RL Taubman, MA Thomas, WD TI Clostridium difficile toxin A as a mucosal adjuvant for glucan binding protein (GBP(59)). SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. ORAVAX INC,CAMBRIDGE,MA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 2668 EP 2668 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68002665 ER PT J AU Smith, DJ Heschel, RL Taubman, MA AF Smith, DJ Heschel, RL Taubman, MA TI Protection from experimental dental caries after immunization with peptides associated with a hypothetical second GTF catalytic site. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 2669 EP 2669 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68002662 ER PT J AU Lackey, M Kaban, LB Glowacki, J AF Lackey, M Kaban, LB Glowacki, J TI Regeneration of fetal rabbit osseous wounds. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,SKELETAL BIOL RES CTR,BOSTON,MA 02114. HSDM,BOSTON,MA. HMS,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 2909 EP 2909 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68002901 ER PT J AU Resillez, F Goldstein, J Smith, D AF Resillez, F Goldstein, J Smith, D TI Salivary immunity and DMFT levels in minority groups. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NYU,COLL DENT,NEW YORK,NY. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 3048 EP 3048 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68003041 ER PT J AU Stultz, J Soparkar, PM Kent, R Cugini, MA Depaola, PF AF Stultz, J Soparkar, PM Kent, R Cugini, MA Depaola, PF TI Longitudinal assessment of root surface status in seniors SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 3050 EP 3050 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68003046 ER PT J AU Yelick, PC Abduljabbar, T Bernier, D Stashenko, P AF Yelick, PC Abduljabbar, T Bernier, D Stashenko, P TI Activin receptor expression in zebrafish craniofacial development. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 FORSYTH DENT CTR,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 3067 EP 3067 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68003059 ER PT J AU Nara, Y Suda, S Nagakura, Y Nitta, T Tanaka, H Dogon, IL AF Nara, Y Suda, S Nagakura, Y Nitta, T Tanaka, H Dogon, IL TI Comparing in-vivo and in-vitro bond strengths using a portable adhesion tester. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,SCH DENT MED,FORSYTH DENT CTR,CAMBRIDGE,MA 02138. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 1997 VL 76 SI SI BP 3218 EP 3218 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WB680 UT WOS:A1997WB68003214 ER PT J AU Bogdanov, A Wright, SC Marecos, EM Bogdanova, A Martin, C Petherick, P Weissleder, R AF Bogdanov, A Wright, SC Marecos, EM Bogdanova, A Martin, C Petherick, P Weissleder, R TI A long-circulating co-polymer in ''passive targeting'' to solid tumors SO JOURNAL OF DRUG TARGETING LA English DT Article DE poly(ethylene glycol); graft-copolymer; cancer; biodistribution; imaging; chemotherapy; cis-diamminedichloroplatinum(II) ID MICROVASCULAR PERMEABILITY; MONOCLONAL-ANTIBODY; STEALTH LIPOSOMES; AGENTS; XENOGRAFT; SURFACE; OXIDE AB A co-polymer of O-methyl polyethylene(glycol)-O'-succinate (MPEGs, m.w. 5100) and poly-1-lysine (PL, median m.w. 32700, degree of polymerization 256) has been synthesized by covalent grafting. The resultant MPEGs-PL (30% modification degree of E-amino groups) had a hydrodynamic diameter corresponding to a 690 kD protein. Free amino groups (180/mol of the co-polymer) were used for conjugation of diethylene pentaacetic or succinic acid residues to MPEGs-PL. The potential of the resultant compound as a carrier of therapeutic and diagnostic drugs was studied using a rodent carcinoma models. The co-polymer had a blood pool half-life of 36h in adenocarcinoma-bearing rats. Radioactively labeled preparations were resistant to trans-chelation with apotransferrin and stable in blood for 24 h. The co-polymer accumulated in solid tumors at the level of 1.5-2% injected dose/g of tumor in 24 h, At that time, 35-40% of the accumulated polymer was associated with tumor cell fraction, The co-polymer non-covalently associated with cis-diamminedichloroplatinum(II), showed a cytostatic effect against mouse F9 carcinoma, and induced a reversal in tumor growth after intravenous administration. RP Bogdanov, A (reprint author), MASSACHUSETTS GEN HOSP,DEPT RADIOL,CTR MOL IMAGING RES,RM 5420,BLDG 149,13TH ST,BOSTON,MA 02129, USA. NR 21 TC 62 Z9 63 U1 1 U2 7 PU HARWOOD ACAD PUBL GMBH PI READING PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 1061-186X J9 J DRUG TARGET JI J. Drug Target. PY 1997 VL 4 IS 5 BP 321 EP & DI 10.3109/10611869708995848 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA XA708 UT WOS:A1997XA70800008 PM 9169989 ER PT J AU Yagnik, PM Schraeder, PL OHara, K AF Yagnik, PM Schraeder, PL OHara, K TI Therapeutic phenytoin levels with tube feeding: New techniques SO JOURNAL OF EPILEPSY LA English DT Article DE phenytoin; tube feeding; seizures; nutrition; blood levels ID ENTERAL NUTRIENT FORMULA; ABSORPTION AB A therapeutic serum level of phenytoin (PHT) is difficult to achieve in patients who receive enteral tube feeding. In four patients, PHT capsules were dissolved in 250 ml warm water and cooled to body temperature before being administered. A therapeutic serum level of PHT was maintained in all four patients. Another group of three patients received PHT suspension, at an interval of 8 h, with water at room temperature. Again serum PHT levels were maintained in the therapeutic range in all three patients. The present preliminary study indicates that bioavailability of PHT is increased by dissolution in water in patients receiving chronic enteral tube feeding. There is a need for further investigation of the kinetics of absorption of PHT and other antiepileptic drugs in patients receiving enteral tube feeding. (C) 1997 by Elsevier Science Inc. C1 ALLEGHENY UNIV HLTH SCI,HAHNEMANN MED COLL,PHILADELPHIA,PA 19102. COOPER HOSP UNIV MED CTR,ROBERT WOOD JOHNSON MED SCH,DIV NEUROL,CAMDEN,NJ 08103. RP Yagnik, PM (reprint author), PHILADELPHIA VA MED CTR,DEPT NEUROL,UNIV & WOODLAND AVE,PHILADELPHIA,PA 19104, USA. NR 11 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0896-6974 J9 J EPILEPSY JI J. Epilepsy PD JAN-FEB PY 1997 VL 10 IS 1 BP 22 EP 25 DI 10.1016/S0896-6974(96)00070-9 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA WP354 UT WOS:A1997WP35400006 ER PT J AU Brown, D Smith, PJS Breton, S AF Brown, D Smith, PJS Breton, S TI Role of V-ATPase-rich cells in acidification of the male reproductive tract SO JOURNAL OF EXPERIMENTAL BIOLOGY LA English DT Article DE epididymis; vas deferens; pH regulation; immunocytochemistry; bafilomycin ID MEDULLARY COLLECTING DUCT; INTERCALATED CELLS; EPITHELIAL-CELLS; RAT EPIDIDYMIS; URINARY ACIDIFICATION; CONTAIN CLATHRIN; PROTON SECRETION; SPERM MOTILITY; TURTLE BLADDER; GOLGI STACK AB Specialized proton-secreting cells play important physiological roles in a variety of tissues, On the basis of the immunocytochemical detection of carbonic anhydrase and V-ATPase in distinct epithelial cells of the epididymis and vas deferens, we predicted that the vacuolar V-ATPase that is located on the apical membrane of these cells should be a major contributor to luminal acidification in parts of the male reproductive tract. Physiological studies using the proton-selective vibrating probe in the vas deferens confirmed this hypothesis, As discussed recently, maintenance of the pH of the reproductive tract is probably under tight physiological control, by analogy with the situation in the kidney. Manipulation of luminal pH might, therefore, provide a point of intervention for the regulation of male fertility. In addition, it is possible that some cases of unexplained male infertility might result from defective acidification, resulting either from pathological states or potentially from environmental factors that may inhibit proton secretory pathways. C1 MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02129. MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02129. HARVARD UNIV,SCH MED,BOSTON,MA 02129. MARINE BIOL LAB,NATL VIBRATING PROBE FACIL,WOODS HOLE,MA 02543. FU NIDCD NIH HHS [DC 42956]; Wellcome Trust [078366] NR 63 TC 60 Z9 62 U1 1 U2 2 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE, CAMBS, ENGLAND CB4 4DL SN 0022-0949 J9 J EXP BIOL JI J. Exp. Biol. PD JAN PY 1997 VL 200 IS 2 BP 257 EP 262 PG 6 WC Biology SC Life Sciences & Biomedicine - Other Topics GA WH719 UT WOS:A1997WH71900007 PM 9050233 ER PT J AU Word, CJ Sawosik, TM Bing, DH AF Word, CJ Sawosik, TM Bing, DH TI Summary of validation studies from twenty-six forensic laboratories in the United States and Canada on the use of the AmpliType(R) PM PCR amplification and typing kit SO JOURNAL OF FORENSIC SCIENCES LA English DT Article; Proceedings Paper CT 47th Annual Meeting of the American-Academy-of-Forensic-Sciences CY FEB 13-18, 1995 CL SEATTLE, WA SP Amer Acad Forens Sci DE forensic science; polymerase chain reaction; DNA typing; PM; polymarker; LDLR; GYPA; HBGG; D7S8; GC ID DEOXYRIBONUCLEIC-ACID DNA; GENOMIC DNA; EXTRACTION; SAMPLES; TRIAL AB A cooperative study was undertaken to collect and summarize the results of validation studies from forensic laboratories in the United States and Canada on the use of the AmpliType(R) PM PCR amplification and typing kit for genetic typing of forensic biological evidence. This report compiles data from 26 laboratories on: 1) reproducibility studies on DNA extracted from various samples, 2) genetic typing of DNA extracted from a variety of biological samples on various substrates, 3) the effects of exogenous chemicals, materials, and environmental factors on test results, 4) sensitivity studies to determine the least detectable amount of extracted genomic DNA that can be reliably typed, 5) analysis of mixtures containing two sources of genomic DNA, 6) cross-hybridization with DNA extracted from various nonhuman species, and 7) evaluation of assay performance on parallel studies with other genetic typing systems on proficiency test panels, mock cases, and adjudicated/nonprobative casework. Equivalent results were obtained by each laboratory that supplied data, demonstrating the reliability and consistency of the test. Overall, it can be concluded from this study that the AmpliType PM PCR amplification and typing kit meets the guidelines of the Technical Working Group on DNA Analysis Methods (TWGDAM) and there is general scientific acceptability of this kit for forensic DNA testing. C1 CBR LABS INC,CLIN TESTING LAB,CTR BLOOD RES,BOSTON,MA 02115. CELLMARK DIAGNOST,GERMANTOWN,MD. PARAXEL,WALTHAM,MA 02154. NR 31 TC 5 Z9 5 U1 0 U2 2 PU AMER SOC TESTING MATERIALS PI W CONSHOHOCKEN PA 100 BARR HARBOR DR, W CONSHOHOCKEN, PA 19428-2959 SN 0022-1198 J9 J FORENSIC SCI JI J. Forensic Sci. PD JAN PY 1997 VL 42 IS 1 BP 39 EP 48 PG 10 WC Medicine, Legal SC Legal Medicine GA WA690 UT WOS:A1997WA69000006 PM 8988573 ER PT J AU Harari, D Gurwitz, JH Avorn, J Bohn, R Minaker, KL AF Harari, D Gurwitz, JH Avorn, J Bohn, R Minaker, KL TI How do older persons define constipation? Implications for therapeutic management SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 48th Annual Meeting of the Gerontological-Society-of-America CY NOV, 1995 CL CHICAGO, IL SP Gerontolog Soc Amer DE constipation; aged; bowel movements; straining; rectal evacuation ID UNITED-STATES; ANORECTAL FUNCTION; POPULATION; LACTULOSE; STOOL AB This study examined the relation between bowel-related symptoms and self-report of constipation in 10,875 subjects aged 60 years and over, who participated in the 1989 National Health Interview Survey. Subjects reporting constipation ''always'' or ''mostly'' over the past 12 months (n = 594) were compared with those who reported never having the symptom (n = 4,192). Straining (adjusted odds ratio 66.7; 95% confidence interval 31.5, 142.4) and hard bowel movements (25.6; 16.7, 38.7) were most strongly associated with self-report of constipation. These findings suggest that treatment for constipation in the older population should be directed as much or more at facilitating comfortable rectal evacuation, as increasing bowel movement frequency. RP Harari, D (reprint author), MASSACHUSETTS GEN HOSP,GERIATR MED UNIT,169 CAMBRIDGE ST,100 CHARLES RIVER PLAZA,5TH FLOO,BOSTON,MA 02114, USA. FU NIA NIH HHS [AG00599, AG04390, AG08812-05] NR 20 TC 37 Z9 38 U1 1 U2 1 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 1997 VL 12 IS 1 BP 63 EP 66 DI 10.1007/s11606-006-0009-z PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA WG811 UT WOS:A1997WG81100009 PM 9034948 ER PT J AU Spiro, A Schnurr, PP Aldwin, CM AF Spiro, A Schnurr, PP Aldwin, CM TI A life-span perspective on the effects of military service SO JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT Conference on Even unto Old Age - The Long-Term Effects of Traumatic Experience CY OCT 14, 1995 CL CAMBRIDGE, MA SP Boston Soc Gerontol Psychiat Inc ID POSTTRAUMATIC-STRESS-DISORDER; WORLD-WAR-II; KEANE PTSD SCALE; TRAUMATIC EVENTS; VIETNAM-WAR; FOLLOW-UP; DELAYED RECOGNITION; FORMER PRISONERS; UNITED-STATES; MALE VETERANS C1 US DEPT VET AFFAIRS,OUTPATIENT CLIN,NORMAT AGING STUDY,BOSTON,MA. BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02215. US DEPT VET AFFAIRS,MED & REF OFF CTR,NATL CTR POSTTRAUMAT STRESS DISORDERS,WHITE RIVER JCT,VT. DARTMOUTH COLL,SCH MED,DEPT PSYCHOL,HANOVER,NH 03755. UNIV CALIF DAVIS,DEPT HUMAN & COMMUNITY DEV,DAVIS,CA. NR 113 TC 20 Z9 20 U1 3 U2 3 PU INT UNIV PRESS INC PI MADISON PA 59 BOSTON POST RD PO BOX 1524, MADISON, CT 06443-1524 SN 0022-1414 J9 J GERIATR PSYCHIAT JI J. Geriatr. Psychiatry PY 1997 VL 30 IS 1 BP 91 EP 128 PG 38 WC Geriatrics & Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA XV730 UT WOS:A1997XV73000006 ER PT J AU Masterman, DL Mendez, MF Fairbanks, LA Cummings, JL AF Masterman, DL Mendez, MF Fairbanks, LA Cummings, JL TI Sensitivity, specificity, and positive predictive value of technetium 99-HMPAO SPECT in discriminating Alzheimer's disease from other dementias SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article ID EMISSION COMPUTED-TOMOGRAPHY; CEREBRAL BLOOD-FLOW; ADRDA WORK GROUP; TC-99M HM-PAO; CLINICAL-DIAGNOSIS; NEUROPATHOLOGICAL FINDINGS; INFARCT DEMENTIA; TEMPORAL-LOBE; BRAIN SPECT; I-123 IMP AB Investigators have reported high sensitivity and specificity values for single photon emission computerized tomography (SPECT) when distinguishing Alzheimer's disease (AD) patients from normal elderly controls or from selected patient groups. The role of SPECT in identifying AD among unselected patients with memory complaints requires investigation. We examined 139 consecutive patients with Tc-99-HMPAO SPECT. NINCDS-ADRDA diagnoses were determined blind to SPECT results, and scans were read and classified by visual inspection blind to clinical diagnoses. Bilateral temporoparietal hypoperfusion (TP) occurred in 75% of probable, 65% of possible, and 45% of unlikely AD patients, yielding a sensitivity of 75% and a specificity of 52% when comparing probable AD versus unlikely AD groups. A positive predictive value of 78% was obtained based on a 69% prevalence of AD in our total clinic population. Patients with false-positive results included a variety of dementing illnesses; all patients with bilateral hypoperfusion had dementia. A pattern of TP on SPECT scans is seen in most patients with AD, but could be found in other dementias as well and cannot be regarded as specific to AD. Reduced TP perfusion discriminated between demented and nondemented individuals. Further strategies for SPECT interpretation that improve diagnostic specificity should be sought. C1 UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BIOBEHAV SCI,SCH MED,NEUROBEHAV UNIT,LOS ANGELES,CA 90095. RP Masterman, DL (reprint author), UNIV CALIF LOS ANGELES,DEPT NEUROL,SCH MED,NEUROBEHAV UNIT,W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90095, USA. FU NIA NIH HHS [AG10123] NR 50 TC 50 Z9 52 U1 0 U2 3 PU DECKER PERIODICALS INC PI HAMILTON PA 4 HUGHSON STREET SOUTH PO BOX 620, LCD 1, HAMILTON ON L8N 3K7, CANADA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD JAN PY 1997 VL 10 IS 1 BP 15 EP 21 PG 7 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA WX819 UT WOS:A1997WX81900004 PM 9100154 ER PT J AU Weber, KSC York, MR Springer, TA Klickstein, LB AF Weber, KSC York, MR Springer, TA Klickstein, LB TI Characterization of lymphocyte function-associated antigen 1 (LFA-1)-deficient T cell lines - The alpha(L) and beta(2) subunits are interdependent for cell surface expression SO JOURNAL OF IMMUNOLOGY LA English DT Article ID LEUKOCYTE ADHESION DEFICIENCY; FUNCTION-ASSOCIATED MOLECULE-1; TYROSINE PHOSPHATASE CD45; POINT MUTATIONS; P150,95 GLYCOPROTEINS; COUNTER-RECEPTOR; MESSENGER-RNA; INTEGRIN; PROTEINS; LFA-1 AB The leukocyte, or beta(2), integrins are heterodimeric cell surface molecules that share a common beta subunit, and have unique alpha subunits, LFA-1 is the predominant beta(2) integrin on lymphocytes, and plays an important role in many lymphocyte functions; however, most studies of the cytoplasmic regions of LFA-1 have been performed in transfected epithelial cells, such as COS, in part because no lymphoid cell lines deficient in the LFA-1 alpha subunit have been described. To address structure-function studies of beta(2) integrins in relevant cell types, two T lymphoblastoid cell clones that completely lack cell surface LFA-1, J-beta(2).7 and SK-beta(2).7, derived from Jurkat and SKW3, respectively, were prepared by chemical mutagenesis and selection. Biosynthetic labeling and immunoprecipitation showed that the J-beta(2).7 clone did not translate any LFA-1 alpha subunit protein, while the SK-beta(2).7 cells did not synthesize any beta(2) subunit protein. Northern blot analysis of poly(A(+)) RNA from these cells revealed an absence of the corresponding mRNA in each case. By transfection analysis, only the a subunit reconstituted LFA-1 expression in the J-beta(2).7 cells, while only the beta subunit restored cell surface LFA-1 expression in the SK-beta(2).7 cells. Functional studies with the parental cell lines, the J-beta(2).7 and SK-beta(2).7 cells, and the transfectants showed that all binding of Jurkat and SKW3 cells to purified ICAM-1 is mediated by LFA-1, and the reconstituted LFA-1 expressed by the J-beta(2).7 and SK-beta(2).7 transfected cells is regulated normally. C1 BRIGHAM & WOMENS HOSP,LMRC,DEPT MED,DIV RHEUMATOL & IMMUNOL,BOSTON,MA 02115. CTR BLOOD RES,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 53 TC 42 Z9 42 U1 0 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 1997 VL 158 IS 1 BP 273 EP 279 PG 7 WC Immunology SC Immunology GA VZ128 UT WOS:A1997VZ12800033 PM 8977199 ER PT J AU Murray, PJ Wang, L Onufryk, C Tepper, RI Young, RA AF Murray, PJ Wang, L Onufryk, C Tepper, RI Young, RA TI T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection SO JOURNAL OF IMMUNOLOGY LA English DT Article ID NECROSIS-FACTOR-ALPHA; INTERFERON-GAMMA; INTERLEUKIN-10 IL-10; IN-VIVO; MICE; LYMPHOCYTE; RECEPTOR; EXPRESSION; RESISTANCE; ANTIBODY AB Pathogenic mycobacteria survive within macrophages despite T cell responses that activate host defenses against most pathogens. Among cytokines produced by T cells, IL-10 is known to negatively regulate Th1 cells as well as macrophages. IL-10 has been shown to inhibit the anti-mycobacterial activity of macrophages in vitro and could account for the ability of mycobacteria to survive intracellularly. To test the inhibitory functions of IL-10 in vivo, transgenic mice that secrete IL-10 from the T cell compartment were constructed and infected with Calmette-Guerin bacillus (Mycobacterium bovis), These mice were unable to clear the infection and developed large bacterial burdens, Nonetheless, their T cells produced abundant amounts of IFN-gamma and IL-2 in response to Ag challenge, These results indicate that the presence of excess IL-10 had little, if any, effect on T cell function or development during the immune response to Calmette-Guerin bacillus, Rather, the data suggest that IL-10 helps maintain mycobacterial infections by acting primarily at the level of the macrophage, overriding anti-mycobacterial signals delivered by IFN-gamma. C1 WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142. MIT,DEPT BIOL,CAMBRIDGE,MA 02139. MASSACHUSETTS GEN HOSP,CTR CANC,CHARLESTOWN,MA 02129. RI Young, Richard/F-6495-2012 OI Young, Richard/0000-0001-8855-8647 NR 33 TC 146 Z9 150 U1 1 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 1997 VL 158 IS 1 BP 315 EP 321 PG 7 WC Immunology SC Immunology GA VZ128 UT WOS:A1997VZ12800039 PM 8977205 ER PT J AU Puri, KD Finger, EB Springer, TA AF Puri, KD Finger, EB Springer, TA TI The faster kinetics of L-selectin than of E-selectin and P-selectin rolling at comparable binding strength SO JOURNAL OF IMMUNOLOGY LA English DT Article ID LEUKOCYTE ADHESION MOLECULE-1; HIGH ENDOTHELIAL VENULES; NODE HOMING RECEPTOR; HUMAN NEUTROPHILS; FUNCTIONAL-CHARACTERIZATION; PHYSIOLOGICAL FLOW; CELL-SURFACE; LYMPHOCYTE ATTACHMENT; GLYCOPROTEIN LIGAND-1; SPATIAL-DISTRIBUTION AB Selectins are a family of lectins that mediate tethering and rolling of leukocytes on endothelium in vascular shear flow, To test the hypothesis that the kinetics and the strength of rolling interactions can be independently varied for different selectin:ligand pairs, we have directly compared all three selectins with regard to distinct measures of selectin-mediated interactions in shear flow: tethering, rolling velocity, and strength of rolling adhesions, At comparable site densities of E-selectin, P-selectin, and the L-selectin counter-receptor CD34, neutrophils tethered with similar efficiency and developed rolling adhesions of similar strength as measured by resistance to detachment, Under the same conditions, neutrophils rolled 7.5- to 10.5-fold faster on CD34 than on E-selectin and P-selectin. These findings suggest that the kinetics of bond dissociation and bond formation are faster for L-selectin than for E- and P-selectin. We also compared the behavior of neutrophils and lymphocytes on the same selectin, Both cell types showed comparable strength of binding to CD34; however, neutrophils rolled with faster velocities than lymphocytes. C1 CTR BLOOD RES,DEPT PATHOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 53 TC 80 Z9 83 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 1997 VL 158 IS 1 BP 405 EP 413 PG 9 WC Immunology SC Immunology GA VZ128 UT WOS:A1997VZ12800050 PM 8977216 ER PT J AU Akagi, J Hodge, JW McLaughlin, JP Gritz, L Mazzara, G Kufe, D Schlom, J Kantor, JA AF Akagi, J Hodge, JW McLaughlin, JP Gritz, L Mazzara, G Kufe, D Schlom, J Kantor, JA TI Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7 SO JOURNAL OF IMMUNOTHERAPY LA English DT Article DE MUC1; B7; vaccine; costimulation; vaccinia ID ACTIVE-SPECIFIC IMMUNOTHERAPY; CARCINOMA-ASSOCIATED ANTIGEN; TUMOR-ASSOCIATED ANTIGENS; BREAST-CANCER; PROTEIN CORE; ADJUVANT; IMMUNITY; SEQUENCE; DF3; LYMPHOCYTES AB Tumor-associated antigens have considerable promise not only as diagnostic or prognostic markers but also as targe ts for active or passive immunotherapy. DF3/MUC1 is a tumor-associated antigen that is overexpressed with an abnormal glycosylation pattern in breast, ovarian, lung, and pancreatic cancers. The major extracellular portion of MUC1 is composed of tandem repeal units of 20 amino acids. Recombinant vaccinia viruses encoding mucin molecules have been constructed by several groups. However, these recombinants have met with limited success in protecting animals from MUC1-expressing tumors because of the vaccinia genome being subject to high-frequency homologous recombination, therefore being unstable in expression of the tandem repeats. In light of these studies, two concurrent strategies were used to improve immune responses to MUC1: a recombinant vaccinia virus was constructed containing a modified ''mini'' MUC1 gene containing only 10 tandem repeat sequences to minimize vaccinia-mediated rearrangement (designated rV-MUC1); and an admixture was used containing rV-MUC1 and a recombinant vaccinia virus containing the gene for the murine T-cell costimulatory molecule B7-1 (rV-B7). The rV-MUC1 gene product maintained a consistent molecular weight throughout several passages, indicating stability of the inserted gene. Mice inoculated with rV-MUC1 demonstrated MUC1-specific cytolytic responses that were further enhanced by admixture with rV-B7. In a MUC1-expressing pulmonary metastases prevention model, mice inoculated two times with rV-MUC1 were protected from the establishment of metastases. No additive effect on antitumor immunity (>90% with rV-MUC1 alone) was observed in mice primed with an admixture of rV-MUC and rV-B7 and boosted with rV-MUC1. When rV-MUC1 was used to treat established MUC1 positive metastases, however, three administrations of rV-MUC1 were not sufficient to confer antitumor effects. In contrast, when tumor-bearing mice were primed with an admixture of rV-MUC1 and rV-B7, followed by two boosts with rV-MUC1, there was a significant reduction in pulmonary metastases (p = < 0.0001), which correlated to 100% survival. Coexpression of the B7 molecule, although not necessary for the induction of an immune response of sufficient magnitude to prevent MUC1 tumors, tvas thus essential in a treatment setting. C1 NCI, TUMOR IMMUNOL & BIOL LAB, NIH, BETHESDA, MD 20892 USA. KUMAMOTO UNIV, SCH MED, DEPT SURG, KUMAMOTO 860, JAPAN. HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC PHARMACOL, BOSTON, MA 02115 USA. THER BIOL CORP, CAMBRIDGE, MA USA. RI Hodge, James/D-5518-2015 OI Hodge, James/0000-0001-5282-3154 NR 32 TC 62 Z9 62 U1 0 U2 1 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 1053-8550 J9 J IMMUNOTHER JI J. Immunother. PD JAN PY 1997 VL 20 IS 1 BP 38 EP 47 DI 10.1097/00002371-199701000-00004 PG 10 WC Oncology; Immunology; Medicine, Research & Experimental SC Oncology; Immunology; Research & Experimental Medicine GA WK735 UT WOS:A1997WK73500004 PM 9101412 ER PT J AU Aiura, K Clark, BD Dinarello, CA Margolis, NH Kaplanski, G Burke, JF Tompkins, RG Gelfand, JA AF Aiura, K Clark, BD Dinarello, CA Margolis, NH Kaplanski, G Burke, JF Tompkins, RG Gelfand, JA TI Interaction with autologous platelets multiplies interleukin-1 and tumor necrosis factor production in mononuclear cells SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID DISSEMINATED INTRAVASCULAR COAGULATION; GROWTH FACTOR-BETA; ACTIVATED PLATELETS; CYTOKINE PRODUCTION; RECEPTOR ANTAGONIST; ESCHERICHIA-COLI; SEPTIC SHOCK; PLASMA-LEVEL; FACTOR-ALPHA; ENDOTOXIN AB The effect of activated platelets on cytokine production by human peripheral blood mononuclear cells (PBMC) was investigated. When PBMC were coincubated with activated autologous platelets amid lipopolysaccharide (LPS, 50-100 pg/mL) for 8 h, the production of interleukin (IL)-1 alpha increased 11- to 18-fold and tumor necrosis factor (TNF)-alpha 3- to 5-fold compared with PBMC without platelets. Activated platelets in a dual-chamber well that prevented platelet-PBMC contact but permitted passage of soluble factors enhanced IL-1 alpha production (P < .01). Platelet-PBMC contact in the chamber resulted in a further enhancement of IL-1 alpha production. These data suggest that platelet-PBMC interaction, both directly and with platelet-derived factors, enhances production of shock-producing IL-1 alpha and TNF-alpha, albeit differently. The interaction of platelets with monocytes may play an important role in the pathophysiology of sepsis and disseminated intravascular coagulation. C1 TUFTS UNIV NEW ENGLAND MED CTR,DEPT MED,BOSTON,MA 02111. TUFTS UNIV,SCH MED,DEPT MED,DIV GEOG MED & INFECT DIS,BOSTON,MA 02111. HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. FU NIAID NIH HHS [AI-15614]; NIGMS NIH HHS [GM-21700, GM-50766] NR 35 TC 25 Z9 27 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637 SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD JAN PY 1997 VL 175 IS 1 BP 123 EP 129 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA WA937 UT WOS:A1997WA93700017 PM 8985205 ER PT J AU Sheridan, R Prelack, K Yin, L Riggi, V AF Sheridan, R Prelack, K Yin, L Riggi, V TI Energy needs are poorly predicted in critically ill elderly SO JOURNAL OF INTENSIVE CARE MEDICINE LA English DT Article ID PARENTERAL-NUTRITION THERAPY; INDIRECT CALORIMETRY; INTENSIVE-CARE; RESPIRATORY-FAILURE; OXYGEN-CONSUMPTION; BURNED PATIENTS; METABOLIC-RATE; WEIR EQUATION; GAS-EXCHANGE; APACHE-II AB Changes in energy expenditure with age have been described, but this physiology is not routinely considered when managing critically ill elderly patients. To allow us to avoid the potential problems associated with underfeeding or overfeeding the critically ill elderly population, with approval of the human studies committee and appropriate consent from legal guardians, 25 critically ill patients over 65 years of age requiring mechanical ventilation underwent expired gas indirect calorimetry. If they had a pulmonary artery catheter in place far clinical reasons, reverse-Fick indirect calorimetry was also performed. Data obtained by indirect calorimetry was compared with commonly applied equations for predicting energy expenditure by statistical methods of correlation and limits of agreement. These 25 patients had an average age of 74 +/- 1.23 (standard error of the mean) and an average APACHE II score of 15. Predictive equations correlated poorly with measured resting energy expenditure, and although they showed reasonable bias, they were imprecise in their estimation of resting energy expenditure. These data suggest that energy expenditure in critically ill, mechanically ventilated elderly patients is highly variable. Although generally overestimating energy needs, currently available equations for predicting energy expenditure in this population are associated with significant bias and imprecision, which may lead to both overfeeding and underfeeding. Although these equations may be suitable as a basis of initiating nutritional support, energy provisions should ideally be guided by indirect calorimetry. C1 MASSACHUSETTS GEN HOSP,SHRINERS BURNS INST,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,SURG SERV,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,DEPT RESP CARE,BOSTON,MA 02114. NR 47 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 SN 0885-0666 J9 J INTENSIVE CARE MED JI J. Intensive Care Med. PD JAN-FEB PY 1997 VL 12 IS 1 BP 45 EP 49 PG 5 WC Critical Care Medicine SC General & Internal Medicine GA XF249 UT WOS:A1997XF24900006 ER PT J AU Fox, FE Kubin, M Cassin, M Niu, ZT Hosoi, J Torii, H Granstein, RD Trinchieri, G Rook, AH AF Fox, FE Kubin, M Cassin, M Niu, ZT Hosoi, J Torii, H Granstein, RD Trinchieri, G Rook, AH TI Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: Effects on B7, interleukin 10, and interleukin 12 SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article DE immunosuppression; neuropeptides; cytokines ID MEDULLARY-THYROID CARCINOMA; LYMPHOCYTE DIFFERENTIATION; CGRP; EXPRESSION; MODULATION; RECEPTORS; HYPERSENSITIVITY; INDUCTION; RESPONSES AB CGRP is a neuropeptide that has previously been described to possess immunosuppressive activities, CGRP is released from peripheral nerves that, in the skin, are in close physical association with dendritic APC, We sought to investigate the mechanisms by which CGRP can inhibit immune responses by studying its effects on human peripheral blood mononuclear cells (PBMC), Using allogeneic monocytes as stimulator cells, CGRP could inhibit the proliferation of PBMC by 47% when CGRP was present for the duration of culture, Interestingly, when the stimulator monocytes were incubated with CGRP for 2 h prior to irradiation then washed, the observed inhibition increased to 85%, suggesting that CGRP was exerting a direct effect on the monocyte stimulator population, Finally, the recall response to tetanus toroid (TT) by PBMC from individuals vaccinated with TT 14 d prior was inhibited by 25-50% in the presence of CGRP, Also, CGRP decreased the levels of B7.2 but not B7.1 on treated monocytes, and this inhibition could be abrogated by the addition of anti-IL-10 antibody, suggesting that the inhibition was mediated by an increase in IL-10 production, Moreover, increased IL-10 production was confirmed by ELISA, Both IL-12 p40 and IFN-gamma levels in CGRP-treated cultures were found to be decreased by approximately 30%, The decrease in IL-12 p40 levels could be reversed by addition of anti-IL-10, These data suggest that CGRP inhibits PBMC proliferation, in part, through the release of IL-10, which in turn can downregulate important co-stimulatory molecules and the cytokines IL-12 and IFN-gamma. C1 WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104. MASSACHUSETTS GEN HOSP,HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. RP Fox, FE (reprint author), UNIV PENN,DEPT DERMATOL,SCH MED,415 CURIE BLVD,ROOM 238 CRB-6142,PHILADELPHIA,PA 19104, USA. FU NCI NIH HHS [CA32898, CA 20833]; NIAMS NIH HHS [R01 AR42429] NR 31 TC 82 Z9 86 U1 0 U2 3 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD JAN PY 1997 VL 108 IS 1 BP 43 EP 48 DI 10.1111/1523-1747.ep12285627 PG 6 WC Dermatology SC Dermatology GA VZ789 UT WOS:A1997VZ78900009 PM 8980285 ER PT J AU Rhodes, LE Tsoukas, MM Anderson, RR Kollias, N AF Rhodes, LE Tsoukas, MM Anderson, RR Kollias, N TI Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article DE iontophoresis; photobleaching; photodynamic therapy ID TOPICAL PHOTODYNAMIC THERAPY; ENDOGENOUS PROTOPORPHYRIN-IX; DELTA-AMINOLEVULINIC-ACID; BASAL-CELL CARCINOMA; 5-AMINOLEVULINIC ACID; INDUCED PORPHYRIN; TUMORS; FLUORESCENCE; PHOTOSENSITIZATION; PENETRATION AB Photodynamic therapy (PDT) with topical 5-aminolevulinic acid (ALA) is increasingly employed for skin cancer, yet ALA dosing is crude, Using iontophoresis, we developed a rapid and quantifiable system for topical ALA delivery, with measurement of subsequent PpIX fluorescence and phototoxicity, ALA was iontophoresed from a 2% solution into upper inner arm skin of 13 healthy volunteers, Six doses of ALA were delivered with a series of charges varying from 3-120 milliCoulombs (mC); four additional doses were given with a charge of 60 mC, Five hours post-iontophoresis, sites were irradiated with broadband yellow-red light, the series of six ALA doses receiving 100 J/cm(2), while the four identical doses received 6.25, 12.5, 25, and 50 J/cm(2), respectively. Resultant erythema was measured by reflectance spectroscopy. The time course of PpIX fluorescence was ALA-dose-dependent. With charge less than or equal to 24 mC, PpIX fluorescence peaked at 3 h and returned to zero at 9-10 h, whereas charges > 24 mC had a sustained peak at 5-10 h, falling to zero by 24 h, Pre-irradiation, PpIX fluorescence correlated with ALA dose (r = 1.0), PpIX fluorescence fell immediately post-irradiation (p < 0.0001); recovery levels at 3 h correlated with ALA dose (p < 0.0001), Delayed erythema correlated with ALA dose and irradiation dose (p < 0.0001, p < 0.01, respectively), Both PpIX fluorescence intensity pre-irradiation and fall in PpIX fluorescence postirradiation correlated with erythema (r = 0.98), Hence, PpIX synthesis is ALA-dose-dependent, and phototoxicity can be predicted from ALA dose, irradiation dose, and photobleaching of PpIX, This reproducible system allows accurate dosimetry in topical PDT and facilitates study of ALA metabolism. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,WELLMAN LABS PHOTOMED,BOSTON,MA 02114. RI Rhodes, Lesley/H-5324-2015 OI Rhodes, Lesley/0000-0002-9107-6654 NR 32 TC 86 Z9 90 U1 0 U2 4 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD JAN PY 1997 VL 108 IS 1 BP 87 EP 91 DI 10.1111/1523-1747.ep12285644 PG 5 WC Dermatology SC Dermatology GA VZ789 UT WOS:A1997VZ78900018 PM 8980294 ER PT J AU Sternini, C AF Sternini, C BE Hauser, C TI Organization of the peripheral nervous system: Autonomic and sensory ganglia SO JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997 LA English DT Proceedings Paper CT 45th Annual Symposium on the Biology of the Skin - Cutaneous Innervation and Neurobiology of the Skin CY JUL 20-24, 1996 CL SNOWMASS, CO SP Natl Psoriasis Fdn, Orentreich Fdn Adv Sci, Univ Colorado Canc Ctr DE peptides; peptide receptors; sympathetic ganglia; parasympathetic ganglia AB Major advances have been made in our understanding of autonomic and sensory transmission and function during the past two decades. These include (i) the establishment of the role of sympathetic and parasympathetic ganglia in relaying neuronal information from the central nervous system to effector organs, (ii) the recognition that enteric ganglia, the third component of the autonomic nervous system, contain independent integrative circuits that control complex local activities, (iii) the evidence for local effector functions of primary sensory nerves in addition to their role in sensory transmission, and (iv) the discovery of plasticity of both autonomic and sensory neurons during disease states and inflammation. A major contribution to these new concepts has been the recognition that in both autonomic and sensory ganglia a variety of transmitters coexist in single neurons, Go-transmission is a widespread phenomenon that enables autonomic and sensory neurons to exert fine and highly regulated control of various functions such as circulation, respiration, digestion, and immune response, This chapter will focus on the general principles and specific features of autonomic and sensory ganglia, with a particular emphasis on their general organization and neurochemical properties. Classical concepts and modern principles of classification of autonomic and sensory ganglia are discussed. RP Sternini, C (reprint author), W LOS ANGELES VET AFFAIRS MED CTR,CURE DDRC,11301 WILSHIRE BLVD,BLDG 115,ROOM 203,LOS ANGELES,CA 90073, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA COMMERCE PLACE 350 MAIN ST, MALDEN, MA 02148 PY 1997 BP 1 EP 7 PG 7 WC Dermatology SC Dermatology GA BJ37T UT WOS:A1997BJ37T00001 ER PT J AU Sims, CD Butler, PEM Casanova, R Randolph, MA Yaremchuk, MJ AF Sims, CD Butler, PEM Casanova, R Randolph, MA Yaremchuk, MJ TI Prolonged general anesthesia for experimental craniofacial surgery in fetal swine SO JOURNAL OF INVESTIGATIVE SURGERY LA English DT Article DE anesthesia; craniofacial; fetal; in utero; pregnant; sow AB A protocol utilizing high preoperative doses of altrenogest (Regu-Mate) and a ''balanced'' general anesthesia regimen consisting of isoflurane at subanesthetic doses supplemented with intravenous doses of sodium thiopental was developed to prevent preterm labor, minimize intracranial fetal cerebral edema, and decrease postpartum mortality of fetal swine after undergoing complex in utero craniofacial procedures. A total of 20 fetal piglets at 75% gestation were exposed to prolonged (>3 h) anesthesia conditions of which 7 piglets were randomly selected to undergo experimental craniofacial procedures consisting of periosteal stripping of frontal and parietal bone segments with/without extensive coronal suture fusion procedures. Neither sows nor piglets were lost to anesthetic complications during the initial laparotomy or subsequent cesarean delivery. None of the sows experienced uterine sepsis or underwent preterm labor. The overall survival rate for all piglets exposed to prolonged anesthesia conditions was 95% at 4 weeks and 45% at 11 weeks after surgery. The experimental group's survival was 85.7% at 4 weeks and 28.5% at 11 weeks after surgery. RP Sims, CD (reprint author), HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DIV PLAST SURG,ACC 453 25 FRUIT ST,BOSTON,MA 02114, USA. NR 10 TC 4 Z9 4 U1 0 U2 0 PU TAYLOR & FRANCIS PI BRISTOL PA 1900 FROST ROAD, SUITE 101, BRISTOL, PA 19007-1598 SN 0894-1939 J9 J INVEST SURG JI J. Invest. Surg. PD JAN-APR PY 1997 VL 10 IS 1-2 BP 53 EP 57 DI 10.3109/08941939709032126 PG 5 WC Surgery SC Surgery GA WQ595 UT WOS:A1997WQ59500009 PM 9100176 ER PT J AU Huang, Y Ghosh, MJ LopesVirella, MF AF Huang, Y Ghosh, MJ LopesVirella, MF TI Transcriptional and post-transcriptional regulation of LDL receptor gene expression in PMA-treated THP-1 cells by LDL-containing immune complexes SO JOURNAL OF LIPID RESEARCH LA English DT Article DE cholesterol; macrophage; Fc gamma receptor ID LOW-DENSITY-LIPOPROTEIN; MONOCYTE-DERIVED MACROPHAGES; CAROTID ATHEROSCLEROSIS; OXIDIZED LDL; ACCUMULATION; BINDING; INSULIN; RABBIT; IGG AB We have previously shown that uptake of low density lipoprotein-containing immune complexes (LDL-IC) by human monocyte-derived macrophages led to the transformation of these cells into foam cells and induced a paradoxical increase in receptor-mediated binding of I-125-labeled LDL due to an increase in the number of LDL receptors (LDLR). The same metabolic changes are also observed in PMA-treated THP-1 cells after incubation for 2 h with 150 mu g/ml of immune complexes containing either native, oxidized (ox), or malondialdehyde (mda) LDL. After stimulation, PMA-treated THP-1 cells showed not only a 40-fold increase in I-125-labeled LDL binding but also a 40-fold increase in the immunoreactive LDL-R protein, confirming that the increase in LDL binding is due to an increase LDLR number. In this study ive have investigated, in PMA-treated THP-1 cells, the regulatory mechanism(s) responsible for the increased receptor-mediated binding of LDL induced by LDL-IC. By Northern blot and nuclear run-on analysis we have shown transcriptional activation of the LDL-R gene with a 7-fold increase in the LDL-R mRNA level in LDL-IC stimulated cells. Due to the marked difference between the increase in LDL-R mRNA and LDL-R protein, we estimated LDLR mRNA stability using a inhibitor chase method and have shown that LDL-IC did not alter the LDL-R mRNA stability in THP-1 cells. We have also demonstrated, using cycloheximide as a inhibitor of protein synthesis, that the marked increase in LDL-R protein observed in LDL-IC-stimulated THP-1 cells resulted from de novo synthesis of LDL-R protein. To determine whether the increase in transcriptional activity of the LDLR gene was secondary to changes in the cholesterol regulatory pool we performed experiments in which the cell cholesterol content was modified by the addition of either 25-hydroxycholesterol and mevalonate or inhibitors of ACAT activity (SA-58035 and progesterone). These experiments showed that the enhanced LDL-R expression was not affected by the addition of any of the above compounds. In conclusion, LDL-IC induced both transcriptional and post-transcriptional activation of the LDL-R gene in PMA-treated THP-I cells and this induction was independent of the free cholesterol content of these cells. C1 MED UNIV S CAROLINA,DEPT MED,CHARLESTON,SC 29425. MED UNIV S CAROLINA,DEPT MICROBIOL & IMMUNOL,CHARLESTON,SC 29425. RALPH H JOHNSON VET ADM MED CTR,CHARLESTON,SC 29401. FU NHLBI NIH HHS [HL46815] NR 27 TC 27 Z9 30 U1 0 U2 1 PU LIPID RESEARCH INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD JAN PY 1997 VL 38 IS 1 BP 110 EP 120 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA WH710 UT WOS:A1997WH71000012 PM 9034205 ER PT J AU Torchilin, VP AF Torchilin, VP TI Targeting of liposomes within cardiovascular system SO JOURNAL OF LIPOSOME RESEARCH LA English DT Article ID EXPERIMENTAL MYOCARDIAL-INFARCTION; MYOSIN-SPECIFIC ANTIBODY; ISCHEMIC-HEART-DISEASE; CARDIAC MYOSIN; CIRCULATION TIME; DRUG DELIVERY; ACCUMULATION; LOCALIZATION; REPERFUSION; MEMBRANE AB Our studies on the targeting of liposomes and liposome-associated pharmaceuticals within the cardiovascular system are reviewed. The delivery of diagnostic and therapeutic agents in plain liposomes, immunoliposomes, long-circulating liposomes and long-circulating immunoliposomes into the sites of vascular injuries and myocardial infarction is discussed. In vitro, ex vivo, and in vivo experiments present a general view on the advantages and limitations of using liposome-mediated targeting. Liposomes capable of targeting pathological areas of the blood vessel wall both, in vitro and ex vivo are described, as well as liposome able to be internalized by normal endothelial cells. Liposome-mediated drug targeting to compromised myocardium is reviewed with a primary impact on liposomes with anti-cardiac myosin antibodies. Targeted visualization of myocardial infarction with diagnostic liposomes is discussed. Efficient accumulation of long-circulating immunoliposomes in the infarct zone is demonstrated, and a relative importance of different variables, such as liposome size, targetability, and prolonged circulation time, for target accumulation is analyzed. The use of immunoliposomes for targeted sealing of hypoxia-caused damages in plasmic membranes of cardiocytes is considered as a new approach in the therapeutic use of liposomes.Our studies on the targeting of liposomes and liposome-associated pharmaceuticals within the cardiovascular system are reviewed. The delivery of diagnostic and therapeutic agents in plain liposomes, immunoliposomes, long-circulating liposomes and long-circulating immunoliposomes into the sites of vascular injuries and myocardial infarction is discussed. In vitro, ex vivo, and in vivo experiments present a general view on the advantages and limitations of using liposome-mediated targeting. Liposomes capable of targeting pathological areas of the blood vessel wall both, in vitro and ex vivo are described, as well as liposome able to be internalized by normal endothelial cells. Liposome-mediated drug targeting to compromised myocardium is reviewed with a primary impact on liposomes with anti-cardiac myosin antibodies. Targeted visualization of myocardial infarction with diagnostic liposomes is discussed. Efficient accumulation of long-circulating immunoliposomes in the infarct zone is demonstrated, and a relative importance of different variables, such as liposome size, targetability, and prolonged circulation time, for target accumulation is analyzed. The use of immunoliposomes for targeted sealing of hypoxia-caused damages in plasmic membranes of cardiocytes is considered as a new approach in the therapeutic use of liposomes. C1 Massachusetts Gen Hosp, Ctr Imaging & Pharmaceut Res, Charlestown, MA 02129 USA. RP Torchilin, VP (reprint author), Massachusetts Gen Hosp, Ctr Imaging & Pharmaceut Res, Charlestown, MA 02129 USA. NR 43 TC 3 Z9 3 U1 0 U2 7 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 USA SN 0898-2104 J9 J LIPOSOME RES JI J. Liposome Res. PY 1997 VL 7 IS 4 BP 433 EP 454 DI 10.3109/08982109709035511 PG 22 WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA YR134 UT WOS:000071463500007 ER PT J AU Seidman, LJ Caplan, BB Tolomiczenko, GS Turner, WM Penk, WE Schutt, RK Goldfinger, SM AF Seidman, LJ Caplan, BB Tolomiczenko, GS Turner, WM Penk, WE Schutt, RK Goldfinger, SM TI Neuropsychological function in homeless mentally ill individuals SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article ID CARD SORTING TEST; SCHIZOPHRENIC-PATIENTS; FOLLOW-UP; PERFORMANCE; DYSFUNCTION; RELATIVES; REDUCTION; MEN AB Because little data are available on the neuropsychological functioning of severely and persistently mentally ill (SPMI) persons who are homeless, our primary goal was to describe accurately and extensively the general neuropsychological functioning of a large group of such homeless individuals. In addition, we have sought to examine the relationship between some neuropsychological functions and demographic, illness, and clinical state measures in this population. A 5-hour neuropsychological test battery was administered to 116 SPMI homeless individuals. Neuropsychological, diagnostic, substance abuse, clinical, and psychopathology data were obtained in a standardized manner. SPMI homeless individuals were significantly impaired on a wide range of neuropsychological functions. Specific test performances were most significantly related to precursor variables (level of education and parental socioeconomic status) and state variables (level of psychosis and anticholinergic medication dose). Gender and substance abuse had significant effects Limited to sustained attention. Neuropsychological performance was impaired in this sample of homeless SPMI persons. Further research, using profile analysis to directly compare groups composed of homeless persons without psychiatric illness or demographically matched persons of comparable psychiatric status who are not homeless will help clarify the role of homelessness and psychosis on neuropsychological function. C1 HARVARD UNIV,SCH MED,HARVARD INST PSYCHIAT EPIDEMIOL & GENET,BOSTON,MA 02115. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PSYCHIAT,BOSTON,MA. HARVARD UNIV,BROCKTON W ROXBURY VET AFFAIRS MED CTR,SCH MED,DEPT PSYCHIAT,BOSTON,MA. UNIV MASSACHUSETTS,BOSTON,MA 02125. VET ADM MED CTR,BEDFORD,MA. MASSACHUSETTS DEPT MENTAL HLTH,BOSTON,MA. RP Seidman, LJ (reprint author), HARVARD UNIV,SCH MED,MASSACHUSETTS MENTAL HLTH CTR,DEPT PSYCHIAT,NEUROPSYCHOL LAB,S530,BOSTON,MA 02115, USA. FU PHS HHS [1R18 MI 14808001] NR 49 TC 22 Z9 22 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD JAN PY 1997 VL 185 IS 1 BP 3 EP 12 DI 10.1097/00005053-199701000-00002 PG 10 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA WD517 UT WOS:A1997WD51700001 PM 9040527 ER PT J AU Evins, AE Amico, ET Shih, V Goff, DC AF Evins, AE Amico, ET Shih, V Goff, DC TI Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics SO JOURNAL OF NEURAL TRANSMISSION LA English DT Article DE schizophrenia; negative symptoms; clozapine; glutamate; aspartate; glycine; amino acid; psychopharmacology ID AMINO-ACID CONCENTRATIONS; CEREBROSPINAL-FLUID; D-CYCLOSERINE; SCHIZOPHRENIC-PATIENTS; MONOAMINE METABOLITES; ANTIPSYCHOTIC-DRUGS; NEUROTOXICITY; DYSFUNCTION; HYPOTHESIS AB To examine whether serum excitatory amino acid concentrations change with clozapine treatment and whether these changes correlate with improvement in negative symptoms, serum excitatory amino acids were measured and clinical scales administered in seven subjects with schizophrenia before and after switching from conventional neuroleptics to clozapine. Clozapine treatment was associated with increased serum glutamate and aspartate concentrations. Clinical improvement was negatively correlated with baseline glycine concentrations. These results support the hypothesis that clozapine acts at least in part by increasing glutamatergic activity. C1 MASSACHUSETTS GEN HOSP,PSYCHOT DISORDERS PROGRAM,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA. NR 19 TC 51 Z9 53 U1 0 U2 3 PU SPRINGER-VERLAG WIEN PI VIENNA PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA SN 0300-9564 J9 J NEURAL TRANSM JI J. Neural Transm. PY 1997 VL 104 IS 6-7 BP 761 EP 766 DI 10.1007/BF01291892 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA YB368 UT WOS:A1997YB36800017 PM 9444574 ER PT J AU Roberts, DR Vincent, DJ Speer, AM Bohning, DE Cure, J Young, J George, MS AF Roberts, DR Vincent, DJ Speer, AM Bohning, DE Cure, J Young, J George, MS TI Multi-modality mapping of motor cortex: comparing echoplanar BOLD fMRI and transcranial magnetic stimulation SO JOURNAL OF NEURAL TRANSMISSION LA English DT Article; Proceedings Paper CT 5th Annual Meeting of the International-Society-of-Magnetic-Resonance-in-Medicine CY APR 12-18, 1997 CL VANCOUVER, CANADA SP Int Soc Magnet Resonance Med DE transcranial magnetic stimulation; magnetic resonance imaging; motor cortex ID BRAIN-STIMULATION; FUNCTIONAL MRI; LOCALIZATION; PET AB Multiple non-invasive methods of imaging brain function are now available for presurgical planning and neurobiological research. As these new methods become available, it is important to understand their relative advantages and liabilities, as well as how the information gained compares across different methods. A current and future trend in neurobiological studies as well as presurgical planning is to combine information from different imaging techniques. Multi-modal integration may perhaps give more powerful information than each modality alone, especially when one of the methods is transcranial magnetic stimulation (TMS), with its ability to non-invasively activate the brain. As an initial venture in cross comparing new imaging methods, we performed the following 2 studies, locating motor cortex with echoplanar BOLD fMRI and TMS. The two methods can be readily integrated, with concurring results, although each have important limitations. C1 MED UNIV S CAROLINA, DEPT RADIOL, CHARLESTON, SC 29425 USA. MED UNIV S CAROLINA, DEPT PSYCHIAT, CHARLESTON, SC 29425 USA. MED UNIV S CAROLINA, DEPT NEUROL, CHARLESTON, SC 29425 USA. RALPH H JOHNSON VET AFFAIRS MED CTR, CHARLESTON, SC USA. NR 37 TC 20 Z9 20 U1 0 U2 0 PU SPRINGER-VERLAG WIEN PI VIENNA PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA SN 0300-9564 J9 J NEURAL TRANSM JI J. Neural Transm. PY 1997 VL 104 IS 8-9 BP 833 EP 843 DI 10.1007/BF01285552 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA YH660 UT WOS:A1997YH66000006 PM 9451716 ER PT J AU Yao, JK Zhu, P Wilds, DJ vanKammen, DP AF Yao, JK Zhu, P Wilds, DJ vanKammen, DP TI A simplified routine assay for urinary 3-methoxy-4-hydroxyphenylglycol SO JOURNAL OF NEURAL TRANSMISSION LA English DT Article DE 3-methoxy-4-hydroxyphenylglycol (MHPG); MHPG sulfate; MHPG glucuronide; glusulase; glucuronidase; sulfatase; high-pressure liquid chromatography (HPLC); electrochemical detection (ECD) ID NOREPINEPHRINE METABOLISM; MASS FRAGMENTOGRAPHY; BRAIN; MHPG; ACID; AMITRIPTYLINE; CONVERSION; EXCRETION; PLASMA; GLYCOL AB Urinary 3-methoxy-4-hydroxyphenylglycol (MHPG) level may provide us with a biochemical index for central noradrenergic activity. Previous methods for assaying MHPG ill urine often lacked specificity, sensitivity, cost-effectiveness or convenience. We now describe a simplified routine assay for urinary MHPG by high-pressure liquid chromatography using electrochemical detection. For convenience and cost-effectiveness within a typical batch assay of total MHPG, 0.5 mL of urine sample, 50 mu L of glusulase and 4 mu g iso-vanillyl alcohol (internal standard) were used to hydrolyze conjugated MHPG at 37 degrees C overnight. Alternatively, for a same-day operation, it is efficient to hydrolyze the sample at 50 degrees C for 3 hours. Each sample was separated isocratically on a reversed-phase column (Ultracarb 5 ODS) at 25 degrees C with the flow rate at 1 mL/min. Intra- and inter-assay coefficients of variation were found to be 4.0% (n = 10) and 5.0% (n = 27), respectively, for MHPG at a mean concentration of 1.9 mg/L. Sulfatase or glucuronidase can be substituted for glusulase to obtain either sulfate- or glucuronide-conjugated MHPG. This procedure requires smaller sample amounts and less preparation time without compromising sensitivity and reproducibility. C1 UNIV PITTSBURGH,MED CTR,WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA. RP Yao, JK (reprint author), VA PITTSBURGH HEALTHCARE SYST,7180 HIGHLAND DR,PITTSBURGH,PA 15206, USA. FU NIMH NIH HHS [MH 44841, MH 43742] NR 32 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER-VERLAG WIEN PI VIENNA PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA SN 0300-9564 J9 J NEURAL TRANSM JI J. Neural Transm. PY 1997 VL 104 IS 8-9 BP 967 EP 975 DI 10.1007/BF01285564 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA YH660 UT WOS:A1997YH66000018 PM 9451728 ER PT J AU DeLorey, TM Handforth, A Asatourian, A Homanics, GE Ferguson, C Minassian, B DelgadoEscueta, AV Olsen, RW AF DeLorey, TM Handforth, A Asatourian, A Homanics, GE Ferguson, C Minassian, B DelgadoEscueta, AV Olsen, RW TI Mice lacking the GABA(A) receptor beta(3) subunit gene have some of the characteristics of Angelmann syndrome. SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract C1 UNIV CALIF LOS ANGELES,DEPT MOL & MED PHARMACOL,LOS ANGELES,CA 90095. W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90073. UNIV PITTSBURGH,DEPT ANESTHESIOL CRIT CARE MED,PITTSBURGH,PA 15261. UNIV TORONTO,HOSP SICK CHILDREN,DIV NEUROL,TORONTO,ON M5G 1X8,CANADA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PY 1997 VL 69 SU S BP S236 EP S236 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA XM285 UT WOS:A1997XM28500928 ER PT J AU Kaufman, MJ Pollack, MH Kukes, TJ Rose, SL Mendelson, JH Lukas, SE Cohen, BM Renshaw, PF AF Kaufman, MJ Pollack, MH Kukes, TJ Rose, SL Mendelson, JH Lukas, SE Cohen, BM Renshaw, PF TI Cerebral metabolic abnormalities in methadone-maintained polydrug abusers detected with P-31 MRS SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract C1 HARVARD UNIV,MCLEAN HOSP,SCH MED,ALCOHOL & DRUG ABUSE RES CTR,BELMONT,MA 02178. HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,ANXIETY DISORDERS PROGRAM,BELMONT,MA 02178. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PY 1997 VL 69 SU S BP S169 EP S169 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA XM285 UT WOS:A1997XM28500663 ER PT J AU Moskowitz, MA AF Moskowitz, MA TI Reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knockout mice SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PY 1997 VL 69 SU S BP S228 EP S228 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA XM285 UT WOS:A1997XM28500898 ER PT J AU Sheng, M AF Sheng, M TI Isolation of ion channel-binding proteins by yeast two-hybrid system SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract C1 HOWARD HUGHES MED INST,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT NEUROBIOL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PY 1997 VL 69 SU S BP S54 EP S54 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA XM285 UT WOS:A1997XM28500212 ER PT J AU Yao, JK vanKammen, DP Reddy, RD AF Yao, JK vanKammen, DP Reddy, RD TI Reduced status of plasma antioxidant capacity in schizophrenia SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract C1 VA PITTSBURGH HLTH CARE SYST,PITTSBURGH,PA 15206. UNIV PITTSBURGH,MED CTR,WPIC,PITTSBURGH,PA 15213. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PY 1997 VL 69 SU S BP S250 EP S250 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA XM285 UT WOS:A1997XM28500986 ER PT J AU Berezovska, O Xia, MQ Page, K Wasco, W Tanzi, RE Hyman, BT AF Berezovska, O Xia, MQ Page, K Wasco, W Tanzi, RE Hyman, BT TI Developmental regulation of presenilin mRNA expression parallels notch expression SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Article DE Alzheimer disease; development; notch; presenilins ID FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; MAMMALIAN NOTCH; GENE; HOMOLOG AB Mutations in the presenilin (PS) 1 and 2 genes are associated with autosomal dominant Alzheimer disease. PS1 shares striking homology with sel-12, a C. elegans gene implicated in the function of lin-12/Notch, a protein important in neurogenesis. We studied mRNA expression using RT-PCR and in situ hybridization techniques during neural development in mouse and rat. Strong expression of PSs and Notch1 was observed in embryos, especially in the ventricular zone, which decreased gradually as embryos developed. Very low levels of PSs and Notch were present in adulthood, their signals present primarily in the hippocampus and cerebellum. These observations show that, like Notch, PS1 and PS2 are strongly developmentally regulated, and support the plausibility of an interaction between PSs and Notch. C1 MASSACHUSETTS GEN HOSP EAST,ALZHEIMER RES UNIT,CHARLESTOWN,MA 02129. HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. FU NIA NIH HHS [3P50 AG 05134] NR 17 TC 61 Z9 63 U1 0 U2 0 PU AMER ASSN NEUROPATHOLOGISTS INC PI LAWRENCE PA 1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 SN 0022-3069 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD JAN PY 1997 VL 56 IS 1 BP 40 EP 44 DI 10.1097/00005072-199701000-00004 PG 5 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA WC097 UT WOS:A1997WC09700004 PM 8990127 ER PT J AU Bove, GM Moskowitz, MA AF Bove, GM Moskowitz, MA TI Primary afferent neurons innervating guinea pig dura SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article ID SUPERIOR SPERMATIC NERVE; STEM TRIGEMINAL NEURONS; SUBSTANCE-P; MECHANICAL STIMULATION; POLYMODAL RECEPTORS; RAT SKIN; ELECTRICAL-STIMULATION; DISCHARGE PROPERTIES; SENSORY INNERVATION; MATER-ENCEPHALI AB We made recordings from filaments of guinea pig nasociliary nerve to study response properties of afferent axons innervating the anterior superior sagittal sinus and surrounding dura mater. We analyzed 38 units in 14 experiments. Units were initially located with the use of mechanical stimuli, and were then characterized by their conduction velocity and sensitivities to mechanical, thermal, and chemical stimuli. Single-unit recordings revealed innervation of dura and superior sagittal sinus by slowly conducting axons, mostly in the unmyelinated range. The receptive fields were 1-30 mm(2), and typically had one to three punctate spots of highest sensitivity. All units tested responded to topical application of chemical agents. Ninety-seven percent of units responded to 10(-5) M capsaicin, 79% responded to a mixture of inflammatory mediators, and 37% responded to an acidic buffer (pH 5). These data underline the importance of chemical sensitivity in intracranial sensation. Heat and cold stimuli evoked responses in 56 and 41% of units tested, respectively. Although the response patterns during heating were typical of polymodal nociceptors innervating other tissues, the thresholds were lower than for other tissues (32.3-42 degrees C). Cooling led to a phasic discharge, with thresholds between 25 and 32 degrees C. Although units had different combinations of responses to mechanical, chemical, and thermal stimuli, when grouped by their sensitivities the groups did not differ regarding mechanical thresholds or presence of ongoing activity. This suggests that meningeal primary afferents are relatively homogeneous. Sensitivities of these units are in general consistent with nociceptors, although the thermal thresholds differ. These data provide the first detailed report of response properties of intracranial primary afferent units, likely to be involved in transmission of nociception and possibly mediation of intracranial pain. C1 MASSACHUSETTS GEN HOSP, DEPT NEUROSURG, CHARLESTOWN, MA 02129 USA. HARVARD UNIV, SCH MED, DEPT NEUROL, CHARLESTOWN, MA 02129 USA. RI Moskowitz, Michael/D-9916-2011 FU NIAMS NIH HHS [F32 ARO-8239]; NINDS NIH HHS [NS-21558] NR 80 TC 64 Z9 64 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD JAN PY 1997 VL 77 IS 1 BP 299 EP 308 PG 10 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA WG229 UT WOS:A1997WG22900031 PM 9120572 ER PT J AU Tejedor, FJ Bokhari, A Rogero, O Gorczyca, M Zhang, JW Kim, E Sheng, M Budnik, V AF Tejedor, FJ Bokhari, A Rogero, O Gorczyca, M Zhang, JW Kim, E Sheng, M Budnik, V TI Essential role for dlg in synaptic clustering of shaker K+ channels in vivo SO JOURNAL OF NEUROSCIENCE LA English DT Article DE discs-large; Drosophila; glutamatergic synapse; I-A; ion channel clustering; MAGUK; neuromuscular junction; PDZ; potassium channels; PSD-95/SAP90; Shaker; synapse; synapse targeting ID TUMOR-SUPPRESSOR GENE; VOLTAGE-CLAMP ANALYSIS; DROSOPHILA-MELANOGASTER; POTASSIUM CURRENTS; SEPTATE JUNCTIONS; NERVOUS-SYSTEM; HOMOLOG; PROTEIN; EXPRESSION; SYNAPSES AB (T)he assemblage of specific ion channels and receptors at synaptic sites is crucial for signaling between pre- and postsynaptic cells. However, the mechanisms by which proteins are targeted to and clustered at synapses are poorly understood. Here we show that the product of the Drosophila discs-large gene, DLG, is colocalized with Shaker K+ channels, which are clustered at glutamatergic synapses at the larval neuromuscular junction. In heterologous cells, DLG can cluster Shaker-type K+ channels, and, in the yeast two-hybrid system, the DLG PDZ1-2 domains bind directly to the C-terminal tail of Shaker proteins. We also demonstrate that DLG-Shaker interactions are required in vivo for Shaker clustering at the neuromuscular junction. Synaptic clustering of Shaker channels is abolished not only by mutations in dlg but also by a mutation in Shaker that deletes its C-terminal DLG binding motif. Analyses of various dlg mutant alleles suggest that channel clustering and synaptic targeting functions depend on distinct DLG domains. These studies demonstrate for the first time that DLG plays an important role in synaptic organization in vivo that correlates with its ability to bind directly to specific membrane proteins of the synapse. C1 UNIV MASSACHUSETTS,DEPT BIOL,MORRILL SCI CTR,AMHERST,MA 01003. UNIV ALICANTE,INST NEUROSCI,CONSEJO SUPER INVEST CIENT,UNIDAD ASOCIADA,SAN JUAN 03080,ALICANTE,SPAIN. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROBIOL,BOSTON,MA 02114. RI Kim, Eunjoon/C-1566-2011; OI Tejedor, Francisco J/0000-0003-1942-2580 FU NINDS NIH HHS [KO4 NS01786, R01 NS030072, R01 NS30072] NR 44 TC 218 Z9 220 U1 0 U2 5 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JAN 1 PY 1997 VL 17 IS 1 BP 152 EP 159 PG 8 WC Neurosciences SC Neurosciences & Neurology GA WJ677 UT WOS:A1997WJ67700014 PM 8987744 ER PT J AU Sridhar, TS Brown, MC Sewell, WF AF Sridhar, TS Brown, MC Sewell, WF TI Unique postsynaptic signaling at the hair cell efferent synapse permits calcium to evoke changes on two time scales SO JOURNAL OF NEUROSCIENCE LA English DT Article DE cochlea; outer hair cell; cyclopiazonic acid; subsurface cisterna; ryanodine; acetylcholine ID GUINEA-PIG COCHLEA; ENDOPLASMIC-RETICULUM; SARCOPLASMIC-RETICULUM; OLIVOCOCHLEAR-BUNDLE; SMOOTH-MUSCLE; STIMULATION; ACETYLCHOLINE; NEURONS; RAT; CA-2+-ATPASE AB The cholinergic efferent fibers to the outer hair cells (OHCs) of the mammalian cochlea suppress sound-evoked activity of the auditory nerve on two time scales via one nicotinic receptor. A rapid action (tens of milliseconds) is responsible for modulating auditory nerve responses to acoustic stimulation. A slower action (tens of seconds) may protect the ear from acoustic overstimulation. The rapid action is likely caused by calcium influx through the nicotinic receptor that leads to opening of calcium-activated potassium (K-Ca) channels, but the mechanism of the slower action has not been explained. To investigate this mechanism, we perfused the cochlea with agents that alter intracellular calcium release and uptake. Both fast and slow effects were enhanced by perfusion of the cochlea with ryanodine, an agonist of calcium-induced calcium release (CICR). Antagonists of sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA), cyclopiazonic acid, and thapsigargin (1) selectively enhanced the magnitude of slow effects, (2) prevented the diminution of slow effects with continued efferent stimulation, and (3) spread the range of frequencies over which slow effects were observed. We propose that the slow effect is attributable to release of calcium from the subsurface cisterna of the OHC, perhaps triggered by CICR from the synaptic cisterna; the two time scales of efferent action may result from the unique arrangement of the two cisternae in the base-lateral region of the OHC. C1 MASSACHUSETTS EYE & EAR INFIRM,EATON PEABODY LAB,DEPT OTOLARYNGOL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT OTOL & LARYNGOL,BOSTON,MA 02115. MIT,HARVARD MIT DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139. HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115. NR 41 TC 112 Z9 117 U1 0 U2 4 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JAN 1 PY 1997 VL 17 IS 1 BP 428 EP 437 PG 10 WC Neurosciences SC Neurosciences & Neurology GA WJ677 UT WOS:A1997WJ67700038 PM 8987768 ER PT J AU Schmahmann, JD Pandya, DN AF Schmahmann, JD Pandya, DN TI Anatomic organization of the basilar pontine projections from prefrontal cortices in rhesus monkey SO JOURNAL OF NEUROSCIENCE LA English DT Article DE frontal lobe; pons; cerebellum; connections; anatomy; behavior; cognition ID POSTERIOR PARIETAL CORTEX; FRONTAL EYE FIELD; CORTICOPONTINE PROJECTION; MACAQUE MONKEY; MACACA-FASCICULARIS; MOTOR IMAGERY; CONNECTIONS; CEREBELLAR; NUCLEI; AREAS AB In our ongoing attempt to determine the anatomic substrates that could support a cerebellar contribution to cognitive processing, we investigated the prefrontal cortical projections to the basilar pens. A detailed understanding of these pathways is needed, because the prefrontal cortex is critical for a number of complex cognitive operations, and the corticopontine projection is the obligatory first step in the corticopontocerebellar circuit. Prefrontopontine connections were studied using the autoradiographic technique in rhesus monkey. The pontine projections were most prominent and occupied the greatest rostrocaudal extent of the pens when derived from the dorso-lateral prefrontal convexity, including areas 8Ad, 9/46d, and 10. Lesser pontine projections were observed from the medial prefrontal convexity and area 45B in the inferior limb of the arcuate sulcus. In contrast, ventral prefrontal and orbitofrontal cortices did not demonstrate pontine projections. The prefrontopontine terminations were located preferentially in the paramedian nucleus and in the medial parts of the peripeduncular nucleus, but each cortical area appeared to have a unique complement of pontine nuclei with which it is connected. The existence of these corticopontine pathways from prefrontal areas concerned with multiple domains of higher-order processing is consistent with the hypothesis that the cerebellum is an essential node in the distributed corticosubcortical neural circuits subserving cognitive operations. C1 HARVARD UNIV,SCH MED,BOSTON,MA 02114. BETH ISRAEL HOSP,HARVARD NEUROL UNIT,BOSTON,MA 02114. BOSTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,BOSTON,MA 02114. RP Schmahmann, JD (reprint author), MASSACHUSETTS GEN HOSP,DEPT NEUROL,BURNHAM 823,FRUIT ST,BOSTON,MA 02114, USA. FU PHS HHS [16841] NR 95 TC 197 Z9 199 U1 2 U2 9 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JAN 1 PY 1997 VL 17 IS 1 BP 438 EP 458 PG 21 WC Neurosciences SC Neurosciences & Neurology GA WJ677 UT WOS:A1997WJ67700039 PM 8987769 ER PT J AU Hsu, DW Efird, JT HedleyWhyte, ET AF Hsu, DW Efird, JT HedleyWhyte, ET TI Progesterone and estrogen receptors in meningiomas: Prognostic considerations SO JOURNAL OF NEUROSURGERY LA English DT Article DE meningioma; progesterone receptor; estrogen receptor; mitotic index; immunocytochemistry ID MONOCLONAL-ANTIBODY KI-67; EPIDERMAL GROWTH-FACTOR; SEX STEROID-RECEPTORS; INTRACRANIAL MENINGIOMAS; BREAST-CANCER; HORMONE RECEPTORS; MEDROXYPROGESTERONE ACETATE; CEREBRAL MENINGIOMAS; BINDING-ACTIVITY; RECURRENCE AB Meningiomas often contain steroid hormone receptors, but the correlation of receptor presence with patient outcome or mitotic index is unclear. Intracranial meningiomas from 70 patients (27 males and 43 females, mean age 52.9 + 1.7 years [mean +/- standard error of the mean], range 15-78 years) were evaluated immunocytochemically for female sex hormone receptors using specific monoclonal antibodies. Prognostic correlations were determined using statistical analyses that included clinical and histological variables. Twenty-eight tumors were benign, 27 had atypical features, and 15 were malignant. Thirty tumors were meningotheliomatous, 11 were fibroblastic, 28 were transitional, and one was secretory. Twenty-nine of the 70 primary tumors recurred (mean interval to recurrence 50.1 +/- 10 months). The mean progression-free follow-up period for patients without recurrence was 82.1 +/- 7.7 months. Nuclear staining for the progesterone receptor (PR) was found in 58 cases (83%) and PR status was scored as 0 (0% nuclei positive), 1 (< 1%), 2 (1-9%), 3 (10-49%), or 4 (> 50%). Only six tumors (8.6%) contained nuclear estrogen receptor (ER) staining, which was limited to a small number of nuclei (< 1%). Fisher's exact test (two-tailed) showed an inverse correlation between tumor grade and PR staining score (p less than or equal to 0.001), with 96% of benign and 40% of malignant meningiomas containing PR-positive nuclei. No correlation between age or histological subtype and PR score was detected. Meningiomas from female patients had more PRs (p less than or equal to 0.05). Analysis of variance revealed that the mitotic index (total counts of mitoses per 10 high-power fields) for tumors with 0 PR staining (18 +/- 4.4) was higher (p less than or equal to 0.0001) than for those with PR scores of 1 to 4 (4.3 +/- 1.9, 5.1 +/- 2, 2.2 +/- 0.8, and 1.7 +/- 0.9, respectively). Univariate analysis indicated that the absence of PR, high mitotic index, and higher tumor grade were significant factors for shorter disease-free intervals. Multivariate analysis showed that a three-factor interaction model, with a PR score of 0, mitotic index greater than 6, and malignant tumor grade, was a highly significant predictor (p < 0.0001) for worse outcome in patients harboring meningiomas. These data indicate that the presence of PRs, even in a small number of tumor cells, is a favorable prognostic factor for meningiomas. C1 MASSACHUSETTS GEN HOSP,DIV NEUROPATHOL,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA. HARVARD UNIV,SCH MED,DEPT RADIAT THERAPY,BOSTON,MA. NR 68 TC 168 Z9 177 U1 0 U2 4 PU AMER ASSOC NEUROLOGICAL SURGEONS PI CHARLOTTESVILLE PA UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 SN 0022-3085 J9 J NEUROSURG JI J. Neurosurg. PD JAN PY 1997 VL 86 IS 1 BP 113 EP 120 DI 10.3171/jns.1997.86.1.0113 PG 8 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA VZ522 UT WOS:A1997VZ52200016 PM 8988089 ER PT J AU Narula, J Krishnan, SC Rahimtoola, SH AF Narula, J Krishnan, SC Rahimtoola, SH TI Guides to surgical intervention in chronic aortic regurgitation: Myocytes file a claim SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material ID END-SYSTOLIC DIMENSION; LEFT-VENTRICULAR FUNCTION; VALVE-REPLACEMENT; ASYMPTOMATIC PATIENTS; PROGNOSTIC VALUE; INSUFFICIENCY; PERFORMANCE; ANTIBODY; ECHOCARDIOGRAPHY; SURVIVAL C1 UNIV SO CALIF,LOS ANGELES,CA. RP Narula, J (reprint author), MASSACHUSETTS GEN HOSP,HEART FAILURE & CARDIAC TRANSPLANTAT CTR,BIGELOW 632,BOSTON,MA 02114, USA. NR 38 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 1071-3581 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD JAN-FEB PY 1997 VL 4 IS 1 BP 79 EP 82 DI 10.1016/S1071-3581(97)90052-0 PN 1 PG 4 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA WK395 UT WOS:A1997WK39500011 PM 9138843 ER PT J AU Fischman, AJ Babich, JW Elmaleh, DR Barrow, SA Meltzer, P Hanson, RN Madras, BK AF Fischman, AJ Babich, JW Elmaleh, DR Barrow, SA Meltzer, P Hanson, RN Madras, BK TI SPECT imaging of dopamine transporter sites in normal and MPTP-treated rhesus monkeys SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE Parkinson's disease; dopamine transporters; iodine-123-IACFT; carbon-11-CFT; MPTP ID POSITRON EMISSION TOMOGRAPHY; COCAINE RECOGNITION SITES; I-123 BETA-CIT; MONOAMINE REUPTAKE SITES; PARKINSONS-DISEASE; HIGH-AFFINITY; SEROTONIN TRANSPORTERS; NONHUMAN-PRIMATES; SUBSTANTIA NIGRA; BINDING-SITES AB Parkinson's disease is characterized by degeneration of dopamine (DA) neurons and their terminals. Since these neurons contain dopamine transporters (DAT), radioligands that bind to these sites are promising radiopharmaceuticals for diagnosis and therapeutic monitoring of disease progression. We evaluated [I-123]-2 beta-carbomethoxy-3 beta-(4-fluorophenyl)-N-(1 -iodoprop-1-en-3-yl)nortropane ([I-123]IACFT) for SPECT imaging in an MPTP model of parkinsonism. Methods: Three rhesus monkeys were imaged before and at 1 and 2 mo after treatment with MPTP. The SPECT results were correlated with motor behavior and PET imaging with [C-11]-2 beta-carbomethoxy-3 beta-aryltropane ([C-11] - CFT). Also, biodistribution was measured by planar imaging. Results: In normal animals, striatal accumulation of radioactivity was-rapid and peaked within 30 min. Striatal accumulation of [I-123]IACFT was nearly completely displaceable with unlabeled CFT (1 mg/kg) but was not affected by a similar dose of the serotonin (5-HT) transport inhibitor, citalopram. The striatal to cerebellar ratio measured at 30 min. after injection of [I-123]IACFT was significantly higher (p < 0.01) than with [C-11]CFT; similar to 6: 1 versus similar to 2.5: 1. After MPTP treatment this ratio decreased to 1.02:1 with IACFT and 1.23:1 with [C-11]CFT. Blood clearance of [I-123]IACFT was rapid with a terminal t(1/2) of similar to 30 min. HPLC of plasma samples demonstrated that the concentration of intact ligand decreases rapidly, approaching zero by 60 min. Low levels of accumulation were measured in extracranial tissues. Conclusion: These results demonstrate that [I-123]IACFT is an excellent SPECT ligand far dopamine transporter sites that combines the critical characteristics of: (a) high striatal to cerebellar ratios, (b) high selectivity for dopamine versus 5-HT transporter sites, (c) convenient preparation at high-specific activity and radiochemical purity and (d) a striatal localization rate that is well matched to the physical t(1/2) of I-123. C1 HARVARD UNIV,SCH MED,BOSTON,MA 02114. ORGANIX INC,BOSTON,MA. NORTHEASTERN UNIV,DEPT CHEM,BOSTON,MA 02115. NEW ENGLAND REG PRIMATE RES CTR,SOUTHBOROUGH,MA 01772. RP Fischman, AJ (reprint author), MASSACHUSETTS GEN HOSP,DEPT RADIOL,DIV NUCL MED,32 FRUIT ST,BOSTON,MA 02114, USA. FU NIDA NIH HHS [DA 09642, DA 06303]; NINDS NIH HHS [NS 30556] NR 51 TC 33 Z9 33 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD JAN PY 1997 VL 38 IS 1 BP 144 EP 150 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA WB894 UT WOS:A1997WB89400041 PM 8998169 ER PT J AU Hunt, MK Stoddard, AM Glanz, K Hebert, JR Probart, C Sorensen, G Thomson, S Hixson, ML Linnan, L Palombo, R AF Hunt, MK Stoddard, AM Glanz, K Hebert, JR Probart, C Sorensen, G Thomson, S Hixson, ML Linnan, L Palombo, R TI Measures of food choice behavior related to intervention messages in worksite health promotion SO JOURNAL OF NUTRITION EDUCATION LA English DT Article ID DIETARY GUIDELINES; PATTERNS; PROGRAM; FAT; EMPLOYEES; EDUCATION; VALIDITY AB Worksite nutrition educators and researchers need not only nutrient composition data but also information on employees' food choices to create intervention messages that are food-focused and tailored to specific target audiences. This paper describes a method of calculating measures of food choice behavior related to intervention messages and reports relationships between workers' food choices and demographic characteristics. This work was conducted as part of the Working Well Trial, a 5-year worksite cancer prevention randomized, controlled prospective field experiment funded by the National Cancer Institute. It was implemented in 114 worksites employing 37,291 workers who were engaged in a variety of businesses. In the fall of 1990, 20,801 respondents completed and returned a self-administered baseline survey. A modified Block 88-item food frequency questionnaire (FFQ) with portion sizes was used for the quantitative assessment both of nutrient intake and workers' food choices. The worksite mean response rate was 71.6%. Responses to behavioral items regarding meat were used to measure meat preparation behaviors not captured on the FFQ. We found that higher education, greater age, and female gender were associated with food choices closest to the recommendations to increase fiber, fruits, and vegetables and to reduce fat. An exception to this pattern was the recommendation to increase the consumption of beans and lentils, which was associated with lower education, greater age, and male gender. The relationship of job status to the food choice variables was inconsistent across foods and study centers and there were differences between study centers in the magnitude of associations between food choices and demographic characteristics. RP Hunt, MK (reprint author), DANA FARBER CANC INST,DIV CANC EPIDEMIOL & CONTROL,44 BINNEY ST,BOSTON,MA 02115, USA. NR 37 TC 15 Z9 16 U1 1 U2 3 PU DECKER PERIODICALS INC PI HAMILTON PA 4 HUGHSON STREET SOUTH PO BOX 620, LCD 1, HAMILTON ON L8N 3K7, CANADA SN 0022-3182 J9 J NUTR EDUC JI J. Nutr. Educ. PD JAN-FEB PY 1997 VL 29 IS 1 BP 3 EP 11 DI 10.1016/S0022-3182(97)70140-7 PG 9 WC Education, Scientific Disciplines; Nutrition & Dietetics SC Education & Educational Research; Nutrition & Dietetics GA WG864 UT WOS:A1997WG86400002 ER PT J AU Li, KSK Fabian, RL Goodman, ML AF Li, KSK Fabian, RL Goodman, ML TI Malignant fibrous histiocytoma after radiation for ameloblastoma of the maxilla SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID BONE; TUMORS; HEAD; NECK; JAW C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,BOSTON,MA. NR 18 TC 3 Z9 3 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD JAN PY 1997 VL 55 IS 1 BP 85 EP 88 DI 10.1016/S0278-2391(97)90454-7 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WC650 UT WOS:A1997WC65000022 PM 8994474 ER PT J AU Kuramitsu, H Tokuda, M Yoneda, M Duncan, M Cho, MI AF Kuramitsu, H Tokuda, M Yoneda, M Duncan, M Cho, MI TI Multiple colonization defects in a cysteine protease mutant of Porphyromonas gingivalis SO JOURNAL OF PERIODONTAL RESEARCH LA English DT Article DE P-gingivalis; proteases; colonization; adhesins ID VIRULENCE; ADHESION; GENE AB A cysteine protease mutant, G-102, of Porphyromonas gingivalis 381 defective in the rqp-1 gene has been recently constructed in this laboratory. In order to evaluate the role of the protease in the virulence properties of P. gingivalis, a number of putative periodontopathic properties of the mutant were evaluated. Relative to the parental strain, mutant G-102 was demonstrated to be defective in interacting with Gram-positive bacteria as well as cultured epithelial cells. In addition, the mutant was altered in attaching to the protein components of extracellular matrix as well as to type I collagen. Some of these alterations could result from the decreased autoaggregation displayed by mutant G-102 relative to strain 381. However, since the epithelial cell attachment assays were carried out at very low bacterial densities, it is unlikely that reduced autoaggregation of the mutant is responsible for its decreased ability to attach to these eucaryotic cells. Electron microscopic examination of The cells also revealed that mutant G-102 was altered in normal fimbrae expression. In addition, reduced expression of the 43 kDa fimbrial subunit in the mutant was detected with both Western and Northern blotting. These results indicated that the rgp-1 gene product can play either a direct or indirect role in the colonization properties of P. gingivalis. C1 FORSYTH DENT CTR,BOSTON,MA 02115. RP Kuramitsu, H (reprint author), SUNY BUFFALO,DEPT ORAL BIOL,3435 MAIN ST,BUFFALO,NY 14214, USA. FU NIDCR NIH HHS [DE08293] NR 14 TC 19 Z9 19 U1 0 U2 0 PU MUNKSGAARD INT PUBL LTD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 0022-3484 J9 J PERIODONTAL RES JI J. Periodont. Res. PD JAN PY 1997 VL 32 IS 1 BP 140 EP 142 DI 10.1111/j.1600-0765.1997.tb01395.x PN 2 PG 3 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WN711 UT WOS:A1997WN71100010 PM 9085224 ER PT J AU Swartwout, S Niederman, R AF Swartwout, S Niederman, R TI Bacterial metabolite mediated differential human PMN gene expression SO JOURNAL OF PERIODONTAL RESEARCH LA English DT Article DE PMN gene expression; periodontal disease; short chain carboxylic acid; propionic acid ID FATTY-ACIDS; HUMAN-NEUTROPHILS; MESSENGER-RNA; BUTYRATE; PROLIFERATION; PROPIONATE; DISPLAY; VIMENTIN; INVITRO; CELLS C1 FORSYTH DENT CTR,DEPT CELL BIOL,BOSTON,MA 02115. HARVARD UNIV,SCH DENT MED,BOSTON,MA 02115. FU NIDCR NIH HHS [DE08415] NR 29 TC 7 Z9 8 U1 0 U2 0 PU MUNKSGAARD INT PUBL LTD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 0022-3484 J9 J PERIODONTAL RES JI J. Periodont. Res. PD JAN PY 1997 VL 32 IS 1 BP 196 EP 199 DI 10.1111/j.1600-0765.1997.tb01405.x PN 2 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA WN711 UT WOS:A1997WN71100020 PM 9085234 ER PT J AU Hajjar, RJ Schmidt, U Helm, P Gwathmey, JK AF Hajjar, RJ Schmidt, U Helm, P Gwathmey, JK TI Ca++ sensitizers impair cardiac relaxation in failing human myocardium SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID HUMAN VENTRICULAR MYOCARDIUM; POSITIVE INOTROPIC MECHANISM; STAGE HEART-FAILURE; INTRACELLULAR CALCIUM; CA-2+ REGULATION; SKINNED FIBERS; DPI 201-106; EMD-53998; INTACT; FORCE AB The present study was aimed at investigating the effect of two Ca++ sensitizers, EMD 57033 (without significant phosphodiesterase inhibition) and ORG 30029 (with phosphodiesterase inhibition), in myocardium from nonfailing and failing human hearts. In nonfailing myocardium both EMD 57033 and ORG 30029 increased force of contraction by 280 +/- 27% and 94 +/- 13%, respectively (n = 6); the time to 80% relaxation (t(80%)) by 278 +/- 45% and 155 +/- 21%; and diastolic force by 28 +/- 8% and 12 +/- 3%, respectively. In trabeculae from failing myocardium, the increase in active force was similar to that in nonfailing trabeculae (EMD, 305 +/- 30%; ORG, 88 +/- 12% (n = 6)). However, the increase in t(80%) (EMD, 378 +/- 56%; ORG, 230 +/- 26%) and diastolic force (65 +/- 12%; 24 +/- 5%) was more pronounced in failing myocardium. EMD had no effect on the peak of the [Ca++], transient; however, it prolonged the time course of the [Ca++](i) transient in both nonfailing and failing myocardial fibers. ORG increased the peak of the Ca++ transient and prolonged the time course in preparations from both nonfailing and failing hearts. Both EMD and ORG shifted the [Ca++]-force relationship toward lower [Ca++] (EMD > ORG). The Ca++ sensitizers EMD 57033 and ORG 30029 increased active force development in nonfailing and failing human myocardium, but both impaired relaxation in failing myocardium to a greater extent than in nonfailing human myocardium in a concentration-dependent fashion. C1 BOSTON UNIV, SCH MED, INTEGRATED PHYSIOL LABS, EVANS DEPT MED, BOSTON, MA 02118 USA. MASSACHUSETTS GEN HOSP, WHITAKER CARDIOVASC INST, BOSTON, MA 02114 USA. MASSACHUSETTS GEN HOSP, CARDIAC UNIT, HEART FAILURE CTR, BOSTON, MA 02114 USA. FU NHLBI NIH HHS [R01 HL 49574, R44 HL52249] NR 50 TC 66 Z9 66 U1 0 U2 0 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD JAN PY 1997 VL 280 IS 1 BP 247 EP 254 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA WC041 UT WOS:A1997WC04100030 PM 8996203 ER PT J AU Masterman, DL Cummings, JL AF Masterman, DL Cummings, JL TI Frontal-subcortical circuits: The anatomic basis of executive, social and motivated behaviors SO JOURNAL OF PSYCHOPHARMACOLOGY LA English DT Article DE dopamine; frontal-subcortical circuits; matrix; receptors; striatum; striosomes ID BASAL GANGLIA; PARKINSONS-DISEASE; ACETYLCHOLINE-RELEASE; STRIATUM; ORGANIZATION; NEURONS; LOBE; NEUROTRANSMITTERS; INTERNEURONS; CONNECTIONS AB A series of discrete, parallel frontal-subcortical circuits have been demonstrated to link specific areas of the frontal lobe to areas within the basal ganglia and thalamus. A variety of circuit-specific behaviors can be described involving the dorsolateral prefrontal, orbitofrontal and anterior cingulate circuits. Interruptions or imbalance occurring at various levels within these closed looped circuits is felt to underlie the characteristic behavioral patterns seen. The intricate neurochemical arrangement of the striatum and the complex neurotransmitter interactions that occur within these key subcortical structures form the basis for modulatory influences that can affect these circuits. C1 UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA. UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA. W LOS ANGELES VET AFFAIRS MED CTR,PSYCHIAT SERV,BEHAV NEUROSCI SECT,LOS ANGELES,CA. FU NIA NIH HHS [AG10123] NR 55 TC 149 Z9 152 U1 2 U2 11 PU SAGE PUBLICATIONS LTD PI LONDON PA 6 BONHILL STREET, LONDON, ENGLAND EC2A 4PU SN 0269-8811 J9 J PSYCHOPHARMACOL JI J. Psychopharmacol. PY 1997 VL 11 IS 2 BP 107 EP 114 DI 10.1177/026988119701100203 PG 8 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA XK611 UT WOS:A1997XK61100003 PM 9208374 ER PT J AU Sorensen, G Youngstrom, R Maclachlan, C Gibson, SJ Emmons, K Johnston, D Levenstein, C AF Sorensen, G Youngstrom, R Maclachlan, C Gibson, SJ Emmons, K Johnston, D Levenstein, C TI Labor positions on worksite tobacco control policies: A review of arbitration cases SO JOURNAL OF PUBLIC HEALTH POLICY LA English DT Review ID SMOKING POLICIES; WORKPLACE; ATTITUDES; BAN AB Although worksite smoking restrictions have become increasingly common in recent fears, organized labor has generally not been involved in the adoption of these policies; some evidence suggests that unions often oppose the adoption of worksite smoking policies. To contribute to an understanding of labor's role in tobacco control policies, this paper reports the results of a review of 85 arbitration cases and 5 cases of unfair labor practices charges published between 1986 and 1994 In most of the cases reviewed, management unilaterally imposed a new smoking policy, which the union then grieved. Union opposition to the policy generally focused on the process by which the policy was adopted, rather than the content of the policy; the concern was that management had breached its duty to bargain with the union regarding the adoption of the policy. These results underline the importance of joint labor-management actions on worksite tobacco control policies. C1 Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. Massachusetts Dept Ind Accid, Div Dispute Resolut, Review Board, Boston, MA 02111 USA. Law Off Sarah Gibson, Boston, MA 02109 USA. Univ Massachusetts, Dept Work Environm, Lowell, MA 01854 USA. RP Sorensen, G (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Ctr Community Based Res, 44 Binney St, Boston, MA 02115 USA. NR 12 TC 9 Z9 9 U1 1 U2 1 PU JOURNAL PUBLIC HEALTH POLICY PI S BURLINGTON PA 208 MEADOWOOD DR, S BURLINGTON, VT 05403 USA SN 0197-5897 J9 J PUBLIC HEALTH POL JI J. Public Health Policy PY 1997 VL 18 IS 4 BP 433 EP 452 DI 10.2307/3343523 PG 20 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA ZG486 UT WOS:000073008500003 PM 9519619 ER PT J AU Meier, CA AF Meier, CA TI Regulation of gene expression by nuclear hormone receptors SO JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH LA English DT Article; Proceedings Paper CT 7th Swiss Workshop of Methodology in Receptor Research CY MAR 17-21, 1996 CL MEIRINGEN, GERMANY ID ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTORS; PROLIFERATOR-ACTIVATED RECEPTORS; LIGAND-BINDING DOMAIN; ESTROGEN-RECEPTOR; THYROID-HORMONE; CRYSTAL-STRUCTURE; PROSTATE-CANCER; DIRECT REPEATS; CROSS-TALK AB Steroids and thyroid hormones, as well as vitamin D, retinoids and some nutrient metabolites (fatty acids, prostaglandins, farnesol metabolites) act by binding to members of the zinc-finger containing superfamily of nuclear hormone receptors. These receptor proteins bind directly to specific DNA recognition sequences (hormone response elements) in the promoter region of target genes, resulting in the alteration of the transcription initiation rate. While the principle of action of these receptors appears to be quite simple, the promiscuous behavior of some members of this family as well as cross-talk with other signaling systems result in an intricate regulatory network with distinct particularities for each receptor type. Specific areas of current interest in nuclear receptor research are: (i) the mechanisms for target gene specificity, which occur at the level of receptor expression, ligand metabolism and/or DNA sequence; (ii) cross-talk with other signaling systems resulting in the modulation of the transcriptional activity of the ligand-activated receptor through phosphorylation and/or heterodimerization with shared nuclear factors; and (iii) the discovery of novel agonistic and antagonistic ligands for established and orphan nuclear receptors. Recent insights through screening strategies for putative ligands, the cloning of co-activator proteins, as well as the characterization of human and animal models with germline and somatic mutations in nuclear receptors have resulted in important insights into some of the above questions, which are fundamental for a better understanding of the role of these hormone-activated transcription factors during development and cell differentiation. RP Meier, CA (reprint author), MASSACHUSETTS GEN HOSP,DIV ENDOCRINE,FRUIT ST,BOSTON,MA 02114, USA. NR 45 TC 43 Z9 47 U1 0 U2 1 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 1079-9893 J9 J RECEPT SIGNAL TR R JI J. Recept. Signal Transduct. Res. PY 1997 VL 17 IS 1-3 BP 319 EP 335 DI 10.3109/10799899709036612 PG 17 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA WE762 UT WOS:A1997WE76200023 PM 9029499 ER PT J AU Brothers, TE Frank, CE Frank, B Robison, JG Elliott, BM Schutte, HD Merrill, KD Friedman, RJ AF Brothers, TE Frank, CE Frank, B Robison, JG Elliott, BM Schutte, HD Merrill, KD Friedman, RJ TI Is duplex venous surveillance worthwhile after arthroplasty? SO JOURNAL OF SURGICAL RESEARCH LA English DT Article; Proceedings Paper CT Annual Symposium of the Association-of-Veterans-Administration-Surgeons CY APR 28-30, 1996 CL DETROIT, MI SP Assoc Vet Adm Surgeons ID DEEP-VEIN THROMBOSIS; HIP-SURGERY; IMPEDANCE PLETHYSMOGRAPHY; PULMONARY-EMBOLISM; MAJOR HIP; DIAGNOSIS; THROMBOEMBOLISM; ULTRASONOGRAPHY; PROPHYLAXIS; VENOGRAPHY AB Deep venous thrombosis (DVT) complicates 60% of knee and 80% of hip arthroplasties performed without prophylactic therapy. Routine postoperative duplex ultrasound surveillance has been proposed for the detection of venous thrombosis following arthroplasty. In order to determine whether surveillance represents an effective strategy to detect postoperative DVT when prophylaxis is used, surveillance duplex exams obtained after primary or revision hip or knee arthroplasty were analyzed using decision analysis techniques. DVT was suspected clinically after 95 of 738 (13%) arthroplasties, with no symptoms suggestive of DVT after the remaining 643 procedures. Surveillance duplex scans were performed within 2 weeks of 371 procedures, while no surveillance studies were performed after the remaining 272 procedures. In these asymptomatic patients only 2 (0.5%) surveillance duplex studies were positive for DVT. In contrast, 4 of 37 (11%) duplex exams and 5 of 62 (8%) contrast phlebograms performed among symptomatic patients were positive for DVT. The overall incidence of DVT after arthroplasty in the entire population was 1.4% (10/738) with no pulmonary emboli. Patient follow-up averaged 162 +/- 285 days. Using the 1995 Medicare reimbursement of $163 for venous duplex, the incremental cost was $35,000 to detect 1 additional unsuspected DVT and $110,000 per additional quality-adjusted life-year gained. The low incidence of clinically significant DVT and pulmonary emboli with current prophylaxis does not justify an aggressive screening program. Decision analysis suggests that a greater incidence of DVT is required for screening to be worthwhile. (C) 1997 Academic Press. C1 MED UNIV S CAROLINA, CHARLESTON, SC 29425 USA. RP Brothers, TE (reprint author), RALPH HENRY JOHNSON DEPT VET AFFAIRS MED CTR, CHARLESTON, SC 29425 USA. NR 37 TC 13 Z9 14 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD JAN PY 1997 VL 67 IS 1 BP 72 EP 78 DI 10.1006/jsre.1996.4962 PG 7 WC Surgery SC Surgery GA WK047 UT WOS:A1997WK04700014 PM 9070185 ER PT J AU Biederman, J Wilens, T Mick, E Faraone, SV Weber, W Curtis, S Thornell, A Pfister, K Jetton, JG Soriano, J AF Biederman, J Wilens, T Mick, E Faraone, SV Weber, W Curtis, S Thornell, A Pfister, K Jetton, JG Soriano, J TI Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE attention-deficit hyperactivity disorder; substance use disorder; drug; alcohol; children ID ATTENTION-DEFICIT HYPERACTIVITY; SEEKING COCAINE ABUSERS; PSYCHIATRIC-DISORDERS; OPIATE ADDICTS; DRUG-USE; COMORBIDITY; BOYS; CHILDHOOD; ALCOHOL; ADOLESCENTS AB Objective: To evaluate whether attention-deficit hyperactivity disorder (ADHD) is a risk factor for psychoactive substance use disorders (PSUD), attending to issues of psychiatric comorbidity, family history, and adversity. Method: Using assessments from multiple domains, the authors examined 140 ADHD and 120 normal control subjects at baseline and 4 years later. Drug and alcohol abuse and dependence were operationally defined. Results: No differences were detected in the rates of alcohol or drug abuse or dependence or in the rates of abuse of individual substances between the groups; both ADHD and control probands had a 15% rate of PSUD. Conduct and bipolar disorders predicted PSUD, independently of ADHD status. Family history of substance dependence and antisocial disorders was associated with PSUD in controls but less clearly so in ADHD probands. Family history of ADHD was not associated with risk for PSUD. ADHD probands had a significantly shorter time period between the onsets of abuse and dependence compared with controls (1.2 years versus 3 years, p < .01). Conclusions: Adolescents with and without ADHD had a similar risk for PSUD that was mediated by conduct and bipolar disorder. Since the risk for PSUD has been shown to be elevated in adults with ADHD when compared with controls, a sharp increase in PSUD is to be expected in grown-up ADHD children during the transition from adolescence to adulthood. C1 HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115. HARVARD UNIV,MASSACHUSETTS HLTH CTR,INST PSYCHIAT EPIDEMIOL & GENET,DEPT PSYCHIAT,BOSTON,MA 02115. HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115. RP Biederman, J (reprint author), MASSACHUSETTS GEN HOSP,PEDIAT PSYCHOPHARMACOL UNIT,PSYCHIAT SERV,ACC 725,FRUIT ST,BOSTON,MA 02114, USA. OI Mick, Eric/0000-0001-8505-8145; Faraone, Stephen/0000-0002-9217-3982 FU NIMH NIH HHS [R01 MH41314-07] NR 48 TC 297 Z9 303 U1 3 U2 14 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD JAN PY 1997 VL 36 IS 1 BP 21 EP 29 DI 10.1097/00004583-199701000-00013 PG 9 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA WA553 UT WOS:A1997WA55300013 PM 9000777 ER PT J AU Milberger, S Biederman, J Faraone, SV Chen, L Jones, J AF Milberger, S Biederman, J Faraone, SV Chen, L Jones, J TI ADHD is associated with early initiation of cigarette smoking in children and adolescents SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE attention-deficit hyperactivity disorder; cigarette smoking; children; adolescents; comorbidity ID HIGH-SCHOOL-STUDENTS; MATERNAL SMOKING; DRUG-USE; NICOTINE DEPENDENCE; PSYCHIATRIC STATUS; PRENATAL EXPOSURE; HYPERACTIVE BOYS; RISK-FACTORS; TOBACCO USE; FOLLOW-UP AB Objective: The association between attention-deficit hyperactivity disorder (ADHD) and cigarette smoking in children and adolescents was evaluated. Method: Subjects were 6- to 17-year-old boys with DSM-III-R ADHD (n = 128) and non-ADHD comparison boys (n = 109) followed prospectively for 4 years into mid-adolescence. Information on cigarette smoking was obtained in a standardized manner blind to the proband's clinical status. Cox proportional hazard models were used to predict cigarette smoking at follow-up using baseline characteristics as predictors. Results: ADHD was a significant predictor of cigarette smoking at follow-up into mid-adolescence. Our findings also revealed that ADHD was associated with an early initiation of cigarette smoking. This was the case even after controlling for socioeconomic status, IQ, and psychiatric comorbidity. In addition, among children with ADHD, there was a significant positive association between cigarette smoking and conduct, major depressive, and anxiety disorders. Conclusions: ADHD, particularly the comorbid subtype, is a significant risk factor for early initiation of cigarette smoking in children and adolescents. Considering the prevalence and early childhood onset of ADHD, these findings highlight the importance of smoking prevention and cessation programs for children and adolescents with ADHD. C1 MASSACHUSETTS GEN HOSP,PEDIAT PSYCHOPHARMACOL UNIT,BOSTON,MA 02114. HARVARD UNIV,INST PSYCHIAT EPIDEMIOL & GENET,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BOSTON,MA 02115. HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115. OI Faraone, Stephen/0000-0002-9217-3982 FU NIMH NIH HHS [R01 MH-41314-01A2] NR 62 TC 316 Z9 320 U1 4 U2 16 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD JAN PY 1997 VL 36 IS 1 BP 37 EP 44 DI 10.1097/00004583-199701000-00015 PG 8 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA WA553 UT WOS:A1997WA55300015 PM 9000779 ER PT J AU Wilens, TE Biederman, J Spencer, TJ AF Wilens, TE Biederman, J Spencer, TJ TI Case study: Adverse effects of smoking marijuana while receiving tricyclic antidepressants SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE tricyclic antidepressant; marijuana; pediatric; adverse effects ID ATTENTION-DEFICIT HYPERACTIVITY; ADOLESCENT SUBSTANCE-ABUSERS; PSYCHIATRIC COMORBIDITY; USE DISORDERS; DEPRESSION; ANXIETY; ADHD; BOYS AB increasingly, children and adolescents are being treated for underlying psychopathology commonly associated with the psychoactive substance use disorders. Despite this apparent increase in using medication, little is known about the interaction of drugs of abuse with the psychotropic medications. The authors describe four cases of male adolescents aged 15 to 18 years being treated with a tricyclic antidepressant for attention-deficit hyperactivity disorder who manifested transient cognitive changes, delirium, and tachycardia after smoking marijuana. C1 HARVARD UNIV,SCH MED,BOSTON,MA. RP Wilens, TE (reprint author), MASSACHUSETTS GEN HOSP,PEDIAT PSYCHOPHARMACOL UNIT,ACC 725,BOSTON,MA 02114, USA. FU NIMH NIH HHS [MH01175A02] NR 30 TC 29 Z9 29 U1 0 U2 2 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD JAN PY 1997 VL 36 IS 1 BP 45 EP 48 DI 10.1097/00004583-199701000-00016 PG 4 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA WA553 UT WOS:A1997WA55300016 PM 9000780 ER PT J AU Stafford, RS Blumenthal, D Pasternak, RC AF Stafford, RS Blumenthal, D Pasternak, RC TI Variations in cholesterol management practices of US physicians SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID CORONARY HEART-DISEASE; HIGH BLOOD CHOLESTEROL; UNITED-STATES; HYPERCHOLESTEROLEMIA; PREVENTION; GUIDELINES; MORTALITY AB Objectives. This study sought to evaluate national cholesterol management practices of U.S. physicians. Background. Past studies show that nonclinical factors affect physician practices. We tested the hypothesis that physician and patient characteristics influence cholesterol management. Methods. We used a stratified, random sample of 2,332 office based physicians providing 56,215 visits to adults in the 1991-1992 National Ambulatory Medical Care Surveys. We investigated physicians' reporting of cholesterol related screening, counseling or medications during office visits and used multiple logistic regression to assess independent predictors. Results. An estimated 1.12 billion adult office visits occurred in 1991 and 1992 (95% confidence interval 1.06 to 1.18 billion). For the 1.03 billion visits by patients without reported hyperlipidemia, cholesterol screening (2.8% of visits) and counseling (1.2%) were not frequent. The likelihood of screening increased with older age, cardiovascular disease risk factors, white race and private insurance. We estimate that only 1 in 12 adults received cholesterol screening annually. In the 85 million visits by patients with hyperlipidemia, cholesterol testing was reported in 22.9%, cholesterol counseling in 34.4% and lipid-lowering medications in 23.1%. Testing was more likely in diabetic and nonobese patients. Counseling was more likely with younger age, cardiovascular disease and private insurance. Medications use was associated with cardiovascular disease, Northeast region of the United States, nonobese patients and visits to internists, Physician practices did not differ by patient gender. Conclusions. Although clinical conditions strongly influence cholesterol management, the appropriateness of variations noted by payment source, geographic region and physician specialty deserve further evaluation. These variations and the low estimated volume of services suggest that physicians have not fully adopted recommended cholesterol management practices. (C) 1997 by the American College of Cardiology C1 MASSACHUSETTS GEN HOSP,DIV GEN INTERNAL MED,HLTH POLICY RES & DEV UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA. FU AHRQ HHS [R01HS07892-01A2] NR 35 TC 93 Z9 94 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JAN PY 1997 VL 29 IS 1 BP 139 EP 146 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA WB902 UT WOS:A1997WB90200020 PM 8996306 ER PT J AU Schwartz, MW Seeley, RJ AF Schwartz, MW Seeley, RJ TI The new biology of body weight regulation SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Review ID NEUROPEPTIDE GENE-EXPRESSION; OBESE GENE; ENERGY-BALANCE; OB/OB MOUSE; OB PROTEIN; INSULIN; FOOD; HYPERPHAGIA; PLASMA; HYPOTHALAMUS AB A growing body of evidence suggests that energy balance (the difference between energy intake and expenditure) and body fuel stores in the form of adipose tissue are maintained by the body within a narrow range. This regulation of adiposity is mediated by the secretion of hormonal signals into the circulation in proportion to body adipose stores and their subsequent actions on brain systems that control caloric intake and energy expenditure. hs a result, changes in energy balance sufficient to alter fuel stores elicit compensatory changes in energy intake and expenditure that return fat stores to their regulated level Recent scientific breakthroughs have identified the key components of this physiologic system. These include the circulating signals, leptin (the hormone encoded by the ob gene that is secreted by fat cells) and the pancreatic hormone insulin; and brain peptides such as neuropeptide YI which is released from nerve terminals in the hypothalamus to elicit changes in feeding behavior and energy expenditure that mediate adaptive changes in energy balance. This article reviews the discovery of leptin and its receptor and discusses the interaction of leptin and insulin with the hypothalamic neuropeptide Y system. These observations provide a basis for understanding how weight lost during a period of negative energy balance (because of the inability to consume and/or store sufficient energy to meet ongoing energy demands) is eventually recovered. As our understanding of this weight-regulatory system increases, new insights into the causes of human obesity are likely to follow. Such insights may yield improvements in the medical and nutrition management of obese patients. C1 UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195. UNIV WASHINGTON,DEPT PSYCHOL,SEATTLE,WA 98195. RP Schwartz, MW (reprint author), VET AFFAIRS PUGET SOUND HLTH CARE SYST,1660 S COLUMBIAN WAY,SEATTLE,WA 98108, USA. RI Schwartz, Michael/H-9950-2012 FU NIDDK NIH HHS [DK35816]; NINDS NIH HHS [NS32273] NR 41 TC 64 Z9 65 U1 1 U2 11 PU AMER DIETETIC ASSOC PI CHICAGO PA 216 W JACKSON BLVD #800, CHICAGO, IL 60606-6995 SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD JAN PY 1997 VL 97 IS 1 BP 54 EP 58 DI 10.1016/S0002-8223(97)00018-7 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA WM907 UT WOS:A1997WM90700012 PM 8990418 ER PT J AU Murphy, SN Rabbani, UH Barnett, GO AF Murphy, SN Rabbani, UH Barnett, GO TI Using software agents to maintain autonomous patient registries for clinical research SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article AB A software agent is an application that can function in an autonomous and intelligent fashion. We have used mobile software agents to maintain clinicians' patient research databases (patient registries). Agents were used to acquire data from the clinician and place it into the registries, copy data from hospital databases into the registries, and report data from the registries. The agents were programmed with the intelligence to navigate through complex network security, interact with legacy systems, and protect themselves from various forms of failure at multiple levels. To maximize the separation between our system and the hospital information infrastructure we often used Java, a platform-independent language, to program and distribute our software agents. By using mobile agents, we were able to distribute the computing time required by these applications to underutilized host machines upon which the registries could be maintained. C1 Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. RP Murphy, SN (reprint author), Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. NR 7 TC 0 Z9 0 U1 0 U2 1 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 1997 SU S BP 71 EP 75 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA V3182 UT WOS:000171774300016 ER PT J AU Zielstorff, RD Estey, G Vickery, A Hamilton, G Fitzmaurice, JB Barnett, GO AF Zielstorff, RD Estey, G Vickery, A Hamilton, G Fitzmaurice, JB Barnett, GO TI Evaluation of a decision support system for pressure ulcer prevention and management: Preliminary findings SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article AB A decision support system for prevention and management of pressure ulcers was developed based on AHCPR guidelines and other sources. The system was implemented for 21 weeks on a 20-bed clinical care unit. Fifteen nurses on that unit volunteered as subjects of the intervention to see whether use of the system would have a positive effect on their knowledge about pressure ulcers and on their decision-making skills related to this topic. A similar care unit was used as a control. In addition, the system was evaluated by experts for its instructional adequacy, and by end users for their satisfaction with the system. Preliminary results show no effect on knowledge about pressure ulcers and no effect on clinical decision making skills. The system was rated positively for instructional adequacy, and positively for user satisfaction. User interviews related to satisfaction supplemented the quantitative findings, A discussion of the issues of conducting experiments like this in today's clinical environment is included. C1 Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Nursing, Boston, MA 02114 USA. RP Zielstorff, RD (reprint author), Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. FU AHRQ HHS [5 R18 HS06575]; NLM NIH HHS [5 R01 LM05200, 1 T15 LM07092] NR 4 TC 4 Z9 4 U1 0 U2 2 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 1997 SU S BP 248 EP 252 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA V3182 UT WOS:000171774300051 PM 9357626 ER PT J AU Kittredge, R Rabbani, U Melanson, F Barnett, O AF Kittredge, R Rabbani, U Melanson, F Barnett, O TI Experiences in deployment of a Web-based CIS for referring physicians SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article AB Improving the timeliness and efficiency of information exchange between the hospital and clinicians in the health care community is an area of active interest at the Massachusetts General Hospital (MGH). Providing computer-based access to referring physicians who are not formally affiliated with the hospital is a particular challenge, since these offices are not connected to the hospital network and lack the standard hospital workstation hardware and software. Installing clients for the hospital's clinical applications at these sites has been a difficult and costly proposition. The emergence of Web technology yields an alternative method for developing clinical applications for this remote, diverse user population. We present our experiences during the first six months of deployment of a Web-based clinical information system designed for use by referring physicians. C1 Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. RP Kittredge, R (reprint author), Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. NR 7 TC 1 Z9 1 U1 1 U2 1 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 1997 SU S BP 320 EP 324 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA V3182 UT WOS:000171774300065 ER PT J AU Detmer, WM Barnett, GO Hersh, WR AF Detmer, WM Barnett, GO Hersh, WR TI MedWeaver: Integrating decision support, literature searching, and Web exploration using the UMLS Metathesaurus SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article AB Integrating functions from disparate and widely-distributed information systems has been an interest of the medical informatics community for some time. Barriers to progress have included the lack of network-accessible information sources, inadequate methods for inter-system messaging, and lack of vocabulary translation services. With the advent of the World Wide Web (WWW) and the evolution of the National Library of Medicine's Unified Medical Language System (UMLS), it is now possible to develop applications that integrate functions from diverse, distributed systems. In this paper we describe one such system, MedWeaver, a WWW application that integrates functions from a decision support application (DXplain), a literature searching system (WebMedline), and a clinical Web searching system (CliniWeb) using the UMLS Metathesaurus for vocabulary translation. This system demonstrates how application developers can design systems around anticipated clinical information needs and then draw together the needed content and functionality from diverse sources. C1 Stanford Univ, Med Ctr, Sect Med Informat, Stanford, CA 94305 USA. Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. Oregon Hlth Sci Univ, Ctr Biomed Informat Commun, Portland, OR 97201 USA. RP Detmer, WM (reprint author), Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA 22903 USA. OI Hersh, William/0000-0002-4114-5148 NR 16 TC 6 Z9 6 U1 0 U2 0 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 1997 SU S BP 490 EP 494 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA V3182 UT WOS:000171774300099 ER PT J AU de Estrada, WD Murphy, S Barnett, GO AF de Estrada, WD Murphy, S Barnett, GO TI Puya: A method of attracting attention to relevant physical findings SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article AB Puya is a method that compares the physical exam in an electronic clinical note with a set of stereotypical physical exam sentences that have been previously classified as "normal". The note is then displayed in a web browser with normal findings clearly delineated. The list of stereotypical sentences comes from a set of physical findings found within extensive electronic medical record. This list is then screened to select only those that represent "normal" findings, a process that yields 96% total agreement among 4 clinicians surveyed. This final list of stereotypical "normal" sentences accounts for 64% of the clinical narrative text. Sentences in the clinical note that do not match sentences in the "normal" list are assumed to be "abnormal". Puya screened 98 clinical notes consisting of 610 individual sentences. Puya achieved a sensitivity of 100%, a specificity of 63%, a positive predictive value of 44% and a negative predictive value of 100%. This leads to an application that reduces informational noise. C1 Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. RP de Estrada, WD (reprint author), Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 0 U2 1 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 1997 SU S BP 509 EP 513 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA V3182 UT WOS:000171774300103 ER PT J AU Aryel, RM Cai, J Chueh, HC Barnett, GO AF Aryel, RM Cai, J Chueh, HC Barnett, GO TI Maintaining the integrity of a Web-based medical vocabulary glossary SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article AB Medical vocabulary databases are vital components of electronic medical record (EMR) systems. While their performance and efficiency has been extensively explored by many authors, few have dealt with the maintenance of their semantic integrity. Clinicians' preference for an optimistic system has introduced a need for monitoring and filtering proposed additions to the vocabulary tables. We propose the use of batch processing and memo-posting as means of implementing a World-Wide-Web-based Controlled Vocabulary Glossary as a monitored optimistic system. C1 Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. RP Aryel, RM (reprint author), Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. NR 8 TC 0 Z9 0 U1 1 U2 1 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 1997 SU S BP 600 EP 604 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA V3182 UT WOS:000171774300121 ER PT J AU Berkowicz, DA Chueh, HC Barnett, GO AF Berkowicz, DA Chueh, HC Barnett, GO TI Design considerations in migrating an obstetrics clinical record to the Web SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article AB Recently the American College of Obstetricians and Gynecologists (ACOG) embarked on an effort to promote the development of nationally networked obstetrical records. The Laboratory of Computer Science, (LCS) is collaborating with them to help achieve this goal through the development of a web-based prototype of an electronic medical record (EMR) which would allow the entry and display of typical clinical information for the obstetric patient. The process of porting a stand alone application to the web environment necessitated the development of a robust software scheme that could exploit the strengths of Web-based technologies and avoid some of the drawbacks inherent in a stateless environment. C1 Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. RP Berkowicz, DA (reprint author), Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. NR 4 TC 1 Z9 1 U1 0 U2 0 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 1997 SU S BP 754 EP 758 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA V3182 UT WOS:000171774300151 ER PT J AU Hulse, M Zielstorff, RD Estey, G AF Hulse, M Zielstorff, RD Estey, G TI User-interface design of a Web-based clinical decision support system SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 1997 SU S BP 951 EP 951 PG 1 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA V3182 UT WOS:000171774300280 ER PT J AU Li, FP Abramson, DH Tarone, RE Kleinerman, RA Fraumeni, JF Boice, JD AF Li, FP Abramson, DH Tarone, RE Kleinerman, RA Fraumeni, JF Boice, JD TI Hereditary retinoblastoma, lipoma, and second primary cancers SO JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID TUMORS; SARCOMA; BENIGN; GENE C1 HARVARD UNIV,DANA FARBER CANC INST,DIV CANC EPIDEMIOL & CONTROL,BOSTON,MA. HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115. CORNELL UNIV,MED CTR,NEW YORK HOSP,OPHTHALM ONCOL CTR,NEW YORK,NY 10021. NCI,DIV CANC EPIDEMIOL & GENET,BETHESDA,MD 20892. OI Kleinerman, Ruth/0000-0001-7415-2478 FU NCI NIH HHS [N01CP05609, N01CP85604] NR 12 TC 33 Z9 33 U1 1 U2 2 PU NATL CANCER INSTITUTE PI BETHESDA PA 9030 OLD GEORGETOWN RD, BETHESDA, MD 20814 SN 0027-8874 J9 J NATL CANCER I JI J. Natl. Cancer Inst. PD JAN 1 PY 1997 VL 89 IS 1 BP 83 EP 84 DI 10.1093/jnci/89.1.83 PG 2 WC Oncology SC Oncology GA VZ936 UT WOS:A1997VZ93600021 PM 8978411 ER PT J AU Sammel, MD Ryan, LM Legler, JM AF Sammel, MD Ryan, LM Legler, JM TI Latent variable models for mixed discrete and continuous outcomes SO JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-METHODOLOGICAL LA English DT Article DE exponential family; hierarchical models; latent trait; mixed effects ID LONGITUDINAL DATA-ANALYSIS; GENERALIZED LINEAR-MODELS; EM ALGORITHM; MAXIMUM-LIKELIHOOD; BINARY AB We propose a latent variable model for mixed discrete and continuous outcomes. The model accommodates any mixture of outcomes from an exponential family and allows for arbitrary covariate effects, as well as direct modelling of covariates on the latent variable. An EM algorithm is proposed for parameter estimation and estimates of the latent variables are produced as a by-product of the analysis. A generalized likelihood ratio test can be used to test the significance of covariates affecting the latent outcomes. This method is applied to birth defects data, where the outcomes of interest are continuous measures of size and binary indicators of minor physical anomalies. Infants who were exposed in utero to anticonvulsant medications are compared with controls. C1 DANA FARBER CANC INST,BOSTON,MA 02115. NCI,BETHESDA,MD 20892. RP Sammel, MD (reprint author), HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA. RI Ryan, Louise/A-4562-2009 OI Ryan, Louise/0000-0001-5957-2490 NR 33 TC 146 Z9 147 U1 1 U2 6 PU BLACKWELL PUBL LTD PI OXFORD PA 108 COWLEY RD, OXFORD, OXON, ENGLAND OX4 1JF SN 0035-9246 J9 J ROY STAT SOC B MET JI J. R. Stat. Soc. Ser. B-Methodol. PY 1997 VL 59 IS 3 BP 667 EP 678 DI 10.1111/1467-9868.00090 PG 12 WC Statistics & Probability SC Mathematics GA XD527 UT WOS:A1997XD52700010 ER PT J AU ONunain, S Perez, I Roelke, M Osswald, S McGovern, BA Brooks, DR Torchiana, DF Vlahakes, GJ Ruskin, J Garan, H AF ONunain, S Perez, I Roelke, M Osswald, S McGovern, BA Brooks, DR Torchiana, DF Vlahakes, GJ Ruskin, J Garan, H TI The treatment of patients with infected implantable cardioverter-defibrillator systems SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID MALIGNANT VENTRICULAR ARRHYTHMIAS; PACEMAKER LEADS; COMPLICATIONS; MANAGEMENT; EFFICACY; EXTRACTION; REMOVAL; DEVICE AB Objective: The purpose of this study was to evaluate the treatment of patients with infected implantable cardioverter-defibrillator systems. Methods: Retrospective analysis was done of the cases of 21 patients treated for implantable cardioverter-defibrillator infection during an 11-year period. Results: Of 723 cardioverter-defibrillator implantations (550 primary implants, 173 replacements), nine (1.2%) were complicated by early postoperative device-related infections, Late infections developed in two patients 19 and 22 months, respectively, after implantation, Ten other patients were transferred to our institution for treatment of cardioverter-defibrillator infection. The time from implantation to overt infection was 2.2 +/- 1.3 months, excluding the two late infections, The responsible organisms were Staphylococcus aureus (9), Staphylococcus epidermidis (6), Streptococcus hemolyticus (1), gram-negative bacteria (3), Candida albicans (1), and Corynebacterium (1), All patients were treated with intravenous antibiotic drugs, Total system removal was done in 15 patients and partial removal in 2; in 4, the cardioverter-defibrillator system was not explanted, There were no perioperative deaths, A new implantable cardioverter-defibrillator system was reimplanted in 7 patients after 2 to 6 weeks of antibiotic therapy, Ten patients were treated without reimplantation (2 arrhythmia operation, 8 antiarrhythmic drugs), Four patients (3 patients without explantation and 1 with partial system removal) were treated with maintenance long-term antibiotic therapy, During a mean follow-up of 21 +/- 2.8 months, no patient had clinical recurrence of infection, One patient treated with antiarrhythmic drugs without system reimplantation died suddenly, Conclusions: Infections that involve implantable cardioverter-defibrillator systems can be safely managed by removing the entire system with reimplantation after intravenous antibiotic therapy, In selected patients in whom the risk for system explantation is high and anticipated life expectancy is short, long-term antibiotic therapy to suppress low-virulence infections may represent an acceptable alternative. C1 MASSACHUSETTS GEN HOSP,CARDIAC SURG UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT SURG,CARDIAC SURG UNIT,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT MED,CARDIAC UNIT,BOSTON,MA 02115. NR 18 TC 36 Z9 36 U1 0 U2 2 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD JAN PY 1997 VL 113 IS 1 BP 121 EP 129 DI 10.1016/S0022-5223(97)70407-0 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA WC267 UT WOS:A1997WC26700020 PM 9011681 ER PT J AU Letourneau, EJ Schewe, PA Frueh, BC AF Letourneau, EJ Schewe, PA Frueh, BC TI Preliminary evaluation of sexual problems in combat veterans with PTSD SO JOURNAL OF TRAUMATIC STRESS LA English DT Article DE GRISS; PTSD; sexual; problems; veterans AB This study evaluated the potential relationship between posttraumatic stress disorder (PTSD) and sexual problems. The Golombok Rust Inventory of Sexual Satisfaction was mailed to combat veterans currently in treatment at an outpatient PTSD clinic. Completed questionnaires were received from 90 patients. Results indicated that over 80% of subjects were experiencing clinically relevant sexual difficulties Impotence and premature ejaculation were the most frequently reported problems that have corresponding psychological diagnoses. The rates of sexual problems for this sample of veterans with PTSD was similar to those reported in other studies and exceeded rates of similar problems found in samples from community samples. These data suggest that PTSD may be a risk factor for sexual problems. C1 UNIV CHICAGO,DEPT PSYCHOL,PREVENT RES TRAINING PROGRAM,CHICAGO,IL 60637. MED UNIV S CAROLINA,RALPH H JOHNSON VET AFFAIRS MED CTR,DEPT PSYCHIAT & BEHAV SCI,COLUMBIA,SC 29209. RP Letourneau, EJ (reprint author), AUGUSTA STATE UNIV,AUGUSTA,GA 30904, USA. NR 14 TC 60 Z9 60 U1 1 U2 7 PU PLENUM PUBL CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD JAN PY 1997 VL 10 IS 1 BP 125 EP 132 DI 10.1002/jts.2490100112 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA WE880 UT WOS:A1997WE88000011 PM 9018683 ER PT J AU Barry, MJ Fowler, FJ Bin, L Pitts, JC Harris, CJ Mulley, AG AF Barry, MJ Fowler, FJ Bin, L Pitts, JC Harris, CJ Mulley, AG TI The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists SO JOURNAL OF UROLOGY LA English DT Article DE prostatic hypertrophy; prostatectomy; urinary retention; prognosis AB Purpose: We defined outcomes for men with a clinical diagnosis of benign prostatic hyperplasia. Materials and Methods: We followed for 4 years 500 candidates for elective prostatectomy treated nonoperatively in 5 North American urology practices. Results: There were 371 survivors with complete data at 4 years. Of 60 men with mild, 245 with moderate and 66 with severe baseline symptoms 10, 24 and 39%, respectively, had undergone surgery; 27, 31 and 27%, respectively, were on pharmacological therapy, and 63, 45 and 33%, respectively, were off active treatment at 4 years. Mild or moderate symptoms were noted at 4 years in 83, 59 and 23% of the patients, respectively, while 17, 41 and 77%, respectively, had severe symptoms or had undergone surgery. Conclusions: Outcomes for men with a clinical diagnosis of benign prostatic hyperplasia depend on initial symptom severity. However, the course of symptoms also varies among patients even with the same initial symptom severity. C1 MASSACHUSETTS GEN HOSP,DIV GEN INTERNAL MED,BOSTON,MA 02114. UNIV MASSACHUSETTS,SURG RES CTR,BOSTON,MA 02125. COLORADO PERMANENTE MED GRP,DEPT UROL,DENVER,CO. S REG UROL GRP HLTH COOPERAT PUGET SOUND,TACOMA,WA. RP Barry, MJ (reprint author), MASSACHUSETTS GEN HOSP,MED PRACTICES EVALUAT CTR,BOSTON,MA 02114, USA. FU AHRQ HHS [HS 06540, HS 08397, HS 06336] NR 14 TC 96 Z9 97 U1 1 U2 2 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 1997 VL 157 IS 1 BP 10 EP 14 DI 10.1016/S0022-5347(01)65267-4 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA VW915 UT WOS:A1997VW91500004 PM 8976204 ER PT J AU VandeWater, L AF VandeWater, L TI Mechanisms by which fibrin and fibronectin appear in healing wounds: Implications for Peyronie's disease SO JOURNAL OF UROLOGY LA English DT Article DE penile induration; extracellular matrix; fibronectins; neovascularization ID ENDOTHELIAL GROWTH-FACTOR; ANGIOGENESIS; EXPRESSION; OVEREXPRESSION; KERATINOCYTES; MACROPHAGES; RECEPTORS; RAT AB Purpose: The extracellular matrix that is present at sites of tissue repair in most instances undergoes an orderly transition from a fibrin containing matrix to collagen-rich scar. However, in some conditions, such as Peyronie's disease, fibrin persists. Evidence from a number of experimental systems indicates that extracellular matrix proteins and their receptors serve an important function in regulating cell behaviors. Thus, the presence of the fibrin matrix is likely to have important implications in the course of either normal or pathogenic wound healing as occurs in Peyronie's disease. Potential mechanisms by which the fibrin rich provisional matrix appears in healing wounds are presented. Materials and Methods: Methodologies, such as in situ hybridization, immunolocalization and labeled tracer techniques, were used in our study. Results: We found by these approaches that the 2 general mechanisms that contribute to the generation of the wound extracellular matrix are leakage of plasma proteins, such as plasma fibronectin and fibrinogen, and the synthesis of variants of fibronectin by wound cells. Conclusions: Developing an understanding of the mechanisms that regulate the appearance of these matrix proteins may provide new avenues for therapy in conditions such as Peyronie's disease in which the temporal pattern of the provisional matrix deposition is abnormal. C1 MASSACHUSETTS GEN HOSP,SHRINERS BURNS INST,CTR ENGN MED,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA. RP VandeWater, L (reprint author), BETH ISRAEL HOSP,DEPT PATHOL,330 BROOKLINE AVE,BOSTON,MA 02215, USA. FU NIGMS NIH HHS [GM-36812] NR 21 TC 26 Z9 27 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 1997 VL 157 IS 1 BP 306 EP 310 DI 10.1016/S0022-5347(01)65366-7 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA VW915 UT WOS:A1997VW91500103 PM 8976286 ER PT J AU Stampfer, DS McDougal, WS AF Stampfer, DS McDougal, WS TI Inhibition of the sodium/hydrogen antiport by ammonium ion SO JOURNAL OF UROLOGY LA English DT Article DE sodium hydrogen antiport; metabolic acidosis; ammonium ID DIVERSION; SODIUM AB Purpose: Previous work from our laboratory suggests that one mechanism of ammonium transport across the intestinal membrane may be substitution of ammonium for sodium in the sodium/hydrogen antiport. This study further supports this mechanism by demonstrating an inhibitory role for ammonium in the sodium/hydrogen exchange. Materials and Methods: Whole brush border intestinal enterocytes were studied, incorporating a fluorescent marker for sodium transport. The kinetics of the effect of ammonium on sodium transport were determined. Results: Ammonium is an inhibitor of sodium in the sodium/hydrogen exchanger. Quantitatively, the inhibition appears to be competitive. Conclusions: The inhibitory effect of ammonium on sodium/hydrogen exchange supports a mechanism of ionized ammonium transport where it substitutes for sodium in the sodium/hydrogen exchanger. This is a mechanism by which hyperchloremic metabolic acidosis occurs following urinary intestinal diversion. C1 MASSACHUSETTS GEN HOSP,DEPT UROL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA. FU NIDDK NIH HHS [R01 DK46825] NR 7 TC 17 Z9 17 U1 0 U2 1 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 1997 VL 157 IS 1 BP 362 EP 365 DI 10.1016/S0022-5347(01)65378-3 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA VW915 UT WOS:A1997VW91500115 PM 8976298 ER PT J AU Alson, MD Lang, EV Kaufman, JA AF Alson, MD Lang, EV Kaufman, JA TI Pedal arterial imaging SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article DE arteries, extremities; extremities, angiography; foot, anatomy ID PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; DIGITAL SUBTRACTION ANGIOGRAPHY; PERIPHERAL VASCULAR-DISEASE; SAPHENOUS-VEIN BYPASS; LOWER-LIMB ISCHEMIA; LOWER-EXTREMITY; OCCLUSIVE DISEASE; DIABETIC-PATIENTS; MR-ANGIOGRAPHY; DISTAL BYPASS C1 UNIV IOWA HOSP & CLIN,UNIV IOWA COLL MED,DEPT RADIOL 3890 JPP,IOWA CITY,IA 52242. VET AFFAIRS MED CTR,DEPT RADIOL,PALO ALTO,CA 94304. STANFORD UNIV,SCH MED,DEPT RADIOL,PALO ALTO,CA 94304. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 56 TC 21 Z9 21 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD JAN-FEB PY 1997 VL 8 IS 1 BP 9 EP 18 DI 10.1016/S1051-0443(97)70507-4 PN 1 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA WR459 UT WOS:A1997WR45900003 PM 9025033 ER PT J AU Abbott, WM Green, RM Matsumoto, T Wheeler, JR Miller, N Veith, FJ Suggs, WD Hollier, L Money, S Garrett, HE Moore, WS Dean, RH Cronenwett, JL Carter, S Greenhalgh, RM ODonnell, TF AF Abbott, WM Green, RM Matsumoto, T Wheeler, JR Miller, N Veith, FJ Suggs, WD Hollier, L Money, S Garrett, HE Moore, WS Dean, RH Cronenwett, JL Carter, S Greenhalgh, RM ODonnell, TF TI Prosthetic above-knee femoropopliteal bypass grafting: Results of a multicenter randomized prospective trial SO JOURNAL OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT 50th Annual Meeting of the Society-for-Vascular-Surgery CY JUN 11-12, 1996 CL CHICAGO, IL SP Soc Vasc Surg ID AUTOLOGOUS SAPHENOUS-VEIN; EXPANDED POLYTETRAFLUOROETHYLENE; PREFERENTIAL USE; TERM; REVASCULARIZATION; RECONSTRUCTIONS; EXPERIENCE; POPLITEAL AB Purpose:There are excellent arguments in favor of the preferential use of prosthetic grafts above the knee for the treatment of infrainguinal occlusive disease. This approach has been popularized on the basis of the seemingly acceptable results when using polytetrafluoroethylene (PTFE). However, in many centers, knitted Dacron polyester has been used in these patients, and there are several studies that show equivalent and, in some, superior results with Dacron when compared with PTFE. The purpose of this study was to examine these results in a definitive way. Methods: A randomized prospective trial in eight clinical academic centers in the United States and Canada was initiated in 1991. Two hundred forty-four patients eligible for such a study, by virtue of criteria extant in each institution at the time, were centrally randomized. They underwent placement of either a knitted Dacron polyester graft impregnated with collagen or a thin-wall expanded reenforced PTFE graft to the above-knee popliteal artery, usually from the common femoral artery. They were frequently observed by protocol for as long as 5 years by a physical examination noninvasive hemodynamic study, including duplex scanning in many instances. Continuing patency was noted, as were other potential adverse outcome events. The data were analyzed by the log-rank test for cumulative patency and expressed as Kaplan-Meier awes. Data were further analyzed with a Cox proportional hazards model. Results: There were no differences in graft groups in demographic or comorbid factors. The procedural mortality rate was zero, and the morbidity rate was low (6.5%). The long-term patient survival rate was excellent (77% at 3 years). At the end of these years, no statistical significance in primary or secondary patency rates was observed between the two grafts (primary patency rate, 62%+/-14.4% for Dacron; 57%+/-15.5% for PTFE). No unexpected adverse outcomes on limb status were noted. Patency rates in both graft groups were inferior in patients who received small grafts (5 to 6 mm vs 7 to 8 mm; hazards ratio, 4.15) and younger (<65 years) smoking patients. Conclusions: The fact that these two prosthetic grafts performed in equivalent fashion in a controlled, well-conducted prospective study is not surprising in spite of the previous work that suggested differences. If the preferential use of synthetic bypass grafts above the knee is to be used, it should be restricted to older nonsmokers with favorable anatomy. In that instance, the choice of graft material will depend on handling characteristics and cost. Above-knee prostheses should be only selectively used in younger, smoking patients, and graft size should be carefully considered in patients who undergo this operation. RP Abbott, WM (reprint author), MASSACHUSETTS GEN HOSP,15 PARKMAN ST,ACC 4,SUITE 458,BOSTON,MA 02114, USA. NR 22 TC 111 Z9 117 U1 1 U2 5 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JAN PY 1997 VL 25 IS 1 BP 19 EP 28 DI 10.1016/S0741-5214(97)70317-3 PG 10 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA WG200 UT WOS:A1997WG20000003 PM 9013904 ER PT J AU Wands, JR Lavaissiere, L Moradpour, D delaMonte, S Mohr, L Nicolau, C Tanaka, S AF Wands, JR Lavaissiere, L Moradpour, D delaMonte, S Mohr, L Nicolau, C Tanaka, S TI Immunological approach to hepatocellular carcinoma SO JOURNAL OF VIRAL HEPATITIS LA English DT Article; Proceedings Paper CT EASL Presidents Meeting on Immunology for the Hepatologist CY APR 08-09, 1997 CL LONDON, ENGLAND SP EASL DE tumour antigens; monoclonal antibodies; IRS-1; gene therapy ID INSULIN-RECEPTOR SUBSTRATE-1; ASPARTYL BETA-HYDROXYLASE; RAT HEPATOCYTE PROLIFERATION; MAP KINASE KINASE; NEOPLASTIC TRANSFORMATION; CELL-FATE; PROTEIN-S; MALIGNANT PHENOTYPE; SIGNAL-TRANSDUCTION; ANKYRIN REPEATS AB A library of monoclonal antibodies (MoAbs) has been produced against a human hepatocellular carcinoma (HCC) cell line designated FOCUS in order to study the antigenic properties of transformed hepatocytes. Several monoclonal antibodies (MoAbs) were initially selected for study since they bound to antigens which were overexpressed in HCC tissues compared with the adjacent uninvolved normal liver counterpart: in addition, these MoAbs revealed low level antigen expression on other normal human tissues, Subsequently, HCC cell lines were metabolically labelled and the antigens further characterized by immunoprecipitation and Western blot analysis, If the MoAb recognized a primary linear epitope on a protein, cloning was performed using a lambda GT11 cDNA expression library prepared from the FOCUS HCC cell line, These studies characterized the HCC associated antigen(si at the molecular level, This review illustrates the value of such an experimental approach to search for and identify HCC associated antigens and emphasizes the biological properties of novel proteins may be defined and characterized by these techniques. More important, our investigations have described unique proteins that may not only be important in the pathogenesis of HCC IT but also demonstrates how such antigen-antibody systems may be used to develop strategies for immuno-targetting and gene therapy of HCC. C1 HARVARD UNIV,SCH MED,CHARLESTOWN,MA. RP Wands, JR (reprint author), MASSACHUSETTS GEN HOSP,CTR CANC,MOL HEPATOL LAB,BLDG 149 13TH ST,7TH FLOOR,CHARLESTOWN,MA 02129, USA. FU NCI NIH HHS [CA-35711]; NIAAA NIH HHS [AA-08169, AA-02666] NR 72 TC 14 Z9 15 U1 0 U2 1 PU BLACKWELL SCIENCE LTD PI OXFORD PA P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PY 1997 VL 4 SU 2 BP 60 EP 74 DI 10.1111/j.1365-2893.1997.tb00181.x PG 15 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA YH077 UT WOS:A1997YH07700008 PM 9429211 ER PT J AU Lill, NL Tevethia, MJ Eckner, R Livingston, DM Modjtahedi, N AF Lill, NL Tevethia, MJ Eckner, R Livingston, DM Modjtahedi, N TI p300 family members associate with the carboxyl terminus of simian virus 40 large tumor antigen SO JOURNAL OF VIROLOGY LA English DT Article ID LARGE-T-ANTIGEN; SV40 LARGE-T; RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; CELLULAR TRANSCRIPTION FACTOR; EMBRYONAL CARCINOMA-CELLS; REGION 1A PROTEINS; TRANSFORMED-CELLS; MONOCLONAL-ANTIBODIES; GROWTH-FACTOR AB Several cellular polypeptides critical for growth regulation interact with DNA tumor virus oncoproteins. p400 is a cellular protein which binds to the adenovirus E1A oncoprotein(s). The biological function of p400 is not yet known, but it is structurally and immunologically closely related to p300 and CREB-binding protein, two known E1A-binding transcription adapters. Like p300, p400 is a phosphoprotein that binds to the simian virus 40 large tumor antigen (T). In anti-T coimmunoprecipitation experiments, staggered deletions spanning the amino-terminal 250 amino acids of T did not abrogate T binding to either p400 or p300. A T species composed of residues 251 to 708 bound both p400 and p300, while a T species defective in p53 binding was unable to bind either detectably. Anti-p53 immunoprecipitates prepared from cells containing wild-type T also contained p400 and p300. Hence, both p400 and p300 can bind (directly or indirectly) to a carboxyl-terminal fragment of T which contains its p53 binding domain. Since the p53 binding domain of T contributes to its immortalizing and transforming activities, T-p400 and/or T-p300 interactions may participate in these functions. C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV NEOPLAST DIS MECHANIMS,BOSTON,MA 02115. PENN STATE UNIV,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033. FU NCI NIH HHS [CA24964] NR 93 TC 71 Z9 72 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 1997 VL 71 IS 1 BP 129 EP 137 PG 9 WC Virology SC Virology GA VX292 UT WOS:A1997VX29200016 PM 8985331 ER PT J AU Scaglioni, PP Melegari, M Wands, JR AF Scaglioni, PP Melegari, M Wands, JR TI Posttranscriptional regulation of hepatitis B virus replication by the precore protein SO JOURNAL OF VIROLOGY LA English DT Article ID SECRETORY CORE PROTEIN; PRE-C REGION; E-ANTIGEN; VIRAL REPLICATION; CELL-LINE; PREGENOME ENCAPSIDATION; REVERSE TRANSCRIPTION; TRANSIENT EXPRESSION; FULMINANT-HEPATITIS; RETROVIRAL VECTORS AB Hepadnaviruses encode two core-related open reading frames. One directs the synthesis of the p21 core protein, which subsequently becomes a structural component of the viral nucleocapsid. The other produces a p25 precore protein that is targeted by a signal peptide to a cell secretory pathway where N-terminal processing will create a p22 species. This molecule will be further modified at the C-terminal region to generate p17, and the truncated protein is secreted from the cell as hepatitis B e antigen (HBeAg), The function of the precore gene in the biology of hepadnaviruses is unknown. We found that ablation of the precore gene resulted in the generation of a hepatitis B virus (HBV) species,vith a high-replication-level phenotype. More important, expression in trans of physiologic levels of p25 restored viral replication to wild-type levels, Moreover, transient or stable overexpression of the precore gene resulted in striking inhibition of HBV replication, The molecular species responsible for this viral inhibitory effect was identified as the p22 nonsecreted HBeAg precursor protein. By sucrose gradient sedimentation analysis, we determined that expression of p22 leads to the formation of nucleocapsids similar to those made with wild-type p21 core protein, Immunoprecipitation experiments revealed that the p21 and p22 physically interact and form hybrid nucleocapsid structures devoid of pregenomic viral RNA. These experiments suggest that expression of the precore gene may be important in the regulation of HBV replication and describe a possible molecular mechanism(s) for this effect. C1 HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,CANC CTR,MOL HEPATOL LAB,CHARLESTOWN,MA 02129. OI Scaglioni, Pier Paolo/0000-0002-6036-5138 FU NCI NIH HHS [CA-35711]; NIAAA NIH HHS [AA-02169] NR 54 TC 132 Z9 148 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 1997 VL 71 IS 1 BP 345 EP 353 PG 9 WC Virology SC Virology GA VX292 UT WOS:A1997VX29200041 PM 8985356 ER PT J AU Zuo, FR Kraus, RJ Gulick, T Moore, DD Mertz, JE AF Zuo, FR Kraus, RJ Gulick, T Moore, DD Mertz, JE TI Direct modulation of simian virus 40 late gene expression by thyroid hormone and its receptor SO JOURNAL OF VIROLOGY LA English DT Article ID RETINOIC ACID RECEPTORS; LIGAND-DEPENDENT DISSOCIATION; LONG TERMINAL REPEAT; NUCLEAR RECEPTOR; TRANSCRIPTION FACTOR; RESPONSE ELEMENTS; CO-REPRESSOR; V-ERBA; GLUCOCORTICOID RECEPTOR; CONFORMATIONAL-CHANGES AB Transcription of the late genes of simian virus 40 (SV40) is repressed during the early phase of the lytic cycle of infection of primate cells by the binding of cellular factors, called IBP-s, to the SV40 late promoter; repression is relieved after the onset of viral DNA replication by titration of these repressors (S. R. Wiley, R. J. Kraus, F. R. Zuo, E. E. Murray, K. Loritz, and J. E. Mertz, Genes Dev. 7:2206-2219, 1993). Recently, we showed that IBP-s consists of several members of the steroid/thyroid hormone receptor superfamily (F. Zuo and J. E. Mertz, Proc. Natl. Acad. Sci. USA 92:8586-8590, 1995). Here, we show that the thyroid hormone receptor TR alpha 1, in combination with retinoid X receptor alpha (RXR alpha), is specifically bound at the transcriptional initiation site of the major late promoter of SV40; This binding repressed transcription from the SV40. late promoter by preventing the formation of pre-initiation complexes. Addition of the thyroid hormone 3,5,3'-L-triiodothyronine (T-3) resulted in reversal of this repression in cotransfected CV-1 cells. Interestingly, repression did not occur when this thyroid response element (TRE) was translocated to 50 bp upstream of the major late initiation site. Binding of TR alpha 1/RXR alpha heterodimers to this TRE induced bending of the promoter DNA. We conclude that hormones and their receptors can directly affect the expression of SV40, probably by affecting protein-protein and protein-DNA interactions involved in the formation of functional preinitiation complexes. C1 MASSACHUSETTS GEN HOSP,DEPT MOL BIOL,BOSTON,MA 02114. RP Zuo, FR (reprint author), UNIV WISCONSIN,SCH MED,MCARDLE LAB CANC RES,MADISON,WI 53706, USA. FU NCI NIH HHS [CA07175, CA22443]; NIDDK NIH HHS [DK43382] NR 86 TC 19 Z9 19 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 1997 VL 71 IS 1 BP 427 EP 436 PG 10 WC Virology SC Virology GA VX292 UT WOS:A1997VX29200052 PM 8985367 ER PT J AU Sabolic, I Brown, D Gluck, SL Alper, SL AF Sabolic, I Brown, D Gluck, SL Alper, SL TI Regulation of AE1 anion exchanger and H+-ATPase in rat cortex by acute metabolic acidosis and alkalosis SO KIDNEY INTERNATIONAL LA English DT Article ID RABBIT COLLECTING DUCT; INTERCALATED CELLS; KIDNEY BAND-3; EPITHELIAL-CELLS; DEPLETION; MEMBRANE; IMMUNOLOCALIZATION; COLOCALIZATION; LOCALIZATION; EXPRESSION AB The cortical collecting duct (CCD) mediates net secretion or reabsorption of protons according to systemic acid/base status. Using indirect immunofluorescence, we examined the localization and abundance of the vacuolar H+-ATPase and the AE1 anion exchanger in intercalated cells (IC) of rat kidney connecting segment (CNT) and CCD during acute (6 hr) metabolic (NH4Cl) acidosis and respiratory (NaHCO3) alkalosis. AE1 immunostaining intensify quantified by confocal microscopy was elevated in metabolic acidosis and substantially reduced in metabolic alkalosis. AE1 immunostaining was restricted to Type A IC in all conditions, and the fraction of AE1(+) IC was unchanged in CNT and CCD. Metabolic acidosis was accompanied by redistribution of H+-ATPase immunostaining towards the apical surface of IC, and metabolic alkalosis was accompained by H+-ATPase redistribution towards the basal surface of IC. Therefore, acute metabolic acidosis produced changes consistent with increased activity of Type A IC and decreased activity of Type B IC, whereas acute metabolic alkalosis produced changes corresponding to increased activity of Type B IC and decreased activity of Type A IC. These data demonstrate that acute systemic acidosis and alkalosis modulate the cellular distribution of two key transporters involved in proton secretion in the distal nephron. C1 BETH ISRAEL HOSP,MOL MED UNIT,BOSTON,MA 02215. BETH ISRAEL HOSP,RENAL UNIT,BOSTON,MA 02215. INST MED RES & OCCUPAT HLTH,ZAGREB,CROATIA. MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110. WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110. FU FIC NIH HHS [1-RO3-TW00512 A-01-A1]; NIDDK NIH HHS [DK42956, DK43495] NR 50 TC 96 Z9 96 U1 0 U2 2 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 1997 VL 51 IS 1 BP 125 EP 137 DI 10.1038/ki.1997.16 PG 13 WC Urology & Nephrology SC Urology & Nephrology GA WB338 UT WOS:A1997WB33800016 PM 8995726 ER PT J AU Tan, AU Levine, BS Mazess, RB Kyllo, DM Bishop, CW Knutson, JC Kleinman, KS Coburn, JW AF Tan, AU Levine, BS Mazess, RB Kyllo, DM Bishop, CW Knutson, JC Kleinman, KS Coburn, JW TI Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D-2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism SO KIDNEY INTERNATIONAL LA English DT Article; Proceedings Paper CT 28th Annual Meeting of the American-Society-of-Nephrology CY NOV 03-08, 1995 CL SAN DIEGO, CA SP Amer Soc Nephrol ID DOSE INTRAVENOUS CALCITRIOL; DIALYSIS PATIENTS; VITAMIN-D; CALCIUM-METABOLISM; PROSPECTIVE TRIAL; UREMIC PATIENTS; RENAL-FAILURE; PULSE THERAPY; BONE-DISEASE; PHOSPHATE AB Calcitriol, as used for treating secondary hyperparathyroidism, has a low therapeutic index. The safety and efficacy of the vitamin D analog, 1 alpha(OH)-vitamin D-2 (1 alpha D-2), which has less toxicity in animals than 1 alpha(OH)-vitamin D-3, was tested in a multicenter study of 24 hemodialysis patients with secondary hyperparathyroidism [serum intact (i) PTH > 400 pg/ml]. Calcium-based phosphate binders alone were used to maintain serum phosphorus less than or equal to 6.9 mg/dl. After eight weeks without calcitriol (washout), oral 1 alpha D-2, 4 mu g/day or 4 mu g thrice weekly, was started, with thr dose adjusted over 12 weeks to maintain serum IPTH between 130 and 250 pg/ml. Pre-treatment serum iPTH fell from 672 +/- 70 pg/ml (SEM) to 289 +/- 36 after treatment (P < 0.05). The maximal decrease in serum iPTH was 48 to 96%, with 87.5% of patients reaching target IPTH levels. The final dose of 1 alpha D-2 averaged 14.2 mu g/week. Pre-treatment serum calcium rose modestly from 8.8 +/- 0.2 mg/dl to 9.5 +/- 0.2 after treatment (P < 0.001). Only once did modest hypercalcemia (serum Ca > 11.2 mg/dl) necessitate stopping treatment. Neither the average serum P level, the incidence of hyperphosphatemia, nor the dose of phosphate binders changed from washout to treatment. Thus, oral 1 alpha D-2, is highly efficacious in suppressing secondary hyperparathyroidism in hemodialysis patients and is safe despite exclusive use of calcium-based phosphate-binders. Future studies should clarify the optimal dosage regimen. C1 W LOS ANGELES VET AFFAIRS MED CTR,WADSWORTH DIV,MED & RES SERV,LOS ANGELES,CA 90073. UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024. BONE CARE INT INC,MADISON,WI. NR 35 TC 110 Z9 112 U1 0 U2 1 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 1997 VL 51 IS 1 BP 317 EP 323 DI 10.1038/ki.1997.39 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA WB338 UT WOS:A1997WB33800039 PM 8995749 ER PT J AU Longtine, J Roberts, DJ AF Longtine, J Roberts, DJ TI The incidence of Factor V Leiden in fetal thrombotic events SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. CHILDRENS HOSP,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 2 EP 2 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48601111 ER PT J AU Pinar, H Rubin, LP Kovacs, CA Kronenberg, HM AF Pinar, H Rubin, LP Kovacs, CA Kronenberg, HM TI Targeted disruption of the PTHrP gene interferes with alveolar differentiation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 BROWN UNIV,SCH MED,DEV PATHOL PROGRAM,PROVIDENCE,RI 02912. BROWN UNIV,SCH MED,DEPT PEDIAT,PROVIDENCE,RI 02912. BROWN UNIV,WOMEN & INFANTS HOSP,PROVIDENCE,RI. HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT MED,ENDOCRINE UNIT,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 26 EP 26 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48601135 ER PT J AU Nielsen, GP OConnell, JX Rosenberg, AE AF Nielsen, GP OConnell, JX Rosenberg, AE TI Intramuscular myxoma. A clinicopathologic study of 51 cases with emphasis on the hypercellular variant. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. VANCOUVER HOSP & HLTH SCI CTR,VANCOUVER,BC V5Z 1M9,CANADA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 50 EP 50 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600065 ER PT J AU Goulart, R Prioleau, J Sager, R Schnitt, S AF Goulart, R Prioleau, J Sager, R Schnitt, S TI Maspin protein expression in pre-invasive breast lesions. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,BOSTON,MA. BETH ISRAEL HOSP,DANA FARBER CANC INST,BOSTON,MA 02215. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 93 EP 93 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600108 ER PT J AU Jacobs, TW Siziopikou, KP Prioleau, JE Raza, S Baum, JK Hayes, DF Schnitt, SJ AF Jacobs, TW Siziopikou, KP Prioleau, JE Raza, S Baum, JK Hayes, DF Schnitt, SJ TI Do prognostic marker studies on breast core needle biopsy specimens accurately reflect the marker status of the tumor? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 BETH ISRAEL HOSP,DANA FARBER CANC INST,BOSTON,MA 02215. HARVARD UNIV,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 97 EP 97 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600112 ER PT J AU Matsubara, O Kagata, Y Imazeki, N Kitada, N Oogouchi, Y Senoo, A Mark, EJ AF Matsubara, O Kagata, Y Imazeki, N Kitada, N Oogouchi, Y Senoo, A Mark, EJ TI Aortic valve lesions in Takayasu's arteritis: Pathological examination of surgically removed and autopsied aortic valves in 12 patients. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NATL DEF MED COLL,TOKOROZAWA,SAITAMA,JAPAN. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 148 EP 148 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600163 ER PT J AU Bardales, RH Pitman, MB Stanley, MW Korourian, S Suhrland, MJ AF Bardales, RH Pitman, MB Stanley, MW Korourian, S Suhrland, MJ TI Urine cytology of urinary bladder adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 UNIV ARKANSAS MED SCI HOSP,LITTLE ROCK,AR 72205. JOHN L MCCLELLAN MEM VET ADM MED CTR,LITTLE ROCK,AR. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. MONTEFIORE MED CTR,BRONX,NY 10467. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 166 EP 166 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600181 ER PT J AU Centeno, BA Brugge, WR Warshaw, AL Lewandrowski, KB AF Centeno, BA Brugge, WR Warshaw, AL Lewandrowski, KB TI Endoscopic ultrasound guided fine needle aspiration of pancreatic cystic lesions. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 170 EP 170 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600185 ER PT J AU Flynn, C Pitman, M AF Flynn, C Pitman, M TI Cytohistological correlation of subclassified ASCUS Pap smears SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 177 EP 177 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600192 ER PT J AU Tambouret, R Beil, D Pitman, M AF Tambouret, R Beil, D Pitman, M TI Benign glandular cells in post-hysterectomy vaginal smears SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 213 EP 213 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600228 ER PT J AU Wu, H Frable, W Powers, C Khurana, K Stanley, M Bardales, R Pitman, M AF Wu, H Frable, W Powers, C Khurana, K Stanley, M Bardales, R Pitman, M TI The morphologic spectrum of mucoepidermoid carcinoma on fine needle aspiration biopsy (FNAB). SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 217 EP 217 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600232 ER PT J AU Baldassano, MF Bailey, EM Ferry, JA Harris, NL Duncan, LM AF Baldassano, MF Bailey, EM Ferry, JA Harris, NL Duncan, LM TI Marginal zone lymphoma (MZL) and cutaneous lymphoid hyperplasia (CLH): Morphologic and immunophenotypic features. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 225 EP 225 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600240 ER PT J AU Flotte, T Lerner, L BlackSchaffer, S Bell, D GraemeCook, F AF Flotte, T Lerner, L BlackSchaffer, S Bell, D GraemeCook, F TI Teledermatopathology: Feasibility and problems SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 236 EP 236 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600251 ER PT J AU Amin, MB Gomez, JA Young, RH AF Amin, MB Gomez, JA Young, RH TI Urothelial transitional cell carcinoma (TCC) with endophytic growth patterns. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 HENRY FORD HOSP,DETROIT,MI 48202. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 388 EP 388 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600403 ER PT J AU Amin, MB Mohsin, SK Oliva, E Linden, MD Young, RH AF Amin, MB Mohsin, SK Oliva, E Linden, MD Young, RH TI Urethral carcinomas with glandular differentiation: An immunohistochemical (IHC) investigation. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 HENRY FORD HOSP,DETROIT,MI 48202. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 389 EP 389 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600404 ER PT J AU AlvaradoCabrero, I Navani, SS Young, RH Scully, RE AF AlvaradoCabrero, I Navani, SS Young, RH Scully, RE TI Endometrioid carcinoma of the fallopian tube: A clinicopathologic analysis of 26 cases. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 553 EP 553 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600568 ER PT J AU Eichhorn, JH Bell, DA Young, RH Scully, RE AF Eichhorn, JH Bell, DA Young, RH Scully, RE TI Ovarian serous borderline tumors of solid, micropapillary and cribriform types: A study of 42 cases. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 572 EP 572 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600587 ER PT J AU Nielsen, GP Prat, J Young, RH Scully, RE AF Nielsen, GP Prat, J Young, RH Scully, RE TI Primary angiosarcoma of the ovary. A clinicopathologic study of seven cases. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,BOSTON,MA. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 613 EP 613 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600628 ER PT J AU Nielsen, GP Oliva, E Rosenberg, AE Prat, J Young, RH Scully, RE AF Nielsen, GP Oliva, E Rosenberg, AE Prat, J Young, RH Scully, RE TI Primary rhabdomyosarcoma of the ovary. A clinicopathologic study of 13 cases. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,BOSTON,MA. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 614 EP 614 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600629 ER PT J AU Oliva, E Clement, PB Young, RH Scully, RE AF Oliva, E Clement, PB Young, RH Scully, RE TI Mixed stromal and smooth muscle tumors of the uterus: Clinicopathologic study of 10 cases. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. VANCOUVER HOSP & HLTH SCI CTR,VANCOUVER,BC V5Z 1M9,CANADA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 617 EP 617 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600632 ER PT J AU Oliva, E Nielsen, GP Clement, PB Young, RH Scully, RE AF Oliva, E Nielsen, GP Clement, PB Young, RH Scully, RE TI Epithelioid smooth muscle tumors of the uterus. A clinicopathologic analysis of 80 cases. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA. VANCOUVER HOSP & HLTH SCI CTR,VANCOUVER,BC V5Z 1M9,CANADA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 618 EP 618 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600633 ER PT J AU Weir, MM Bell, DA Young, RH AF Weir, MM Bell, DA Young, RH TI Transitional cell metaplasia of the uterine cervix and vagina: An underrecognized lesion that may be confused with high grade dysplasia. A report of 59 cases. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 648 EP 648 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600663 ER PT J AU Zheng, W Welt, C LambertMesserlian, G Sung, CJ Schneyer, AL Felix, JC AF Zheng, W Welt, C LambertMesserlian, G Sung, CJ Schneyer, AL Felix, JC TI Asymmetric expression of inhibin and activin in ovarian epithelial carcinoma. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033. BROWN UNIV,SCH MED,DEPT PATHOL,PROVIDENCE,RI 02912. MASSACHUSETTS GEN HOSP,DEPT MED,REPROD ENDOCRINE UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 652 EP 652 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600667 ER PT J AU Zubovits, JT Clement, PB Young, RH Scully, RE AF Zubovits, JT Clement, PB Young, RH Scully, RE TI Malignant mullerian mixed tumors (MMMTs) of the uterine cervix: A clinicopathological study of 8 cases. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. VANCOUVER HOSP & HLTH SCI CTR,VANCOUVER,BC V5Z 1M9,CANADA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 653 EP 653 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600668 ER PT J AU Ingle, R Jennings, TA Goodman, ML Pilch, BZ Bergman, S Ross, JS AF Ingle, R Jennings, TA Goodman, ML Pilch, BZ Bergman, S Ross, JS TI CD44 expression sinonasal inverted papillomas (SIP) and associated squamous cell carcinoma (SCC). SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 ALBANY MED COLL,ALBANY,NY 12208. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 667 EP 667 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600682 ER PT J AU Nguyen, PL Savilo, E Harris, NL AF Nguyen, PL Savilo, E Harris, NL TI Primary low-grade lymphomas in the spleen (PLGSL). SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 765 EP 765 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600780 ER PT J AU delaMonte, SM Sohn, YK Wands, JR Bloch, KD AF delaMonte, SM Sohn, YK Wands, JR Bloch, KD TI Aberrant ceNOS expression correlates with neuritic sprouting & apoptosis in neurodegenerative diseases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 874 EP 874 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600889 ER PT J AU delaMonte, SM Paul, K Wands, JR AF delaMonte, SM Paul, K Wands, JR TI Reduced mitochondrial (MT) DNA content and MT gene expression with apoptosis in AIDS encephalopathy. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 875 EP 875 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600890 ER PT J AU Kilgallen, C DiazCano, S Eng, C Wolfe, HJ AF Kilgallen, C DiazCano, S Eng, C Wolfe, HJ TI Glial cell line-derived neurotrophic factor (GDNF) expression in normal and neoplastic tissues: An immunohistochemical study. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 TUFTS UNIV,DANA FARBER CANC INST,DEPT PATHOL,BOSTON,MA 02111. HARVARD UNIV,SCH MED,BOSTON,MA. RI Diaz-Cano, Salvador/B-5256-2008 OI Diaz-Cano, Salvador/0000-0003-1245-2859 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 879 EP 879 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600894 ER PT J AU Zukerberg, LR Vidal, M Tsai, LH AF Zukerberg, LR Vidal, M Tsai, LH TI A novel CDK5 interactor. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 909 EP 909 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600924 ER PT J AU Matsubara, O Imazeki, N Oogouchi, Y Kagara, Y Kitada, N Senoo, A Mark, EJ AF Matsubara, O Imazeki, N Oogouchi, Y Kagara, Y Kitada, N Senoo, A Mark, EJ TI Mast cell hyperplasia in development of diffuse alveolar damage (DAD)/acute interstitial pneumonia (AIP) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NATL DEF MED COLL,TOKOROZAWA,SAITAMA,JAPAN. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 984 EP 984 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48600999 ER PT J AU Kilgallen, C Smith, W Shapiro, S DiazCano, S Vijg, J Eng, C Wolfe, HJ AF Kilgallen, C Smith, W Shapiro, S DiazCano, S Vijg, J Eng, C Wolfe, HJ TI Long chain PCR on archival material for rapid detection of point mutations and molecular screening for prognostic factors in neoplastic progression SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,BOSTON,MA. TUFTS UNIV,SCH MED,DEPT PATHOL,BETH ISRAEL HOSP,DANA FARBER CANC INST,BOSTON,MA 02111. RI Diaz-Cano, Salvador/B-5256-2008 OI Diaz-Cano, Salvador/0000-0003-1245-2859 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1997 VL 76 IS 1 BP 1072 EP 1072 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA WD486 UT WOS:A1997WD48601087 ER PT J AU Rauch, SD Oas, JG AF Rauch, SD Oas, JG TI Intratympanic gentamicin for treatment of intractable Meniere's disease: A preliminary report SO LARYNGOSCOPE LA English DT Article; Proceedings Paper CT Meeting of the Eastern-Section of the American-Laryngological-Rhinological-and-Otological-Society CY JAN 25-27, 1996 CL PHILADELPHIA, PA SP Amer Laryngol Rhinol & Otol Soc, E Sect DE gentamicin; intratympanic therapy; Meniere's disease; vertigo AB Topical administration of aminoglycoside antibiotics in the middle ear can achieve ''chemical labyrinthectomy'' in patients with intractable Meniere's disease. Herein we report our results of intratympanic gentamicin therapy in 21 patients using two different dosing protocols, twice weekly and twice daily (b.i.d.). Both hearing and vertigo outcome were evaluated. Complete control of episodic vertigo was achieved initially in 20 of 21 patients (95.2%). However, 6 of 20 responders (30%) developed relapsing symptoms within 12 months. Retreatment was successful in 75% of these patients, Overall, hearing was preserved or improved in 62% of cases, worse in 24%, and not yet tested in 14%. When the cumulative dose of gentamicin was less than or equal to 4 injections in the first week, only 1 of 14 (7.1%) lost hearing. Intratympanic gentamicin offers better risk/benefit outcome than other invasive therapies for intractable Meniere's disease. C1 HARVARD UNIV,SCH MED,DEPT OTOL & LARYNGOL,CAMBRIDGE,MA 02138. RP Rauch, SD (reprint author), MASSACHUSETTS EYE & EAR INFIRM,DEPT OTOLARYNGOL,243 CHARLES ST,BOSTON,MA 02114, USA. NR 16 TC 55 Z9 57 U1 0 U2 1 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 1997 VL 107 IS 1 BP 49 EP 55 DI 10.1097/00005537-199701000-00012 PG 7 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA WD689 UT WOS:A1997WD68900012 PM 9001265 ER PT B AU Pogue, BW Hasan, T AF Pogue, BW Hasan, T BE Jacques, SL Katzir, A TI Quantitative fluorescence measurements from tissue using confocal detection SO LASER-TISSUE INTERACTION VIII, PROCEEDINGS OF SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Laser-Tissue Interaction VIII CY FEB 09-12, 1997 CL SAN JOSE, CA SP USA Off Sci Res, Int Biomed Opt Soc, Soc Photo Opt Instrumentat Engineers, Amer Soc Laser Med & Surg Inc DE fluorescence; tissue; confocal; scattering; optical coefficients; photosensitizer; uptake; absorption; fluorophore AB Fluorescence intensity measurements from fluorophore molecules present in tissue can be affected by the intrinsic scattering and absorption of the tissue. Using detection of the fluorescence from small regions of tissue (smaller than the average scattering length of the tissue) the fluorescent intensity signal is not significantly affected by the background absorption in the tissue. Confocal microscopic measurements have been examined here in an effort to develop a system in which the fluorescent intensity measured from tissue is linearly proportional to only the fluorophore concentration and the input light irradiance. Monte Carlo simulations confirm that by constraining the detected area to smaller than the average scattering length, that the fluorescence measurements are not significantly affected by intrinsic absorption. This type of system is useful for quantification of photosensitizer concentrations in tissue during photodynamic therapy or for pharmacokinetic measurements of uptake in tissue. Preliminary measurements confirm that this method should be equivalent to fluorescence-based tissue extraction methods of photosensitizer uptake in tissue. RP Pogue, BW (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,DEPT DERMATOL,WELLMAN LABS PHOTOMED,BOSTON,MA 02114, USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU SPIE - INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA PO BOX 10, BELLINGHAM, WA 98227-0010 BN 0-8194-2386-6 J9 P SOC PHOTO-OPT INS PY 1997 VL 2975 BP 202 EP 207 DI 10.1117/12.275480 PG 6 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BJ12Q UT WOS:A1997BJ12Q00022 ER PT B AU Ross, EV Glatter, RD Duke, D Grevelink, JM AF Ross, EV Glatter, RD Duke, D Grevelink, JM BE Anderson, RR Bartels, KE Bass, LS Gregory, KW Harris, DM Lui, H Malek, RS Muller, GJ Pankratov, MM Perlmutter, AP Reidenbach, HD Tate, LP Watson, GM Katzir, A TI Effects of overlap and pass number in CO2 laser skin resurfacing: Preliminary results of residual thermal damage, cell death, and wound healing SO LASERS IN SURGERY: ADVANCED CHARACTERIZATION, THERAPEUTICS, AND SYSTEMS VII, PROCEEDINGS OF SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Lasers in Surgery - Advanced Characterization, Therapeutics, and Systems VII CY FEB 08-09, 1997 CL SAN JOSE, CA SP Int Biomed Opt Soc, Soc Photo Opt Instrumentat Engineers, Amer Soc Laser Med & Surg Inc DE thermal damage; CO2 laser; skin resurfacing; scar AB Newer CO2 laser systems incorporating short pulse and scanning technology have been used effectively to resurface the skin. Although scarring is rare, as the number of resurfacing cases has increased, some hypertrophic scarring has been observed. Previous dermabrasion and continuous wave (CW) CO2 studies suggest that depth of injury and/or thermal damage are important predictors of scarring for a given anatomic region. To determine if overlapping laser pulses/scans significantly altered wound healing, we examined residual thermal damage, cell death, and histologic and clinical wound healing in a farm pig. The Ultrapulse and SilkTouch systems were used with various radiant exposures, degrees of overlap, and numbers of passes. Thermal damage was assessed by histology, and dermal cell viability was measured with nitrotetrazolium blue staining. Presence or absence of clinical scarring was determined by noting textural change and loss of skin markings. We observed that thermal damage and cell death depth did not increase significantly with pass number; however, by double-pulsing or double-scanning sites, residual thermal damage and cell death depth were increased as much as 100% over areas without immediate overlap of laser impacts. Also, scarring was increased focally in areas with overlap. We conclude that immediate overlapping of CO2 laser pulses/scans is a significant risk factor in increasing thermal damage, cell death, and scarring. RP Ross, EV (reprint author), MASSACHUSETTS GEN HOSP,DERMATOL LASER CTR,BOSTON,MA 02114, USA. NR 0 TC 8 Z9 8 U1 0 U2 0 PU SPIE - INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA PO BOX 10, BELLINGHAM, WA 98227-0010 BN 0-8194-2381-5 J9 P SOC PHOTO-OPT INS PY 1997 VL 2970 BP 395 EP 405 DI 10.1117/12.275020 PG 11 WC Engineering, Biomedical; Optics; Surgery SC Engineering; Optics; Surgery GA BH93E UT WOS:A1997BH93E00053 ER PT J AU Reiken, SR Wolfort, SF Berthiaume, F Compton, C Tompkins, RG Yarmush, ML AF Reiken, SR Wolfort, SF Berthiaume, F Compton, C Tompkins, RG Yarmush, ML TI Control of hypertrophic scar growth using selective photothermolysis SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE hypertrophic scar; microvasculature; pulsed dye laser ID PULSED DYE-LASER; PORT-WINE STAINS; MESSENGER-RNA; KELOIDS; COLLAGEN; MICE AB Background and Objective: Previous studies have shown a clinical improvement of hypertrophic scars (HS) after treatment with a pulsed dye laser. The objective of this study was to investigate the effects of variations in pulse wavelength and energy density on HS tissue using human HS implanted in athymic mice. Study Design/Materials and Methods: Small pieces (similar to 1 mm(3)) of HS tissue were implanted into athymic mice and allowed to grow for 5 days. The implant site was then exposed to a single 450 ps pulse, and implant growth and histology were monitored for an additional 12 days. Laser wavelength and energy density ranges tested were 585-600 nm and 2-10 J/cm(2), respectively. Results: Using a wavelength of 585 nm, laser treatment inhibited implant growth by 70% at 6 J/cm(2) and 92% at 10 J/cm(2), respectively. The inhibitory effect decreased as the laser wavelength was increased from 585 to 600 nm. A widespread destruction of the implant microvasculature with a minor effect on surrounding extracellular matrix at the highest light dose were observed. Conclusion: Pulsed laser treatment inhibits HS implant growth in nude mice. This effect is Likely mediated by selective photothermolysis of the implant microvasculature. (C) 1997 Wiley-Liss, Inc. C1 MASSACHUSETTS GEN HOSP,SURG SERV,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,CTR ENGN MED,BOSTON,MA 02114. NR 22 TC 59 Z9 62 U1 0 U2 2 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 1997 VL 21 IS 1 BP 7 EP 12 DI 10.1002/(SICI)1096-9101(1997)21:1<7::AID-LSM2>3.0.CO;2-U PG 6 WC Dermatology; Surgery SC Dermatology; Surgery GA XH886 UT WOS:A1997XH88600002 PM 9228634 ER PT J AU Ross, EV Domankevitz, Y Anderson, RR AF Ross, EV Domankevitz, Y Anderson, RR TI Effects of heterogeneous absorption of laser radiation in biotissue ablation: Characterization of ablation of fat with a pulsed CO2 laser SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE laser ablation; fat; mass loss; CO2 laser ID TISSUE ABLATION AB Background and Objective: Physicians encounter several clinical situations in which fat must be removed. In this study, the characterization of fat ablation produced by a pulsed CO2 laser is reported. Study Design/Materials and Methods: An RF excited 800 mu s pulsed CO2 laser operating at 10.6 mu m was used to ablate fresh porcine fat. The heat of ablation and ablation threshold were determined using a mass loss technique. Absorption coefficients for fat and dermis were determined by attenuated total reflection spectroscopy. Results: Threshold radiant exposure and heat of ablation for fat were calculated from the mass loss measurements to be 1.05 J/cm(2) and 2.4 J/cm(3), respectively. The absorption coefficients of fat and dermis at 10.6 mu m were 250 and 780 cm(-1), respectively. Pulsed CO2 laser ablation of fat caused ejection of fat droplets, which ignited after high fluence pulses. Conclusion: A pulsed CO2 laser can effectively ablate fat with a threshold fluence and efficiency comparable to other soft tissues. Our data suggest that fat ablation occurs primarily through the ejection of intact fat particles via the explosive vaporization of intervening water ''lakes.'' (C) 1997 Wiley-Lies, Inc. C1 MASSACHUSETTS GEN HOSP,DEPT DERMATOL,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,WELLMAN LABS PHOTOMED,BOSTON,MA 02114. NR 16 TC 9 Z9 10 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 1997 VL 21 IS 1 BP 59 EP 64 DI 10.1002/(SICI)1096-9101(1997)21:1<59::AID-LSM9>3.0.CO;2-X PG 6 WC Dermatology; Surgery SC Dermatology; Surgery GA XH886 UT WOS:A1997XH88600009 PM 9228641 ER PT J AU Strong, LH Berthiaume, F Yarmush, ML AF Strong, LH Berthiaume, F Yarmush, ML TI Control of fibroblast populated collagen lattice contraction by antibody targeted photolysis of fibroblasts SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE hypertrophic scarring; scar contracture; wound contraction ID MONOCLONAL-ANTIBODY; COATED PITS; HYPERTROPHIC SCAR; CELLS; INVITRO; HEMATOPORPHYRIN; TISSUE; ENDOCYTOSIS; LIPOSOMES; RECEPTORS AB Background and Objective: Hypertrophic scarring and rigid scar contracture are disorders of wound healing for which there is presently no effective therapy. The dermal fibroblast plays a major role in scar fibrillogenesis and contracture. The objective of this study was to establish a selective and effective method to destroy fibroblasts. Study Design/Materials and Methods: An antifibroblast conjugate was synthesized by covalent attachment of the antifibroblast antibody PR2D3 to the photosensitizer Sn-chlorin e6. Fibroblasts were cultured in fibroblast-populated collagen lattices (FPCLs), incubated with the conjugate and exposed to light. The effect of the treatment on cell viability and the rate of contraction of the FPCL were assessed. Results: The toxicity of antifibroblast conjugates increased with increasing conjugate concentration, light dose, and number of photosensitizers per antibody molecule, until nearly complete killing was achieved. The rate of lattice contraction after irradiation linearly correlated with the remaining viable fraction of fibroblasts. These conjugates were not cytotoxic to keratinocytes cultured on collagen lattices, and nonspecific conjugates could not cause significant fibroblast killing. Spatial selectivity was demonstrated using a light mask. Conclusions: Antibody-targeted photolysis is an effective and selective technique for controlling FPCL contraction in vitro and may have potential in vivo applications to modulate extracellular matrix remodeling by connective tissue cells. (C) 1997 Wiley-Liss, Inc. C1 MASSACHUSETTS GEN HOSP,SURG SERV,CTR ENGN MED,BOSTON,MA 02114. HARVARD UNIV,SCH MED,SHRINERS BURN INST,DEPT SURG,BOSTON,MA 02114. NR 41 TC 4 Z9 4 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 1997 VL 21 IS 3 BP 235 EP 247 DI 10.1002/(SICI)1096-9101(1997)21:3<235::AID-LSM3>3.0.CO;2-R PG 13 WC Dermatology; Surgery SC Dermatology; Surgery GA XV003 UT WOS:A1997XV00300003 PM 9291080 ER PT J AU Schomacker, KT Walsh, A Gregory, KW Kochevar, IE AF Schomacker, KT Walsh, A Gregory, KW Kochevar, IE TI Cell damage induced by Angiovist-970 and 308nm excimer laser radiation SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE laser angioplasty; radiographic contrast media; cytotoxic photoproducts ID PHOTOPRODUCTS; ANGIOPLASTY; ERYTHROCYTES; LYMPHOCYTES; AMIODARONE; INTENSITY AB Background and Objective: Radiographic contrast media containing iodine-labeled organic compounds can be present in the irradiated field during laser angioplasty using 308 nm excimer laser radiation. These compounds absorb light at 308 nn and may undergo photochemical reactions that produce products that damage cells. Study Design/Materials and Methods: This study was undertaken to determine whether photoproducts that damage human lymphocytes in vitro are formed when Angiovist 370 (AV), a contrast medium containing triiodinated aromatic compounds, is exposed to 308 nm radiation. Results: The absorption spectrum of AV developed a new peak at 360 nn that extended to wavelengths greater than 500 nn when dilute AV solutions were exposed to 308 nm radiation indicating that photoproducts were formed. Irradiating dilute AV solutions above a layer of human lymphocytes caused a dose-dependent decrease in thymidine incorporation using fluence rates between 5.2 x 10(6) and 1.0 x 10(8) W/cm(2). Decreased DNA synthesis was independent of the pulse length (10 ns vs. 230 ns) but was lower, at a given dose, when the highest fluence rate was used. Incubation of lymphocytes with preirradiated AV solutions also decreased incorporation of thymidine in a radiation dose-dependent manner. The cell damaging photoproducts in preirradiated AV solutions were unstable; within 15 min, the effectiveness had decreased by similar to 85%. Conclusions: These results indicate that exposure of AV to 308 nn excimer laser radiation produces photochemical products that damage human cells in vitro. (C) 1997 Wiley-Liss, Inc. C1 MASSACHUSETTS GEN HOSP,WELLMAN LABS PHOTOMED,BOSTON,MA 02114. FU NIGMS NIH HHS [R01 GM30755] NR 17 TC 1 Z9 1 U1 0 U2 2 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 1997 VL 20 IS 2 BP 111 EP 118 PG 8 WC Dermatology; Surgery SC Dermatology; Surgery GA WL151 UT WOS:A1997WL15100001 PM 9047164 ER PT J AU McAuliffe, DJ Lee, S Flotte, TJ Doukas, AG AF McAuliffe, DJ Lee, S Flotte, TJ Doukas, AG TI Stress-wave-assisted transport through the plasma membrane in vitro SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE ablation; cell viability; drug delivery; membrane permeability; shock waves; thymidine ID LITHOTRIPTER SHOCK-WAVES; INVITRO; CISPLATIN; TUMORS; CELLS; PERMEABILITY; EXPOSURE AB Background and Objective: Laser-induced stress waves have been shown to alter the permeability of the plasma membrane without affecting cell viability. The aim of the work reported here was to quantify the molecular uptake by cell cultures in vitro and determine optimal stress-wave parameters. Study Design/Materials and Methods: Human peripheral blood mononuclear cells were exposed to laser-induced stress waves in an experimental arrangement that eliminated interference from ancillary effects such as plasma, heat, or cavitation. A radiolabeled compound (tritiated thymidine) was used as the probe. Results: Stress waves enhanced the diffusion of tritiated thymidine by inducing a transient permeabilization of the plasma membrane. Furthermore, maximum intracellular concentration (2 x 10(5) thymidine molecules/cell or 10% of the extracellular concentration) was reached with only 2-3 stress waves. Conclusion: Laser-induced stress waves provide an efficient method for delivering molecules through the plasma membrane into the cytoplasm of cells. (C) 1997 Wiley-Liss, Inc. C1 MASSACHUSETTS GEN HOSP,WELLMAN LABS PHOTOMED,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02114. NR 28 TC 39 Z9 40 U1 0 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 1997 VL 20 IS 2 BP 216 EP 222 PG 7 WC Dermatology; Surgery SC Dermatology; Surgery GA WL151 UT WOS:A1997WL15100014 PM 9047177 ER PT J AU Berger, JW AF Berger, JW TI Thermal modelling of micropulsed diode laser retinal photocoagulation SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE diode; laser; photocoagulation; retina; thermal ID DYE FLUORESCENCE TRANSMISSION; BLOOD IN-VITRO; ENDOPHOTOCOAGULATION; ENERGY; RPE AB Background and Objective: Recent studies have sought to utilize diode laser ''micropulsing'' in order to preserve therapeutic efficacy of retinal photocoagulation while minimizing pain and subjacent tissue injury. A model for the transient thermal tissue response to continuous and micropulsed diode laser output is presented in order to understand the laser-tissue interactions and to generate optimum parameters for exploiting potential advantages of micropulsed application. Study Design/Materials and Methods: The tissue thermal response was calculated by convolving the analytical solution to the three-dimensional, isotropic heat conduction equation with a source term corresponding to the spot size of the laser incident on the absorbing retinal pigment epithelium (RPE) and choroid layers of the ocular fundus. Thermal localization is quantitated by comparing the temperature rise in the RPF (T(RPE)) and deep choroid (T(Ch)). A 1-watt (average power), 200-mu m diameter, 100 ms pulse (continuous or micropulsed) of 810 nn radiation was modelled to be incident on a geometric idealization of the human retina and choroid. Results: A temperature gradient is rapidly established with only modest temperature augmentation between 10 and 100 ms. At 100 ms, T(RPE) and T(Ch) are 32 and 23 C, respectively, for continuous application, and 41 and 27 C for 2 ms on/off micropulsed application. For a duty factor (total laser ''on'' time divided by pulse length) of 50%, T(RPE)/T(Ch) is maximal for a micropulse on/off duration of 2 ms; however, the variation over micropulse durations from 200 mu s to 50 ms is small. In addition, whereas end-pulse T(RPE)/T(Ch) is greater for 2 ms on/off application when compared with continuous delivery (1.53 vs. 1.39), thermal relaxation during pulse quiescence in the micropulsed mode allows for an early increase in deep choroidal temperature with respect to T(RPE). For ten 200 mu s pulses equally separated over 100 ms (duty factor = 2%), T(RPE)/T(Ch)= 3.2. With more numerous, lower power micropulses, T(RPF)/T(Ch) decreases monotonically to 1.39 as the duty factor is increased to 100%. Conclusion: These modelling studies provide the first quantitative predictions of thermal localization achieved with diode laser micropulsing and demonstrate that short pulse lengths and low duty factors allow for maximum thermal localization. These studies will potentiate pulse-shape optimization strategies for diode laser retinal photocoagulation applications. (C) 1997 Wiley-Liss, Inc. C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,LASER RES LAB,BOSTON,MA 02114. NR 24 TC 24 Z9 27 U1 0 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 1997 VL 20 IS 4 BP 409 EP 415 DI 10.1002/(SICI)1096-9101(1997)20:4<409::AID-LSM6>3.0.CO;2-U PG 7 WC Dermatology; Surgery SC Dermatology; Surgery GA WW728 UT WOS:A1997WW72800006 PM 9142680 ER PT J AU Kelly, K AF Kelly, K TI Help yourself: Problem solving for the disabled - Bucy,DR SO LIBRARY JOURNAL LA English DT Book Review RP Kelly, K (reprint author), MASSACHUSETTS GEN HOSP,TREADWELL LIB,BOSTON,MA 02114, USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU BOWKER MAGAZINE GROUP CAHNERS MAGAZINE DIVISION PI NEW YORK PA 249 W 17TH ST, NEW YORK, NY 10011 SN 0363-0277 J9 LIBR J JI Libr. J. PD JAN PY 1997 VL 122 IS 1 BP 84 EP 84 PG 1 WC Information Science & Library Science SC Information Science & Library Science GA WC742 UT WOS:A1997WC74200046 ER PT J AU Kelly, K AF Kelly, K TI ''I have arrived before my words'': The autobiographical writings of homeless women - Pugh,D, Tietjen,J SO LIBRARY JOURNAL LA English DT Book Review RP Kelly, K (reprint author), MASSACHUSETTS GEN HOSP LIB,BOSTON,MA, USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU BOWKER MAGAZINE GROUP CAHNERS MAGAZINE DIVISION PI NEW YORK PA 249 W 17TH ST, NEW YORK, NY 10011 SN 0363-0277 J9 LIBR J JI Libr. J. PD JAN PY 1997 VL 122 IS 1 BP 112 EP 112 PG 1 WC Information Science & Library Science SC Information Science & Library Science GA WC742 UT WOS:A1997WC74200185 ER PT S AU Wong, H Davis, RC Hill, JS Yang, D Schotz, MC AF Wong, H Davis, RC Hill, JS Yang, D Schotz, MC BE Rubin, B Dennis, EA TI Lipase engineering: A window into structure-function relationships SO LIPASES, PART A: BIOTECHNOLOGY SE Methods in Enzymology LA English DT Review ID RECEPTOR-RELATED PROTEIN; CELL-SURFACE PROTEOGLYCANS; LIPOPROTEIN-LIPASE; HEPATIC LIPASE; DOMAIN; BINDS; EVOLUTION; MUTAGENESIS; EXPRESSION; CATABOLISM C1 UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA. RP Wong, H (reprint author), W LOS ANGELES VET AFFAIRS MED CTR, LIPID RES LAB, 11301 WILSHIRE BLVD, LOS ANGELES, CA 90073 USA. NR 24 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 0-12-182185-4 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1997 VL 284 BP 171 EP 184 PG 14 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BJ57Q UT WOS:A1997BJ57Q00009 PM 9379933 ER PT S AU Hill, JS Davis, RC Yang, D Schotz, MC Wong, H AF Hill, JS Davis, RC Yang, D Schotz, MC Wong, H BE Rubin, B Dennis, EA TI Hepatic lipase: High-level expression and subunit structure determination SO LIPASES, PART A: BIOTECHNOLOGY SE Methods in Enzymology LA English DT Review ID HUMAN LIPOPROTEIN-LIPASE; RECEPTOR-RELATED PROTEIN; HIGH-DENSITY-LIPOPROTEINS; TRIGLYCERIDE LIPASE; PANCREATIC LIPASE; RADIATION INACTIVATION; CHIMERIC LIPASE; MOLECULAR-SIZE; RAT-LIVER; DOMAIN C1 UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA. RP Hill, JS (reprint author), W LOS ANGELES VET AFFAIRS MED CTR, LIPID RES LAB, 11301 WILSHIRE BLVD, LOS ANGELES, CA 90073 USA. FU NHLBI NIH HHS [HL28481] NR 45 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 0-12-182185-4 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1997 VL 284 BP 232 EP 246 PG 15 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BJ57Q UT WOS:A1997BJ57Q00013 PM 9379936 ER PT S AU Holm, C Contreras, JA Verger, R Schotz, MC AF Holm, C Contreras, JA Verger, R Schotz, MC BE Rubin, B Dennis, EA TI Large-scale purification and kinetic properties of recombinant hormone-sensitive lipase from baculovirus-insect cell systems SO LIPASES, PART A: BIOTECHNOLOGY SE Methods in Enzymology LA English DT Review ID RAT ADIPOSE-TISSUE; CATALYZED HYDROLYSIS; NUCLEOTIDE-SEQUENCE; MONOMOLECULAR FILMS; LIPOPROTEIN-LIPASE; BETA-CYCLODEXTRIN; MORAXELLA TA144; IDENTIFICATION; GENE; ACETYLCHOLINESTERASE C1 CNRS, UPR 9025, IFRCI, LAB LIPOLYSE ENZYMAT, F-13402 MARSEILLE, FRANCE. W LOS ANGELES VET AFFAIRS MED CTR, LIPID RES LAB, LOS ANGELES, CA 90073 USA. UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA. RP Holm, C (reprint author), LUND UNIV, DEPT CELL & MOL BIOL, SECT MOL SIGNALLING, S-22100 LUND, SWEDEN. FU NHLBI NIH HHS [HL-28481] NR 41 TC 10 Z9 10 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 0-12-182185-4 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1997 VL 284 BP 272 EP 284 PG 13 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BJ57Q UT WOS:A1997BJ57Q00016 PM 9379939 ER PT J AU Breton, S Smith, P Brown, D AF Breton, S Smith, P Brown, D TI A proton-pumping H+-ATPase in acidifying cells within male reproductive tract SO M S-MEDECINE SCIENCES LA French DT Article ID COLLECTING DUCT ACIDIFICATION; INTERCALATED CELLS; RAT EPIDIDYMIS; CARBONIC-ANHYDRASE; EPITHELIAL-CELLS; PH; KIDNEY; MOTILITY; TESTIS; SPERM RP Breton, S (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP EAST,SCH MED,RENAL UNIT,149 13TH ST,CHARLESTOWN,MA 02129, USA. NR 35 TC 1 Z9 1 U1 0 U2 0 PU JOHN LIBBEY EUROTEXT LTD PI MONTROUGE PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE SN 0767-0974 J9 M S-MED SCI JI M S-Med. Sci. PD JAN PY 1997 VL 13 IS 1 BP 57 EP 60 PG 4 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA WF618 UT WOS:A1997WF61800010 ER PT J AU Bartzokis, G Beckson, M Hance, DB Marx, P Foster, JA Marder, SR AF Bartzokis, G Beckson, M Hance, DB Marx, P Foster, JA Marder, SR TI MR evaluation of age-related increase of brain iron in young adult and older normal males SO MAGNETIC RESONANCE IMAGING LA English DT Article; Proceedings Paper CT 2nd Annual Meeting of the Society-of-Magnetic-Resonance CY AUG 06-12, 1994 CL SAN FRANCISCO, CA SP Soc Magnet Resonance DE magnetic resonance; ferritin; T-2 relaxation time; field strength dependence of transverse relaxation rate (R(2)); extrapyramidal nuclei ID DIFFERENT FIELD STRENGTHS; ALZHEIMERS-DISEASE; T2 VALUES; TRANSVERSE RELAXATION; 1.5 T; FERRITIN; HYPOINTENSITY; DEPOSITION; MICROSCOPY; TISSUE AB The purposes of this study were to extend the investigation of age-related increases in brain iron to a younger age group, replicate previously published results, and further evaluate the validity of a novel noninvasive magnetic resonance (MR) method for measuring tissue iron (ferritin) levels with specificity. The method consists of measuring the dependence of tissue transverse relaxation rates (R(2)) on the field strength of MR instruments. Two MR instruments operating at 1.5 and 0.5 T were used to measure the field-dependent R(2) increase (FDRI) in the frontal white matter, caudate, putamen, and globus pallidus. A group of 13 normal adult males(ages 21-77), with seven subjects below and six above age 35, was examined. As expected from postmortem and prior FDRI data, robust and significant age-related increases in FDRI were observed in the caudate, putamen, and globus pallidus, with the globus pallidus FDRI increasing sharply in the second decade and reaching a plateau after age 30. In addition, we replicated previous reports showing very high correlations between FDRI and published brain iron levels for the four regions examined. The data replicate and extend previous FDRI observations on brain aging and are consistent with postmortem data on age-related increases in brain iron. These results are relevant to the investigation of age-related neurodegenerative diseases in which iron may catalyze toxic free radical reactions. (C) 1997 Elsevier Science Inc. RP Bartzokis, G (reprint author), W LOS ANGELES VA MED CTR,BRENTWOOD DIV,RES SERV,11301 WILSHIRE BLVD,MAIL CODE B-151H,LOS ANGELES,CA 90073, USA. RI Bartzokis, George/K-2409-2013 NR 49 TC 115 Z9 117 U1 0 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0730-725X J9 MAGN RESON IMAGING JI Magn. Reson. Imaging PY 1997 VL 15 IS 1 BP 29 EP 35 DI 10.1016/S0730-725X(96)00234-2 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA WP120 UT WOS:A1997WP12000004 PM 9084022 ER PT B AU Copeland, KW Hwang, CJS AF Copeland, KW Hwang, CJS BE Khosrowpour, M TI Streamlining procurement through Electronic Commerce: An Internet approach SO MANAGING INFORMATION TECHNOLOGY RESOURCES AND APPLICATIONS IN THE WORLD ECONOMY LA English DT Proceedings Paper CT 1997 Information-Resources-Management-Association International Conference CY 1997 CL VANCOUVER, CANADA SP Informat Resources Management Assoc AB The Presidential memorandum, dated October 1993, and entitled "Steamlining Procurement Through Electronic Commerce" set ill motion a flurry of federal activity to meet the goals and deadlines that were entailed in the memo. By January 1997 all Federal purchases are to be made using Electronic Commerce to the maximum extent possible. This study includes an architecture that meets the goals and objectives of the President's initiative by looking to Internet technologies to accomplish the stated goals. The architecture leverages existing EDI infrastructure and allows the employing purchaser to do business with all of its trading partners electronically, whether or not the trading partner is EDI enabled. The inclusion of electronic credit card payments makes this application a financial application as well as a procurement application. The credit card inclusion elminates the need for invoicing and the requisite settlement procedures that accompany an invoicing process. C1 US Dept Vet Affairs, Off Acquisit & Mat Management, Austin, TX 78772 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU IDEA GROUP PUBLISHING PI HERSHEY PA 1331 E CHOCOLATE AVE, HERSHEY, PA 17033-1117 USA BN 1-878289-45-4 PY 1997 BP 357 EP 363 PG 7 WC Information Science & Library Science; Management SC Information Science & Library Science; Business & Economics GA BK87T UT WOS:000073729300059 ER PT B AU Copeland, KW Hwang, CJS AF Copeland, KW Hwang, CJS BE Khosrowpour, M TI Intranets as infrastructure for federal procurement applications SO MANAGING INFORMATION TECHNOLOGY RESOURCES AND APPLICATIONS IN THE WORLD ECONOMY LA English DT Proceedings Paper CT 1997 Information-Resources-Management-Association International Conference CY 1997 CL VANCOUVER, CANADA SP Informat Resources Management Assoc AB With the occurrence of the the Internet explosion, all federal agencies are looking rewards the Internet for future solutions and applications. Federal procurement activities in fact, have already been mandated by the President to do Electronic Commerce to the maximum extent possible. This mandate requires the building of infrastructure to allow Web applications to be implemented and supported. The Full Service Intranet is infrastructure that allows quick employment, widespread benefits, and fast return on invested monies. This same infrastructure allows employees the opportunity to learn and practice required skills Jar building and maintaining Web applications. Bur most importantly, this infrastructure gives organizations the ability to support Web applications by giving the external applications internal use. The Full Service Intranet is necessary to accomplish the already stated objectives of the Executive Branch of the Federal Government. The Full Service Intranet is necessary to accomplish the already stated objectives of the Executive Branch of the Federal Government. C1 US Dept Vet Affairs, Off Acquisit & Mat Management, Austin, TX 78772 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU IDEA GROUP PUBLISHING PI HERSHEY PA 1331 E CHOCOLATE AVE, HERSHEY, PA 17033-1117 USA BN 1-878289-45-4 PY 1997 BP 364 EP 368 PG 5 WC Information Science & Library Science; Management SC Information Science & Library Science; Business & Economics GA BK87T UT WOS:000073729300060 ER PT J AU New, HV Kavka, AI Smith, JC Green, JBA AF New, HV Kavka, AI Smith, JC Green, JBA TI Differential effects on Xenopus development of interference with type IIA and type IIB activin receptors SO MECHANISMS OF DEVELOPMENT LA English DT Article DE Xenopus; mesoderm induction; activin; activin receptor ID NEURAL INDUCTION; MORPHOGEN GRADIENT; MESODERM INDUCTION; VENTRAL MESODERM; AXIAL STRUCTURES; MESSENGER-RNA; BETA FAMILY; TGF-BETA; EMBRYOS; EXPRESSION AB One candidate for a mesoderm-inducing factor in early amphibian development is activin, a member of the TGF beta family. Overexpression of a truncated form of an activin receptor Type IIB abolishes activin responsiveness and mesoderm formation in vivo. The Xenopus Type IIA activin receptor XSTK9 differs from the Type IIB receptor by 43 and 25% in extracellular and intracellular domains respectively, suggesting the possibility of different functions in vivo. In this paper, we compare the Type IIA receptor with the Type IIB to test such a possibility Simple overexpression of the wild-type receptors reveals minimal differences, but experiments with dominant negative mutants of each receptor show qualitatively distinct effects. We show that while truncated (kinase domain-deleted) Type IIB receptors cause axial defects as previously described, truncated type IIA receptors cause formation of secondary axes, similar to those seen by overexpression of truncated receptors for BMP-4, another TGF beta family member. Furthermore, in animal cap assays, truncated type IIB receptors inhibit induction of all mesodermal markers tested, while truncated type TIA receptors suppress induction only of ventral markers; the anterior/dorsal marker goosecoid is virtually unaffected. The suppression of ventral development by the type IIA truncated receptor suggests either that the truncated Type IIA receptor interferes with ventral BMP pathways, or that activin signaling through the Type IIA receptor is necessary for ventral patterning. (C) 1997 Elsevier Science Ireland Ltd. C1 HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115. DANA FARBER CANC INST,DIV MOL GENET,BOSTON,MA 02115. NATL INST MED RES,DIV DEV BIOL,LONDON NW7 1AA,ENGLAND. RI Green, Jeremy/F-3630-2010 OI Green, Jeremy/0000-0002-6102-2620 NR 53 TC 18 Z9 18 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0925-4773 J9 MECH DEVELOP JI Mech. Dev. PD JAN PY 1997 VL 61 IS 1-2 BP 175 EP 186 DI 10.1016/S0925-4773(96)00639-9 PG 12 WC Developmental Biology SC Developmental Biology GA WK611 UT WOS:A1997WK61100015 PM 9076687 ER PT J AU Niemierko, A AF Niemierko, A TI Reporting and analyzing dose distributions: A concept of equivalent uniform dose SO MEDICAL PHYSICS LA English DT Article DE effective uniform dose; EUD; reporting dose; dose-volume distribution; DVH; three-dimensional treatment planning; biological modeling ID 3-DIMENSIONAL TREATMENT; RADIATION HEPATITIS; VOLUME HISTOGRAMS; RADIOTHERAPY; PROBABILITY; TUMOR; IRRADIATION; THERAPY; MODEL AB Modern treatment planning systems for three-dimensional treatment planning provide three-dimensionally accurate dose distributions for each individual patient. These data open up new possibilities for more precise reporting and analysis of doses actually delivered to irradiated organs and volumes of interest. A new method of summarizing and reporting inhomogeneous dose distributions is reported here. The concept of equivalent uniform dose (EUD) assumes that any two dose distributions are equivalent if they cause the same radiobiological effect. In this paper the EUD concept for tumors is presented, for which the probability of local control is assumed to be determined by the expected number of surviving clonogens, according to Poisson statistics. The EUD can be calculated directly from the dose calculation points or, from the corresponding dose-volume distributions (histograms). The fraction of clonogens surviving a dose of 2 Gy (SF2) is chosen to be the primary operational parameter characterizing radiosensitivity of clonogens. The application of the EUD concept is demonstrated on a clinical dataset. The causes of flattening of the observed dose-response curves become apparent since the EUD concept reveals the finer structure of the analyzed group of patients in respect to the irradiated volumes and doses actually received. Extensions of the basic EUD concept to include nonuniform density of clonogens; dose per fraction effects, repopulation of clonogens, and inhomogeneity of patient population are discussed and compared with the basic formula. (C) 1997 American Association of Physicists in Medicine. C1 HARVARD UNIV,SCH MED,BOSTON,MA. RP Niemierko, A (reprint author), MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,DIV RADIAT BIOPHYS,BOSTON,MA 02214, USA. FU NCI NIH HHS [CA 21239, CA 50628] NR 27 TC 578 Z9 589 U1 6 U2 26 PU AMER INST PHYSICS PI WOODBURY PA CIRCULATION FULFILLMENT DIV, 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2999 SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JAN PY 1997 VL 24 IS 1 BP 103 EP 110 DI 10.1118/1.598063 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA WD507 UT WOS:A1997WD50700010 PM 9029544 ER PT B AU Steil, GM AF Steil, GM BE Bergman, RN Lovejoy, JC TI Choosing an optimal sampling schedule for the identification of minimal model insulin sensitivity SO MINIMAL MODEL APPROACH AND DETERMINANTS OF GLUCOSE TOLERANCE SE PENNINGTON CENTER NUTRITION SERIES LA English DT Proceedings Paper CT 3rd International Symposium on Minimal Modeling CY JUN 09-10, 1994 CL BATON ROUGE, LA SP Pennington Biomed Res Ctr AB Methodology involved in choosing an optimally-reduced sampling schedule for the identification of the :Minimal Model is detailed in this paper. The 12-sample protocol that results from this methodology is shown to be unbiased, and to be well correlated with the full 30-sample protocol. Nonetheless, the reduction in sample number results in a higher coefficient of variation (CV) for the estimated insulin sensitivity (S-I) and results in a loss of power. The effect of adding 1, 2, or 10 samples to the original 12-sample schedule was then evaluated. Increasing the number of samples generally improved the correlation of the reduced versus full sample estimates of S-I but did not result in a lower CV. It is concluded that the full 30-sample estimate is probably preferable for small clinical studies and that the reduced-sample protocol is more applicable to epidemiologic studies. C1 Joslin Diabet Ctr, Boston, MA 02215 USA. RP Steil, GM (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LOUISIANA STATE UNIV PRESS PI BATON ROUGE PA BATON ROUGE, LA 70803 USA BN 0-8071-2238-6 J9 PENN CTR N PY 1997 VL 7 BP 123 EP 141 PG 19 WC Endocrinology & Metabolism; Medicine, General & Internal; Nutrition & Dietetics SC Endocrinology & Metabolism; General & Internal Medicine; Nutrition & Dietetics GA BK19D UT WOS:000071453100003 ER PT J AU Luo, ZJ Diaz, B Marshall, MS Avruch, J AF Luo, ZJ Diaz, B Marshall, MS Avruch, J TI An intact Raf zinc finger is required for optimal binding to processed Ras and for Ras-dependent Raf activation in situ SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID PROTEIN-KINASE-KINASE; TERMINAL REGULATORY DOMAIN; PLASMA-MEMBRANE; IDENTIFICATION; C-RAF-1; PURIFICATION; P21(RAS); EXPRESSION; PATHWAY; COMPLEX AB The function of the c-Raf-1 zinc finger domain in the activation of the Raf kinase was examined by the creation of variant zinc finger structures, Mutation of Raf Cys 165 and Cys 168 to Ser strongly inhibits the Res-dependent activation of c-Raf-1 by epidermal growth factor (EGF). Deletion of the Raf zinc finger and replacement with a homologous zinc finger from protein kinase C gamma (PKC gamma) (to give gamma/Raf) also abrogates EGF-induced activation but enables a vigorous phorbol myristate acetate (PMA)-induced activation PMA activation of gamma/Raf does not require endogenous Ras or PKCs and probably occurs through a PMA-induced recruitment of gamma/Raf to the plasma membrane. The impaired ability of EGF to activate the Raf zinc finger variants in situ is attributable, at least in part, to a major decrement in their binding to Ras-GTP; both Raf zinc finger variants exhibit decreased association with Ras(V12) in situ upon coexpression in COS cells, as well as diminished binding in vitro to immobilized, processed COS recombinant Ras(V12)-GTP. In contrast, Raf binding to unprocessed COS or prokaryotic recombinant Ras-GTP is unaffected by Raf zinc finger mutation, Thus, the Raf zinc finger contributes an important component to the overall binding to Ras-GTP in situ, through an interaction between the zinc finger and an epitope on Ras, distinct from the effector loop, that is present only on prenylated Ras. C1 HARVARD UNIV,MED SERV DEPT,SCH MED,MASSACHUSETTS GEN HOSP,CHARLESTOWN,MA 02129. INDIANA UNIV,DEPT MED,DIV HEMATOL & ONCOL,INDIANAPOLIS,IN 46202. INDIANA UNIV,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202. INDIANA UNIV,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202. RP Luo, ZJ (reprint author), MASSACHUSETTS GEN HOSP,DIABET UNIT,149 13TH ST,CHARLESTOWN,MA 02129, USA. NR 41 TC 96 Z9 97 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 1997 VL 17 IS 1 BP 46 EP 53 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA WA233 UT WOS:A1997WA23300006 PM 8972184 ER PT J AU Schaefer, BC Strominger, JL Speck, SH AF Schaefer, BC Strominger, JL Speck, SH TI Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID NASOPHARYNGEAL CARCINOMA-CELLS; BURKITTS-LYMPHOMA CELLS; NUCLEAR ANTIGEN EBNA-1; DNA METHYLATION; GENE-EXPRESSION; MEMBRANE-PROTEIN; CPG ISLAND; B-CELLS; INFECTED LYMPHOCYTES; HODGKINS-DISEASE AB Epstein-Barr virus (EBV) is capable of adopting three distinct forms of latency: the type III latency program, in which six EBV-encoded nuclear antigens (EBNAs) are expressed, and the type I and type II latency programs, in which only a single viral nuclear protein, EBNA1, is produced. Several groups have reported heavy CpG methylation of the EBV genome in Burkitt's lymphoma cell lines which maintain type I latency, and loss of viral genome methylation in tumor cell lines has been correlated with a switch to type III latency, Here, evidence that the type III latency program must be inactivated by methylation to allow EBV to enter the type I or type II restricted latency program is provided, The data demonstrates that the EBNA1 gene promoter, Qp, active in types I and II latency, is encompassed by a CpG island which is protected from methylation. CpG methylation inactivates the type III latency program and consequently allows the type I or II latency program to operate by alleviating EBNA1-mediated repression of Qp, methylation of the type III latency EBNA gene promoter, Cp, appears to be essential to prevent type III latency, since EBNA1 is expressed in all latently infected cells and, as shown here, is the only viral antigen required for activation of Cp, EBV is thus a pathogen which subverts host-cell-determined methylation to regulate distinct genetic programs. C1 WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110. WASHINGTON UNIV,SCH MED,DEPT MOL MICROBIOL,ST LOUIS,MO 63110. WASHINGTON UNIV,SCH MED,DIV MOL ONCOL,ST LOUIS,MO 63110. DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115. OI Schaefer, Brian C/0000-0001-8877-3507 FU NCI NIH HHS [CA47554, CA58524] NR 85 TC 64 Z9 65 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 1997 VL 17 IS 1 BP 364 EP 377 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA WA233 UT WOS:A1997WA23300039 PM 8972217 ER PT J AU DelAMonte, SM Bloch, KD AF DelAMonte, SM Bloch, KD TI Aberrant expression of the constitutive endothelial nitric oxide synthase gene in Alzheimer disease SO MOLECULAR AND CHEMICAL NEUROPATHOLOGY LA English DT Article DE constitutive endothelial nitric oxide synthase gene; Alzheimer disease; Down syndrome; neuritic sprouting; dystrophic dendrites; neuronal ID APOLIPOPROTEIN-E; NEURONS; CELLS; PATHOLOGY; DEMENTIA; GROWTH; ALLELE; RATS AB Neuritic pathology is a major neuroanatomical correlate of dementia in Alzheimer disease (AD). Nitric oxide (NO) is linked to neuritic growth and synaptic plasticity. Expression of one of the enzymes responsible for NO synthesis, the constitutive endothelial NO synthase (ceNOS), was investigated in brains of AD and Down syndrome patients using RNase protection assays, in situ hybridization, and immunocytochemistry. In end-stage AD, ceNOS expression was reduced in cortical neurons, and the enzyme was aberrantly translocated to membranes of proliferated swollen or collapsed neuritic processes. In addition, ceNOS expression was strikingly increased in glial cells characterized mainly as protoplasmic (Type 2) astrocytes, which are responsible for maintaining the structural and functional integrity of cell processes in the CNS. In Down syndrome, similar abnormalities emerged by the third decade, preceding the cognitive decline and establishment of CERAD criteria for AD, indicating that aberrant ceNOS expression occurs early in the course of neurodegeneration. The results suggest that aberrant ceNOS translocation and gene regulation may have important roles in the pathogenesis of AD neuritic pathology. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CARDIOVASC RES CTR,DEPT MED,BOSTON,MA 02114. RP DelAMonte, SM (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,CTR CANC,SCH MED,DIV NEUROPATHOL,DEPT PATHOL,BOSTON,MA 02114, USA. FU NHLBI NIH HHS [HL 45895]; NINDS NIH HHS [NS29793] NR 43 TC 44 Z9 44 U1 1 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 SN 1044-7393 J9 MOL CHEM NEUROPATHOL JI Mol. Chem. Neuropathol. PD JAN-FEB PY 1997 VL 30 IS 1-2 BP 139 EP 159 PG 21 WC Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA WK182 UT WOS:A1997WK18200010 PM 9138425 ER PT J AU Beal, MF Matthews, RT AF Beal, MF Matthews, RT TI Coenzyme Q(10) in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases SO MOLECULAR ASPECTS OF MEDICINE LA English DT Article; Proceedings Paper CT 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q CY MAY, 1996 CL ANCONA, ITALY DE oxidative damage; Huntington's disease; Parkinson's disease; neuroprotection; mitochondria ID LOW-DENSITY-LIPOPROTEIN; ENERGY-METABOLISM; MITOCHONDRIAL ENCEPHALOMYOPATHY; INDUCED DEGENERATION; LIPID-PEROXIDATION; ELECTRON-TRANSFER; RAT-LIVER; IN-VIVO; THERAPY; UBIQUINONE AB Coenzyme Q(10) is an essential cofactor of the electron transport chain and is an antioxidant. We examined the effects of oral feeding with coenzyme Q(10) in young animals on brain concentrations. Feeding with coenzyme Q(10) at a dose of 200 mg/kg for 1-2 months in young rats resulted in significant increases in liver concentrations, however, there was no significant increase in brain concentrations of either reduced-or total coenzyme Q(10) levels. Nevertheless there was a reduction in malonate-induced increases in 2,5 dihydroxybenzoic acid to salicylate, consistent with an antioxidant effect. In other studies Re found that oral administration of coenzyme Q(10) significantly reduced increased concentrations of lactate in the occipital cortex of Huntington's disease patients. These findings suggest that coenzyme Q(10) might be useful in treating neurodegenerative diseases. (C) 1997 Elsevier Science Ltd. C1 MASSACHUSETTS GEN HOSP,NEUROL SERV,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02114. NR 35 TC 23 Z9 24 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0098-2997 J9 MOL ASPECTS MED JI Mol. Asp. Med. PY 1997 VL 18 SU S BP S169 EP S179 PG 11 WC Biochemistry & Molecular Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Research & Experimental Medicine GA XR183 UT WOS:A1997XR18300021 PM 9266519 ER PT J AU Soloveva, V Graves, RA Rasenick, MM Spiegelman, BM Ross, SR AF Soloveva, V Graves, RA Rasenick, MM Spiegelman, BM Ross, SR TI Transgenic mice overexpressing the beta 1-adrenergic receptor in adipose tissue are resistant to obesity SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID UNCOUPLING PROTEIN GENE; BETA(3)-ADRENERGIC RECEPTOR; BROWN-FAT; BETA-3-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; ADENYLATE-CYCLASE; DOWN-REGULATION; EXPRESSION; WHITE; THERMOGENESIS AB The ratio of alpha- to beta-receptors is thought to regulate the lipolytic index of adipose depots. To determine whether increasing the activity of the beta(1)-adrenergic receptor (AR) in adipose tissue would affect the lipolytic rate or the development of this tissue, we used the enhancer-promoter region of the adipocyte lipid-binding protein (aP2) gene to direct expression of the human beta(1)AR cDNA to adipose tissue. Expression of the transgene was seen only in brown and white adipose tissue. Adipocytes from transgenic mice were more responsive to beta AR agonists than were adipocytes from nontransgenic mice, both in terms of cAMP production and lipolytic rates. Transgenic animals were partially resistant to diet-induced obesity. They had smaller adipose tissue depots than their nontransgenic littermates, reflecting decreased lipid accumulation in their adipocytes. In addition to increasing the lipolytic rate, overexpression of the beta(1)AR induced the abundant appearance of brown fat cells in subcutaneous white adipose tissue. These results demonstrate that the beta(1)AR is involved in both stimulation of lipolysis and the proliferation of brown fat cells in the context of the whole organism. Moreover, it appears that it is the overall beta AR activity, rather than the particular subtype, that controls these phenomena. C1 UNIV PENN, CTR CANC, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA. UNIV ILLINOIS, SCH MED, DEPT BIOCHEM, CHICAGO, IL 60612 USA. UNIV ILLINOIS, SCH MED, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60612 USA. UNIV CHICAGO, SCH MED, DEPT MED, CHICAGO, IL 60637 USA. HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA. HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA. NR 42 TC 75 Z9 75 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD JAN PY 1997 VL 11 IS 1 BP 27 EP 38 DI 10.1210/me.11.1.27 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA WA750 UT WOS:A1997WA75000003 PM 8994185 ER PT J AU Gnudi, L Frevert, EU Houseknecht, KL Erhardt, P Kahn, BB AF Gnudi, L Frevert, EU Houseknecht, KL Erhardt, P Kahn, BB TI Adenovirus-mediated gene transfer of dominant negative ras(asn17) in 3T3L1 adipocytes does not alter insulin-stimulated PI3-kinase activity or glucose transport SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; GLYCOGEN-SYNTHESIS; SIGNALING PATHWAY; MAMMALIAN-CELLS; ADIPOSE-CELLS; DNA-SYNTHESIS; S6 KINASE; RAS AB Recent studies suggest that the ras-map kinase and PI3-kinase cascades converge, We sought to determine whether PI3-kinase is downstream of ras in insulin signaling in a classic insulin target cell. We generated a recombinant adenovirus encoding dominant negative ras by cloning the human H-ras cDNA with a ser to asn substitution at amino acid 17 (ras(asn17)) into the pACCMVpLpA vector and cotransfecting 293 cells with the pJM17 plasmid containing the adenoviral genome, Efficiency of gene transfer was assessed by infecting fully differentiated 3T3L1 adipocytes with a recombinant adenovirus expressing beta-galactosidase (beta-gal); greater than 70% of cells were infected. Infection of adipocytes with ras(asn17) resulted in 10-fold greater expression than endogenous ras. This high efficiency gene transfer allowed biochemical assays, Insulin stimulation of ras-GTP formation was inhibited in ras(asn17)-expressing cells. Map kinase gel mobility shift revealed that insulin (1 uM) or epidermal growth factor (100 ng/ml) resulted in the appearance of a hyperphosphorylated species of p42 map kinase in uninfected cells and those expressing beta-gal but not in cells expressing ras(asn17). In contrast, insulin increased IRS-l-associated PI3-kinase activity approximately 10-fold in control cells and high level overexpression of ras(asn17) did not impair this effect. Similarly, insulin and epidermal growth factor activation of total (no immunoprecipitation) PI3-kinase activity in both cytosol and total cellular membranes and insulin stimulation of glucose transport were not affected by expression of dominant negative ras, Thus, adenovirus-mediated gene transfer is effective for studying insulin signaling in fully differentiated insulin target cells, Inhibition of ras activation abolishes insulin-stimulated phosphorylation of map kinase but does not affect insulin stimulation of PI3-kinase activity, In normal cell physiology, PI3-kinase does not appear to be downstream of ras in mediating the actions of insulin. C1 BETH ISRAEL HOSP,BOSTON,MA 02215. DANA FARBER CANC INST,BOSTON,MA 02215. HARVARD UNIV,SCH MED,DEPT MED,DIV ENDOCRINOL,BOSTON,MA 02215. FU NIA NIH HHS [AG00294]; NIDDK NIH HHS [DK-45874, DK-43051] NR 35 TC 26 Z9 26 U1 0 U2 0 PU ENDOCRINE SOC PI BETHESDA PA 4350 EAST WEST HIGHWAY SUITE 500, BETHESDA, MD 20814-4110 SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD JAN PY 1997 VL 11 IS 1 BP 67 EP 76 DI 10.1210/me.11.1.67 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA WA750 UT WOS:A1997WA75000007 PM 8994189 ER PT J AU Zhang, M Sheng, SJ Maass, N Sager, R AF Zhang, M Sheng, SJ Maass, N Sager, R TI mMaspin: The mouse homolog of a human tumor suppressor gene inhibits mammary tumor invasion and motility SO MOLECULAR MEDICINE LA English DT Article ID EPIDERMAL GROWTH-FACTOR; DUCTAL MORPHOGENESIS; EPITHELIAL-CELLS; MTS1 GENE; GLAND; EXPRESSION; MASPIN; PURIFICATION; PROTEINASES; SERPINS AB Background: The human maspin gene encodes a protein in the serine proteinase inhibitor (serpin) family with tumor-suppressing functions in cell culture and in nude mice. In order to examine the role of maspin in an intact mammal, we cloned and sequenced the cDNA of mouse maspin. The recombinant protein was produced and its activity in cell culture was assessed. Materials and Methods: Mouse maspin (mMaspin) was cloned by screening a mouse mammary gland cDNA library with the human maspin cDNA probe. Northern blot analysis was used to examine the expression patterns in mouse tissues, mammary epithelial cells, and carcinomas. Recombinant mMaspin protein was produced in E. coli. Invasion and motility assays were used to assess the biological function of mMaspin. Results: mMaspin is 89% homologous with human maspin at the amino acid level. Like its human homolog, mMaspin is expressed in normal mouse mammary epithelial cells and down-regulated in mouse breast tumor cell lines. The expression is altered at different developmental stages in mammary gland. Addition of the recombinant mMaspin protein to mouse tumor cells was shown to inhibit invasion in a dose-dependent manner. As with the human protein, recombinant mMaspin protein also inhibited mouse mammary tumor motility. Deletion in the putative mMaspin reactive site loop (RSL) region resulted in the loss of its inhibitory functions. Conclusions: mMaspin is the mouse homolog of a human tumor suppressor gene. The expression of mMaspin is down-regulated in tumor cells and is altered at different developmental stages of mammary gland. mMaspin has inhibitory properties similar to those of human maspin in cell culture, suggesting that the homologous proteins play similar physiological roles in vivo. C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. RI Maass, Nicolai/F-2639-2014 FU NCI NIH HHS [5-T32-CA 09361-14, CA61253] NR 25 TC 61 Z9 62 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 1076-1551 J9 MOL MED JI Mol. Med. PD JAN PY 1997 VL 3 IS 1 BP 49 EP 59 PG 11 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA WH770 UT WOS:A1997WH77000006 PM 9132279 ER PT B AU Behar, O AF Behar, O BE Borsook, D TI Semaphorin genes and dorsal root ganglion axonal guidance SO MOLECULAR NEUROBIOLOGY OF PAIN SE PROGRESS IN PAIN RESEARCH AND MANAGEMENT LA English DT Proceedings Paper CT Conference on Molecular Aspects of the Neurobiology of Pain as part of the Celebration to Mark the 150th Anniversary of the First Public Demonstration of Ether CY OCT 15-17, 1996 CL BOSTON, MA SP Massachusetts Gen Hosp, Harvard Med Sch C1 Massachusetts Gen Hosp, Dept Anesthesiol & Crit Care, Neural Plast Res Grp, Boston, MA 02114 USA. RP Behar, O (reprint author), Massachusetts Gen Hosp, Dept Anesthesiol & Crit Care, Neural Plast Res Grp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU INT ASSOC STUDY PAIN (IASP) PRESS PI SEATTLE PA 909 NE 43RD ST, SUITE 304, SEATTLE, WA 98105 USA BN 0-931092-19-1 J9 PROG PAIN RES MANAG PY 1997 VL 9 BP 13 EP 22 PG 10 WC Biochemistry & Molecular Biology; Clinical Neurology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BK46M UT WOS:000072280000002 ER PT B AU Kobierski, LA AF Kobierski, LA BE Borsook, D TI Cytokines and inflammation in the central nervous system SO MOLECULAR NEUROBIOLOGY OF PAIN SE PROGRESS IN PAIN RESEARCH AND MANAGEMENT LA English DT Proceedings Paper CT Conference on Molecular Aspects of the Neurobiology of Pain as part of the Celebration to Mark the 150th Anniversary of the First Public Demonstration of Ether CY OCT 15-17, 1996 CL BOSTON, MA SP Massachusetts Gen Hosp, Harvard Med Sch C1 Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Charlestown, MA USA. RP Kobierski, LA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Charlestown, MA USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU INT ASSOC STUDY PAIN (IASP) PRESS PI SEATTLE PA 909 NE 43RD ST, SUITE 304, SEATTLE, WA 98105 USA BN 0-931092-19-1 J9 PROG PAIN RES MANAG PY 1997 VL 9 BP 45 EP 58 PG 14 WC Biochemistry & Molecular Biology; Clinical Neurology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BK46M UT WOS:000072280000004 ER PT B AU Woolf, CJ AF Woolf, CJ BE Borsook, D TI Molecular signals responsible for the reorganization of the synaptic circuitry of the dorsal horn after peripheral nerve injury: The mechanisms of tactile Allodynia SO MOLECULAR NEUROBIOLOGY OF PAIN SE PROGRESS IN PAIN RESEARCH AND MANAGEMENT LA English DT Proceedings Paper CT Conference on Molecular Aspects of the Neurobiology of Pain as part of the Celebration to Mark the 150th Anniversary of the First Public Demonstration of Ether CY OCT 15-17, 1996 CL BOSTON, MA SP Massachusetts Gen Hosp, Harvard Med Sch C1 Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Charlestown, MA USA. RP Woolf, CJ (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Charlestown, MA USA. NR 0 TC 35 Z9 35 U1 0 U2 2 PU INT ASSOC STUDY PAIN (IASP) PRESS PI SEATTLE PA 909 NE 43RD ST, SUITE 304, SEATTLE, WA 98105 USA BN 0-931092-19-1 J9 PROG PAIN RES MANAG PY 1997 VL 9 BP 171 EP 200 PG 30 WC Biochemistry & Molecular Biology; Clinical Neurology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BK46M UT WOS:000072280000010 ER PT J AU Nierenberg, AA Mulroy, R AF Nierenberg, AA Mulroy, R TI Declaration of treatment failures SO MOOD DISORDERS SE MODERN PROBLEMS OF PHARMACOPSYCHIATRY LA English DT Article ID COLLABORATIVE RESEARCH-PROGRAM; SEROTONIN REUPTAKE INHIBITORS; RESISTANT MAJOR DEPRESSION; MENTAL-HEALTH TREATMENT; ANTIDEPRESSANT TREATMENT; REFRACTORY DEPRESSION; UNIPOLAR DEPRESSION; NATIONAL-INSTITUTE; DOSE FLUOXETINE; EFFICACY RP Nierenberg, AA (reprint author), MASSACHUSETTS GEN HOSP,DEPRESS & CLIN RES PROGRAM,15 PARKMAN ST,ACC 815,BOSTON,MA 02114, USA. NR 78 TC 8 Z9 8 U1 0 U2 1 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0077-0094 J9 MOD PROBL PHARM PY 1997 VL 25 BP 17 EP 33 DI 10.1159/000061672 PG 17 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA BJ75D UT WOS:A1997BJ75D00002 PM 9344367 ER PT J AU Shapiro, BE Soto, O Shafqat, S Blumenfeld, H AF Shapiro, BE Soto, O Shafqat, S Blumenfeld, H TI Adult botulism SO MUSCLE & NERVE LA English DT Article DE botulism; botulinum toxicity; acute paralytic disorders ID DISORDERS RP Shapiro, BE (reprint author), MASSACHUSETTS GEN HOSP,DEPT NEUROL,WAC-835,FRUIT ST,BOSTON,MA 02114, USA. NR 13 TC 14 Z9 14 U1 0 U2 1 PU JOHN WILEY & SONS INC PI NEW YORK PA 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD JAN PY 1997 VL 20 IS 1 BP 100 EP 102 DI 10.1002/(SICI)1097-4598(199701)20:1<100::AID-MUS14>3.0.CO;2-8 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA VZ332 UT WOS:A1997VZ33200016 PM 8995590 ER PT S AU Feschenko, MS Wetzel, RK Sweadner, KJ AF Feschenko, MS Wetzel, RK Sweadner, KJ BE Beauge, LA Gadsby, DC Garrahan, PJ TI Phosphorylation of Na,K-ATPase by protein kinases - Sites, susceptibility, and consequences SO NA/K-ATPASE AND RELATED TRANSPORT ATPASES: STRUCTURE, MECHANISM, AND REGULATION SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT VIIIth International Conference on the Na/K-ATPase (and Related Transport ATPases) CY AUG 26-30, 1996 CL MAR DEL PLATA, ARGENTINA ID CATALYTIC SUBUNIT; ALPHA-SUBUNITS C1 Massachusetts Gen Hosp, Ctr Neurosci, Lab Membrane Biol, Charlestown, MA 02129 USA. RP Sweadner, KJ (reprint author), Massachusetts Gen Hosp, Ctr Neurosci, Lab Membrane Biol, 149 13th St, Charlestown, MA 02129 USA. FU NINDS NIH HHS [NS 27653] NR 13 TC 27 Z9 27 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-060-3 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1997 VL 834 BP 479 EP 488 DI 10.1111/j.1749-6632.1997.tb52306.x PG 10 WC Biochemistry & Molecular Biology; Biophysics; Multidisciplinary Sciences; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Biophysics; Science & Technology - Other Topics; Pharmacology & Pharmacy GA BK07V UT WOS:000071090100087 PM 9405850 ER PT S AU Kasturi, R McLean, LR Margolies, MN Ball, WJ AF Kasturi, R McLean, LR Margolies, MN Ball, WJ BE Beauge, LA Gadsby, DC Garrahan, PJ TI High affinity anti-digoxin antibodies as model receptors for cardiac glycosides - Comparisons with N+,K+-ATPase SO NA/K-ATPASE AND RELATED TRANSPORT ATPASES: STRUCTURE, MECHANISM, AND REGULATION SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT VIIIth International Conference on the Na/K-ATPase (and Related Transport ATPases) CY AUG 26-30, 1996 CL MAR DEL PLATA, ARGENTINA C1 Univ Cincinnati, Cincinnati, OH 45267 USA. Hoechst Mar Roussel, Cincinnati, OH 45215 USA. Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Kasturi, R (reprint author), Univ Cincinnati, Cincinnati, OH 45267 USA. FU NHLBI NIH HHS [R01 HL47415, 5 T32 HLO7382-19] NR 6 TC 1 Z9 1 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-060-3 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1997 VL 834 BP 634 EP 636 DI 10.1111/j.1749-6632.1997.tb52335.x PG 3 WC Biochemistry & Molecular Biology; Biophysics; Multidisciplinary Sciences; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Biophysics; Science & Technology - Other Topics; Pharmacology & Pharmacy GA BK07V UT WOS:000071090100116 PM 9405877 ER PT J AU Robertson, MJ Cameron, C Lazo, S Cochran, KJ Voss, SD Ritz, J AF Robertson, MJ Cameron, C Lazo, S Cochran, KJ Voss, SD Ritz, J TI Costimulation of human natural killer cell proliferation: Role of accessory cytokines and cell contact-dependent signals SO NATURAL IMMUNITY LA English DT Article DE natural killer cells; proliferation; costimulation; interleukin 2; interleukin 12; interleukin 15 ID NECROSIS FACTOR-ALPHA; HUMAN NK CELLS; HUMAN PERIPHERAL-BLOOD; T-CELLS; ADOPTIVE IMMUNOTHERAPY; INTERFERON-GAMMA; IL-2 RECEPTOR; BETA-CHAIN; ACTIVATION; INTERLEUKIN-2 AB Despite the importance of natural killer (NK) cells in the immune response, the regulation of human NK cell growth has not been well characterized. We have hypothesized that, similar to the proliferation of T and B lymphocytes, optimal proliferation of NK cells requires costimulatory signals as well as a primary mitogenic stimulus. Evidence for costimulation by both soluble cytokines and cell contact-dependent factors is presented. Soluble IL-1 and TNF were found to augment NK cell proliferation in response to primary mitogenic cytokines, including IL-2, IL-4, IL- 7, and IL-12. The costimulatory effect of IL-1 and TNF is strongly enhanced by the calcium ionophore ionomycin. Coculture of NK cells with irradiated K562 cells can largely substitute for the costimulatory signal provided by ionomycin. Costimulation by K562 requires intimate cell contact and is not reconstituted by cell-free supernatants. Activated T lymphocytes can also mediate contact-dependent costimulation of NK cells; resting PBMC, several NK-sensitive cell lines, and all NK-resistant cell lines tested were not found to be costimulatory. Engagement of CD16 did not augment NK cell proliferation. Thus, triggering of natural killing or antibody-dependent cell-mediated cytotoxicity (ADCC) does not consistently provide a costimulatory signal for NK cell proliferation. Cell contact-dependent costimulation of NK cells does not appear to involve known receptors that can costimulate T cells, including CD2, CD27, CD28, CD29, or LFA-1. The molecular nature of the putative NK cell costimulatory receptor remains to be elucidated. Nevertheless, human NK cells could be expanded in vitro using leukocyte-conditioned medium (LCM) as a source of IL-2 and accessory cytokines and ionomycin to bypass the putative receptor for cell contact-dependent costimulation. NK cells expanded in LCM and ionomycin express typical NK cell antigens and mediate natural killing and ADCC. Further characterization of the Costimulation costimulatory signals for NK cell proliferation may elucidate the physiologic regulation of NK cell growth and may ultimately allow more effective manipulation of these lymphocytes in the immunotherapy of human diseases. C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA. NR 59 TC 7 Z9 10 U1 1 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-8916 J9 NAT IMMUN JI Nat. Immun. PY 1997 VL 15 IS 5 BP 213 EP 226 PG 14 WC Cell Biology; Immunology SC Cell Biology; Immunology GA YC907 UT WOS:A1997YC90700001 ER PT J AU Peters, R Sikorski, RS AF Peters, R Sikorski, RS TI Protein databases on the WWW SO NATURE BIOTECHNOLOGY LA English DT Editorial Material RP Peters, R (reprint author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING CO PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 SN 1087-0156 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD JAN PY 1997 VL 15 IS 1 BP 90 EP 90 DI 10.1038/nbt0197-90 PG 1 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA WA729 UT WOS:A1997WA72900031 PM 9035114 ER PT J AU Li, QY NewburyEcob, RA Terrett, JA Wilson, DI Curtis, ARJ Yi, CH Gebuhr, T Bullen, PJ Robson, SC Strachan, T Bonnet, D Lyonnet, S Young, ID Raeburn, JA Buckler, AJ Law, DJ Brook, JD AF Li, QY NewburyEcob, RA Terrett, JA Wilson, DI Curtis, ARJ Yi, CH Gebuhr, T Bullen, PJ Robson, SC Strachan, T Bonnet, D Lyonnet, S Young, ID Raeburn, JA Buckler, AJ Law, DJ Brook, JD TI Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family SO NATURE GENETICS LA English DT Article ID CONSERVED PROTEIN MOTIF; HEART-HAND SYNDROME; MESODERM FORMATION; DROSOPHILA-MELANOGASTER; INSITU HYBRIDIZATION; WAARDENBURG SYNDROME; MOUSE BRACHYURY; OPTOMOTOR-BLIND; GRAM SYNDROME; SYNDROME MAPS AB Holt-Gram syndrome is a developmental disorder affecting the heart and upper limb, the gene for which was mapped to chromosome 12 two years ago. We have now identified a gene for this disorder (HOS1). The gene (TBX5) is a member of the Brachyury (T) family corresponding to the mouse Tbx5 gene. We have identified six mutations, three in HOS families and three in sporadic HOS cases. Each of the mutations introduces a premature stop codon in the TBX5 gene product. Tissue in situ hybridization studies on human embryos from days 26 to 52 of gestation reveal expression of TBX5 in heart and limb. consistent with a role in human embryonic development. C1 UNIV NOTTINGHAM, QUEENS MED CTR, SCH MED, DEPT GENET, NOTTINGHAM NG7 2UH, ENGLAND. UNIV NOTTINGHAM, CITY HOSP, NHS TRUST, CTR GENET MED, NOTTINGHAM NG5 1PB, ENGLAND. ROYAL HOSP SICK CHILDREN, DEPT CLIN GENET, BRISTOL BS2 8JJ, AVON, ENGLAND. UNIV NEWCASTLE UPON TYNE, DEPT HUMAN GENET, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND. UNIV NEWCASTLE UPON TYNE, DEPT FETAL MED, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND. UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA. HOP NECKER ENFANTS MALAD, DEPT PEDIAT, INSERM U393, F-75743 PARIS, FRANCE. MASSACHUSETTS GEN HOSP, DEPT NEUROGENET, CHARLESTOWN, MA USA. RI Wilson, David/A-6264-2010; OI Brook, John David/0000-0002-5946-6740 FU NHGRI NIH HHS [HG00209] NR 86 TC 555 Z9 569 U1 6 U2 21 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD JAN PY 1997 VL 15 IS 1 BP 21 EP 29 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA WA373 UT WOS:A1997WA37300016 PM 8988164 ER PT J AU Stoffers, DA Zinkin, NT Stanojevic, V Clarke, WL Habener, JF AF Stoffers, DA Zinkin, NT Stanojevic, V Clarke, WL Habener, JF TI Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence SO NATURE GENETICS LA English DT Article ID TRANSCRIPTION FACTOR EXPRESSION; INSULIN GENE; GLUCOSE-CONCENTRATION; CONGENITAL ABSENCE; DIABETES-MELLITUS; HOMEOBOX FACTOR; FACTOR STF-1; ISLET CELLS; HOMEODOMAIN; INSUFFICIENCY AB The homeodomain protein IPF1 (also known as IDX1, STF1 and PDX1; see Methods) is critical for development of the pancreas in mice and is a key factor for the regulation of the insulin gene in the beta-cells of the endocrine pancreas(1-6). Targeted disruption of the Ipf1 gene encoding IPF1 in transgenic mice results in a failure of the pancreas to develop (pancreatic agenesis)(4,7). Here, we report the identification of a single nucleotide deletion within codon 63 of the human IPF1 gene (13q12.1) in a patient with pancreatic agenesis. The patient is homozygous for the point deletion, whereas both parents are heterozygotes for the same mutation. The deletion was not found in 184 chromosomes from normal individuals, indicating that the mutation is unlikely to be a rare polymorphism. The point deletion causes a frame shift at the C-terminal border of the transactivation domain of IPF1 resulting in the translation of 59 novel codons before termination, aminoproximal to the homeodomain essential for DNA binding, Expression of mutant IPF1 in Cos-1 cells confirms the expression of a prematurely terminated truncated protein of 16 kD. Thus, the affected patient should have no functional IPF1 protein. Given the essential role of IPF1 in pancreas development, it is likely that this autosomal recessive mutation is the cause of the pancreatic agenesis phenotype in this patient. Thus, IPF1 appears to be a critical regulator of pancreas development in humans as well as mice. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,LAB MOL ENDOCRINOL,HOWARD HUGHES MED INST,BOSTON,MA 02114. UNIV VIRGINIA,DEPT PEDIAT,CHARLOTTESVILLE,VA 22908. RI Stoffers, Doris/H-6157-2012 NR 29 TC 675 Z9 696 U1 2 U2 11 PU NATURE PUBLISHING CO PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 SN 1061-4036 J9 NAT GENET JI Nature Genet. PD JAN PY 1997 VL 15 IS 1 BP 106 EP 110 DI 10.1038/ng0197-106 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA WA373 UT WOS:A1997WA37300032 PM 8988180 ER PT J AU Fink, K Namura, S Zhu, J Endres, M Srinivasan, A Tomaselli, KJ YUan, J Moskowitz, MA AF Fink, K Namura, S Zhu, J Endres, M Srinivasan, A Tomaselli, KJ YUan, J Moskowitz, MA TI CPP32 activation and cleavage in neuronal apoptosis after transient focal cerebral ischemia SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,CHARLESTOWN,MA 02129. IDUN PHARMACEUT INC,LA JOLLA,CA 92037. HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0028-1298 J9 N-S ARCH PHARMACOL JI Naunyn-Schmiedebergs Arch. Pharmacol. PY 1997 VL 356 IS 4 SU 1 BP 52 EP 52 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA XY872 UT WOS:A1997XY87200052 ER PT J AU Ferger, B Zorn, EC vanAmsterdam, C Seyfried, C Kuschinsky, K AF Ferger, B Zorn, EC vanAmsterdam, C Seyfried, C Kuschinsky, K TI In vivo evaluation of free radical production after glutamate stimulation and possible free radical trapping with PBN and selegiline in the striatum of rats SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CHARLESTOWN,MA 02129. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0028-1298 J9 N-S ARCH PHARMACOL JI Naunyn-Schmiedebergs Arch. Pharmacol. PY 1997 VL 355 IS 4 SU S BP 322 EP 322 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA WV420 UT WOS:A1997WV42000346 ER PT S AU Srivastava, MD Walker, WA AF Srivastava, MD Walker, WA BE Bellanti, JA Bracci, R Prindull, G Xanthou, M TI The development of the mucosal immune system in the sick neonate SO NEONATAL HEMATOLOGY AND IMMUNOLOGY III SE INTERNATIONAL CONGRESS SERIES LA English DT Proceedings Paper CT 3rd Neonatal Hematology and Immunology Symposium CY SEP 29-OCT 01, 1996 CL WASHINGTON, DC SP European Soc Pediat Hematol & Immunol RP Srivastava, MD (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,COMBINED PROGRAM PEDIAT GASTROENTEROL & NUTR,BOSTON,MA 02115, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE PUBL B V PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0531-5131 BN 0-444-82573-8 J9 INT CONGR SER PY 1997 VL 1131 BP 115 EP 120 PG 6 WC Hematology; Immunology; Pediatrics SC Hematology; Immunology; Pediatrics GA BK03A UT WOS:A1997BK03A00016 ER PT J AU Scherzer, CR Landwehrmeyer, GB Kerner, JA Standaert, DG Hollingsworth, ZR Daggett, LP Velicelebi, G Penney, JB Young, AB AF Scherzer, CR Landwehrmeyer, GB Kerner, JA Standaert, DG Hollingsworth, ZR Daggett, LP Velicelebi, G Penney, JB Young, AB TI Cellular distribution of NMDA glutamate receptor subunit mRNAs in the human cerebellum SO NEUROBIOLOGY OF DISEASE LA English DT Article ID METHYL-D-ASPARTATE; EXCITATORY AMINO-ACIDS; PURKINJE-CELLS; MOLECULAR-CLONING; MESSENGER-RNAS; PHARMACOLOGICAL CHARACTERIZATION; FUNCTIONAL-CHARACTERIZATION; DIFFERENTIAL EXPRESSION; HUMAN BRAIN; RAT-BRAIN AB We have used a quantitative in situ hybridization method with human ribonucleotide probes to examine the regional and cellular distribution of N-methyl-D-aspartate receptor (NMDAR) subunit mRNAs in the human cerebellum. Purkinje cells showed very dense labeling for NMDAR1 mRNA, dense labeling for NMDAR2A mRNA, and moderate labeling for NMDAR2D mRNA, whereas labeling for NMDAR2C mRNA was low. Granule cells showed high hybridization signals for the NMDAR1 and NMDAR2C mRNAs and moderate signals for the NMDAR2A and NMDAR2D mRNAs. In addition intense labeling with the NMDAR2B probe was observed in medium-sized neurons with chromophilic cell bodies in the upper part of the granule cell layer, most likely representing Golgi cells. Neurons in the molecular layer, i.e., basket cells and stellate cells, showed moderate hybridization signals for NMDAR1 and NMDAR2D and low signal for NMDAR2C. Each type of cerebellar neuron analyzed displayed a distinct NMDAR2 subunit profile, suggesting that they are likely to have NMDA receptors with distinct properties. (C) 1997 Academic Press. C1 UNIV FREIBURG, DEPT NEUROL, D-79106 FREIBURG, GERMANY. SIBIA NEUROSCI INC, LA JOLLA, CA 92037 USA. RP MASSACHUSETTS GEN HOSP, DEPT NEUROL, FRUIT ST, BOSTON, MA 02114 USA. OI Standaert, David/0000-0003-2921-8348 FU NIA NIH HHS [AG11337]; NIMH NIH HHS [MH/NS 31862]; NINDS NIH HHS [NS31579] NR 56 TC 19 Z9 19 U1 1 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 EI 1095-953X J9 NEUROBIOL DIS JI Neurobiol. Dis. PY 1997 VL 4 IS 1 BP 35 EP 46 DI 10.1006/nbdi.1997.0136 PG 12 WC Neurosciences SC Neurosciences & Neurology GA XR535 UT WOS:A1997XR53500004 PM 9258910 ER PT J AU Matthews, RT Beal, MF Fallon, J Fedorchak, K Huang, PL Fishman, MC Hyman, BT AF Matthews, RT Beal, MF Fallon, J Fedorchak, K Huang, PL Fishman, MC Hyman, BT TI MPP+ induced substantia nigra degeneration is attenuated in nNOS knockout mice SO NEUROBIOLOGY OF DISEASE LA English DT Article ID NITRIC-OXIDE SYNTHASE; SUPEROXIDE-DISMUTASE; TYROSINE NITRATION; PARKINSONS-DISEASE; NEUROTOXICITY; PEROXYNITRITE; INHIBITION; MPTP; ASTROCYTES; 1-METHYL-4-PHENYLPYRIDINIUM AB Recent studies showed that neuronal nitric oxide synthase (nNOS) plays a role in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. In the present study we examined the effects of striatal injection of 1-methyl-4-phenylpyridinium (MPP+) on substantia nigra degeneration in mutant mice lacking the nNOS gene or the endothelial nitric oxide synthase (eNOS) gene. Both striatal lesion volume and substantia nigra degeneration were significantly attenuated in the nNOS mutant mice but not in the eNOS mutant mice. The mice lacking nNOS showed a significant attenuation of MPP+-induced increases of 3-nitrotyrosine concentrations in the striatum. In a separate experiment administration of 7-nitroindazole for 48 h after MPP+ injections significantly attenuated substantia nigra degeneration in rats. Immunohistochemical studies showed apposition of nNOS-positive neuronal processes on tyrosine hydroxylase-positive neurons. These results provide further evidence that neuronally derived NO and peroxynitrite play a role in MPP+ neurotoxicity. (C) 1997 Academic Press. C1 HARVARD UNIV,SCH MED,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT MED,CARDIOVASC RES CTR,CHARLESTOWN,MA 02138. HARVARD UNIV,SCH MED,CHARLESTOWN,MA 02138. RP Matthews, RT (reprint author), MASSACHUSETTS GEN HOSP,NEUROL SERV,NEUROCHEM LAB,BOSTON,MA 02114, USA. FU NINDS NIH HHS [NS31579, NS16367] NR 36 TC 52 Z9 54 U1 0 U2 0 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PY 1997 VL 4 IS 2 BP 114 EP 121 DI 10.1006/nbdi.1997.0141 PG 8 WC Neurosciences SC Neurosciences & Neurology GA XZ532 UT WOS:A1997XZ53200003 PM 9331901 ER PT S AU Tondo, L Jamison, KR Baldessarini, RJ AF Tondo, L Jamison, KR Baldessarini, RJ BE Staff, DM Mann, JJ TI Effect of lithium maintenance on suicidal behavior in major mood disorders SO NEUROBIOLOGY OF SUICIDE: FROM THE BENCH TO THE CLINIC SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Suicide Research Workshops - From the Bench to the Clinic CY NOV 14-15, 1996 CL WASHINGTON, D.C. SP NIMH, Amer Suicide Fdn ID MANIC-DEPRESSIVE PATIENTS; BIPOLAR DISORDER; MORTALITY; RISK; DISCONTINUATION; PREVENTION; ILLNESS; PROPHYLAXIS; POPULATION AB We reviewed evidence of a possible antisuicide action of lithium maintenance treatment in mood disorders. Of 28 published studies involving: over 17,000 patients with major affective illnesses, most yielded supportive evidence: risk of suicides and attempts averaged 3.2 versus 0.37 per 100 patient-years without versus with lithium (8.6-fold difference). In a new study of 284 bipolar I- and II-disordered patients, corresponding rates (2.2 vs. 0.39/100 patient-years) differed by 5.6-fold (p < 0.001); moreover, after discontinuing lithium, rates of suicidal acts rose by 7-fold (16-fold within the first year), and fatalities increased by nearly 9-fold. Lithium maintenance treatment in recurring major mood disorders has strong evidence of antisuicide effects not demonstrated with any other mood stabilizer. Close association of suicide and depression in bipolar disorder emphasizes the need for improved identification and treatment of bipolar depression. C1 Univ Cagliari, Dept Psychol, Cagliari, Sardinia, Italy. Lucio Bini Mood Disorders Ctr, Cagliari, Sardinia, Italy. Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. Massachusetts Gen Hosp, Bipolar & Psychot Disorders Program, McLean Div, Belmont, MA 02178 USA. Massachusetts Gen Hosp, Psychopharmacol Program, McLean Div, Belmont, MA 02178 USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA. RP Baldessarini, RJ (reprint author), McLean Hosp, Mailman Res Ctr, 115 Mill St, Belmont, MA 02178 USA. EM rjb@mrc309.mclean.org FU NIMH NIH HHS [MH-47370] NR 56 TC 115 Z9 117 U1 0 U2 3 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-094-8 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1997 VL 836 BP 339 EP 351 DI 10.1111/j.1749-6632.1997.tb52369.x PG 13 WC Multidisciplinary Sciences; Psychiatry SC Science & Technology - Other Topics; Psychiatry GA BK30V UT WOS:000071743800018 PM 9616808 ER PT J AU Wright, MT Cummings, JL Mendez, MF Foti, DJ AF Wright, MT Cummings, JL Mendez, MF Foti, DJ TI Bipolar syndromes following brain trauma SO NEUROCASE LA English DT Article DE bipolar syndromes; traumatic brain injury; pathogenesis; differential diagnosis; treatment ID HEAD-INJURY; SECONDARY MANIA; AFFECTIVE-DISORDER; LITHIUM; LESIONS; DEPRESSION; ILLNESS; STATE AB A number of illnesses can produce mood abnormalities. Case reports suggest that syndromes resembling idiopathic bipolar disorders can follow traumatic brain injuries (TBI). We describe a TBI patient who developed episodes of depression and mania after his injuries and review the recent literature on posttraumatic bipolar syndromes. While unipolar depression is common after TBI, bipolar syndromes occur in only a small segment of the TBI population. A bipolar syndrome can appear immediately after a TBI or after a delay of months or years. Patients with post-traumatic mania are often irritable and aggressive. Factors that may predispose a TBI patient to bipolar illness include an inherited vulnerability to mood disorders, preexistent frontal subcortical and diencephalic atrophy, and post-traumatic seizures. Studies of patients who developed a bipolar syndrome after a brain insult show a preponderance of right hemisphere lesions, particularly right orbitofrontal and basotemporal cortical, caudate and thalamic lesions. Right cortical lesions can produce unipolar mania, and right subcortical lesions can produce mania and depression. Right basotemporal cortical dysfunction may play an important role in both primary and post-traumatic bipolar syndromes. Patients with post-traumatic bipolar syndromes can be treated effectively with medication or electroconvulsive therapy. C1 UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024. UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024. W LOS ANGELES VET AFFAIRS MED CTR,PSYCHIAT SERV,BEHAV NEUROSCI SECT,LOS ANGELES,CA 90073. NR 43 TC 1 Z9 1 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP SN 1355-4794 J9 NEUROCASE JI Neurocase PY 1997 VL 3 IS 2 BP 111 EP 118 DI 10.1080/13554799708404044 PG 8 WC Clinical Neurology; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA XL491 UT WOS:A1997XL49100004 ER PT J AU Mendez, MF Bagert, BA EdwardsLee, T AF Mendez, MF Bagert, BA EdwardsLee, T TI Self-injurious behavior in frontotemporal dementia SO NEUROCASE LA English DT Article ID COMPULSIVE BEHAVIOR; MENTAL-RETARDATION; DEGENERATION; MUTILATION; SEROTONIN; DOPAMINE; DISEASE AB Frontotemporal dementia (FTD) may be one of the most common neurodegenerative dementias with onset before age 65. Investigators have only recently characterized FTD, which encompasses Pick's disease as well as non-specific degeneration of the frontal lobes, Neuropsychiatric symptoms are the main features of FTD and include disinhibition, apathy, obsessive-compulsive behavior, and the Kluver-Bucy syndrome, We report a patient with FTD who developed prominent self-injurious behavior (SIB) consisting of persistent self-biting and hair-pulling, Stereotypical, repetitive SIB usually occurs in patients with autism or mental retardation; sie is rarely discussed in patients with dementia. This report extends the neuropsychiatric spectrum of FTD to encompass sie and discusses the potential mechanisms for SIB in these patients, The most likely contributing source for their self-injury is the development of obsessive-compulsive behaviors in the presence of coincident self-directed behaviors, Hyperorality from anterior temporal involvement and the release of primitive grooming behavior from frontal degeneration are self-directed behaviors that contribute to the specific manifestations of sie among FTD patients, The pharmacological management of SIB emphasizes drugs that work through opioid, serotonergic, or dopaminergic systems. C1 W LOS ANGELES VET AFFAIRS MED CTR,NEUROBEHAV UNIV 691 116AF,PSYCHIAT SERV,LOS ANGELES,CA 90073. UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024. NR 28 TC 9 Z9 9 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP SN 1355-4794 J9 NEUROCASE JI Neurocase PY 1997 VL 3 IS 4 BP 231 EP 236 PG 6 WC Clinical Neurology; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA XX984 UT WOS:A1997XX98400001 ER PT J AU Wilkinson, CW Peskind, ER Raskind, MA AF Wilkinson, CW Peskind, ER Raskind, MA TI Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging SO NEUROENDOCRINOLOGY LA English DT Article DE adrenal steroids; corticotropin; feedback; metyrapone; aging; clinical neuroendocrinology ID DEXAMETHASONE SUPPRESSION TEST; CORTICOSTEROID RECEPTORS; ADRENOCORTICAL AXIS; BINDING GLOBULIN; RAT-BRAIN; AGE; ACTH; HYPERSECRETION; HIPPOCAMPUS; RESISTANCE AB Aging-related reduction in the sensitivity of the hypothalamic-pituitary-adrenal (HPA) axis to glucocorticoid feedback inhibition has been demonstrated in rodents, but aging effects on glucocorticoid feedback inhibition in humans are unclear. This study assessed the influence of aging on the sensitivity of the human HPA axis to feedback inhibition induced by cortisol. Endogenous cortisol feedback inhibition was removed by treatment with metyrapone, which reduces cortisol synthesis by inhibiting 11 beta-hydroxylase. Feedback inhibition was then reintroduced by infusing exogenous cortisol. Sixteen young (26 +/- 1 years old) and 16 older (70 +/- 2 years old) subjects underwent three study conditions in random order. In the two cortisol infusion conditions, oral metyrapone treatment was followed by intravenous infusion of 0.03 mg/kg/h (83 nmol/kg/h) or 0.06 mg/kg/h (166 nmol/kg/h) cortisol for 150 min. Feedback sensitivity was estimated by the latency to and extent of decline of plasma ACTH concentration during and following the cortisol infusion. In a placebo condition, placebo tablets were substituted for metyrapone and normal saline infusion was substituted for cortisol. Blood samples were drawn twice prior to and at 15-min intervals for 4 h following the onset of the infusions, and plasma was assayed for 11-deoxycortisol, cortisol and ACTH. Plasma cortisol suppression and ACTH and 11-deoxycortisol elevations did not differ between age groups after metyrapone. Older subjects exhibited delayed and blunted ACTH responses to infused cortisol. Within older subjects, the ACTH response to the higher dose cortisol infusion was blunted in older women compared to older men. These data provide direct evidence for reduced responsiveness to glucocorticoid feedback inhibition in human aging. C1 VA PUGET SOUND HLTH CARE SYST,PSYCHIAT SERV 116A,SEATTLE,WA 98108. VA PUGET SOUND HLTH CARE SYST,CTR GERIATR RES EDUC & CLIN,SEATTLE,WA 98108. UNIV WASHINGTON,SCH MED,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195. FU NIA NIH HHS [AG08419, AG05136] NR 36 TC 119 Z9 122 U1 0 U2 6 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PD JAN PY 1997 VL 65 IS 1 BP 79 EP 90 DI 10.1159/000127167 PG 12 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA WE621 UT WOS:A1997WE62100010 PM 9032777 ER PT J AU Litvan, I Agid, Y Goetz, C Jankovic, J Wenning, GK Brandel, JP Lai, EC Verny, M RayChaudhuri, K McKee, A Jellinger, K Pearce, RKB Bartko, JJ AF Litvan, I Agid, Y Goetz, C Jankovic, J Wenning, GK Brandel, JP Lai, EC Verny, M RayChaudhuri, K McKee, A Jellinger, K Pearce, RKB Bartko, JJ TI Accuracy of the clinical diagnosis of corticobasal degeneration: A clinicopathologic study SO NEUROLOGY LA English DT Article; Proceedings Paper CT Movement Disorder Society Symposium on Cortical-Basal Ganglionic Degeneration(CBGD) and Its Relationship to Other Asymmetrical Cortical Degeneration Syndromes(ACDs) CY OCT, 1995 CL WASHINGTON, DC SP Movement Disorder Soc ID PROGRESSIVE SUPRANUCLEAR PALSY; BASAL GANGLIONIC DEGENERATION; MULTIPLE SYSTEM ATROPHY; NEURONAL ACHROMASIA; NATURAL-HISTORY; CORTICONIGRAL DEGENERATION; NEUROFIBRILLARY TANGLES; PARKINSONS-DISEASE; KAPPA-COEFFICIENT; CATEGORICAL-DATA AB The accuracy of the clinical diagnosis of corticobasal degeneration (CBD) is unknown. To determine its diagnostic accuracy, we presented 105 cases with known neuropathologic diagnoses, including CBD (n = 10), progressive supranuclear palsy (PSP, n = 24), Parkinson's disease (n = 15), diffuse Lewy body disease (n = 14), multiple system atrophy (n = 16), postencephalitic parkinsonism (n = 7), Pick's disease (n = 7), Creutzfeldt-Jacob disease (n = 4), Alzheimer's disease (n = 4), vascular parkinsonism (n = 3), and Whipple's disease (n = 1), as clinical vignettes to six neurologists unaware of the autopsy findings. Reliability was measured with the kappa statistics. The neurologists' clinical diagnoses were compared with clinicopathologic diagnoses for sensitivity, specificity, and positive predictive values at first and last clinic visits. The group reliability for the diagnosis of CBD significantly improved from moderate for the first visit (mean = 34 months after onset) to substantial for the last (68 months after onset). For the first visit, mean sensitivity for CBD was low (35%), but specificity was near-perfect (99.6%). For the last visit, mean sensitivity minimally increased (48.3%), and specificity remained stable. False-negative misdiagnoses mainly occurred with PSP. False-positive diagnoses were rare. The extremely low sensitivity of the clinical diagnosis of CBD suggests that this disorder is markedly underdiagnosed. Although the validity of the clinical diagnosis might have been improved if neurologists could have examined these patients, more important is that this disorder was misdiagnosed by the primary neurologists. In our data set, the best predictors for the diagnosis of CBD included limb dystonia, ideomotor apraxia, myoclonus, and asymmetric akinetic-rigid syndrome with late onset of gait or balance disturbances. C1 HOP LA PITIE SALPETRIERE,FED NEUROL,PARIS,FRANCE. HOP LA PITIE SALPETRIERE,INSERM,U289,PARIS,FRANCE. RUSH MED COLL,DEPT NEUROL,CHICAGO,IL 60612. BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030. NEUROL INST,PARKINSONS DIS SOC BRAIN TISSUE BANK,LONDON,ENGLAND. INST PSYCHIAT,DEPT NEUROL,LONDON SE5 8AF,ENGLAND. HOP LA PITIE SALPETRIERE,RAYMOND ESCOUROLLE NEUROPATHOL LAB,INSERM,U360,PARIS,FRANCE. MASSACHUSETTS GEN HOSP,DEPT NEUROPATHOL,BOSTON,MA 02114. LAINZ HOSP,LUDWIG BOLTZMANN INST CLIN NEUROBIOL,A-1130 VIENNA,AUSTRIA. NIMH,DIV EPIDEMIOL & RES STUDIES,BETHESDA,MD 20892. RP Litvan, I (reprint author), NINCDS,NEUROEPIDEMIOL BRANCH,NIH,FED BLDG,ROOM 714,BETHESDA,MD 20892, USA. OI Litvan, Irene/0000-0002-3485-3445; Ray Chaudhuri, K/0000-0003-2815-0505 NR 73 TC 282 Z9 286 U1 0 U2 4 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN PY 1997 VL 48 IS 1 BP 119 EP 125 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA WC676 UT WOS:A1997WC67600024 PM 9008506 ER PT J AU Blacker, D Haines, JL Rodes, L Terwedow, H Go, RCP Harrell, LE Perry, RT Bassett, SS Chase, G Meyers, D Albert, MS Tanzi, R AF Blacker, D Haines, JL Rodes, L Terwedow, H Go, RCP Harrell, LE Perry, RT Bassett, SS Chase, G Meyers, D Albert, MS Tanzi, R TI ApoE-4 and age at onset of Alzheimer's disease: The NIMH genetics initiative SO NEUROLOGY LA English DT Article ID APOLIPOPROTEIN-E POLYMORPHISM; EPSILON-4 ALLELE; RISK; ASSOCIATION; POPULATION; FREQUENCY; DIAGNOSIS; LONGEVITY; RELATIVES AB Objective: To explore the impact of apoE-4 on Alzheimer's disease (AD) and its age at onset. Design: A genetic linkage study using affected relative pairs, predominantly siblings. Setting: Three academic medical centers ascertained subjects from memory disorder clinics, nursing homes, and the local community. Subjects: 310 families including 679 subjects with AD by NINCDS/ADRDA and/or Khachaturian criteria and 231 unaffected subjects. Outcome measure: ApoE genotype. Analytic methods: Association, affected pedigree member, sibling pair, and lod score analyses. Results: ApoE-4 was strongly associated with AD in this sample (allele frequency = 0.46 vs. 0.14 in controls, p < 0.000001). Results of lod score, affected pedigree member analysis, and sib-pair analysis also supported apoE-4 as a risk factor for AD. When the sample was stratified on family mean age at onset, the risk conferred by apoE-4 was most marked in the 61 to 65 age group. Individuals with two copies of apoE-4 had a significantly lower age at onset than those with one or no copies (66.4 vs. 72.0, p < 0.001), but individuals with one copy did not differ from those with none. Within families, the individual with the earliest age at onset had, on average, significantly more apoE-4 alleles (p < 0.0001) than the individual with the latest onset. Discussion: This work supports previous reports of an association between apoE-4 and the development of AD and demonstrates that apoE-4 exerts its maximal effect before age 70. These findings have important implications for the potential use of apoE genotyping for diagnosis and prediction of disease. They also underscore the need to identify additional genetic factors involved in AD with onset beyond age 70 years. C1 MASSACHUSETTS GEN HOSP,CHARLESTOWN,MA 02129. HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138. UNIV ALABAMA,SCH MED,BIRMINGHAM,AL. JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD. RI Haines, Jonathan/C-3374-2012 FU NIMH NIH HHS [K21 MH01118, U01 MH46281, U01 MH51066] NR 45 TC 324 Z9 331 U1 2 U2 14 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN PY 1997 VL 48 IS 1 BP 139 EP 147 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA WC676 UT WOS:A1997WC67600027 PM 9008509 ER PT J AU Nachmanoff, DB Segal, RA Dawson, DM Brown, RB DeGirolani, U AF Nachmanoff, DB Segal, RA Dawson, DM Brown, RB DeGirolani, U TI Hereditary ataxia with sensory neuronopathy: Biemond's ataxia SO NEUROLOGY LA English DT Article ID MACHADO-JOSEPH DISEASE; SPINOCEREBELLAR ATAXIA; CEREBELLAR-ATAXIA AB We report the case of a man with late-onset hereditary ataxia and sensory loss. Three of his sisters were affected by a similar disorder; to date no other members of his family have developed symptoms. The clinical features of this family are similar to a rare form of autosomal dominant hereditary ataxia, recently classified as SCA4. Postmortem findings indicate that this syndrome is marked by degeneration of cerebellar Purkinje cells, dorsal root sensory ganglion neurons, and the ascending posterior columns. Similar clinical and pathologic findings were reported by Biemond in 1954. C1 BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV NEUROPATHOL,BOSTON,MA 02115. BRIGHAM & WOMENS HOSP,DEPT NEUROL,BOSTON,MA 02115. BETH ISRAEL HOSP,DEPT NEUROL,BOSTON,MA 02215. BROCKTON W ROXBURY VET AFFAIRS MED CTR,BOSTON,MA. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. NR 8 TC 22 Z9 23 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN PY 1997 VL 48 IS 1 BP 273 EP 275 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA WC676 UT WOS:A1997WC67600052 PM 9008534 ER PT J AU Preston, DC Shapiro, BE AF Preston, DC Shapiro, BE TI Meeting badge neuropathy SO NEUROLOGY LA English DT Article C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,BOSTON,MA. RP Preston, DC (reprint author), BRIGHAM & WOMENS HOSP,DIV NEUROL,75 FRANCIS ST,BOSTON,MA 02115, USA. NR 3 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN PY 1997 VL 48 IS 1 BP 289 EP 290 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA WC676 UT WOS:A1997WC67600060 PM 9008542 ER PT J AU Fouad, G Dalakas, M Servidei, S Mendell, JR VandenBergh, P Angelini, C Alderson, K Griggs, RC Tawil, R Gregg, R Hogan, K Powers, PA Weinberg, N Malonee, W Ptacek, LJ AF Fouad, G Dalakas, M Servidei, S Mendell, JR VandenBergh, P Angelini, C Alderson, K Griggs, RC Tawil, R Gregg, R Hogan, K Powers, PA Weinberg, N Malonee, W Ptacek, LJ TI Genotype-phenotype correlations of DHP receptor alpha(1)-subunit gene mutations causing hypokalemic periodic paralysis SO NEUROMUSCULAR DISORDERS LA English DT Article DE hypokalemic periodic paralysis; muscle weakness; mutation ID PARAMYOTONIA-CONGENITA; CALCIUM; FAMILIES; HYPOPP AB Hypokalemic periodic paralysis (hypoKPP) is an autosomal dominant or sporadic disorder characterized by periodic, reversible attacks of muscle weakness. Mutations in the skeletal muscle dihydropyridine receptor alpha(1)-subunit that functions as a calcium channel (CACNLIA3) cause hypoKPP. We studied a group of 45 hypoKPP probands and demonstrated mutations in 30 of them. When compared with patients in whom CACNL1A3 mutations were not identified, those with mutations had an earlier age of onset and more often had a family history of hypoKPP. To date, three mutations have been identified. The R1239G mutation has only been found in one family. Of the 30 probands with recognized mutations, R528H accounted for 43% and R1239H was seen in 53%. Age of onset and potassium levels during attacks were lower in patients with the R1239H mutation than those with R528H. Cardiac dysrhythmias co-segregated with hypoKPP in one small kindred with the R528 H mutation. No mutations were identified in exons of the gene encoding the S4 segments of domains one and three or the cytoplasmic loop between domains two and three. In addition to the 45 hypoKPP probands, an additional 11 probands with clinical variants of hypoKPP (three thyrotoxic hypoKPP and eight Andersen syndrome patients) were examined for CACNLIA3 mutations and none were found. (C) 1997 Elsevier Science B.V. C1 UNIV UTAH,DEPT NEUROL,SALT LAKE CITY,UT 84112. UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112. UNIV UTAH,PROGRAM HUMAN MOL BIOL & GENET,SALT LAKE CITY,UT 84112. NINCDS,NIH,BETHESDA,MD 20892. UNIV CATTOLICA SACRO CUORE,FAC MED & CHIRURG AGOSTINO GEMELLI,ROME,ITALY. OHIO STATE UNIV,DEPT NEUROL,COLUMBUS,OH 43210. UNIV BRUSSELS,CLIN ST LUC,SERV NEUROL,BRUSSELS,BELGIUM. UNIV PADUA,PADUA,ITALY. NEUROMUSCULAR ASSOCIATES INC,SALT LAKE CITY,UT 84112. UNIV ROCHESTER,MED CTR,NEUROMUSCULAR DIS CTR,ROCHESTER,NY 14642. UNIV WISCONSIN,WAISMAN CTR MENTAL RETARDAT & HUMAN DEV,MADISON,WI 53706. UNIV WISCONSIN,WILLIAM S MIDDLETON MEM VET HOSP,MADISON,WI 53706. UNIV WISCONSIN,DEPT ANESTHESIOL,MADISON,WI 53706. PEDIAT HLTH CARE ASSOCIATES,YPSILANTI,MI 48197. HUTCHINSON CLIN,HUTCHINSON,KS. OI Angelini, Corrado/0000-0002-9554-8794 FU NCRR NIH HHS [M01-RR00064]; NHGRI NIH HHS [8 R01 HG00367]; NICHD NIH HHS [HD00940]; Telethon [0916C] NR 20 TC 69 Z9 73 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0960-8966 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD JAN PY 1997 VL 7 IS 1 BP 33 EP 38 DI 10.1016/S0960-8966(96)00401-4 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA WN036 UT WOS:A1997WN03600006 PM 9132138 ER PT J AU Chae, T Kwon, YT Bronson, R Dikkes, P Li, E Tsai, LH AF Chae, T Kwon, YT Bronson, R Dikkes, P Li, E Tsai, LH TI Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality SO NEURON LA English DT Article ID CYCLIN-DEPENDENT KINASE-5; CENTRAL NERVOUS-SYSTEM; CDC2-LIKE KINASE; PROTEIN-KINASE; REELER MICE; MOUSE; EXPRESSION; BRAIN; ORGANIZATION; DISRUPTION AB The adult mammalian cortex is characterized by a distinct laminar structure generated through a well-defined pattern of neuronal migration. Successively generated neurons are layered in an ''inside-out'' manner to produce six cortical laminae. We demonstrate here that p35, the neuronal-specific activator of cyclin-dependent kinase 5, plays a key role in proper neuronal migration. Mice lacking p35, and thus p35/cdk5 kinase activity, display severe cortical lamination defects and suffer from sporadic adult lethality and seizures. Histological examination reveals that the mutant mice lack the characteristic laminated structure of the cortex. Neuronal birth-dating experiments indicate a reversed packing order of cortical neurons such that earlier born neurons reside in superficial layers and later generated neurons occupy deep layers. The phenotype of p35 mutant mice thus demonstrates that the formation of cortical laminar structure depends on the action of the p35/cdk5 kinase. C1 TUFTS UNIV,USDA,HUMAN NUTR RES CTR AGING,SCH VET MED,BOSTON,MA 02111. TUFTS UNIV,SCH VET MED,DEPT PATHOL,BOSTON,MA 02111. CHILDRENS HOSP,DEPT NEUROL,DIV NEUROL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT MED,MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129. RP Chae, T (reprint author), HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115, USA. FU NICHD NIH HHS [P30-HD18655]; NIGMS NIH HHS [GM52106, GM53049] NR 39 TC 574 Z9 592 U1 2 U2 9 PU CELL PRESS PI CAMBRIDGE PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA SN 0896-6273 J9 NEURON JI Neuron PD JAN PY 1997 VL 18 IS 1 BP 29 EP 42 DI 10.1016/S0896-6273(01)80044-1 PG 14 WC Neurosciences SC Neurosciences & Neurology GA WE718 UT WOS:A1997WE71800006 PM 9010203 ER PT J AU Yu, XJ Cutrer, FM Moskowitz, MA Waeber, C AF Yu, XJ Cutrer, FM Moskowitz, MA Waeber, C TI The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater SO NEUROPHARMACOLOGY LA English DT Article DE sumatriptan; CP-122,288; 5-carboxamidotryptamine; GR-127,935; migraine; 5-HT1B/1D receptor; neurogenic inflammation; dura mater ID RECOMBINANT HUMAN 5-HT1D-ALPHA; CLONED HUMAN 5-HT1D-ALPHA; BLOOD-VESSELS; ANTIMIGRAINE DRUG; BINDING-SITES; AGONIST; RAT; BRAIN; KETANSERIN; SEROTONIN AB The aim of this study was to examine whether GR-127,935, a 5-HT1B/1D receptor antagonist, blocks the inhibitory effects of sumatriptan, CP-122,288 and 5-carboxamidotryptamine (5-CT) on plasma protein extravasation, within guinea pig and rat dura mater, following electric stimulation of the trigeminal ganglion. Binding studies first established that GR-127,935 shows a 500-fold selectivity for 5-HT1D binding sites (labeled by [H-3]L-694,247) versus 5-HTIF binding sites (labeled by [3H]sumatriptan in the presence of 50 nM 5-carboxamidotryptamine) in guinea pig forebrain homogenates (pK(D) +/- SD = 7.0 +/- 0.2 at 5-HT1F sites and 9.7 +/- 0.1 at 5-HT1D sites). In guinea pigs, GR-127,935 showed partial agonist activity and inhibited dural plasma protein extravasation. Increasing doses of GR-127,935 reversed the effect of sumatriptan, but did not affect the action of 5-CT and CP-122,288 (at a dose as high as 2 mu mol/kg). Sumatriptan, CP 122,288 and 5-CT dose-responsively inhibited plasma protein extravasation. Ata dose of 2 mu mol/kg (but not at 0.2 mu mol/kg), GR-127,935 right-shifted the dose-response curve of sumatriptan. No significant rightward shift was observed in the dose-response of CP-122,288 and 5-CT. In rats, GR-127,935 did not show any significant partial agonist activity. A dose of 0.2 mu mol/kg was sufficient to right-shift the dose-response curve of sumatriptan. These data suggest that sumatriptan inhibits neurogenic inflammation via 5-HT1D alpha receptors in guinea pigs and 5-HT1D beta (5-HT1B) receptors in rats. Additional receptor subtypes are likely to be involved in the inhibition of plasma extravasation by CP-122,288 and 5-CT. Pertussis toxin reduced the inhibitory effects of both sumatriptan and 5-CT, but not of muscimol, known to act at GABA(A) receptors. These results suggest that 5-CT, as well as sumatriptan, act at a receptor linked to an inhibitory G-protein. (C) 1997 Elsevier Science Ltd. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CHARLESTOWN,MA 02129. RI Moskowitz, Michael/D-9916-2011; Waeber, Christian/A-8333-2009 OI Waeber, Christian/0000-0001-6078-0027 FU NINDS NIH HHS [1PO 1NS35611-01, K08 NS 01803] NR 39 TC 30 Z9 31 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0028-3908 J9 NEUROPHARMACOLOGY JI Neuropharmacology PD JAN PY 1997 VL 36 IS 1 BP 83 EP 91 DI 10.1016/S0028-3908(96)00149-9 PG 9 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA WN039 UT WOS:A1997WN03900009 PM 9144644 ER PT S AU Dalkara, T Moskowitz, MA AF Dalkara, T Moskowitz, MA BE Green, AR Cross, AJ TI Neurotoxic and neuroprotective roles of nitric oxide in cerebral ischaemia SO NEUROPROTECTIVE AGENTS AND CEREBRAL ISCHAEMIA SE International Review of Neurobiology LA English DT Review ID AORTIC ENDOTHELIAL-CELLS; VASCULAR SMOOTH-MUSCLE; PROTEIN-KINASE-C; L-ARGININE; NADPH-DIAPHORASE; BLOOD-FLOW; MESSENGER-RNA; RAT-BRAIN; DEPENDENT VASODILATION; SELECTIVE-INHIBITION C1 MASSACHUSETTS GEN HOSP, NEUROSURG SERV, CHARLESTOWN, MA 02129 USA. HARVARD UNIV, SCH MED, CHARLESTOWN, MA 02129 USA. HACETTEPE UNIV, DEPT NEUROL, TR-06100 ANKARA, TURKEY. RP Dalkara, T (reprint author), MASSACHUSETTS GEN HOSP, DEPT NEUROL, STROKE & NEUROVASC REGULAT LAB, 149 13TH ST, CNY 6403, CHARLESTOWN, MA 02129 USA. RI Moskowitz, Michael/D-9916-2011 FU NINDS NIH HHS [NS 10828, NS 26361] NR 131 TC 31 Z9 35 U1 0 U2 2 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0074-7742 BN 0-12-197880-X J9 INT REV NEUROBIOL JI Int. Rev. Neurobiol. PY 1997 VL 40 BP 319 EP 336 PG 18 WC Neurosciences SC Neurosciences & Neurology GA BH11D UT WOS:A1997BH11D00014 PM 8989627 ER PT J AU Beal, MF AF Beal, MF TI Oxidative damage in neurodegenerative diseases SO NEUROSCIENTIST LA English DT Review DE free radicals; peroxynitrite; Alzheimer's; Parkinson's; Huntington's; amyotrophic lateral sclerosis ID AMYOTROPHIC-LATERAL-SCLEROSIS; SUPEROXIDE-DISMUTASE ACTIVITY; NADH-UBIQUINONE REDUCTASE; NITRIC-OXIDE SYNTHASE; ALZHEIMERS-DISEASE; TRANSGENIC MICE; HYDROGEN-PEROXIDE; HEME OXYGENASE-1; NEUROFIBRILLARY PATHOLOGY; HEART-MITOCHONDRIA AB Increasing evidence has implicated oxidative damage in the pathogenesis of neurodegenerative diseases, The major source of free radicals in the cell is the mitochondria. Peroxynitrite is formed by the reaction of superoxide with nitric oxide, and it produces both oxidative damage and protein nitration. Mutations in CuZn superoxide dismutase associated with familial ALS may result in increased (-OH) radical generation or in increased reactivity with peroxynitrite to nitrate proteins. There is evidence for increased oxidative damage in Alzheimer's disease and Parkinson's disease in neurons undergoing neurodegenerative changes. A role for oxidative damage in Parkinson's disease toxicity and in Huntington's disease is supported by studies in animal models. Improved antioxidant therapies may prove useful in slowing or halting the progression of neurodegenerative diseases. C1 MASSACHUSETTS GEN HOSP,NEUROL SERV,BOSTON,MA 02114. NR 65 TC 46 Z9 49 U1 0 U2 1 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 1073-8584 J9 NEUROSCIENTIST JI Neuroscientist PD JAN PY 1997 VL 3 IS 1 BP 21 EP 27 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA WC678 UT WOS:A1997WC67800012 ER PT J AU Barker, FG Jannetta, PJ Bissonette, DJ Jho, HD AF Barker, FG Jannetta, PJ Bissonette, DJ Jho, HD TI Trigeminal numbness and tic relief after microvascular decompression for typical trigeminal neuralgia SO NEUROSURGERY LA English DT Article ID RETROGASSERIAN GLYCEROL RHIZOTOMY; LOCALLY WEIGHTED REGRESSION; CANCER CLINICAL-TRIALS; PERCUTANEOUS MICROCOMPRESSION; SMOOTHING SCATTERPLOTS; CONSECUTIVE PATIENTS; GASSERIAN GANGLION; FOLLOW-UP; SURVIVAL; RHIZOLYSIS AB OBJECTIVE: After most operative treatments for trigeminal neuralgia, long-term tic relief is closely correlated with postoperative numbness in the trigeminal distribution. Microvascular decompression (MVD) is proposed to relieve tic through a nontraumatic mechanism. We investigated the relationship between postoperative trigeminal numbness and tic relief in a large, prospectively followed cohort of patients treated with MVD for typical trigeminal neuralgia. METHODS: Of 1204 patients who underwent MVD for typical tic during a 20-year period, 522 had single MVDs on a single side, had not undergone ablative trigeminal procedures before or after MVD, and were still being followed in 1994. In 1994, patients graded facial numbness using a questionnaire (response rate, 92%) with a 5-point scale. Multivariate Cox and logistic regression methods were used. The analyses were adjusted for the time that had passed between the performance of MVD and the completion of the questionnaire (minimum, 2 yr). RESULTS: Seventeen percent of patients reported some degree of persistent facial numbness. Decompression of a vein at MVD (odds ratio, 2.5) and failure to find compression by the superior cerebellar artery (odds ratio, 2.0) independently predicted postoperative facial numbness, which in turn predicted postoperative burning and aching facial pain (odds ratio, 5.2-5.9). A trend toward worse outcome was noted in patients with numb faces (P = 0.3). Similar findings were noted in subgroups of patients in whom the superior cerebellar artery was decompressed at MVD (n = 381) and in whom a superior cerebellar artery with no vein was found (n = 120). In the latter subgroup, facial numbness (5.8% of patients) significantly predicted worse long-term outcome (P = 0.03). CONCLUSION: We found no evidence that postoperative trigeminal numbness predicts relief of typical tic after MVD. Trigeminal numbness was related to operative findings at MVD and predicted postoperative burning and aching facial pain. To minimize postoperative facial dysesthesia, trauma to the trigeminal root during MVD should be avoided when possible. C1 UNIV PITTSBURGH,DEPT NEUROL SURG,PITTSBURGH,PA 15260. RP Barker, FG (reprint author), MASSACHUSETTS GEN HOSP,NEUROSURG SERV,32 FRUIT ST,BOSTON,MA 02114, USA. NR 35 TC 53 Z9 54 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0148-396X J9 NEUROSURGERY JI Neurosurgery PD JAN PY 1997 VL 40 IS 1 BP 39 EP 45 DI 10.1097/00006123-199701000-00008 PG 7 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA VY973 UT WOS:A1997VY97300020 PM 8971822 ER PT J AU Spangler, WJ Cosgrove, GR Moumdjian, RA Montes, LL AF Spangler, WJ Cosgrove, GR Moumdjian, RA Montes, LL TI Cerebral arterial ectasia and tuberous sclerosis: Case report SO NEUROSURGERY LA English DT Article DE arterial ectasia; cerebral aneurysm; childhood; tuberous sclerosis ID POLYCYSTIC KIDNEY-DISEASE; INTRACRANIAL ANEURYSMS; NEURORADIOLOGY; CHILDREN AB OBJECTIVE AND IMPORTANCE: Tuberous sclerosis is associated with a wide variety of central nervous system abnormalities. Cerebrovascular anomalies are extremely rare, but a case of cerebral arterial ectasia and giant fusiform aneurysm formation in a young child is reported. CLINICAL PRESENTATION: A 5-month-old male patient with tuberous sclerosis presented with seizures, a subependymal tumor, and intraventricular hemorrhage. Cerebral angiography demonstrated a large fusiform aneurysm of the left cavernous internal carotid artery as well as arterial ectasia of the proximal left anterior cerebral and middle cerebral arteries. The patient developed hydrocephalus and died of infectious complications after repeated shunt procedures. CONCLUSION: Tuberous sclerosis is commonly associated with central nervous system lesions. Although rare, cerebrovascular anomalies and aneurysms should be considered in the differential diagnosis of mass lesions to avoid an ill-advised biopsy of a vascular lesion, which could have disastrous consequences. C1 HARVARD UNIV, MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROSURG, NEUROSURG SERV, BOSTON, MA 02114 USA. MONTREAL CHILDRENS HOSP, DEPT NEUROSURG, MONTREAL, PQ H3H 1P3, CANADA. MCGILL UNIV, MONTREAL, PQ, CANADA. NR 28 TC 12 Z9 12 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-396X J9 NEUROSURGERY JI Neurosurgery PD JAN PY 1997 VL 40 IS 1 BP 191 EP 193 DI 10.1097/00006123-199701000-00042 PG 3 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA VY973 UT WOS:A1997VY97300093 PM 8971842 ER PT J AU Catalano, PJ McDaniel, KL Moser, VC AF Catalano, PJ McDaniel, KL Moser, VC TI The IPCS Collaborative Study on Neurobehavioral Screening Methods: VI. Agreement and reliability of the data SO NEUROTOXICOLOGY LA English DT Article DE functional observational battery; motor activity; reliability estimates; percent agreement AB The IPCS Collaborative Study on Neurobehavioral Screening Methods was undertaken to determine the intra-and inter-laboratory reliability of a functional observational battery (FOB) and an automated assessment of motor activity in eight laboratories world-wide. The effects of seven chemicals (acrylamide, bis-acrylamide, p,p'-DDT, lead acetate, parathion, toluene, and triethyl tin) were studied during two dosing regimens: single-dose and four-week repeated dosing. All participating laboratories generally could detect and characterize the effects of known neurotoxicants, even though there were some differences in outcome on specific endpoints. The results were further evaluated to assess the agreement across laboratories in the dose-response data at the expected times of maximal effect (time of peak effect for the single-dose studies, and during or at the end of dosing for repeated-exposure studies). Percent agreement was calculated as the percentage of laboratories agreeing on an outcome (whether it be a significant dose effect or not). As an alternative approach, slopes of the dose-response functions were calculated, and reliability of those slope estimates across laboratories and chemicals was determined. Reliability was defined as the degree of agreement across laboratories (intra-class correlation coefficient) of the dose-response slopes within and between chemicals. These reliability estimates were calculated for each domain and for each endpoint. Relative reliability of the endpoints was evaluated, and hypotheses concerning the influence of outlying data were tested. The data clearly showed that reliability was not influenced by the objectivity or subjectivity of the test measure. Thus these data provide additional information regarding the reliability and robustness of the tests across the participating laboratories. (C) 1997 Intox Press, Inc. C1 US EPA, NTD, Div Neurotoxicol, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA. Dana Farber Canc Inst, Div Biostat, Boston, MA 02115 USA. RP Moser, VC (reprint author), US EPA, NTD, Div Neurotoxicol, Natl Hlth & Environm Effects Res Lab, MD-74B, Res Triangle Pk, NC 27711 USA. NR 7 TC 11 Z9 13 U1 1 U2 2 PU INTOX PRESS INC PI LITTLE ROCK PA PO BOX 24865, LITTLE ROCK, AR 72221 USA SN 0161-813X J9 NEUROTOXICOLOGY JI Neurotoxicology PY 1997 VL 18 IS 4 BP 1057 EP 1064 PG 8 WC Neurosciences; Pharmacology & Pharmacy; Toxicology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology GA YT265 UT WOS:000071582400007 PM 9457734 ER PT S AU Fischman, AJ Babich, JW AF Fischman, AJ Babich, JW BE Freeman, LM TI Radiolabeled peptides: A new class of imaging agents SO NUCLEAR MEDICINE ANNUAL, 1997 SE NUCLEAR MEDICINE ANNUAL LA English DT Review ID VASOACTIVE-INTESTINAL-PEPTIDE; SINGLE-CHAIN-FV; ATRIAL NATRIURETIC FACTOR; RADIOIODINATED SOMATOSTATIN ANALOG; POSITRON EMISSION TOMOGRAPHY; ACUTE BACTERIAL-INFECTION; RECEPTOR-POSITIVE TUMORS; WATERY-DIARRHEA SYNDROME; PLATELET FACTOR 4; MONOCLONAL-ANTIBODIES RP Fischman, AJ (reprint author), HARVARD UNIV, MASSACHUSETTS GEN HOSP,SCH MED,DEPT RADIOL, DIV NUCL MED, 32 FRUIT ST, BOSTON, MA 02114 USA. NR 131 TC 3 Z9 3 U1 2 U2 3 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA E WASHINGTON SQ, PHILADELPHIA, PA 19105 USA SN 0272-0108 BN 0-397-58464-4 J9 NUCL MED A PY 1997 BP 103 EP 131 PG 29 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA BJ11V UT WOS:A1997BJ11V00005 ER PT J AU Martinez, E Moore, DD Keller, E Pearce, D Robinson, V MacDonald, PN Simons, SS Sanchez, E Danielsen, M AF Martinez, E Moore, DD Keller, E Pearce, D Robinson, V MacDonald, PN Simons, SS Sanchez, E Danielsen, M TI The Nuclear Receptor Resource project SO NUCLEIC ACIDS RESEARCH LA English DT Article AB We have expanded the original Glucocorticoid Receptor Resource (GRR) database to include several individual resources as part of a larger project called the Nuclear Receptor Resource (NRR), In addition to the GRR, the NRR currently features the Thyroid Hormone Receptor Resource, the Androgen Receptor Resource, the Mineralocorticoid Receptor Resource, the Vitamin D Receptor Resource, and the Steroid Receptor Associated Proteins Resource, The goal of the NRR project is to provide a comprehensive resource for information on the nuclear receptor superfamily, and to provide a forum for the dissemination and discussion of both published and unpublished material on these proteins, Although the individual resources are managed from different servers, all the files are integrated and can be accessed through the project's Home Page, housed at http://nrr.georgetown.edu/nrr.html. In the near future, we hope to expand the project to contain information on other nuclear receptors and to better our electronic publication system, To accomplish this, we encourage the involvement of nuclear receptor investigators in the NRR. C1 GEORGETOWN UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20007. HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT MOL BIOL & GENET,BOSTON,MA 02114. EASTERN VIRGINIA MED SCH,GLENNAN CTR,NORFOLK,VA 23507. UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94110. ST LOUIS UNIV,HLTH SCI CTR,DEPT PHARMACOL & PHYSIOL SCI,ST LOUIS,MO 63104. NIDDK,STEROID HORMONES SECT,NIH,BETHESDA,MD 20892. MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699. RI Danielsen, Mark/B-1606-2008 OI Danielsen, Mark/0000-0002-0923-9945 FU NIDDK NIH HHS [R01 DK43382]; PHS HHS [K04 02105] NR 0 TC 8 Z9 8 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP SN 0305-1048 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD JAN 1 PY 1997 VL 25 IS 1 BP 163 EP 165 DI 10.1093/nar/25.1.163 PG 3 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA WD443 UT WOS:A1997WD44300039 PM 9016529 ER PT S AU Zielstorff, RD Barnett, GO Estey, G Hamilton, G Vickery, A Welebob, E Fitzmaurice, JB Shahzad, C AF Zielstorff, RD Barnett, GO Estey, G Hamilton, G Vickery, A Welebob, E Fitzmaurice, JB Shahzad, C BE Gerdin, U Tallberg, M Wainwright, P TI A knowledge-based decision support system for prevention and treatment of pressure ulcers SO NURSING INFORMATICS: THE IMPACT OF NURSING KNOWLEDGE ON HEALTH CARE INFORMATICS SE STUDIES IN HEALTH TECHNOLOGY AND INFORMATICS LA English DT Proceedings Paper CT 6th Triennial International Congress of IMIA-NI on Nursing Informatics - The Impact of Nursing Knowledge on Health Care Informatics (NI 97) CY 1997 CL STOCKHOLM, SWEDEN SP Int Med Informat Assoc, Special Interest Grp Nursing Informat, No Nurses Federat, Swedish Nurses Assoc, Swedish Assoc Hlth Officers, Swedish Federat Cty Council, Stockholm Univ Coll Hlth Sci, Swedish Inst Hlth Serv Dev, S Stockholm Hlth Care Dist AB As part of a research project intended to provide problem-based knowledge to clinicians at the point of care, we have developed a system that supports the nurse's development of patient-specific guideline-based treatment plans for patients who have pressure ulcers or are at risk for developing them The system captures coded data about assessment, diagnosis and interventions using a point-and-click interface. Knowledge is accessible to the user vial I) hypertext links from the data entry screens;a) explicit entry into an indexed version of the guideline; 3) imbedded knowledge-based rules that critique the diagnosis and offer guidance for treatment; and 4) explicit entry into interactive algorithms The system has been implemented experimentally on one care unit at our hospital, where its impact will be assessed in comparison with a control unit. Data on 113 patients were entered during the al-week experimental period The system is being evaluated for its instructional adequacy, its impact on clinicians' decision-making and knowledge, and on processes of care. Users' perceptions of the system are also being evaluated. Dissemination issues in the context of today's health care environment are addressed. RP Zielstorff, RD (reprint author), MASSACHUSETTS GEN HOSP,COMP SCI LAB,BOSTON,MA 02114, USA. FU AHRQ HHS [5 R18 HS06575]; NLM NIH HHS [1 T15 LM07092, 5 RO1 LM05200] NR 0 TC 0 Z9 0 U1 0 U2 0 PU I O S PRESS PI AMSTERDAM PA VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS SN 0926-9630 BN 90-5199-362-5 J9 ST HEAL T PY 1997 VL 46 BP 291 EP 295 PG 5 WC Medical Informatics; Nursing SC Medical Informatics; Nursing GA BJ94F UT WOS:A1997BJ94F00050 PM 10175412 ER PT S AU Nadel, HM Schifiliti, C AF Nadel, HM Schifiliti, C BE Gerdin, U Tallberg, M Wainwright, P TI Perspectives on the design and implementation of an electronic medical record for obstetrics practice SO NURSING INFORMATICS: THE IMPACT OF NURSING KNOWLEDGE ON HEALTH CARE INFORMATICS SE STUDIES IN HEALTH TECHNOLOGY AND INFORMATICS LA English DT Proceedings Paper CT 6th Triennial International Congress of IMIA-NI on Nursing Informatics - The Impact of Nursing Knowledge on Health Care Informatics (NI 97) CY 1997 CL STOCKHOLM, SWEDEN SP Int Med Informat Assoc, Special Interest Grp Nursing Informat, No Nurses Federat, Swedish Nurses Assoc, Swedish Assoc Hlth Officers, Swedish Federat Cty Council, Stockholm Univ Coll Hlth Sci, Swedish Inst Hlth Serv Dev, S Stockholm Hlth Care Dist RP Nadel, HM (reprint author), MASSACHUSETTS GEN HOSP,VINCENT DEPT OBSTET & GYNECOL,32 FRUIT ST,BOSTON,MA 02114, USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU I O S PRESS PI AMSTERDAM PA VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS SN 0926-9630 BN 90-5199-362-5 J9 ST HEAL T PY 1997 VL 46 BP 535 EP 535 PG 1 WC Medical Informatics; Nursing SC Medical Informatics; Nursing GA BJ94F UT WOS:A1997BJ94F00092 ER PT J AU Hodgson, DM Chiappelli, F Morrow, NS Taylor, AN AF Hodgson, DM Chiappelli, F Morrow, NS Taylor, AN TI Chronic dietary restriction influences tumor metastasis in the rat: Parametric considerations SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL LA English DT Article ID INDUCED MAMMARY TUMORIGENESIS; KILLER-CELL-ACTIVITY; CALORIC RESTRICTION; FOOD RESTRICTION; GROWTH-FACTOR; ENERGY RESTRICTION; INDUCED INHIBITION; PROMOTION PHASE; STRESS; GLUCOCORTICOIDS AB Chronic dietary restriction is a well-documented means of inhibiting tumor growth. This study examines the effects of chronic dietary restriction on tumor metastasis in the rat. We investigate the effect of 1) the degree of food restriction, 2) the effect of preexposure to food restriction, and 3) the duration of food restriction after tumor inoculation on tumor metastasis. We also compare two methods of dietary restriction: 1) the time that food is available and 2) the amount of food available. Our findings demonstrate that rats restricted to 50% of an ad libitum diet Sor one week before inoculation with MADB106 tumor cells and for three weeks after inoculation exhibit a significant (p < 0.001) reduction in lung colonization compared with animals fed ad libitum. Animals restricted to access to food for 4 hrs/day (60% of ad libitum) for the same period of time exhibit significantly (p < 0.005) greater lung tumor colonization than animals fed nd libitum. Preadaptation to the feeding regimen for one week before tumor inoculation proved to be critical in inhibiting tumor metastasis. The tumor-inhibitory effect was not significantly influenced by the duration of restriction after inoculation or by the manner in which food restriction was implemented. Finally, we demonstrate that inhibition of tumor colonization may be mediated by enhanced natural killer cell activity in the early postinoculation period. C1 UNIV CALIF LOS ANGELES, SCH DENT, LOS ANGELES, CA 90073 USA. W LOS ANGELES VET AFFAIRS MED CTR, RES SERV, LOS ANGELES, CA 90073 USA. UNIV CALIF LOS ANGELES, W LOS ANGELES VET AFFAIRS MED CTR, CTR ULCER RES & EDUC, LOS ANGELES, CA 90024 USA. RP Hodgson, DM (reprint author), UNIV CALIF LOS ANGELES, DEPT NEUROBIOL, SCH MED, FRANZ HALL RM 1282A, 405 HILGARD AVE, LOS ANGELES, CA 90095 USA. RI Hodgson, Deborah/C-1950-2008 OI Hodgson, Deborah/0000-0002-1522-0212 FU NCI NIH HHS [CA-16042]; PHS HHS [4-784612-34323] NR 52 TC 4 Z9 4 U1 0 U2 0 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 0163-5581 J9 NUTR CANCER JI Nutr. Cancer PY 1997 VL 28 IS 2 BP 189 EP 198 PG 10 WC Oncology; Nutrition & Dietetics SC Oncology; Nutrition & Dietetics GA XU423 UT WOS:A1997XU42300013 PM 9290127 ER PT S AU Chobanian, MC Fahien, L Brazy, PC AF Chobanian, MC Fahien, L Brazy, PC BE ODonovan, DJ Endou, H Schoolwerth, AC Tizianello, A Walls, J TI Metabolic requirement for inorganic phosphate by renal proximal tubules: Influence upon L-glutamine metabolism SO NUTRITIONAL AND ACID-BASE ASPECTS OF AMINO ACID METABOLISM SE CONTRIBUTIONS TO NEPHROLOGY LA English DT Article; Proceedings Paper CT 7th International Ammoniagenesis Workshop CY MAY 20-23, 1996 CL GALWAY, IRELAND SP Gambro Ltd, Shire Pharm Ltd, Janssen Cilag Ltd, Pfizer Corp, Univ Kyorin, Sch Med, Tokyo, Bord Failte, Conf Bur Ireland, Univ Coll, Galway ID SODIUM-TRANSPORT; RABBIT; GLUCONEOGENESIS; AMMONIAGENESIS; STIMULATION; MECHANISMS; DEPLETION; CRABTREE; CORTEX; RAT C1 UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706. UNIV WISCONSIN,SCH MED,DEPT MED,MADISON,WI 53706. WILLIAM S MIDDLETON MEM VET ADM MED CTR,MADISON,WI 53705. RP Chobanian, MC (reprint author), UNIV WISCONSIN,SCH MED,DEPT PEDIAT,ROOM 3590 MSC,1300 UNIV AVE,MADISON,WI 53706, USA. NR 25 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0302-5144 BN 3-8055-6490-2 J9 CONTRIB NEPHROL JI Contrib.Nephrol. PY 1997 VL 121 BP 85 EP 92 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA BJ75M UT WOS:A1997BJ75M00013 PM 9336702 ER PT J AU Iakoubov, LZ Torchilin, VP AF Iakoubov, LZ Torchilin, VP TI A novel class of antitumor antibodies: Nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice SO ONCOLOGY RESEARCH LA English DT Article DE antinuclear autoantibody; monoclonal antibody; nucleosome; tumor cell surface; cancer therapy; aging ID CELL-SURFACE; NATURAL ANTIBODIES; HUMAN TUMORS; LUPUS; DNA; CANCER; SPECIFICITIES; RECEPTOR; PROTEINS; LPR/LPR AB Antinuclear autoantibodies (ANAs) of healthy aged mice were recently found to specifically interact with the surface of various tumor vs. normal cells. We characterize the specificity of three monoclonal ANAs from healthy aged Balb/c mice by indirect immunofluorescent staining of fixed Hep-2 cells, ELISA assays, and Western blotting analysis. Two of these monoclonal antibodies, 2C5 and 1G3, exhibited specificity for nucleosomes. Subsequent flow cytometry experiments demonstrated that the 2C5 antibody recognizes nucleosomes on the surface of mouse EL4 T-lymphoma cells because antibody binding could be eliminated by pretreatment of these cells with DNase or heparin and approximately 10-fold increased after preincubation of cells with nucleosomes. The injection of monoclonal antibody 2C5 into ANA-negative young mice 1 day before tumor cell inoculation and on days 1, 3, and 5 thereafter significantly suppressed tumor development and increased survival. The antitumor activity of the 2C5 antibody is demonstrated for two syngeneic mouse tumor models, EL4 T-lymphoma and B16 melanoma. In vitro analyses revealed antibody-dependent cellular cytotoxicity (ADCC) as one antitumor mechanism of the 2C5 antibody. Based on these results, we postulate a beneficial role of antinucleosome autoantibodies as tumor-protective agents for an aging host or for antibody-mediated cancer therapy, and further speculate that the presence of such antibodies represents a so far unrecognized mechanism of immune surveillance against tumors. C1 Massachusetts Gen Hosp, Dept Radiol, Ctr Imaging & Pharmaceut Res, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Torchilin, VP (reprint author), Massachusetts Gen Hosp, Dept Radiol, Ctr Imaging & Pharmaceut Res, 149 13th St, Charlestown, MA 02129 USA. NR 32 TC 65 Z9 68 U1 0 U2 5 PU COGNIZANT COMMUNICATION CORP PI ELMSFORD PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA SN 0965-0407 J9 ONCOL RES JI Oncol. Res. PY 1997 VL 9 IS 8 BP 439 EP 446 PG 8 WC Oncology SC Oncology GA YM996 UT WOS:000071122700006 PM 9436197 ER PT J AU Pang, XP Hershman, JM Karsan, A AF Pang, XP Hershman, JM Karsan, A TI TNF-alpha induction of A1 expression in human cancer cells SO ONCOLOGY RESEARCH LA English DT Article DE TNF-alpha; A1; MnSOD; cancer cells ID TUMOR-NECROSIS-FACTOR; MANGANOUS SUPEROXIDE-DISMUTASE; THYROID-CARCINOMA CELLS; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; ANTITUMOR ACTIONS; FACTOR RECEPTOR; KAPPA-B; BCL-2; DEATH AB Al, a member of the Bcl-2 gene family, was originally identified as a hemopoietic-specific early response gene. Later it was found that Al was overexpressed in human stomach cancer tissues and was induced by tumor necrosis factor-alpha (TNF-alpha) in human vascular endothelial cells. However, its expression in human cancer cells has not been well characterized. In the present study, we examined the expression of Al, as well as the antioxidant manganous superoxide dismutase (MnSOD), in four human thyroid carcinoma cell lines, two human pancreatic carcinoma cell lines, and two human prostate carcinoma cell lines. Al mRNA was expressed in all four thyroid carcinoma cell lines. TNF-alpha induced Al in a time-and dose-dependent manner. In contrast, Al mRNA was not detectable in the pancreatic and prostate carcinoma cell lines in the presence or absence of TNF-alpha. However, TNF-alpha induced manganous superoxide dismutase (MnSOD) mRNA in all the cell lines tested. Furthermore, an agonist antibody to the p55 TNF-alpha receptor induced Al, but the agonist antibody against p75 TNF-alpha receptor did not have this effect. The results indicate that Al is expressed in human thyroid carcinoma cells and TNF-alpha induces Al through the p55 TNF-alpha receptor-mediated pathway. C1 W Los Angeles Vet Affairs Med Ctr, Thyroid Canc Res Lab, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Div Endocrinol & Metab, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90073 USA. St Pauls Hosp, UBC, McDonald Res Labs, Vancouver, BC V6Z 1Y6, Canada. RP Pang, XP (reprint author), W Los Angeles Vet Affairs Med Ctr, Thyroid Canc Res Lab, Bldg 114,Room 200,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM xpang@ucla.edu RI Karsan, Aly/K-2067-2015 FU NCI NIH HHS [CA 61863] NR 30 TC 9 Z9 9 U1 0 U2 0 PU COGNIZANT COMMUNICATION CORP PI ELMSFORD PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA SN 0965-0407 J9 ONCOL RES JI Oncol. Res. PY 1997 VL 9 IS 11-12 BP 623 EP 627 PG 5 WC Oncology SC Oncology GA ZF081 UT WOS:000072860700008 PM 9563010 ER PT J AU delaMaza, MS Foster, CS Jabbur, NS AF delaMaza, MS Foster, CS Jabbur, NS TI Scleritis-associated uveitis SO OPHTHALMOLOGY LA English DT Article ID EPISCLERITIS; DISEASES AB Purpose: Anterior uveitis may accompany scleritis. This study was undertaken to analyze the incidence, characteristics, and meaning of uveitis in the course of scleritis. Methods: Patient characteristics, scleritis type, ocular complications, and specific systemic diseases were evaluated in patients with scleritis-associated uveitis; comparisons were made between patients with scleritis-associated uveitis and patients with scleritis without uveitis. Results: Seventy three (42%) of 172 patients with scleritis had anterior uveitis. Scleritis-associated uveitis ranged from mild to moderate intensity and always was related to the presence of active scleritis. Patients with scleritis-associated uveitis had more necrotizing scleritis (37%, P = 0.0001), decrease in vision (49%, P = 0.0046), peripheral ulcerative keratitis (22%, P = 0.0095), and glaucoma (19%, P = 0.0313) than did patients with scleritis without uveitis. Patients with scleritis-associated uveitis did not have any specific associated systemic disease more often than did patients with scleritis without uveitis. Conclusion: Extension of scleral inflammation to the anterior uveal tract is a consequence of a more severe disease with possible ocular complications that may cause progressive visual loss. The occurrence of anterior uveitis in the course of scleritis entails a poor ocular prognosis. The authors believe, therefore, that the anterior uveal tract should be evaluated at every follow-up visit of a patient with scleritis, so that emergence of this important prognostic condition (anterior uveitis) may be detected promptly and systemic therapy instituted appropriately. C1 HARVARD UNIV, MASSACHUSETTS EYE & EAR INFIRM, SCH MED, OCULAR IMMUNOL SERV, BOSTON, MA USA. HARVARD UNIV, MASSACHUSETTS EYE & EAR INFIRM, SCH MED, HILLES IMMUNOL LAB, BOSTON, MA USA. NR 13 TC 19 Z9 23 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD JAN PY 1997 VL 104 IS 1 BP 58 EP 63 PG 6 WC Ophthalmology SC Ophthalmology GA WE575 UT WOS:A1997WE57500020 PM 9022105 ER PT J AU Finkelstein, M Legmann, A Rubin, PAD AF Finkelstein, M Legmann, A Rubin, PAD TI Projectile metallic foreign bodies in the orbit - A retrospective study of epidemiologic factors, management, and outcomes SO OPHTHALMOLOGY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Academy-of-Ophthalmology CY OCT 30-NOV 03, 1994 CL SAN FRANCISCO, CA SP Amer Acad Ophthalmol ID OCULAR INJURIES AB Purpose: Intraorbital projectile metallic foreign bodies are associated with significant ocular and orbital injuries. The authors sought to evaluate epidemiologic factors, the incidence of associated ocular and orbital injury, and the nature and necessity of surgical intervention in these cases. Methods: Charts of all patients with projectile intraorbital metallic foreign bodies seen at our institution (27) over the preceding 7 years were evaluated with respect to age, sex, type of injury, associated ocular and orbital injuries, location of the projectile (anterior, epibulbar, or posterior), postinjury visual acuity, and surgical intervention. Results: The majority of patients were male, between the ages of 11 and 30, and had BB pellet injuries. Thirteen projectiles were lodged anteriorly, 4 were in an epibulbar position, and the remaining 10 were posterior to the equator. Twelve of 13 anterior, and 4 of 4 epibulbar foreign bodies were removed surgically, whereas only 2 of 10 posterior foreign bodies required surgery. No case of surgical intervention resulted in a decrease of visual acuity. Associated ocular injuries were both more common and severe in patients with posteriorly located foreign bodies. Final visual acuity was better at presentation and at discharge in patients with anteriorly located foreign bodies. Conclusion: Intraorbital projectile metallic foreign bodies can be a source of significant ocular morbidity. Management of these cases is dependent on the location of the projectile. Ancillary radiographic studies can be helpful. Surgery to remove the projectile should be considered in each case, but foreign bodies that are not readily accessible often may be left safely in place. Closer regulation of the pellet gun industry, with an emphasis on education and protective eyewear use, would be helpful in reducing these injuries. C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 12 TC 44 Z9 44 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0161-6420 J9 OPHTHALMOLOGY JI Ophthalmology PD JAN PY 1997 VL 104 IS 1 BP 96 EP 103 PG 8 WC Ophthalmology SC Ophthalmology GA WE575 UT WOS:A1997WE57500028 PM 9022111 ER PT S AU Kwong, KK Chesler, DA AF Kwong, KK Chesler, DA BE Villringer, A Dirnagl, U TI The MR T-1 based perfusion model SO OPTICAL IMAGING OF BRAIN FUNCTION AND METABOLISM 2: PHYSIOLOGICAL BASIS AND COMPARISON TO OTHER FUNCTIONAL NEUROIMAGING METHODS SE Advances in Experimental Medicine and Biology LA English DT Article; Proceedings Paper CT International Symposium on Optical Imaging and Metabolism CY MAY 01-02, 1995 CL BERLIN, GERMANY SP Volkswagen Stift, Hertie Stift, Bayer, Fresenius, Hamamatsu Protonics, Sanofi Winthrop, IBM, Siemens AG AB There are a number of theoretical and practical questions one needs to consider to understand and optimize contrast to noise of the versatile T-1 based perfusion model. We made an evaluation of the several popular T-1 based methods currently applied to measure flow and flow change. C1 HARVARD UNIV, SCH MED, HOSP NMR CTR 2301, CHARLESTOWN, MA 02129 USA. RP Kwong, KK (reprint author), MASSACHUSETTS GEN HOSP, DEPT RADIOL, NMR CTR, BLDG 149, 13TH ST, CHARLESTOWN, MA 02129 USA. NR 11 TC 1 Z9 1 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0065-2598 BN 0-306-45585-4 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1997 VL 413 BP 27 EP 34 PG 8 WC Medicine, Research & Experimental; Clinical Neurology; Neurosciences; Radiology, Nuclear Medicine & Medical Imaging SC Research & Experimental Medicine; Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA BJ16K UT WOS:A1997BJ16K00003 PM 9238482 ER PT B AU Pogue, BW Lilge, L Zhang, K Wilson, BC Redmond, RW Hasan, T AF Pogue, BW Lilge, L Zhang, K Wilson, BC Redmond, RW Hasan, T BE Dougherty, TJ Katzir, A TI Measurement of the triplet state yield of photosensitizers in scattering media SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY VI, PROCEEDINGS OF SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy VI CY FEB 08-09, 1997 CL SAN JOSE, CA SP Int Biomed Opt Soc, Soc Photo Opt Instrumentat Engineers, Amer Soc Laser Med & Surg Inc AB A methodology is presented which enables quantification of the fraction of photosensitizer which is photo-converted to the triplet state within homogeneously scattering media. The method relies on a correlation of absorbance with diffuse reflectance changes measured in samples of photosensitizer in scattering medium and can estimate the fraction of photosensitizer molecules present in the active monomeric form. The validity of this approach is demonstrated for the sensitizer tin etioporphyrin (SnET2) in a model system of lipid in water emulsion and is expected to be applicable to biological systems such as cell suspensions and tissue. RP Pogue, BW (reprint author), HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,WELLMAN LABS PHOTOMED,DEPT DERMATOL,BOSTON,MA 02114, USA. RI Lilge, lothar/J-6434-2013 NR 0 TC 1 Z9 1 U1 0 U2 1 PU SPIE - INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA PO BOX 10, BELLINGHAM, WA 98227-0010 BN 0-8194-2383-1 J9 P SOC PHOTO-OPT INS PY 1997 VL 2972 BP 168 EP 172 DI 10.1117/12.273502 PG 5 WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BH84A UT WOS:A1997BH84A00020 ER PT J AU Potts, JT Gardella, TJ Juppner, H Kronenberg, H AF Potts, JT Gardella, TJ Juppner, H Kronenberg, H TI The history of parathyroid hormone and its receptor: Structure-based design of parathyroid hormone analogues SO OSTEOPOROSIS INTERNATIONAL LA English DT Article; Proceedings Paper CT Conference on Osteoporosis Update 1997 CY NOV 13-16, 1997 CL OSAKA, JAPAN ID BINDING; REGION; DETERMINANTS; PTH-(1-34); DOMAINS; PROTEIN; LIGAND C1 Harvard Univ, Sch Med, Endocrine Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Potts, JT (reprint author), Harvard Univ, Sch Med, Endocrine Unit, 55 Fruit St,Bartlett 516, Boston, MA 02114 USA. NR 19 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER-VERLAG LONDON LTD PI GODALMING PA SWEETAPPLE HOUSE CATTESHALL ROAD, GODALMING GU7 3DJ, SURREY, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PY 1997 VL 7 SU 3 BP 169 EP 173 DI 10.1007/BF03194366 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA YP533 UT WOS:000071287400033 ER PT J AU Teknos, TN Metson, R Chasse, T Balercia, G Dickersin, GR AF Teknos, TN Metson, R Chasse, T Balercia, G Dickersin, GR TI New developments in the diagnosis of Kartagener's syndrome SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Academy-of-Otolaryngology-Head-and-Neck-Surgery CY SEP 18-21, 1994 CL SAN DIEGO, CA SP Amer Acad Otolaryngol Head & Neck Surg ID PRIMARY CILIARY DYSKINESIA; IMMOTILE-CILIA; ULTRASTRUCTURE; ABNORMALITIES; EFFICACY; MOTILITY; DISEASE; TRACT; ARMS AB Kartagener's syndrome is characterized by the clinical triad of bronchitis, sinusitis, and situs inversus. An inherited ultrastructural defect results in ciliary immotility with impaired mucociliary clearance throughout the pulmonary and sinonasal passages. Until recently, the diagnosis of Kartagener's syndrome was made on the basis of a qualitative decrease in the number of dynein arms and subjective abnormalities in other ciliary components on electron microscopy. New investigations, however, have defined objective methods of diagnosis on the basis of quantitative ciliary measurements. The use of these methods in a series of 17 cases of suspected ciliary immotility resulted in a reversal of diagnosis in 6 cases (35%) that previously were considered normal. These results suggest that the prevalence of inherited ciliary dyskinesias is much greater than currently is recognized. The early identification and treatment of individuals with these disorders could lead to a reduction in irreversible sinus and pulmonary pathologic conditions with improved long-term survival. C1 HARVARD UNIV,SCH MED,MASSACHUSETTS EYE & EAR INFIRM,DEPT OTOLARYNGOL,CAMBRIDGE,MA 02138. HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT PATHOL,CAMBRIDGE,MA 02138. UNIV VERONA,DEPT NORMAL HUMAN ANAT & HISTOL,I-37100 VERONA,ITALY. NR 24 TC 14 Z9 19 U1 0 U2 2 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD JAN PY 1997 VL 116 IS 1 BP 68 EP 74 DI 10.1016/S0194-5998(97)70354-1 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA WE761 UT WOS:A1997WE76100014 PM 9018261 ER PT J AU Kam, RML Garan, H McGovern, BA Ruskin, JN Harthorne, JW AF Kam, RML Garan, H McGovern, BA Ruskin, JN Harthorne, JW TI Transient right bundle branch block causing R wave attenuation postdefibrillation SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article DE implantable defibrillator; permanent pacemaker undersensing; right bundle branch block AB KAIM, R.M.L., ET AL.: Transient Right Bundle Branch Block Causing R Wave Attenuation Postdefibrillation, Transient and significant decrease in R wave amplitude, associated with transient right bundle branch block, was noted to occur after defibrillation in a defibrillator patient. The mechanism is probably stunning of the right bundle branch, causing right intraventricular conduction delay and decrease in signal amplitude reaching the endocardial sensing dipoles. C1 MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114. NR 2 TC 7 Z9 8 U1 0 U2 0 PU FUTURA PUBL CO PI ARMONK PA 135 BEDFORD RD, PO BOX 418, ARMONK, NY 10504-0418 SN 0147-8389 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD JAN PY 1997 VL 20 IS 1 BP 130 EP 131 DI 10.1111/j.1540-8159.1997.tb04823.x PN 1 PG 2 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA WE956 UT WOS:A1997WE95600019 PM 9121959 ER PT J AU Goudsouzian, NG AF Goudsouzian, NG TI Mivacurium in infants and children SO PAEDIATRIC ANAESTHESIA LA English DT Review DE neuromuscular relaxants; mivacurium; effective doses; side effects; combination with other relaxants ID INDUCED NEUROMUSCULAR BLOCKADE; CHLORIDE BW B1090U; ATYPICAL PLASMA CHOLINESTERASE; OXIDE-NARCOTIC ANESTHESIA; NITROUS-OXIDE; INFUSION REQUIREMENTS; HALOTHANE; PHARMACODYNAMICS; SUCCINYLCHOLINE; PHARMACOLOGY AB Mivacurium is the only available short-acting nondepolarizing muscle relaxant in clinical use. It is a bis-quaternary benzylisoquinolinium ester hydrolysed by plasma-cholinesterase into inactive compounds. The ED50 and ED95 in children are about 50 mu g.kg(-1) and 90 mu g.kg(-1) respectively. In infants, they have a tendency to be lower. A standard intubating dose of 0.25 mg.kg(-1) causes complete neuromuscular depression in 1.5-2 min, recovery to 5% in 6-10 min, and complete recovery in 15-20 min. The recent tendency is to use 0.3 mg.kg(-1) to obtain better intubating conditions with slight prolongation of effect, Since the recovery profile of mivacurium is independent of the dose and duration, it is most suitable for administration by continuous infusion. The infusion requirement in children is 10-16 mu g.kg(-1) min(-1), which is about twice that of adults. Cutaneous flushes from histamine release are commonly seen with the larger doses of mivacurium; however, the associated hypotensive effects are minimal and counteracted by the tracheal intubation. The duration of action of mivacurium is prolonged in patients with cholinesterase deficiency. Mivacurium's neuromuscular effects can be satisfactorily antagonized by edrophonium or neostigmine. RP Goudsouzian, NG (reprint author), MASSACHUSETTS GEN HOSP,DEPT ANESTHESIA,HARVARD MED SCH,BOSTON,MA 02114, USA. NR 53 TC 9 Z9 10 U1 0 U2 0 PU ARNETTE-BLACKWELL S A PI PARIS PA 224, BD ST GERMAIN, 75007 PARIS, FRANCE SN 1155-5645 J9 PAEDIATR ANAESTH JI Paediatr. Anaesth. PY 1997 VL 7 IS 3 BP 183 EP 190 DI 10.1046/j.1460-9592.1997.d01-74.x PG 8 WC Anesthesiology; Pediatrics SC Anesthesiology; Pediatrics GA XH546 UT WOS:A1997XH54600002 PM 9189962 ER PT S AU Buchbinder, BR AF Buchbinder, BR BE Tuxhorn, I Holthausen, H Boenigk, H TI Presurgical functional brain mapping using MRI SO PAEDIATRIC EPILEPSY SYNDROMES AND THEIR SURGICAL TREATMENT SE CURRENT PROBLEMS IN EPILEPSY LA English DT Proceedings Paper CT 6th International Bethel-Cleveland Epilepsy Symposium CY MAR, 1995 CL BIELEFELD, GERMANY C1 Harvard Univ, Massachusetts Gen Hosp, Dept Radiol, Div Neuroradiol, Boston, MA 02114 USA. RP Buchbinder, BR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Radiol, Div Neuroradiol, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU JOHN LIBBEY & CO PI LONDON PA 13 SMITHS YARD, SUMMERLEY ST, LONDON SW18 4HR, ENGLAND SN 0950-4591 BN 0-86196-536-1 J9 CURR PROB E PY 1997 VL 11 BP 648 EP + PG 20 WC Clinical Neurology; Neurosciences; Pediatrics SC Neurosciences & Neurology; Pediatrics GA BK97C UT WOS:000073966400065 ER PT J AU Kiraly, A Suto, G Guth, P Tache, Y AF Kiraly, A Suto, G Guth, P Tache, Y TI Influence of [4Cl-D-Phe(6),Leu(17)]VIP on VIP- and central TRH-induced gastric hyperemia SO PEPTIDES LA English DT Article DE VIP; VIP antagonist; TRH analog; RX 77368; gastric mucosal blood flow; blood pressure; vagus; gastric vascular resistance ID VASOACTIVE-INTESTINAL-PEPTIDE; MUCOSAL BLOOD-FLOW; THYROTROPIN-RELEASING-HORMONE; HYDROGEN GAS CLEARANCE; VAGAL-STIMULATION; RAT; POLYPEPTIDE; ANTAGONIST; SECRETION; RECEPTOR AB The specific VIP receptor antagonist, [4Cl-D-Phe(6),Leu(17)]VIP, infused iv blocked close-intra-arterial infusion of VIP-induced increase in gastric mucosal blood flow (GMBF, measured by the hydrogen gas clearance), and decrease in mean arterial blood pressure while nor influencing basal levels in urethane-anesthetized rats. The thyrotropin-releasing hormone (TRH) stable analog, RX 77368, injected intracisternally (IC, 30 ng) increased GMBF and blood pressure. The VIP antagonist did not significantly reduce the GMBF response to IC RX 77368 while enhancing the rise in blood pressure. These findings indicate that [4Cl-D-Phe(6),Leu(17)]VIP is an antagonist for exogenous VIP induced gastric hyperemia and hypotension and that VIP modulates the systemic blood pressure response to IC RX 77368 at 30 ng while not playing a primary role in the increase of GMBF. (C) 1997 Elsevier Science Inc. C1 W LOS ANGELES VET AFFAIRS MED CTR,CURE DIGEST DIS RES CTR,LOS ANGELES,CA 90073. UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90073. UNIV CALIF LOS ANGELES,BRAIN RES INST,LOS ANGELES,CA 90073. FU NIDDK NIH HHS [DK-41301, DK-30110]; NIMH NIH HHS [MH-00663] NR 36 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0196-9781 J9 PEPTIDES JI Peptides PY 1997 VL 18 IS 9 BP 1321 EP 1325 DI 10.1016/S0196-9781(97)00208-8 PG 5 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA YF798 UT WOS:A1997YF79800006 PM 9392832 ER PT J AU Bhargava, HN Kumar, S Bian, JT AF Bhargava, HN Kumar, S Bian, JT TI Up-regulation of brain N-methyl-D-aspartate receptors following multiple intracerebroventricular injections of [D-Pen(2),D-Pen(5)]enkephalin and [D-Ala(2),Glu(4)]deltorphin II in mice SO PEPTIDES LA English DT Article DE [D-Pen(2), D-Pen(5)]enkephalin; [D-Ala(2), Glu(4)]deltorphim II; delta(1) and delta(2)-opioid receptors; N-methyl-D-aspartate receptor; [H-3]MK-801; tolerance; brain regions; mice ID D-ALA(2),GLU(4) DELTORPHIN-II; OXIDE SYNTHASE INHIBITION; DIFFERENTIAL ANTAGONISM; NMDA RECEPTOR; SPINAL-CORD; TOLERANCE; MORPHINE; SUBTYPES; AGONIST; ANTINOCICEPTION AB The effects of chronic administration of [D-Pen(2), D-Pen(5)]enkephalin and [D-Ala(2), Glu(4)]deltorphin II, the selective agonists of the delta(1)- and delta(2)-opioid receptors, on the binding of [H-3]MK-801, a noncompetitive antagonist of the N-methyl-D-aspartate receptor, were determined in several brain regions of the mouse. Male Swiss-Webster mice were injected intracerebroventricularly (i.c.v.) with [D-Pen(2), D-Pen(5)]enkephalin or [D-Ala(2), Glu(4)]deltorphin II (20 mu g/mouse) twice a day for 4 days. Vehicle injected mice served as controls. Previously we have shown that the above treatment results in the development of tolerance to their analgesic activity. The binding of [H-3]MK-801 was determined in brain regions (cortex, midbrain, pons and medulla, hippocampus, striatum, hypothalamus and amygdala). At 5 nM concentration, the binding of [H-3]MK-801 was increased in cerebral cortex, hippocampus, and pens and medulla of [D-Pen(2), D-Pen(5)]enkephalin treated mice. In [D-Ala(2), Glu(4)]deltorphin II treated mice, the binding of [H-3]MK-801 was increased in cerebral cortex and hippocampus. The changes in the binding were due to increases in the B-max value of [H-3]MK-801. It is concluded that tolerance to delta(1)- and delta(2)-opioid receptor agonists is associated with up-regulation of brain N-methyl-D-aspartate receptors,however, some brain areas affected differ with the two treatments. The results are consistent with the recent observation from this laboratory that N-methyl-D-aspartate receptors antagonists block tolerance to the analgesic action of delta(1)- and delta(2)-opioid receptor agonists. (C) 1997 Elsevier Science Inc. C1 Univ Illinois, Hlth Sci Ctr, Dept Pharmaceut & Pharmacodynam MC 865, Chicago, IL 60612 USA. Harvard Univ, Dana Farber Inst Canc Res, Boston, MA 02115 USA. Univ Chicago, Sch Med, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA. RP Bhargava, HN (reprint author), Univ Illinois, Hlth Sci Ctr, Dept Pharmaceut & Pharmacodynam MC 865, 833 S Wood St, Chicago, IL 60612 USA. FU NIDA NIH HHS [DA-08867, K02-DA-00130] NR 22 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0196-9781 J9 PEPTIDES JI Peptides PY 1997 VL 18 IS 10 BP 1609 EP 1613 DI 10.1016/S0196-9781(97)00236-2 PG 5 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA YN886 UT WOS:000071218500020 PM 9437723 ER PT J AU Tootell, RBH Dale, AM Hadjikhani, N Liu, AK Marrett, S Mendola, JD AF Tootell, R. B. H. Dale, A. M. Hadjikhani, N. Liu, A. K. Marrett, S. Mendola, J. D. TI Functional organisation of human visual cortex revealed by fMRI SO PERCEPTION LA English DT Meeting Abstract C1 [Tootell, R. B. H.; Dale, A. M.; Hadjikhani, N.; Liu, A. K.; Marrett, S.; Mendola, J. D.] Massachusetts Gen Hosp, MGH NMR Ctr, Charlestown, MA 02129 USA. EM tootell@nmr.mgh.harvard.edu RI Hadjikhani, Nouchine/C-2018-2008 OI Hadjikhani, Nouchine/0000-0003-4075-3106 NR 0 TC 0 Z9 0 U1 0 U2 0 PU PION LTD PI LONDON PA 207 BRONDESBURY PARK, LONDON NW2 5JN, ENGLAND SN 0301-0066 J9 PERCEPTION JI Perception PY 1997 VL 26 SU S BP 114 EP 114 PG 1 WC Ophthalmology; Psychology; Psychology, Experimental SC Ophthalmology; Psychology GA V17AS UT WOS:000207910700312 ER PT J AU Darveau, RP Tanner, A Page, RC AF Darveau, RP Tanner, A Page, RC TI The microbial challenge in periodontitis SO PERIODONTOLOGY 2000 LA English DT Review ID HUMAN GINGIVAL FIBROBLASTS; PORPHYROMONAS BACTEROIDES GINGIVALIS; INTERCELLULAR-ADHESION MOLECULE-1; HELICOBACTER-PYLORI LIPOPOLYSACCHARIDE; HUMAN PERIPHERAL MONOCYTES; OUTER-MEMBRANE VESICLES; TUMOR NECROSIS FACTOR; DEFINED LIPID-A; ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; DENTAL PLAQUE C1 FORSYTH DENT CTR,DEPT BIOADHES,BOSTON,MA 02115. HARVARD UNIV,SCH DENT MED,DEPT PERIODONTOL,BOSTON,MA 02115. UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195. UNIV WASHINGTON,SCH MED,DEPT PERIODONT,SEATTLE,WA 98195. UNIV WASHINGTON,SCH DENT,DEPT PERIODONT,SEATTLE,WA 98195. UNIV WASHINGTON,SCH DENT,DEPT PATHOL,SEATTLE,WA 98195. RP Darveau, RP (reprint author), BRISTOL MYERS SQUIBB,SEATTLE,WA, USA. NR 214 TC 241 Z9 263 U1 0 U2 19 PU MUNKSGAARD INT PUBL LTD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 0906-6713 J9 PERIODONTOL 2000 JI Periodontol. 2000 PY 1997 VL 14 BP 12 EP 32 DI 10.1111/j.1600-0757.1997.tb00190.x PG 21 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA XM107 UT WOS:A1997XM10700002 PM 9567964 ER PT J AU Kochevar, IE AF Kochevar, IE TI This year in photochemistry and photobiology SO PHOTOCHEMISTRY AND PHOTOBIOLOGY LA English DT Editorial Material RP Kochevar, IE (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT DERMATOL,WEL-224,BOSTON,MA 02114, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC PHOTOBIOLOGY PI AUGUSTA PA BIOTECH PARK, 1021 15TH ST, SUITE 9, AUGUSTA, GA 30901-3158 SN 0031-8655 J9 PHOTOCHEM PHOTOBIOL JI Photochem. Photobiol. PD JAN PY 1997 VL 65 IS 1 BP 1 EP 1 DI 10.1111/j.1751-1097.1997.tb01868.x PG 1 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA WD168 UT WOS:A1997WD16800007 ER PT J AU Kochevar, IE AF Kochevar, IE TI Time-resolved techniques SO PHOTOCHEMISTRY AND PHOTOBIOLOGY LA English DT Editorial Material RP Kochevar, IE (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT DERMATOL,WEL-224,BOSTON,MA 02114, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC PHOTOBIOLOGY PI AUGUSTA PA BIOTECH PARK, 1021 15TH ST, SUITE 9, AUGUSTA, GA 30901-3158 SN 0031-8655 J9 PHOTOCHEM PHOTOBIOL JI Photochem. Photobiol. PD JAN PY 1997 VL 65 IS 1 BP R4 EP R4 PG 1 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA WD168 UT WOS:A1997WD16800006 ER PT J AU Jang, JC Leon, P Zhou, L Sheen, J AF Jang, JC Leon, P Zhou, L Sheen, J TI Hexokinase as a sugar sensor in higher plants SO PLANT CELL LA English DT Article ID CARBON CATABOLITE REPRESSION; TRANSGENIC TOBACCO PLANTS; SACCHAROMYCES-CEREVISIAE MUTANTS; YEAST-DERIVED INVERTASE; BETA-CELL GLUCOKINASE; GENE-EXPRESSION; ARABIDOPSIS-THALIANA; GLUCOSE REPRESSION; INDUCIBLE EXPRESSION; CHALCONE SYNTHASE AB The mechanisms by which higher plants recognize and respond to sugars are largely unknown. Here, we present evidence that the first enzyme in the hexose assimilation pathway, hexokinase (HXK), acts as a sensor for plant sugar responses. Transgenic Arabidopsis plants expressing antisense hexokinase (AtHXK) genes are sugar hyposensitive, whereas plants overexpressing AtHXK are sugar hypersensitive. The transgenic plants exhibited a wide spectrum of altered sugar responses in seedling development and in gene activation and repression. Furthermore, overexpressing the yeast sugar sensor YHXK2 caused a dominant negative effect by elevating HXK catalytic activity but reducing sugar sensitivity in transgenic plants. The result suggests that HXK is a dual-function enzyme with a distinct regulatory function not interchangeable between plants and yeast. C1 MASSACHUSETTS GEN HOSP, DEPT MOL BIOL, BOSTON, MA 02114 USA. HARVARD UNIV, SCH MED, DEPT GENET, CAMBRIDGE, MA 02138 USA. NR 100 TC 558 Z9 598 U1 2 U2 46 PU AMER SOC PLANT BIOLOGISTS PI ROCKVILLE PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA SN 1040-4651 J9 PLANT CELL JI Plant Cell PD JAN PY 1997 VL 9 IS 1 BP 5 EP 19 DI 10.1105/tpc.9.1.5 PG 15 WC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology SC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology GA WE142 UT WOS:A1997WE14200002 PM 9014361 ER PT J AU Ashiku, SK Randolph, MA Vacanti, CA AF Ashiku, SK Randolph, MA Vacanti, CA TI Tissue engineered cartilage SO POROUS MATERIALS FOR TISSUE ENGINEERING SE MATERIALS SCIENCE FORUM LA English DT Review DE tissue engineering; biodegradable polymers; cell transplantation; tissue culture; polyethylene oxide; pluronics; calcium alginate; polyglycolic acid ID RABBIT-ARTICULAR-CARTILAGE; BLOCK POLYMER SURFACTANTS; TRACHEAL EPITHELIAL-CELLS; VESICOURETERAL REFLUX; ALGINATE BEADS; ISOLATED EPIPHYSEAL; ADJUVANT ACTIVITY; JOINT SURFACES; COLLAGEN TYPES; CHONDROCYTES AB Cartilage possesses limited capacity for repair and self-regeneration. Consequently, il?injury to cartilaginous tissues results in scar formation leading to permanent loss of structure and function. Increased understanding of chondrocyte physiology has enabled investigators to overcome many of these limitations experimentally. For example, isolated chondrocytes will multiply in culture, but they loose their phenotypic expression in monolayer culture. Using three-dimensional culture techniques. investigators have been able to retain the spherical shape of the chondrocytes, preserve their phenotype as measured by the production of matrix components, and generate cartilage-like; tissue in vitro. The field of tissue engineering has expanded upon this technology using biodegradable polymer templates as temporary support matrices for chondrocyte transplantation leading to neocartilage formation ii? vivo. This paper reviews the advancements in understanding of chondrocyte function and biodegradable polymers leading to the development of tissue engineered cartilage. Summarized here will be our experience with various biodegradable polymers. initially, we investigated the use of polyglycolic acid (PGA) and polylactic acid coated PGA as transplant matrices. Subsequent studies have investigated biodegradable hydrogels such as calcium alginate, polyethylene oxide. polyethylene oxide/polypropylene oxide cn-polymers (Pluronics). All of these materials allow the formation of cartilage matrix in vivo, and each has unique properties that are discussed. Also included is a discussion of potential clinical applications and progress in some of these areas. C1 Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. Univ Massachusetts, Med Ctr, Dept Anesthesiol, Worcester, MA 01655 USA. RP Ashiku, SK (reprint author), Massachusetts Gen Hosp, Dept Surg, Fruit St, Boston, MA 02114 USA. NR 98 TC 22 Z9 28 U1 0 U2 3 PU TRANSTEC PUBLICATIONS LTD PI ZURICH-UETIKON PA BRANDRAIN 6, CH-8707 ZURICH-UETIKON, SWITZERLAND SN 0255-5476 J9 MATER SCI FORUM PY 1997 VL 250 BP 129 EP 150 PG 22 WC Materials Science, Multidisciplinary SC Materials Science GA BK32D UT WOS:000071779800010 ER PT J AU Morgan, BA AF Morgan, BA TI Hox genes and embryonic development SO POULTRY SCIENCE LA English DT Article DE hox gene; embryonic development; retroviral vectors; vertebrate limb ID HOMEOTIC TRANSFORMATIONS; HOMEOBOX GENES; TARGETED DISRUPTIONS; AXIAL SKELETON; MUTANT MICE; EXPRESSION; ANTENNAPEDIA; EVOLUTION; HOXD-11; MUTATIONS AB The hox genes specify regional differences along the anterior-posterior (A/P) axis of the vertebrate embryo. This function appears to reflect an ancestral role of the hox gene complex and is conserved across phyla. During the evolution of vertebrates, this gene complex has been recruited to perform other functions as well, many of which occur later in development. Although mutational analysis in the mouse is well-suited to the study of their early function, that same function limits the utility of mutational analysis in the investigation of later functions. The use of retroviral vectors to alter gene expression in the chick embryo has emerged as an effective way to address these later functions. This paper reviews that approach and its application to the study of the hox genes in the formation of the vertebrate limb. C1 HARVARD UNIV,SCH MED,CHARLESTOWN,MA 02129. RP Morgan, BA (reprint author), MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BLDG 149,13TH ST,CHARLESTOWN,MA 02129, USA. NR 41 TC 9 Z9 9 U1 1 U2 4 PU POULTRY SCIENCE ASSOC INC PI SAVOY PA 1111 NORTH DUNLAP AVE, SAVOY, IL 61874 SN 0032-5791 J9 POULTRY SCI JI Poult. Sci. PD JAN PY 1997 VL 76 IS 1 BP 96 EP 104 PG 9 WC Agriculture, Dairy & Animal Science SC Agriculture GA WG255 UT WOS:A1997WG25500016 PM 9037695 ER PT B AU Merchant, FA Holmes, WH Toner, M AF Merchant, FA Holmes, WH Toner, M BE Boom, H Robinson, C Rutten, W Neuman, M Wijkstra, H TI Analysis of functional recovery in cells treated with co-block polymers after thermal injury SO PROCEEDINGS OF THE 18TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOL 18, PTS 1-5 SE PROCEEDINGS OF THE ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY LA English DT Proceedings Paper CT 18th Annual International Conference of IEEE Engineering-in-Medicine-amd-Biology-Society CY OCT 31-NOV 03, 1996 CL AMSTERDAM, NETHERLANDS SP IEEE Engn Med & Biol Soc AB The purpose of this study was to facilitate the functional recovery of thermally injured cells by employing synthetically engineered biomaterials (surfactant molecules) to stabilize the plasma membrane supramolecular assembly. We have employed morphological and functional viability assays to quantify the survival of heat shocked cells treated with triblock polymer Poloxamer 188 (P-188). The viability of the cells was assessed using two different assays, namely, evaluation of morphology, and cell function via the-ability of cells to reorganize fibroblasts populated collagen lattices (FPCLs). The results of this study indicate that low concentrations of P-188 were effective in increasing both morphological and functional viability of cells following heat injury. Further, it appears that there exists a time window during which the viability of cells treated dth P-188 is enhanced. C1 Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA. RP Merchant, FA (reprint author), Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA BN 0-7803-3812-X J9 P IEEE EMBS PY 1997 VL 18 BP 2182 EP 2183 PG 2 WC Engineering, Biomedical SC Engineering GA BK41A UT WOS:000072079001050 ER PT S AU VanSickle, DP Cooper, RA Gonzalez, J Boninger, ML AF VanSickle, DP Cooper, RA Gonzalez, J Boninger, ML GP IEEE IEEE TI SMART(HUB) and SMART(CASTOR): Force and moment sensing wheelchair wheels SO PROCEEDINGS OF THE 19TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOL 19, PTS 1-6: MAGNIFICENT MILESTONES AND EMERGING OPPORTUNITIES IN MEDICAL ENGINEERING SE PROCEEDINGS OF ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY LA English DT Proceedings Paper CT International Conference of the IEEE Engineering-in-Medicine-and-Biology-Society CY OCT 30-NOV 02, 1997 CL CHICAGO, IL SP IEEE Engn Med & Biol Soc, Natl Inst Hlth AB The SMART(HUB) and SMART(CASTOR) are two new strain-gage based sensors designed to measure the reaction forces and moments at the rear axle and castor spindle, respectively, Both are five degree-of-freedom sensors, which measure all three force components and the two moment components perpendicular to the axes of rotation. These sensors will be used to improve wheelchair designs by allowing advanced engineering techniques such as finite element analysis to be applied with greater confidence. Both sensors are highly linear. When calibrated the lowest correlation coefficient was 0.9965 (N=21) and the cross-axes sensitivity was always less than 5 %. Preliminary data are presented for two wheelchair users propelling over an indoor course and a non-wheelchair user traversing an outdoor course. The indoor data was transferred from a microcontroller-based signal conditioning board to a host PC through a high-speed serial port. For the outdoor data, the microcontroller was programmed to sample the data and to generate a histogram of force and moment frequencies, which was subsequently downloaded. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. RP VanSickle, DP (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. OI Boninger, Michael/0000-0001-6966-919X NR 10 TC 0 Z9 0 U1 1 U2 1 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 1094-687X BN 0-7803-4262-3 J9 P ANN INT IEEE EMBS PY 1997 VL 19 BP 1871 EP 1874 PN 1-6 PG 4 WC Engineering, Biomedical SC Engineering GA BM91F UT WOS:000080103400534 ER PT J AU Weber, GF Ashkar, S Cantor, H AF Weber, GF Ashkar, S Cantor, H TI Interaction between CD44 and osteopontin as a potential basis for metastasis formation SO PROCEEDINGS OF THE ASSOCIATION OF AMERICAN PHYSICIANS LA English DT Article DE lymphocyte homing receptors; chemotaxis; cytokines ID T-CELL ACTIVATION; SECRETED PHOSPHOPROTEIN-I; MESSENGER-RNA; NEOPLASTIC TRANSFORMATION; MONOCLONAL-ANTIBODY; BACTERIAL-INFECTION; GENETIC-RESISTANCE; FIBROBLASTIC CELLS; BONE SIALOPROTEIN; MOLECULAR-CLONING AB Malignant growth has been associated with oncogene activation, telomerase activity, and expression of CD44 splice variants on the cell surface. Though dysregulation of growth control due to expression of oncogene products is fairly well understood, the mechanism of CD44-mediated homing and colony formation in specific tissues has remained cryptic. We have identified the cytokine osteopontin as a ligand for CD44. Osteopontin binds to naturally expressed and stably transfected CD44 in a manner that is specific, dose-dependent, inhibitable by anti-CD44 antibodies, insensitive to competition by Gly-Arg-Gly-Asp-Ser, and sensitive to competition by hyaluronate. The receptor-ligand interaction mediates chemotaxis or attachment, depending on presentation of osteopontin in soluble or immobilized form. In contrast, binding of CD44 to hyaluronate mediates aggregation or attachment but not chemotaxis. We found that two events occurring in malignancy-secretion of osteopontin and expression of CD44v-are linked in such a way that they may cause migration of tumor cells to specific sites of metastasis formation. C1 HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,CHILDRENS HOSP,DEPT ORTHOPED RES,BOSTON,MA 02115. RP Weber, GF (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV IMMUNOPATHOL,LHRRB 218,44 BINNEY ST,BOSTON,MA 02115, USA. FU NIAID NIH HHS [AI 12184, P01 AI 37833] NR 67 TC 85 Z9 87 U1 0 U2 1 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 SN 1081-650X J9 P ASSOC AM PHYSICIAN JI Proc. Assoc. Am. Phys. PD JAN PY 1997 VL 109 IS 1 BP 1 EP 9 PG 9 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA WD146 UT WOS:A1997WD14600001 PM 9010911 ER PT B AU Nadol, JB AF Nadol, JB BE Iurato, S Veldman, JE Bock, GR Gleeson, MJ TI An update on the NIDCD National Temporal Bone Hearing and Balance Pathology Resource Registry in the USA SO PROGRESS IN HUMAN AUDITORY AND VESTIBULAR HISTOPATHOLOGY LA English DT Proceedings Paper CT Symposium on the Current Status of Human Auditory and Vestibular Histopathology CY NOV, 1995 CL CIBA FDN, LONDON, ENGLAND HO CIBA FDN RP Nadol, JB (reprint author), MASSACHUSETTS EYE & EAR INFIRM,243 CHARLES ST,BOSTON,MA 02114, USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU KUGLER PUBLICATIONS BV PI AMSTELVEEN PA PO BOX 516, 1180 AM AMSTELVEEN, NETHERLANDS BN 90-6299-151-3 PY 1997 BP 5 EP 10 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA BJ81G UT WOS:A1997BJ81G00002 ER PT B AU Nadol, JB AF Nadol, JB BE Iurato, S Veldman, JE Bock, GR Gleeson, MJ TI Electron microscopy of the human ear: anatomy and pathology SO PROGRESS IN HUMAN AUDITORY AND VESTIBULAR HISTOPATHOLOGY LA English DT Proceedings Paper CT Symposium on the Current Status of Human Auditory and Vestibular Histopathology CY NOV, 1995 CL CIBA FDN, LONDON, ENGLAND HO CIBA FDN RP Nadol, JB (reprint author), MASSACHUSETTS EYE & EAR INFIRM,243 CHARLES ST,BOSTON,MA 02114, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KUGLER PUBLICATIONS BV PI AMSTELVEEN PA PO BOX 516, 1180 AM AMSTELVEEN, NETHERLANDS BN 90-6299-151-3 PY 1997 BP 47 EP 57 PG 11 WC Otorhinolaryngology SC Otorhinolaryngology GA BJ81G UT WOS:A1997BJ81G00008 ER PT B AU Schuknecht, HF AF Schuknecht, HF BE Iurato, S Veldman, JE Bock, GR Gleeson, MJ TI Inner ear pathology in autoimmune disease SO PROGRESS IN HUMAN AUDITORY AND VESTIBULAR HISTOPATHOLOGY LA English DT Proceedings Paper CT Symposium on the Current Status of Human Auditory and Vestibular Histopathology CY NOV, 1995 CL CIBA FDN, LONDON, ENGLAND HO CIBA FDN RP Schuknecht, HF (reprint author), MASSACHUSETTS EYE & EAR INFIRM,243 CHARLES ST,BOSTON,MA 02114, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KUGLER PUBLICATIONS BV PI AMSTELVEEN PA PO BOX 516, 1180 AM AMSTELVEEN, NETHERLANDS BN 90-6299-151-3 PY 1997 BP 109 EP 115 PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA BJ81G UT WOS:A1997BJ81G00017 ER PT J AU Mitchen, J Oberley, T Wilding, G AF Mitchen, J Oberley, T Wilding, G TI Extended culturing of androgen-responsive human primary epithelial prostate cell isolates by continuous treatment with interstitial collagenase SO PROSTATE LA English DT Article DE prostate; epithelial; collagenase; collagen; androgen ID EPIDERMAL GROWTH-FACTOR; SERUM-FREE; RECEPTOR; LINES; TISSUE; LOCALIZATION; CARCINOMAS; EXPRESSION; BENIGN AB Continuous culturing of two distinct human prostate specimens in the presence of interstitial collagenase added directly to conventional medium resulted in the isolation and extended growth of primary epithelial prostate cell (PEPC) cultures from each. Both continued to proliferate substantially beyond the average time determined for analogous untreated epithelial prostate isolates. Both repeatedly stain positive for keratin and are characteristically epithelial in morphological appearance and growth model. Both express androgen receptor mRNA and stain positive for androgen receptors. PEPC-2 displays an androgen dose-dependent stimulation of cell proliferation, as well as specifically binding H-3-R1881. PEPC-1 exhibits a hypotetraploid karyotype with loss of the Y chromosome. PEPC-2 conserves a normal human ploidy, including the Y chromosome, although there is extensive random chromosome loss. Elimination of the collagenase from the medium resulted in decreased cellular proliferation and accumulation of stainable collagen in both PEPC cultures. Neither PEPC isolate produced tumors in male nude mice, whether injected alone, mixed with matrigel, or combined with prostate or bone fibroblastic cells. (C) 1997 Wiley-Liss, Inc. C1 UNIV WISCONSIN,CTR CLIN CANC,DEPT MED,CTR COMPREHENS CANC,MADISON,WI 53792. UNIV WISCONSIN HOSP & CLIN,WILLIAM S MIDDLETON MEM VET ADM HOSP,MADISON,WI 53792. FU NCI NIH HHS [CA 50590] NR 33 TC 7 Z9 7 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0270-4137 J9 PROSTATE JI Prostate PD JAN 1 PY 1997 VL 30 IS 1 BP 7 EP 19 DI 10.1002/(SICI)1097-0045(19970101)30:1<7::AID-PROS2>3.0.CO;2-N PG 13 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA WE951 UT WOS:A1997WE95100002 PM 9018330 ER PT J AU Goldberg, AL Akopian, T Gaczynska, M Kisselev, A Rock, KL Rohrwild, M AF Goldberg, AL Akopian, T Gaczynska, M Kisselev, A Rock, KL Rohrwild, M TI Function of the proteasome in protein turnover and antigen presentation. SO PROTEIN ENGINEERING LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115. DANA FARBER CANC INST,BOSTON,MA 02115. MIT,CTR CANC RES,CAMBRIDGE,MA 02189. NR 6 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP SN 0269-2139 J9 PROTEIN ENG JI Protein Eng. PY 1997 VL 10 SU S BP 10 EP 10 PG 1 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology GA XD832 UT WOS:A1997XD83200012 ER PT J AU Bogdanov, A Simonova, M Weissleder, R AF Bogdanov, A Simonova, M Weissleder, R TI Towards in vivo imaging of gene expression: The engineering of metal binding sites SO PROTEIN ENGINEERING LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CTR MOL IMAGING RES,BOSTON,MA 02129. NR 3 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP SN 0269-2139 J9 PROTEIN ENG JI Protein Eng. PY 1997 VL 10 SU S BP 22 EP 22 PG 1 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology GA XD832 UT WOS:A1997XD83200027 ER PT J AU Dhopesh, V Macfadden, A Maany, I Gamble, G AF Dhopesh, V Macfadden, A Maany, I Gamble, G TI Absence of parkinsonism among patients in long term neuroleptic therapy who abuse cocaine SO PSYCHIATRIC SERVICES LA English DT Article; Proceedings Paper CT Conference of the Institute-on-Psychiatric-Services CY OCT 06-10, 1995 CL BOSTON, MA SP Inst Psychiat Serv ID DOPAMINE AB The study used the United Parkinson's Disease Scale to compare parkinsonian signs and symptoms among 19 patients in long-term neuroleptic therapy who had a history of cocaine abuse with those among 24 similar patients with no history of cocaine use. There was no significant difference between the two groups' scores. The results suggest that chronic cocaine abuse is not a risk factor for parkinsonism among subjects in long-term neuroleptic therapy. RP Dhopesh, V (reprint author), VET AFFAIRS MED CTR,DEPT PSYCHIAT,UNIV & WOODLAND AVE,PHILADELPHIA,PA 19104, USA. NR 10 TC 6 Z9 6 U1 0 U2 0 PU AMER PSYCHIATRIC ASSOCIATION PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 SN 1075-2730 J9 PSYCHIATR SERV JI Psychiatr. Serv. PD JAN PY 1997 VL 48 IS 1 BP 95 EP 97 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA WA706 UT WOS:A1997WA70600018 PM 9117510 ER PT S AU Rauch, SL Shin, LM AF Rauch, SL Shin, LM BE Yehuda, R McFarlane, AC TI Functional neuroimaging studies in posttraumatic stress disorder SO PSYCHOBIOLOGY OF POSTTRAUMATIC STRESS DISORDER SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Conference on Psychobiology of Posttraumatic Stress Disorder CY SEP 07-10, 1996 CL NEW YORK, NY SP New York Acad Sci ID OBSESSIVE-COMPULSIVE DISORDER; CEREBRAL BLOOD-FLOW; GLUCOSE METABOLIC RATES; POSITRON EMISSION TOMOGRAPHY; PANIC DISORDER; SYMPTOM PROVOCATION; HEALTHY-VOLUNTEERS; PHOBIC FEAR; ANXIETY; NEUROANATOMY C1 MASSACHUSETTS GEN HOSP, DEPT RADIOL, BOSTON, MA 01890 USA. HARVARD UNIV, SCH MED, DEPT PSYCHIAT, BOSTON, MA 01890 USA. HARVARD UNIV, DEPT PSYCHOL, CAMBRIDGE, MA 02138 USA. RP Rauch, SL (reprint author), MASSACHUSETTS GEN HOSP, DEPT PSYCHIAT, BOSTON, MA 01890 USA. NR 49 TC 51 Z9 51 U1 2 U2 4 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-079-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1997 VL 821 BP 83 EP 98 DI 10.1111/j.1749-6632.1997.tb48271.x PG 16 WC Behavioral Sciences; Multidisciplinary Sciences; Psychiatry SC Behavioral Sciences; Science & Technology - Other Topics; Psychiatry GA BJ18D UT WOS:A1997BJ18D00008 PM 9238196 ER PT S AU Wolfe, J Schlesinger, LK AF Wolfe, J Schlesinger, LK BE Yehuda, R McFarlane, AC TI Performance of PTSD patients on standard tests of memory - Implications for trauma SO PSYCHOBIOLOGY OF POSTTRAUMATIC STRESS DISORDER SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Conference on Psychobiology of Posttraumatic Stress Disorder CY SEP 07-10, 1996 CL NEW YORK, NY SP New York Acad Sci ID POSTTRAUMATIC-STRESS-DISORDER; AUTOBIOGRAPHICAL MEMORY; CHILDHOOD ABUSE; RAPE VICTIMS; INFORMATION; THREAT; IMPLICIT; EVENT; CUES C1 NATL CTR PTSD, WOMENS HLTH SCI DIV, BOSTON, MA 02130 USA. TUFTS UNIV, SCH MED, BOSTON, MA 02130 USA. NR 51 TC 22 Z9 22 U1 0 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-079-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1997 VL 821 BP 208 EP 218 DI 10.1111/j.1749-6632.1997.tb48280.x PG 11 WC Behavioral Sciences; Multidisciplinary Sciences; Psychiatry SC Behavioral Sciences; Science & Technology - Other Topics; Psychiatry GA BJ18D UT WOS:A1997BJ18D00017 PM 9238205 ER PT S AU Kellner, M Baker, DG Yehuda, R AF Kellner, M Baker, DG Yehuda, R BE Yehuda, R McFarlane, AC TI Salivary cortisol and PTSD symptoms in Persian Gulf War combatants SO PSYCHOBIOLOGY OF POSTTRAUMATIC STRESS DISORDER SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Conference on Psychobiology of Posttraumatic Stress Disorder CY SEP 07-10, 1996 CL NEW YORK, NY SP New York Acad Sci ID POSTTRAUMATIC-STRESS-DISORDER C1 MT SINAI SCH MED, BRONX VET AFFAIRS MED CTR, DEPT PSYCHIAT, BRONX, NY 10468 USA. UNIV CINCINNATI, MED CTR, DEPT PSYCHIAT, CINCINNATI, OH 45220 USA. VET AFFAIRS MED CTR, CINCINNATI, OH 45220 USA. NR 4 TC 10 Z9 10 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-079-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1997 VL 821 BP 442 EP 443 DI 10.1111/j.1749-6632.1997.tb48300.x PG 2 WC Behavioral Sciences; Multidisciplinary Sciences; Psychiatry SC Behavioral Sciences; Science & Technology - Other Topics; Psychiatry GA BJ18D UT WOS:A1997BJ18D00037 PM 9238225 ER PT S AU Jensen, CF Keller, TW Peskind, ER McFall, ME Veith, RC Martin, D Wilkinson, CW Raskind, MA AF Jensen, CF Keller, TW Peskind, ER McFall, ME Veith, RC Martin, D Wilkinson, CW Raskind, MA BE Yehuda, R McFarlane, AC TI Behavioral and plasma cortisol responses to sodium lactate infusion in posttraumatic stress disorder SO PSYCHOBIOLOGY OF POSTTRAUMATIC STRESS DISORDER SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Conference on Psychobiology of Posttraumatic Stress Disorder CY SEP 07-10, 1996 CL NEW YORK, NY SP New York Acad Sci C1 VA PUGET SOUND HLTH CARE SYST, PSYCHIAT SERV, SEATTLE, WA 98108 USA. VA PUGET SOUND HLTH CARE SYST, CTR GERIATR RES EDUC & CLIN, SEATTLE, WA 98108 USA. UNIV WASHINGTON, SCH MED, DEPT PSYCHIAT & BEHAV SCI, SEATTLE, WA 98108 USA. FU NIA NIH HHS [AG05136] NR 5 TC 5 Z9 5 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-079-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1997 VL 821 BP 444 EP 448 DI 10.1111/j.1749-6632.1997.tb48301.x PG 5 WC Behavioral Sciences; Multidisciplinary Sciences; Psychiatry SC Behavioral Sciences; Science & Technology - Other Topics; Psychiatry GA BJ18D UT WOS:A1997BJ18D00038 PM 9238226 ER PT S AU Kounios, J Litz, B Kaloupek, D Riggs, D Knight, J Weathers, F Anderson, JE Keane, T AF Kounios, J Litz, B Kaloupek, D Riggs, D Knight, J Weathers, F Anderson, JE Keane, T BE Yehuda, R McFarlane, AC TI Electrophysiology of combat-related PTSD SO PSYCHOBIOLOGY OF POSTTRAUMATIC STRESS DISORDER SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Conference on Psychobiology of Posttraumatic Stress Disorder CY SEP 07-10, 1996 CL NEW YORK, NY SP New York Acad Sci ID POSTTRAUMATIC-STRESS-DISORDER; BRAIN C1 VET AFFAIRS MED CTR, NATL CTR PTSD, BOSTON, MA 02130 USA. RP Kounios, J (reprint author), UNIV PENN, DEPT PSYCHOL, 3815 WALNUT ST, PHILADELPHIA, PA 19104 USA. OI Kaloupek, Danny/0000-0002-0795-593X NR 12 TC 5 Z9 5 U1 1 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-079-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1997 VL 821 BP 504 EP 507 DI 10.1111/j.1749-6632.1997.tb48316.x PG 4 WC Behavioral Sciences; Multidisciplinary Sciences; Psychiatry SC Behavioral Sciences; Science & Technology - Other Topics; Psychiatry GA BJ18D UT WOS:A1997BJ18D00053 PM 9238239 ER PT S AU Shin, LM McNally, RJ Kosslyn, SM Thompson, WL Rauch, SL Alpert, NM Metzger, LJ Lasko, NB Orr, SP Pitman, RK AF Shin, LM McNally, RJ Kosslyn, SM Thompson, WL Rauch, SL Alpert, NM Metzger, LJ Lasko, NB Orr, SP Pitman, RK BE Yehuda, R McFarlane, AC TI A positron emission tomographic study of symptom provocation in PTSD SO PSYCHOBIOLOGY OF POSTTRAUMATIC STRESS DISORDER SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Conference on Psychobiology of Posttraumatic Stress Disorder CY SEP 07-10, 1996 CL NEW YORK, NY SP New York Acad Sci ID DISORDER C1 MASSACHUSETTS GEN HOSP, DEPT NEUROL, BOSTON, MA 02114 USA. MASSACHUSETTS GEN HOSP, DEPT RADIOL & PSYCHIAT, BOSTON, MA 02114 USA. HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA. MASSACHUSETTS GEN HOSP, DEPT RADIOL, BOSTON, MA 02114 USA. VA RES SERV, MANCHESTER, NH 03103 USA. RP Shin, LM (reprint author), HARVARD UNIV, DEPT PSYCHOL, WILLIAM JAMES HALL, 33 KIRKLAND ST, CAMBRIDGE, MA 02138 USA. NR 5 TC 70 Z9 70 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-079-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1997 VL 821 BP 521 EP 523 DI 10.1111/j.1749-6632.1997.tb48320.x PG 3 WC Behavioral Sciences; Multidisciplinary Sciences; Psychiatry SC Behavioral Sciences; Science & Technology - Other Topics; Psychiatry GA BJ18D UT WOS:A1997BJ18D00057 PM 9238243 ER PT S AU Garrick, T Morrow, N Eth, S Marciano, D Shalev, A AF Garrick, T Morrow, N Eth, S Marciano, D Shalev, A BE Yehuda, R McFarlane, AC TI Psychophysiologic parameters of traumatic stress disorder in rats SO PSYCHOBIOLOGY OF POSTTRAUMATIC STRESS DISORDER SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Conference on Psychobiology of Posttraumatic Stress Disorder CY SEP 07-10, 1996 CL NEW YORK, NY SP New York Acad Sci ID RESPONSES C1 ST VINCENTS HOSP, NEW YORK, NY USA. HADASSAH UNIV HOSP, IL-91120 JERUSALEM, ISRAEL. RP Garrick, T (reprint author), W LOS ANGELES VET AFFAIRS MED CTR, 11301 WILSHIRE BLVD, LOS ANGELES, CA 90073 USA. NR 6 TC 12 Z9 12 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-079-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1997 VL 821 BP 533 EP 537 DI 10.1111/j.1749-6632.1997.tb48323.x PG 5 WC Behavioral Sciences; Multidisciplinary Sciences; Psychiatry SC Behavioral Sciences; Science & Technology - Other Topics; Psychiatry GA BJ18D UT WOS:A1997BJ18D00060 PM 9238246 ER PT J AU King, AC Volpicelli, JR Frazer, A OBrien, CP AF King, AC Volpicelli, JR Frazer, A OBrien, CP TI Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence SO PSYCHOPHARMACOLOGY LA English DT Article DE naltrexone; alcohol; genetics; social drinkers; family history of alcoholism; Biphasic Alcohol Effects Scale ID CAGE QUESTIONNAIRE; BETA-ENDORPHIN; ETHANOL; RATS; NALOXONE; EFFICACY; INTOXICATION; SENSITIVITY; VALIDATION; PREDICTOR AB We investigated specific subjective effects of naltrexone pretreatment or placebo during various intervals on the breath alcohol level (BAL) curve in nonalcoholic volunteers. Fifteen high-risk (social drinkers with an alcoholic father) and 14 low-risk (no alcoholic relatives in at least two generations) subjects were tested in a double-blind, placebo-controlled study of the effects of 50 mg oral naltrexone on response to a moderate dose of alcohol. Dependent measures included subjective stimulation and sedation subscales from the Biphasic Alcohol Effects Scale (BAES) and mood subscales from the Profile of Mood States (POMS). At rising BALs, high-risk subjects showed a naltrexone-related attenuation of BAES stimulation. This effect was not evident in low-risk subjects, who directionally showed the opposite effect, although nonsignificant. For both groups, there were no significant naltrexone-related effects for BAES sedation; however, naltrexone did affect several POMS scales on alcohol response, such as decreased vigor, and increased fatigue, tension, and confusion. Confusion was significantly elevated for the high-risk group during rising BALs of the naltrexone session. The results suggest a differential response to naltrexone, based on paternal history of alcoholism and level of stimulation experienced during alcohol drinking. C1 UNIV PENN,DEPT PSYCHIAT,TREATMENT RES CTR,PHILADELPHIA,PA 19104. VET AFFAIRS MED CTR,PHILADELPHIA,PA 19104. RP King, AC (reprint author), ROCKEFELLER UNIV,LAB BIOL ADDICT DIS,1230 YORK AVE,NEW YORK,NY 10021, USA. FU NIAAA NIH HHS [R0I-AA0 7517]; NIDA NIH HHS [P50-DA05186]; PHS HHS [T32- 0A 7241] NR 46 TC 177 Z9 179 U1 2 U2 4 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD JAN PY 1997 VL 129 IS 1 BP 15 EP 22 DI 10.1007/s002130050156 PG 8 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA WE139 UT WOS:A1997WE13900002 PM 9122358 ER PT J AU Fava, M Nierenberg, AA Quitkin, FM Zisook, S Pearlstein, T Stone, A Rosenbaum, JF AF Fava, M Nierenberg, AA Quitkin, FM Zisook, S Pearlstein, T Stone, A Rosenbaum, JF TI A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article DE anger attacks; atypical depression; dysthymia; antidepressant treatment; normal controls ID FLUOXETINE TREATMENT; UNIPOLAR DEPRESSION; OUTPATIENTS AB There is clinical and biological evidence suggesting that patients with anger attacks, sudden spells of anger accompanied by intense autonomic activation, may represent a distinct psychopathological subgroup of patients with depressive disorders. We compared the prevalence of anger attacks in 168 outpatients with atypical depression or primary dysthymia with 38 normal subjects and tested the effect of treatment on anger attacks in a double-blind, placebo-controlled trial of sertraline versus imipramine. Patients were randomly assigned to sertraline (n=56), imipramine (n=52), or placebo (n=60) and were administered the Anger Attacks Questionnaire before and after treatment. Depressed outpatients were significantly more likely to report anger attacks than controls. Anger attacks ceased in 53 percent of the patients receiving sertraline, 57 percent of those receiving imipramine, and 37 percent of those in the placebo group. Our findings support previous studies indicating that anger attacks are more prevalent among depressed outpatients than normals. Our results also suggest that sertraline and imipramine may be more effective than placebo in reducing the number of anger attacks following treatment although the differences were not statistically significant. Larger studies are needed to confirm our findings. C1 NEW YORK STATE PSYCHIAT INST & HOSP,DEPT PSYCHIAT,NEW YORK,NY 10032. UNIV CALIF SAN DIEGO,DEPT PSYCHIAT,SAN DIEGO,CA 92103. BUTLER HOSP,DEPT PSYCHIAT,PROVIDENCE,RI 02906. UNIV MASSACHUSETTS,MED CTR,DEPT PSYCHIAT,WORCESTER,MA 01655. RP Fava, M (reprint author), MASSACHUSETTS GEN HOSP,CLIN PSYCHOPHARMACOL UNIT,DEPRESS RES PROGRAM,15 PARKMAN ST,WAC 815,BOSTON,MA 02114, USA. NR 9 TC 39 Z9 41 U1 1 U2 1 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1997 VL 33 IS 1 BP 101 EP 103 PG 3 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA WU646 UT WOS:A1997WU64600015 PM 9133758 ER PT J AU Grinspoon, S Herzog, D Klibanski, A AF Grinspoon, S Herzog, D Klibanski, A TI Mechanisms and treatment options for bone loss in anorexia nervosa SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article; Proceedings Paper CT National-Institutes-of-Health (NIH) Workshop on the Development of Research Priorities in Eating Disorders/7th International Conference on Eating Disorders CY APR 24-25, 1996 CL NEW YORK, NY SP NIH, NIDDKD, NICHHD, Natl Task Force Prevent & Treatment Obes, Off Res Womens Hlth, Off Behav & Social Sci Res, Acad Eating Disorders DE anorexia nervosa; osteoporosis; bone; nutrition; insulin-like growth factor-I (IGF-I) ID GROWTH-FACTOR-I; YOUNG-WOMEN; ADOLESCENT GIRLS; EATING DISORDERS; MINERAL DENSITY; OSTEOPOROSIS; OSTEOPENIA; MASS; AMENORRHEA; METABOLISM AB Osteoporosis is present in over half of all patients with anorexia nervosa. Bone loss often occurs at a young age and may persist even after recovery, predisposing patients to debilitating spinal crush fractures, The pathogenesis of bone loss in anorexia nervosa is not completely understood and may result from a number of mechanisms, including estrogen deficiency, inadequate vitamin and calcium intake, and nutritional effects on bone formation. Recent studies demonstrate that estrogen itself is inadequate to increase bone density in a majority of patients with anorexia nervosa and suggest that nutritionally dependent factors such as insulin-like growth factor-I (IGF-I), a potent bone trophic hormone, may be important in maintaining bone mass. It is hoped that new anabolic strategies to increase osteoblast function will become available in the future, In the interim, weight gain, restoration of gonadal function, and calcium supplementation remain the cornerstones of treatment in this disease. C1 MASSACHUSETTS GEN HOSP,PSYCHIAT UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA. RP Grinspoon, S (reprint author), MASSACHUSETTS GEN HOSP,NEUROENDOCRINE UNIT,BULFINCH 457B,BOSTON,MA 02114, USA. FU NCRR NIH HHS [M01-RR01066]; NIDDK NIH HHS [P32-DK07028, R01-DK52625] NR 35 TC 28 Z9 28 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1997 VL 33 IS 3 BP 399 EP 404 PG 6 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA XZ328 UT WOS:A1997XZ32800011 PM 9550884 ER PT J AU Amsterdam, J GarciaEspana, F Fawcett, J Quitkin, F Reimherr, F Rosenbaum, J AF Amsterdam, J GarciaEspana, F Fawcett, J Quitkin, F Reimherr, F Rosenbaum, J TI Efficacy and safety of fluoxetine in bipolar major depressive episode - A multicenter, prospective trial SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Meeting Abstract C1 UNIV PENN,MED CTR,DEPRESS RES UNIT,PHILADELPHIA,PA 19104. RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612. NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY 10032. UNIV UTAH,SCH MED,SALT LAKE CITY,UT. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1997 VL 33 IS 3 BP 492 EP 492 PG 1 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA XZ328 UT WOS:A1997XZ32800040 ER PT J AU Cohen, LS Goldstein, J Tohen, M Andersen, S Tollefson, G AF Cohen, LS Goldstein, J Tohen, M Andersen, S Tollefson, G TI Sex differences in response to treatment with olanzapine: A preliminary analysis SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,PERINATAL & REPROD PSYCHIAT CLIN RES PROGRAM,BOSTON,MA. ELI LILLY & CO,LILLY CORP CTR,INDIANAPOLIS,IN 46285. NR 0 TC 1 Z9 1 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1997 VL 33 IS 3 BP 506 EP 506 PG 1 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA XZ328 UT WOS:A1997XZ32800054 ER PT J AU Cook, IA Leuchter, AF Uijtdehaage, SHJ Osato, S Holschneider, DH Abrams, M RosenbergThompson, S AF Cook, IA Leuchter, AF Uijtdehaage, SHJ Osato, S Holschneider, DH Abrams, M RosenbergThompson, S TI Altered cerebral energy utilization in late life depression SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Meeting Abstract C1 UNIV CALIF LOS ANGELES,SCH MED,NEUROPSYCHIAT INST & HOSP,QUANTITAT EEG LAB,LOS ANGELES,CA 90024. UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024. W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90073. UNIV SO CALIF,SCH MED,DEPT PSYCHIAT,LOS ANGELES,CA. UNIV SO CALIF,SCH MED,DEPT NEUROL,LOS ANGELES,CA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1997 VL 33 IS 3 BP 508 EP 508 PG 1 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA XZ328 UT WOS:A1997XZ32800056 ER PT J AU Fava, M Burger, J McColl, R Alpert, J Nierenberg, A Pava, J Rosenbaum, JF AF Fava, M Burger, J McColl, R Alpert, J Nierenberg, A Pava, J Rosenbaum, JF TI Cognitive changes in relationship to patterns of response to antidepressant drug treatment SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPRESS CLIN & RES PROGRAM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1997 VL 33 IS 3 BP 519 EP 519 PG 1 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA XZ328 UT WOS:A1997XZ32800067 ER PT J AU Fava, M Mulroy, R Kolsky, AR Alpert, JE Nierenberg, AA Rosenbaum, JF AF Fava, M Mulroy, R Kolsky, AR Alpert, JE Nierenberg, AA Rosenbaum, JF TI The emergence of adverse events following venlafaxine-ER discontinuation SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CLIN PSYCHOPHARMACOL UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 1 U2 1 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1997 VL 33 IS 3 BP 520 EP 520 PG 1 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA XZ328 UT WOS:A1997XZ32800068 ER PT J AU Ghaemi, SN Sachs, GS Chiou, AM Pandurangi, AK Goodwin, FK AF Ghaemi, SN Sachs, GS Chiou, AM Pandurangi, AK Goodwin, FK TI Is bipolar disorder under diagnosed? Are antidepressants overutilized? SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Meeting Abstract C1 GEORGE WASHINGTON UNIV,WASHINGTON,DC 20037. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA. VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298. RI Ghaemi, Nassir/J-4934-2013 NR 0 TC 1 Z9 1 U1 0 U2 1 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1997 VL 33 IS 3 BP 527 EP 527 PG 1 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA XZ328 UT WOS:A1997XZ32800075 ER PT J AU Leuchter, AF Cook, IA Uijtdehaage, SHJ Dunkin, JJ AndersonHanley, C Abrams, M RosenbergThompson, S AF Leuchter, AF Cook, IA Uijtdehaage, SHJ Dunkin, JJ AndersonHanley, C Abrams, M RosenbergThompson, S TI Neurophysiologic prediction of antidepressant treatment response SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Meeting Abstract C1 UNIV CALIF LOS ANGELES,NEUROPSYCHIAT INST & HOSP,QUANTITAT EEG LAB,LOS ANGELES,CA 90024. UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024. W LOS ANGELES VET AFFAIRS MED CTR,MEDICAT DEV RES UNIT,LOS ANGELES,CA 90073. NR 0 TC 0 Z9 0 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1997 VL 33 IS 3 BP 548 EP 548 PG 1 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA XZ328 UT WOS:A1997XZ32800096 ER PT J AU Pollack, M Wolkow, R Clary, C AF Pollack, M Wolkow, R Clary, C TI Sertraline treatment of panic disorder: Combined results from two placebo-controlled trials SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. PFIZER INC,NEW YORK,NY. NR 0 TC 1 Z9 1 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1997 VL 33 IS 3 BP 569 EP 569 PG 1 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA XZ328 UT WOS:A1997XZ32800117 ER PT J AU Solomon, DA Ryan, CE Keitner, GI Miller, IW Shea, MT Kazim, A Keller, MB AF Solomon, DA Ryan, CE Keitner, GI Miller, IW Shea, MT Kazim, A Keller, MB TI A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Meeting Abstract C1 RHODE ISL HOSP,DEPT PSYCHIAT,PROVIDENCE,RI 02903. BROWN UNIV,DEPT PSYCHIAT & HUMAN BEHAV,PROVIDENCE,RI 02912. MASSACHUSETTS GEN HOSP,DEPT PSYCHIAT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 1 U2 1 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1997 VL 33 IS 3 BP 584 EP 584 PG 1 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA XZ328 UT WOS:A1997XZ32800132 ER PT J AU Worthington, JJ Pollack, MH Moroz, G Otto, MW McLean, RYS Rosenbaum, JF AF Worthington, JJ Pollack, MH Moroz, G Otto, MW McLean, RYS Rosenbaum, JF TI Naturalistic study of clonazepam in panic disorder SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT PSYCHIAT,BOSTON,MA 02114. ROCHE BIOMED LABS,CLIN INVEST MED AFFAIRS,NUTLEY,NJ. NR 0 TC 0 Z9 0 U1 0 U2 1 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1997 VL 33 IS 3 BP 606 EP 606 PG 1 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA XZ328 UT WOS:A1997XZ32800154 ER PT J AU Ackerman, DL Greenland, S Bystritsky, A Small, GW AF Ackerman, DL Greenland, S Bystritsky, A Small, GW TI Characteristics of fluoxetine versus placebo responders in a randomized trial of geriatric depression SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article; Proceedings Paper CT 37th Annual Meeting of the National-Center-for-Drug-Evaluation CY MAY 27-30, 1997 CL BOCA RATON, FLORIDA SP Natl Ctr Drug Eval Unit, NIMH DE geriatric psychiatry; depression; treatment outcome; prediction; placebos ID MAJOR DEPRESSION; DOUBLE-BLIND; PREDICTORS; DISORDER; ANTIDEPRESSANTS; METAANALYSIS; EFFICACY; FEATURES; DOXEPIN; IMPACT AB Results from placebo-controlled trials of antidepressants can be used to identify patients most likely to benefit from medication. Using data from a randomized clinical trial of fluoxetine versus placebo for 671 elderly outpatients with major depression, we evaluated characteristics of those who improved with and without active medication. We found that the choice of outcome measure made a difference when evaluating the effectiveness of fluoxetine relative to placebo and determining the accuracy of predictive variables in both treatment groups. Generally, less severe depression predicted favorable response (greater than 50% improvement on the 21-item Hamilton Rating Scale for Depression [HAM-D-21], less than 3 on the Clinical Global Impressions [CGI] and Patient Global Impressions [PGI] Improvement scales) and remission (less than 9 on 6-week HAM-D-21) with both fluoxetine and placebo. Less anxiety/somatization was associated with favorable fluoxetine response, and lower levels of cognitive and sleep disturbance were associated with remission in the placebo group. By contrast, higher levels of psychomotor retardation in the placebo group were associated with clinician and patient ratings of much or very much improved. The similarities among responders in both groups may indicate that some in the fluoxetine group would have improved with placebo. C1 Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Inst Neuropsychiat, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Ctr Aging, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Ackerman, DL (reprint author), Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Box 951772, Los Angeles, CA 90095 USA. FU NIMH NIH HHS [MH-53935] NR 36 TC 10 Z9 10 U1 1 U2 3 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 USA SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1997 VL 33 IS 4 BP 707 EP 714 PG 8 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA YZ164 UT WOS:000072226700014 PM 9493483 ER PT J AU Saba, L Mayer, EA Naliboff, B AF Saba, L Mayer, EA Naliboff, B TI Cross-cultural comparisons of the SCL-90-R among Asian, African-American, Hispanic and White males and females with irritable bowel syndrome SO PSYCHOSOMATIC MEDICINE LA English DT Meeting Abstract C1 UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024. W LOS ANGELES VET AFFAIRS MED CTR,DEPT MED,CURE NEUROENTER BIOL GRP,LOS ANGELES,CA 90024. W LOS ANGELES VET AFFAIRS MED CTR,DEPT PSYCHIAT,CURE NEUROENTER BIOL GRP,LOS ANGELES,CA 90024. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0033-3174 J9 PSYCHOSOM MED JI Psychosom. Med. PD JAN-FEB PY 1997 VL 59 IS 1 BP 99 EP 99 PG 1 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA WF121 UT WOS:A1997WF12100110 ER PT J AU Munakata, J Naliboff, B Gracely, RH Chang, L Mayer, EA AF Munakata, J Naliboff, B Gracely, RH Chang, L Mayer, EA TI Selective affective bias for visceral sensation in the irritable bowel syndrome SO PSYCHOSOMATIC MEDICINE LA English DT Meeting Abstract C1 UNIV CALIF LOS ANGELES,LOS ANGELES,CA. W LOS ANGELES VET AFFAIRS MED CTR,DEPT MED,CURE NEUROENTER BIOL GRP,LOS ANGELES,CA 90073. W LOS ANGELES VET AFFAIRS MED CTR,DEPT PHYSIOL,CURE NEUROENTER BIOL GRP,LOS ANGELES,CA 90073. W LOS ANGELES VET AFFAIRS MED CTR,DEPT PSYCHOL,CURE NEUROENTER BIOL GRP,LOS ANGELES,CA 90073. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0033-3174 J9 PSYCHOSOM MED JI Psychosom. Med. PD JAN-FEB PY 1997 VL 59 IS 1 BP 105 EP 105 PG 1 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA WF121 UT WOS:A1997WF12100132 ER PT J AU Popli, AP Hegarty, JD Siegel, AJ Kando, JC Tohen, M AF Popli, AP Hegarty, JD Siegel, AJ Kando, JC Tohen, M TI Transfer of psychiatric inpatients to a general hospital due to adverse drug reactions SO PSYCHOSOMATICS LA English DT Article ID ADMISSIONS; EVENTS AB The authors review their experience with transfers of hospitalized psychiatric inpatients to general hospitals because of adverse drug reactions (ADRs). A total of 29 medical transfers related to ADRs were found in a review of 10,994 psychiatric inpatient admissions that occurred in a 30-month period between 1990 and 1993 (0.264%). Most cases involved neurological syndromes (76%), particularly delirium (31%). Low-potency antipsychotic agents were most frequently implicated (31%). Most ADRs were of moderate severity, but 8 cases required medical hospitalization (0.07% incidence). These findings indicate that ADRs leading to transfer of hospitalized psychiatric patients to a general medical facility were infrequent (<0.3% of psychiatric admissions) and rarely led to medical hospitalization (<0.1%). C1 HARVARD UNIV,SCH MED,CONSOLIDATED DEPT PSYCHIAT,BOSTON,MA 02115. PSYCHOPHARMACOL TRAINING SERV,PSYCHIAT RES LABS,BOSTON,MA. PHARMACOEPIDEMIOL CTR,BIPOLAR & PSYCHOT PROGRAM,BOSTON,MA. HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,MCLEAN HOSP,DEPT INTERNAL MED & PHARM,BOSTON,MA 02114. NR 10 TC 4 Z9 4 U1 0 U2 0 PU AMER PSYCHIATRIC ASSOCIATION PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD JAN-FEB PY 1997 VL 38 IS 1 BP 35 EP 37 PG 3 WC Psychiatry; Psychology SC Psychiatry; Psychology GA WA081 UT WOS:A1997WA08100005 PM 8997114 ER PT J AU Heckers, S AF Heckers, S TI Neuropsychiatry, neuropsychology, and clinical neuroscience: Emotion, evolution, cognition, language, memory, brain damage, and abnormal behavior, 2nd edition - Joseph,R SO PSYCHOSOMATICS LA English DT Book Review RP Heckers, S (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,PSYCHIAT CONSULTAT SERV,BOSTON,MA 02114, USA. RI Heckers, Stephan/F-3051-2010 OI Heckers, Stephan/0000-0003-3601-9910 NR 1 TC 0 Z9 0 U1 0 U2 2 PU AMER PSYCHIATRIC ASSOCIATION PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD JAN-FEB PY 1997 VL 38 IS 1 BP 81 EP 82 PG 2 WC Psychiatry; Psychology SC Psychiatry; Psychology GA WA081 UT WOS:A1997WA08100012 ER PT J AU Keuthen, NJ OSullivan, RL Hayday, CF Peets, KE Jenike, MA Baer, L AF Keuthen, NJ OSullivan, RL Hayday, CF Peets, KE Jenike, MA Baer, L TI The relationship of menstrual cycle and pregnancy to compulsive hairpulling SO PSYCHOTHERAPY AND PSYCHOSOMATICS LA English DT Article DE trichotillomania; compulsive hairpulling; menstrual cycle; pregnancy ID TRICHOTILLOMANIA AB Background: Trichotillomania (TTM) or compulsive hairpulling is a cyclical disorder that presents predominantly in females, Anecdotal reports of symptom worsening in the premenstruum and during pregnancy led us to retrospectively study the role of these events in hairpulling behavior. Methods: Questionnaires assessing demographics, current hairpulling behavior, and the reported effects of menstruation and pregnancy on urges, actual hairpulling and behavioral control were administered to clinic patients and volunteers at a hairpulling conference. The MGH Hairpulling Scale, Beck Depression Inventory and Beck Anxiety Inventory were also completed. Data from 59 hairpullers were analyzed. Results: Premenstrual symptom exacerbation was reported for actual hairpulling, urge intensity and frequency, and ability to control pulling and was alleviated during menstruation and shortly thereafter. The impact of pregnancy was less unidirectional, with both symptom exacerbation and lessening reported. Conclusions: The menstrual cycle appears to affect compulsive hairpulling and deserves recognition in both the assessment and treatment of this disorder. The impact of pregnancy on TTM is less clear. C1 MASSACHUSETTS GEN HOSP,DEPT PSYCHIAT,CHARLESTOWN,MA. HARVARD UNIV,SCH MED,CHARLESTOWN,MA. RI Citations, TLC SAB/C-4006-2011 NR 21 TC 21 Z9 22 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0033-3190 J9 PSYCHOTHER PSYCHOSOM JI Psychother. Psychosom. PD JAN-FEB PY 1997 VL 66 IS 1 BP 33 EP 37 PG 5 WC Psychiatry; Psychology SC Psychiatry; Psychology GA WB546 UT WOS:A1997WB54600004 PM 8996713 ER PT J AU Jacobson, AM deGroot, M Samson, JA AF Jacobson, AM deGroot, M Samson, JA TI The effects of psychiatric disorders and symptoms on quality of life in patients with Type I and Type II diabetes mellitus SO QUALITY OF LIFE RESEARCH LA English DT Article DE depression; diabetes; psychiatric illness; psychiatric symptoms; quality of life ID STRUCTURED CLINICAL INTERVIEW; HEALTH SURVEY SF-36; OF-LIFE; MEDICAL OUTCOMES; SHORT-FORM; GENERAL-POPULATION; RELIABILITY; VALIDITY; THERAPY; TESTS AB The purpose of this study was to evaluate the influence of psychiatric symptoms and illness status on the health-related quality of life (HRQOL) of outpatients with Type and Type II diabetes mellitus. Using a two-stage design, all patients were assessed by two measures of quality of life (Diabetes Quality of Life Measure; Medical Outcome Study Health Survey) and a psychiatric symptoms checklist (SCL-90-R). Patients scoring 63 or greater on the global severity index of the SCL-90-R and 30% below this cutoff were then evaluated using the Structured Clinical Interview for the DSM-III-R (SCID), Quality of life in both Type and Type II diabetes was influenced by the level of current psychiatric symptoms and presence of co-morbid psychiatric disorder, after controlling for number of diabetic complications (e.g. effect of lifetime psychiatric illness on diabetes-related HRQOL; F = 46.8; df = 3, 135; p < 0.005), These effects were found consistently across specific domains. Both recent and past psychiatric disorders influenced HRQOL, Separate analyses comparing patients with and without depression showed similar effects. No interaction effects between diabetes type, number of complications, and psychiatric status were found in analyses. Finally, increased severity of psychiatric symptoms was correlated with decreased HRQOL in patients without current, recent, or past psychiatric diagnosis. This study shows the consistent, independent contribution of psychiatric symptoms and illness to the HRQOL of patients with a coexisting medical illness. Thus, psychiatric interventions addressing common conditions, such as depression, could improve the HRQOL of patients without changing medical status. C1 MCLEAN HOSP, BOSTON, MA USA. HARVARD UNIV, SCH MED, DEPT PSYCHIAT, BOSTON, MA 02115 USA. RP Jacobson, AM (reprint author), JOSLIN DIABET CTR, PSYCHIAT SERV, 1 JOSLIN PL, BOSTON, MA 02215 USA. FU NIDDK NIH HHS [DK27845, DK42315] NR 34 TC 98 Z9 99 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 EI 1573-2649 J9 QUAL LIFE RES JI Qual. Life Res. PD JAN PY 1997 VL 6 IS 1 BP 11 EP 20 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA WJ597 UT WOS:A1997WJ59700002 PM 9062437 ER PT J AU Rao, PM Rhea, JT Novelline, RA McCabe, CJ Lawrason, JN Berger, DL Sacknoff, R AF Rao, PM Rhea, JT Novelline, RA McCabe, CJ Lawrason, JN Berger, DL Sacknoff, R TI Helical CT technique for the diagnosis of appendicitis: Prospective evaluation of a focused appendix CT examination SO RADIOLOGY LA English DT Article; Proceedings Paper CT 82nd Annual Meeting of the Radiological-Society-of-North-America CY DEC 01-06, 1996 CL CHICAGO, IL SP Radiol Soc N Amer DE appendicitis; appendix; appendix, CT; computed tomography (CT), helical; computed tomography (CT), technology ID BARIUM ENEMA AB PURPOSE: To evaluate a focused, helical computed tomographic (CT) technique for imaging the appendix in patients suspected of having appendicitis. MATERTALS AND METHODS: One hundred patients prospectively underwent appendix CT examination, with use of oral and colon contrast media and contiguous, thin-collimation, helical CT imaging of the right lower quadrant. Results were correlated with the results of surgery and pathologic examination from 61 patients or from clinical follow-up in 39 patients. RESULTS: CT scans were positive for appendicitis in 59 patients: true-positive in 56 patients on the basis of surgery and pathologic examination, and false-positive in two patients on the basis of clinical follow-up; in the case of the other positive scan, the clinical outcome was indeterminate. CT scans were negative for appendicitis in 41 patients: true-negative in five patients on the basis of surgery and pathologic examination, and true-negative in 36 patients on the basis of clinical follow-up. CT had a sensitivity of 100%, a specificity of 95%, a positive predictive value of 97%, a negative predictive value of 100%, and an accuracy of 98%. The normal appendix was always identified. CT helped establish alternative diagnoses in 33 of the 41 patients (80%) in whom the results of CT were negative for appendicitis. CONCLUSION: Appendix CT examination can help diagnose or exclude appendicitis and establish an alternative diagnosis. C1 MASSACHUSETTS GEN HOSP,DEPT SURG,BOSTON,MA 02114. RP Rao, PM (reprint author), MASSACHUSETTS GEN HOSP,DEPT RADIOL,32 FRUIT ST,BOSTON,MA 02114, USA. NR 26 TC 306 Z9 322 U1 0 U2 3 PU RADIOLOGICAL SOC NORTH AMER PI EASTON PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 SN 0033-8419 J9 RADIOLOGY JI Radiology PD JAN PY 1997 VL 202 IS 1 BP 139 EP 144 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA WA401 UT WOS:A1997WA40100025 PM 8988203 ER PT J AU Rao, PM Rhea, JT Novelline, RA AF Rao, PM Rhea, JT Novelline, RA TI CT diagnosis of mesenteric adenitis SO RADIOLOGY LA English DT Article DE appendicitis; appendix, CT; lymphatic system, diseases; mesentery ID ACUTE APPENDICITIS; YERSINIA; ILEITIS AB PURPOSE: To quantify how frequently mesenteric adenitis clinically mimics appendicitis and to determine its appearance at computed tomography (CT). MATERIALS AND METHODS: The medical records of 651 consecutive patients with an admission diagnosis of appendicitis were reviewed to determine how often mesenteric adenitis was the discharge diagnosis. The CT scans of a separate group of 18 patients with a discharge diagnosis of mesenteric adenitis were reviewed. These patients were part of a group of 100 consecutive patients prospectively evaluated with CT of the appendix for clinically suspected appendicitis. RESULTS: Fifty of 651 patients (7.7%) with an admission diagnosis of appendicitis had a discharge diagnosis of mesenteric adenitis. Mesenteric adenitis constituted 50 of the 252 (19.8%) discharge diagnoses other than appendicitis. All 18 CT scans of mesenteric adenitis showed three or more nodes that measured at least 5 mm in shortest axis clustered in the right lower quadrant, with a normal appendix identified. Eight patients had associated ileal or ileocecal wall thickening. CONCLUSION: Mesenteric adenitis is an important clinical mimic of appendicitis. It appears at CT as clustered, enlarged mesenteric lymph nodes with a normal appendix, and there may be associated ileitis or ileocolitis noted. RP Rao, PM (reprint author), MASSACHUSETTS GEN HOSP,DEPT RADIOL,32 FRUIT ST,BOSTON,MA 02114, USA. NR 12 TC 61 Z9 65 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMER PI EASTON PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 SN 0033-8419 J9 RADIOLOGY JI Radiology PD JAN PY 1997 VL 202 IS 1 BP 145 EP 149 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA WA401 UT WOS:A1997WA40100026 PM 8988204 ER PT J AU Goldberg, MA Gazelle, GS Boland, GW Hahn, PF MayoSmith, WW Pivovarov, M Halpern, EF Wittenberg, J AF Goldberg, MA Gazelle, GS Boland, GW Hahn, PF MayoSmith, WW Pivovarov, M Halpern, EF Wittenberg, J TI Focal hepatic lesions: Effect of three-dimensional wavelet compression on detection at CT SO RADIOLOGY LA English DT Article; Proceedings Paper CT 1995 Meeting of the Radiological-Society-of-North-America CY NOV 26-DEC 01, 1995 CL CHICAGO, IL SP Radiol Soc N Amer DE computed tomography (CT), image processing; data compression; images, interpretation; liver, CT ID DIAGNOSTIC-ACCURACY; IMAGE COMPRESSION; RADIOGRAPHS; ROC AB PURPOSE: To evaluate the effect of three-dimensional, wavelet-based compression on the detection of focal hepatic lesions at computed tomography (CT). MATERIALS AND METHODS: CT images obtained in 69 patients with focal hepatic lesions were studied (35 consecutive cases and 34 cases selected to be difficult on the basis of lesion size or contrast). Image data were compressed by means of a three-dimensional, wavelet-based algorithm at ratios of 10:1, 15:1, and 20:1. Normal and abnormal sections (on original and compressed images) were reviewed by using an interactive workstation. Four readers rated the presence or absence of a lesion with a five-point scale. RESULTS: At receiver operating characteristic analysis, no statistically significant difference was detected for all cases considered together. Differences approached but did not reach statistical significance for the diagnostic performance of one reader with compressed images (15:1, P = .054; 20:1, P = .051). For the subset of difficult cases, a significant difference was observed with 20:1 compressed images for one reader (P = .026). Diagnostic performance of readers was less certain in normal than in abnormal cases with both original and compressed images (difference was significant for 15:1 [P = .035] and 20:1 [P < .0001] compressed images). CONCLUSION: Three-dimensional wavelet compression is satisfactory at ratios of at least 10:1. Additional studies with a larger sample would help confirm findings with higher ratios. C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. AMER TELEMED INT,CAMBRIDGE,MA. RP Goldberg, MA (reprint author), HARVARD UNIV,SCH MED,DEPT RADIOL,32 FRUIT ST,BOSTON,MA 02114, USA. NR 28 TC 41 Z9 41 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMER PI EASTON PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 SN 0033-8419 J9 RADIOLOGY JI Radiology PD JAN PY 1997 VL 202 IS 1 BP 159 EP 165 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA WA401 UT WOS:A1997WA40100028 PM 8988206 ER PT J AU Solbiati, L Ierace, T Goldberg, SN Sironi, S Livraghi, T Fiocca, R Servadio, G Rizzatto, G Mueller, PR DelMaschio, A Gazelle, GS AF Solbiati, L Ierace, T Goldberg, SN Sironi, S Livraghi, T Fiocca, R Servadio, G Rizzatto, G Mueller, PR DelMaschio, A Gazelle, GS TI Percutaneous US-guided radio-frequency tissue ablation of liver metastases: Treatment and follow-up in 16 patients SO RADIOLOGY LA English DT Article DE liver neoplasms, secondary; liver neoplasms, therapy; radiofrequency (RF) ablation ID ETHANOL INJECTION THERAPY; HEPATIC METASTASES; COLORECTAL-CANCER; RADIOFREQUENCY ELECTROCAUTERY; HEPATOCELLULAR-CARCINOMA; RESECTION; TUMORS; LASER; HYPERTHERMIA; CRYOSURGERY AB PURPOSE: To determine the potential efficacy of radio-frequency (RF) ablation of liver metastases during long-term follow-up. MATERIALS AND METHODS: Sixteen patients with 31 hepatic metastases were treated with percutaneous, ultrasound-guided RF ablation. RF was applied to monopolar electrodes (2-3-cm tip exposure) either individually or within a multiprobe array (two to four probes) for 6 minutes at 90 degrees C over one to four treatment sessions per metastasis. RESULTS: In only one of 75 sessions, a moderate complication, self-limited intraperitoneal hemorrhage, was observed. Four patients (four lesions) underwent surgical resection 15-60 days after RF treatment. Residual, viable tumor was seen in all of these patients. The remaining 12 patients were followed up for 9-29 months (mean, 18.1 months). In these patients, 18 of 27 lesions remained stable or decreased in size and showed no enhancement at computed tomography and/or magnetic resonance imaging for at least 9 months, Two patients died of disseminated disease at 13 months and one at 16 months. Disease-free survival was achieved in eight patients. CONCLUSION: RF ablation appears to be a simple, safe, and potentially effective treatment for selected patients with liver metastases and may become a less invasive alternative to surgical therapy. C1 HARVARD UNIV,SCH MED,DEPT RADIOL,MASSACHUSETTS GEN HOSP,BOSTON,MA 02115. IST SCI SAN RAFFAELE,DEPT RADIOL,MILAN,ITALY. POLICLIN SAN MATTEO,DEPT PATHOL,I-27100 PAVIA,ITALY. OSPED GEN,DEPT RADIOL,GORIZIA,ITALY. GEN HOSP,DEPT INTENS CARE,I-21052 BUSTRO ARSIZIO,VA,ITALY. OSPED CIVILE,DEPT RADIOL,VIMERCATE,MI,ITALY. RP Solbiati, L (reprint author), GEN HOSP,DEPT RADIOL,PIAZZALE SOLARO 3,I-21052 BUSTRO ARSIZIO,VA,ITALY. RI Fiocca, Roberto/K-9705-2016; OI Fiocca, Roberto/0000-0002-8856-6185; Solbiati, Luigi/0000-0002-3109-1449 NR 47 TC 427 Z9 461 U1 2 U2 9 PU RADIOLOGICAL SOC NORTH AMER PI EASTON PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 SN 0033-8419 J9 RADIOLOGY JI Radiology PD JAN PY 1997 VL 202 IS 1 BP 195 EP 203 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA WA401 UT WOS:A1997WA40100033 PM 8988211 ER PT J AU Livraghi, T Goldberg, SN Monti, F Bizzini, A Lazzaroni, S Meloni, F Pellicano, S Solbiati, L Gazelle, GS AF Livraghi, T Goldberg, SN Monti, F Bizzini, A Lazzaroni, S Meloni, F Pellicano, S Solbiati, L Gazelle, GS TI Saline-enhanced radio-frequency tissue ablation in the treatment of liver metastases SO RADIOLOGY LA English DT Article; Proceedings Paper CT 1995 Meeting of the Radiological-Society-of-North-America CY NOV 26-DEC 01, 1995 CL CHICAGO, IL SP Radiol Soc N Amer DE liver neoplasms, secondary; liver neoplasms, therapy; radiofrequency (RF) ablation ID PERCUTANEOUS ETHANOL INJECTION; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; RADIOFREQUENCY; TUMORS; ARRAYS; PROBE AB PURPOSE: To assess the effect of intraparenchymal saline injection on the results of radio-frequency (RF) tissue ablation. MATERIALS AND METHODS: Ex vivo and in vivo animal RF ablation was performed with and without intraparenchymal saline injection. Initially, saline was injected as a bolus (1-20 mi) before RF application. For subsequent in vivo studies, saline was injected as a bolus before RF application or continuously (1 mL/min) during RF application. Finally, 14 patients with liver metastases and one patient with primary cholangiocarcinoma were treated with the continuous infusion technique. A single RF electrode (tip exposure, 1-3 cm) was used with various ablation parameters. RESULTS: With pretreatment bolus injection of saline, lesions measured 1.4 cm +/- 0.1, 1.6 cm +/- 0.2, and 1.2 cm +/- 0.1 in ex vivo liver, in vivo animal muscle, and in vivo animal liver, respectively. Without saline enhancement, lesion sizes were 1.0 +/- 0.2, 1.2 +/- 0.3 and 0.8 +/- 0.1 cm, respectively. With continuous saline injection in in vivo pig liver, lesion size was 1.8-4.1 cm in diameter. In human tumors, necrosis volume was variable, but complete necrosis was seen in 13 of 25 lesions (diameter, 1.2-3.9 cm). Partial necrosis greater than 50% was seen in 12 lesions (diameter, 1.5-4.5 cm). CONCLUSION: Saline-enhanced RF ablation might permit percutaneous destruction of large liver lesions. C1 OSPED CIVILE,DEPT ANESTHESIOL & INTENS CARE,I-20059 VIMERCATE,MILAN,ITALY. HARVARD UNIV,SCH MED,DEPT RADIOL,MASSACHUSETTS GEN HOSP,BOSTON,MA 02115. POLICLIN S ORSOLA,INST INTERNAL MED 1 & BIOMED TECHNOL,BOLOGNA,ITALY. OSPED SAN BIAGIO,DEPT INTERNAL MED,CLUSONE,ITALY. OSPED GEN,DEPT RADIOL,BUSTRO ARSIZIO,ITALY. RP Livraghi, T (reprint author), OSPED CIVILE,DEPT RADIOL,VIA C BATTISTI 23,I-20059 VIMERCATE,MILAN,ITALY. OI meloni, maria franca/0000-0001-7485-7400; Solbiati, Luigi/0000-0002-3109-1449 NR 16 TC 350 Z9 369 U1 0 U2 2 PU RADIOLOGICAL SOC NORTH AMER PI EASTON PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 SN 0033-8419 J9 RADIOLOGY JI Radiology PD JAN PY 1997 VL 202 IS 1 BP 205 EP 210 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA WA401 UT WOS:A1997WA40100034 PM 8988212 ER PT B AU Zietman, AL Smith, CT Shipley, WU AF Zietman, AL Smith, CT Shipley, WU BE Schroder, FH TI The PSA response following radical radiation therapy for localized prostate cancer SO RECENT ADVANCES IN PROSTATE CANCER AND BPH LA English DT Proceedings Paper CT IV Congress on Progress and Controversies in Oncological Urology (PACIOU IV) CY APR, 1996 CL ROTTERDAM, NETHERLANDS RP Zietman, AL (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT RADIAT ONCOL,GENITOURINARY ONCOL UNIT,BOSTON,MA 02114, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PARTHENON PUBLISHING GROUP LTD PI LANCASTER PA CASTERTON HALL, CARNFORTH, LANCASTER, ENGLAND LA6 2LA BN 1-85070-784-7 PY 1997 BP 241 EP 252 PG 12 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA BH04Y UT WOS:A1997BH04Y00031 ER PT J AU Krzystolik, MG Ciulla, TA Topping, TM Baker, S AF Krzystolik, MG Ciulla, TA Topping, TM Baker, S TI Exogenous Aspergillus niger endophthalmitis in a patient with a filtering bleb SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article C1 OPHTHALM CONSULTANTS BOSTON,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA. MASSACHUSETTS EYE & EAR INFIRM,DEPT OPHTHALMOL,BOSTON,MA 02114. INDIANA UNIV,SCH MED,DEPT OPHTHALMOL,INDIANAPOLIS,IN 46202. CTR EYE RES,BOSTON,MA. NR 8 TC 9 Z9 9 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0275-004X J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PY 1997 VL 17 IS 5 BP 461 EP 462 PG 2 WC Ophthalmology SC Ophthalmology GA YC867 UT WOS:A1997YC86700020 PM 9355201 ER PT J AU Ng, EWM Samiy, N Rubins, JB Cousins, FV Ruoff, KL Baker, AS D'Amico, DJ AF Ng, EWM Samiy, N Rubins, JB Cousins, FV Ruoff, KL Baker, AS D'Amico, DJ TI Implication of pneumolysin as a virulence factor in Streptococcus pneumoniae endophthalmitis SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE Streptococcus pneumoniae; endophthalmitis; pneumolysin; exotoxin; inflammation ID THIOL-ACTIVATED TOXIN; BACTERIAL ENDOPHTHALMITIS; RESPIRATORY BURST; OCULAR INFECTIONS; BACILLUS-CEREUS; DEXAMETHASONE; HEMOLYSIN; CELLS; PATHOGENESIS; MENINGITIS AB Purpose: To determine if pneumolysin, a multifunctional cytotoxin produced by Streptococcus pneumoniae, may be a virulence determinant in the pathogenesis of pneumococcal endophthalmitis. Methods: Lewis rats (n = 20) were injected intravitreally with purified recombinant pneumolysin at the following doses; 3.9 hemolytic units (HU), 39 HU, 390 HU, 3.9 x 10(3) HU, and 3.9 x 10(4) HU. After 24 hours, eyes were examined clinically and enucleated for histopathologic examination to elucidate the dose-response relationship. To determine the temporal progression of the disease model, a second group of rats (n = 8) were injected intravitreally with 390 HU of pneumolysin. At 6 and 48 hours, eyes were examined clinically and enucleated for histopathology. Results: Eyes injected with pneumolysin demonstrated increasing anterior and posterior segment inflammation in response to increasing doses of administered toxin. The onset of inflammation and tissue damage occurred rapidly, and was maximal at 24 to 48 hours. The clinical and histopathologic changes observed mimicked those of S. pneumoniae endophthalmitis. Histopathologic analysis demonstrated rapid onset of iridocyclitis and vitritis with polymorphonuclear leukocyte influx, inner retinal necrosis, and retinal detachment. Retinal pigment epithelial necrosis and choroiditis were noted at the highest doses administered. Inflamed eyes were shown to be sterile. Conclusions: Pneumolysin injected intravitreally induces many of the clinical and histopathologic features of pneumococcal endophthalmitis, and may play an important role in the inflammation and tissue damage that occurs in pneumococcal endophthalmitis. C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, Boston, MA 02114 USA. Vet Affairs Med Ctr, Div Pulm Dis, Minneapolis, MN USA. Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA. Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Infect Dis Serv, Boston, MA USA. RP D'Amico, DJ (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, 243 Charles St, Boston, MA 02114 USA. NR 30 TC 14 Z9 14 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA SN 0275-004X J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PY 1997 VL 17 IS 6 BP 521 EP 529 PG 9 WC Ophthalmology SC Ophthalmology GA YL978 UT WOS:000071014500006 PM 9428015 ER PT J AU Wilkins, JN AF Wilkins, JN TI Pharmacotherapy of schizophrenia patients with comorbid substance abuse SO SCHIZOPHRENIA BULLETIN LA English DT Article ID PSYCHIATRIC-PATIENTS; TARDIVE-DYSKINESIA; NEGATIVE SYMPTOMS; COCAINE USE; FLUPENTIXOL DECANOATE; CLINICAL OBSERVATIONS; OUTPATIENT TREATMENT; ALCOHOL DEPENDENCE; CIGARETTE-SMOKING; REVOLVING-DOOR AB Substance abuse worsens the course of schizophrenia and significantly impairs the relationship between the patient and the health care team, Recent advances in laboratory studies of substance abuse and the pharmacology of schizophrenia open up new possibilities for pharmacotherapy of substance abuse in schizophrenia patients, D-1 dopaminergic receptor agonists may directly block the drive for stimulant use, D-2 dopaminergic receptor antagonists may indirectly block the drive for stimulant and nicotine use,while opioid antagonists appear to reduce the drive to use alcohol, New generations of neuroleptics with serotonin (5-HT2) receptor antagonism and/or 5-HT1A agonist activity may reduce substance abuse in schizophrenia patients who self-medicate negative symptoms or neuroleptic side effects, Pharmacotherapy efficacy may be enhanced by adding contingency management, social skills training, and other manualized programs, Tables are provided of potentially useful medications, Preliminary results are presented of cocaine-abusing schizophrenia patients treated with desipramine and traditional neuroleptics. C1 UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA. W LOS ANGELES VET AFFAIRS MED CTR,COMPREHENS HOMELESS PROGRAMS,LOS ANGELES,CA 90073. RP Wilkins, JN (reprint author), W LOS ANGELES VET AFFAIRS MED CTR,W LOS ANGELES VET AFFAIRS MED CTR MEDICAT DEV UNIT,LOS ANGELES,CA 90073, USA. FU NIDA NIH HHS [R01 DA-06551] NR 97 TC 47 Z9 48 U1 1 U2 4 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PY 1997 VL 23 IS 2 BP 215 EP 228 PG 14 WC Psychiatry SC Psychiatry GA WZ989 UT WOS:A1997WZ98900008 PM 9165632 ER PT J AU Heckers, S AF Heckers, S TI Neuropathology of schizophrenia: Cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems SO SCHIZOPHRENIA BULLETIN LA English DT Review ID PLANUM TEMPORALE ASYMMETRY; CAUDATE NUCLEI VOLUMES; CINGULATE CORTEX; PREFRONTAL CORTEX; ALZHEIMERS-DISEASE; POST-MORTEM; BRAIN-STEM; AUDITORY HALLUCINATIONS; QUANTITATIVE POSTMORTEM; PATHOLOGICAL RESEARCH AB This article reviews neuropathological studies in the search for an anatomical correlate of schizophrenia. Replication of many results has proven to be difficult. A consistent finding is the lack of significant gliosis in the neocortex, Intriguing findings that need further corroboration include decreased volume and cell number of the mediodorsal thalamic nucleus, cytoarchitectural alterations of the prefrontal cortex and upper layers of the anterior cingulate gyrus, and superior temporal gyrus abnormalities. Most neuropathological studies investigate regional brain volume and cell density. Highly variable shrinkage of brain tissue postmortem makes these estimates prone to bias and often not comparable across studies. So far, no strong clinicopathological correlations and no pathological criteria to diagnose schizophrenia have been established. RP Heckers, S (reprint author), HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT PSYCHIAT,WARREN 605,FRUIT ST,BOSTON,MA 02114, USA. RI Heckers, Stephan/F-3051-2010 OI Heckers, Stephan/0000-0003-3601-9910 NR 124 TC 122 Z9 125 U1 0 U2 2 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PY 1997 VL 23 IS 3 BP 403 EP 421 PG 19 WC Psychiatry SC Psychiatry GA XR438 UT WOS:A1997XR43800007 PM 9327506 ER PT B AU Kraeft, SK Hafeli, UO Chen, LB AF Kraeft, SK Hafeli, UO Chen, LB BE Hafeli, U Schutt, W Teller, J Zborowski, M TI Analysis of micro spheres in living cells by confocal microscopy SO SCIENTIFIC AND CLINICAL APPLICATIONS OF MAGNETIC CARRIERS LA English DT Proceedings Paper CT International Conference on Scientific and Clinical Applications of Magnetic Carriers CY SEP 05-07, 1996 CL ROSTOCK, GERMANY AB Confocal laser scanning microscopy is a versatile tool to study small particles in biological tissues. Optical sectioning allows the detection and localization of particles for various biomedical applications, at a single cell level or within a complex tissue. Most applications with particles employ fluorescent particles, and the example of fluorescein-conjugated latex beads as model substrates to study antigen processing in B-lymphocytes is discussed. Detection of particles inside intact B cells clearly demonstrated internalization of the antigen during antigen presentation. Confocal microscopy also allows the analysis of the internal morphology of magnetic microspheres (MMS). Such microspheres designed for targeted radiotherapy were studied together with living or fixed cells using multi-parameter imaging in epi-fluorescent, reflection and transmission modes. The results demonstrate that confocal microscopy is a valid tool to directly analyze the internal composition of magnetic carrier systems as well as their distribution within complex biological tissues. RP Kraeft, SK (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA. RI Hafeli, Urs/B-4097-2012; OI Hafeli, Urs/0000-0003-0671-4509 NR 0 TC 3 Z9 3 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 BN 0-306-45687-7 PY 1997 BP 149 EP 161 PG 13 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Pharmacology & Pharmacy GA BJ32T UT WOS:A1997BJ32T00011 ER PT J AU Williams, ME AF Williams, ME TI What are the clinically important consequences of ESRD - Associated endocrine dysfunction? SO SEMINARS IN DIALYSIS LA English DT Editorial Material ID INSULIN-RESISTANCE; DISEASE; UREMIA; SENSITIVITY; DIALYSIS; GLUCOSE C1 DEACONESS HOSP,JOSLIN DIABET CTR,DIV NEPHROL,BOSTON,MA. NR 25 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 SN 0894-0959 J9 SEMIN DIALYSIS JI Semin. Dial. PD JAN-FEB PY 1997 VL 10 IS 1 BP 16 EP 18 DI 10.1111/j.1525-139X.1997.tb00451.x PG 3 WC Urology & Nephrology SC Urology & Nephrology GA WJ485 UT WOS:A1997WJ48500006 ER PT J AU Pascual, M MachPascual, S Schifferli, JA AF Pascual, M MachPascual, S Schifferli, JA TI Paraproteins and complement depletion: Pathogenesis and clinical syndromes SO SEMINARS IN HEMATOLOGY LA English DT Article; Proceedings Paper CT International Workshop on Multiple Myeloma CY JUL 04, 1996 CL CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS, LAUSANNE, SWITZERLAND HO CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS ID HEPATITIS-C VIRUS; ACQUIRED C1-INHIBITOR DEFICIENCY; NORMOLIPEMIC PLANE XANTHOMATOSIS; CRYOGLOBULINEMIA TYPE-II; CAPILLARY LEAK SYNDROME; NECROBIOTIC XANTHOGRANULOMA; MIXED CRYOGLOBULINEMIA; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; INHIBITOR DEFICIENCY; MONOCLONAL IGG C1 MASSACHUSETTS GEN HOSP,TRANSPLANTAT UNIT,BOSTON,MA 02114. BRIGHAM & WOMENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115. UNIV BASEL,KANTONSSPITAL,MED KLIN B,CH-4031 BASEL,SWITZERLAND. RP Pascual, M (reprint author), MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114, USA. NR 75 TC 7 Z9 7 U1 2 U2 2 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0037-1963 J9 SEMIN HEMATOL JI Semin. Hematol. PD JAN PY 1997 VL 34 IS 1 SU 1 BP 40 EP 48 PG 9 WC Hematology SC Hematology GA WG174 UT WOS:A1997WG17400006 PM 9122745 ER PT S AU Cantley, LC Zhou, SY AF Cantley, LC Zhou, SY BE Corbin, JD Francis, SH TI Specificity in protein-tyrosine kinase signaling SO SIGNAL TRANSDUCTION IN HEALTH AND DISEASE SE ADVANCES IN SECOND MESSENGER AND PHOSPHOPROTEIN RESEARCH LA English DT Review CT 9th International Conference on Second Messengers and Phosphoproteins - Signal Transduction in Health and Disease CY OCT 27-NOV 01, 1995 CL NASHVILLE, TN SP Vanderbilt Univ Med Ctr ID AFFINITY PHOSPHOTYROSYL PEPTIDE; SRC HOMOLOGY-2 DOMAIN; SH2 DOMAIN; CRYSTAL-STRUCTURES; BINDING; MOTIF; PHOSPHORYLATION C1 BETH ISRAEL DEACONNESS MED CTR, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA. MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA. RP Cantley, LC (reprint author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA. RI Cantley, Lewis/D-1800-2014 OI Cantley, Lewis/0000-0002-1298-7653 FU NIGMS NIH HHS [R01 GM056203] NR 17 TC 14 Z9 14 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA E WASHINGTON SQ, PHILADELPHIA, PA 19105 USA SN 1040-7952 BN 0-397-51685-1 J9 ADV SEC MESS PHOSPH JI Adv.Second Messenger Phosphoprotein Res. PY 1997 VL 31 BP 41 EP 48 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA BJ66M UT WOS:A1997BJ66M00004 PM 9344240 ER PT J AU Weber, AL Hug, EB Muenter, MW Curtin, HD AF Weber, AL Hug, EB Muenter, MW Curtin, HD TI Giant-cell tumors of the sphenoid bone in four children: Radiological, clinical, and pathological findings SO SKULL BASE SURGERY LA English DT Article ID SKULL BASE; EOSINOPHILIC GRANULOMA; REPARATIVE GRANULOMA; BROWN TUMOR; HISTIOCYTOSIS-X; AXIAL SKELETON; TEMPORAL BONE; DIAGNOSIS; MRI; SINUS AB We report the clinical, pathological, and radiological findings of giant cell tumor of the sphenoid bone in four children aged 10 to 16 Years. The most common clinical finding was headache, followed by cranial nerve abnormalities. The computed tomgraphic findings of giant cell tumor consist of a lytic defect, sharply marginated:with no sclerosis associated with an expansile, homogeneous mass (isodense with muscle). In the differential diagnosis, the lesion most similar to giant-cell tumor is giant edl granuloma,The different histopathological features of the two lesions are discussed, along with other lesions, in the differential diagnosis. The magnetic resonance features consist of a mass with low signal intensities on T-1- and T-2-weighted images associated with moderate enhancement after introduction of gadolinium. C1 Massachusetts Eye & Ear Infirm, Dept Radiol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Univ Heidelberg, Heidelberg, Germany. RP Weber, AL (reprint author), Massachusetts Eye & Ear Infirm, Dept Radiol, Boston, MA 02114 USA. NR 87 TC 8 Z9 8 U1 0 U2 1 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1052-1453 J9 SKULL BASE SURG JI Skull Base Surg. PY 1997 VL 7 IS 4 BP 163 EP 173 DI 10.1055/s-2008-1058592 PG 11 WC Clinical Neurology; Otorhinolaryngology; Surgery SC Neurosciences & Neurology; Otorhinolaryngology; Surgery GA 179XC UT WOS:000079354500001 PM 17171027 ER PT J AU Badr, MS Morgan, BJ Finn, L Toiber, FS Crabtree, DC Puleo, DS Skatrud, JB AF Badr, MS Morgan, BJ Finn, L Toiber, FS Crabtree, DC Puleo, DS Skatrud, JB TI Ventilatory response to induced auditory arousals during NREM sleep SO SLEEP LA English DT Article DE arousal; sleep discontinuity; NREM sleep ID MUSCLE-ACTIVITY; HUMANS; APNEA; HYPERVENTILATION; AFTERDISCHARGE; STATE AB Sleep state instability is a potential mechanism of central apnea/hypopnea during non-rapid eye movement (NREM) sleep. To investigate this postulate, we induced brief arousals by delivering transient (0.5 second) auditory stimuli during stable NREM sleep in eight normal subjects. Arousal was determined according to American Sleep Disorders Association (ASDA) criteria. A total of 96 trials were conducted; 59 resulted in cortical arousal and 37 did not result in arousal. In trials associated with arousal, minute ventilation ((V) over dot(E)) increased from 5.1 +/- 1.24 minutes to 7.5 +/- 2.24 minutes on the first posttone breath (p = 0.001). However, no subsequent hypopnea or apnea occurred as (V) over dot(E) decreased gradually to 4.8 +/- 1.5 1/minute (p > 0.05) on the fifth posttone breath. Trials without arousal did not result in hyperpnea on the first breath nor subsequent hypopnea. We conclude that 1) auditory stimulation resulted in transient hyperpnea only if associated with cortical arousal; 2) hypopnea or apnea did not occur following arousal-induced hyperpnea in normal subjects; 3) interaction with fluctuating chemical stimuli or upper airway resistance may be required for arousals to cause sleep-disordered breathing. C1 UNIV WISCONSIN,SCH MED,WILLIAM S MIDDLETON MEM VET HOSP,DEPT MED,MED SERV,MADISON,WI. UNIV WISCONSIN,SCH MED,WILLIAM S MIDDLETON MEM VET HOSP,DEPT KINESIOL,MED SERV,MADISON,WI. NR 24 TC 24 Z9 26 U1 0 U2 0 PU AMER SLEEP DISORDERS ASSOC PI ROCHESTER PA 1610 14TH STREET NW SUITE 300, ROCHESTER, MN 55806 SN 0161-8105 J9 SLEEP JI Sleep PY 1997 VL 20 IS 9 BP 707 EP 714 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA YH471 UT WOS:A1997YH47100004 PM 9406322 ER PT J AU Taha, BH Morrell, MJ Wekheiser, M Badr, MS AF Taha, BH Morrell, MJ Wekheiser, M Badr, MS TI Simultaneous digitization of upper airway fiber-optic images and respiratory signals SO SLEEP LA English DT Article DE sleep apnea; upper airway; imaging ID OBSTRUCTIVE SLEEP-APNEA; PHARYNGEAL SIZE; SNORERS; VOLUME; AREA AB We developed an inexpensive and efficient method for simultaneously digitizing respiratory signals and fiber-optic images of the upper airway. The main components of the system are a fiber-optic scope, a charge coupled device video camera, and a personal computer equipped with a frame grabber and an A/D board. The frame grabber digitizes images at five frames per second while the A/D board samples six respiratory signals at 25 samples per second. Digitized images are saved only in the event that the user instructs the computer to do so in order to limit disk space requirements. A circular buffering technique provides continuous storage of the most recent 50 frames in frame grabber memory. This feature gives the user up to 10 seconds, following the beginning of a respiratory event, to initiate the saving of images to computer hard disk. A postacquisition program displays the data acquired during the sleep study and allows the user to interactively select images for subsequent upper airway area measurement. This system enables us to observe and quantify the dynamics of the upper airway during different breathing conditions with minimal time and cost. It is also a potential clinical tool to use to determine the site of obstruction during sleep in patients with obstructive sleep apnea. C1 UNIV WISCONSIN,SCH MED,DEPT PREVENT MED,MADISON,WI 53706. UNIV WISCONSIN,SCH MED,DEPT ELECT & COMP ENGN,MADISON,WI 53706. UNIV WISCONSIN,SCH MED,DEPT MED,MADISON,WI 53706. WILLIAM S MIDDLETON MEM VET ADM MED CTR,MADISON,WI. NR 9 TC 10 Z9 10 U1 1 U2 2 PU AMER SLEEP DISORDERS ASSOC PI ROCHESTER PA 1610 14TH STREET NW SUITE 300, ROCHESTER, MN 55806 SN 0161-8105 J9 SLEEP JI Sleep PY 1997 VL 20 IS 10 BP 883 EP 890 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA YL207 UT WOS:A1997YL20700009 PM 9415949 ER PT J AU Taha, BH Dempsey, JA Weber, SM Badr, MS Skatrud, JB Young, TB Jacques, AJ Seow, KC AF Taha, BH Dempsey, JA Weber, SM Badr, MS Skatrud, JB Young, TB Jacques, AJ Seow, KC TI Automated detection and classification of sleep-disordered breathing from conventional polysomnography data SO SLEEP LA English DT Article DE sleep-disordered breathing; polysomnography; computerized detection ID RESPIRATORY INDUCTIVE PLETHYSMOGRAPH; OXYGEN-SATURATION; HYPOPNEA SYNDROME; OXIMETRY; QUANTIFICATION; ACCURACY; EVENTS; APNEA AB Efficient automated detection of sleep disordered breathing (SDB) rom routine polysomnography (PSG) data is made difficult by the availability of only indirect measurements of breathing. The approach we used to overcome this limitation was to incorporate pulse oximetry into the definitions of apnea and hypopnea. In our algorithm, 1) we begin with the detection of desaturation as a fall in oxyhemoglobin saturation level of 2% or greater once a rate of descent greater than 0.1% per second (but less than 4% per second) has been achieved and then ask if an apnea or hypopnea nias responsible; 2) an apnea is detected if there is a period of no breathing, as indicated by sum respiratory inductive plethysmography (RIP), lasting at least 10 seconds and coincident with the desaturation event; and 3) if there is breathing, a hypopnea is defined as a minimum of three breaths showing at least 20% reduction in sum RIP magnitude from the immediately preceding breath followed by a return to at least 90% of that "baseline" breath. Our evaluation of this algorithm using 10 PSG records containing 1,938 SDB events showed strong event-by-event agreement with manual scoring by an experienced polysomnographer. On the basis of manually verified computer desaturations, detection sensitivity and specificity percentages were, respectively, 73.6 and 90.8% for apneas and 84.1 and 86.1% for hypopneas. Overall, 93.1% of the manually detected events were detected by the algorithm. We have designed an efficient algorithm for detecting and classifying SDB events that emulates manual scoring with high accuracy. C1 Univ Wisconsin, Dept Prevent Med, Madison, WI 53705 USA. Univ Wisconsin, Dept Med, Madison, WI 53705 USA. William S Middleton Mem Vet Hosp, Med Serv, Madison, WI 53705 USA. RP Dempsey, JA (reprint author), Univ Wisconsin, Dept Prevent Med, 504 N Walnut St, Madison, WI 53705 USA. FU NHLBI NIH HHS [P01-HL 42242] NR 20 TC 35 Z9 35 U1 1 U2 2 PU AMER SLEEP DISORDERS ASSOC PI ROCHESTER PA 1610 14TH STREET NW SUITE 300, ROCHESTER, MN 55806 USA SN 0161-8105 J9 SLEEP JI Sleep PY 1997 VL 20 IS 11 BP 991 EP 1001 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA YQ167 UT WOS:000071355600008 PM 9456464 ER PT J AU Francoeur, RB Copley, CK Miller, PJ AF Francoeur, RB Copley, CK Miller, PJ TI The challenge to meet the mental health and biopsychosocial needs of the poor: Expanded roles for hospital social workers in a changing healthcare environment SO SOCIAL WORK IN HEALTH CARE LA English DT Article ID PSYCHIATRIC-PATIENTS; CASE-MANAGEMENT; CARE; SYSTEM; POVERTY; ILLNESS; POLICY; SERVICES AB Despite the absence of coordinated federal health care reform, social workers in hospital settings have opportunities to identify, develop, advocate for, and facilitate access to innovative health care services, resulting in improved capacity to meet the mental health and biopsychosocial needs of the poor and, potentially, reduced hospital costs over time. There are opportunities for expanded roles for social workers in forging better linkages between hospital services and the community developing an integrated biopsychosocial healthcare delivery system within hospitals and primary care settings, utilizing information systems as tools in an integrated system, and advocating for a client-centered approach to mental health services. C1 UNIV PITTSBURGH,SCH SOCIAL WORK,PITTSBURGH,PA 15260. SACRED HEART MED CTR,EUGENE,OR 97440. PORTLAND STATE UNIV,GRAD SCH SOCIAL WORK,PORTLAND,OR 97207. RP Francoeur, RB (reprint author), VA PITTSBURGH HLTH CARE SYST,UNIV DR,PITTSBURGH,PA 15240, USA. NR 44 TC 10 Z9 10 U1 3 U2 5 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 SN 0098-1389 J9 SOC WORK HEALTH CARE JI Soc. Work Health Care PY 1997 VL 26 IS 2 BP 1 EP 13 DI 10.1300/J010v26n02_01 PG 13 WC Social Work SC Social Work GA YL256 UT WOS:A1997YL25600001 PM 9433737 ER PT J AU Sormanti, M Kayser, K Strainchamps, E AF Sormanti, M Kayser, K Strainchamps, E TI A relational perspective of women coping with cancer: A preliminary study SO SOCIAL WORK IN HEALTH CARE LA English DT Article; Proceedings Paper CT 1st International Conference on Social Work in Health and Mental Health CY JAN, 1995 CL HEBREW UNIV JERUSALEM, JERUSALEM, ISRAEL HO HEBREW UNIV JERUSALEM ID SCALE AB To understand fully how a woman copes with cancer, researchers must examine the relational context in which a woman lives, copes, and meets the demands of a life-threatening illness, This paper presents preliminary findings of a study involving thirty-four mothers who have cancer. Survey methods involving a questionnaire were used to look at the relationship of the factors of mutuality, silencing the self schemas, and relationship-focused coping to the psychosocial adaptation to cancer, The findings indicated a significant correlation between silencing the self schemas and health care behaviors. Correlations between mutuality and quality of life approached statistical significance, Based on these findings, suggestions for social work practice with cancer patients and their families are made. C1 BOSTON COLL,GRAD SCH SOCIAL WORK,CHESTNUT HILL,MA 02167. BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. RP Sormanti, M (reprint author), DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA. NR 23 TC 11 Z9 11 U1 0 U2 0 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 SN 0098-1389 J9 SOC WORK HEALTH CARE JI Soc. Work Health Care PY 1997 VL 25 IS 1-2 BP 89 EP 106 DI 10.1300/J010v25n01_10 PG 18 WC Social Work SC Social Work GA XX072 UT WOS:A1997XX07200010 PM 9313306 ER PT J AU Koziel, MJ Walker, BD AF Koziel, MJ Walker, BD TI Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection SO SPRINGER SEMINARS IN IMMUNOPATHOLOGY LA English DT Article ID B VIRUS; CLASS-I; HLA-A2.1 MOLECULES; FINE SPECIFICITY; PERIPHERAL-BLOOD; ANCHOR RESIDUES; TRANSGENIC MICE; MHC MOLECULES; NON-A; PEPTIDES C1 MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138. RP Koziel, MJ (reprint author), BETH ISRAEL DEACONESS MED CTR,DIV INFECT DIS,HIM 223A,1 DEACONESS RD,BOSTON,MA 02215, USA. RI Yang, Chen/G-1379-2010 NR 90 TC 49 Z9 52 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0344-4325 J9 SPRINGER SEMIN IMMUN JI Springer Semin. Immunopathol. PY 1997 VL 19 IS 1 BP 69 EP 83 DI 10.1007/BF00945026 PG 15 WC Immunology; Pathology SC Immunology; Pathology GA XL682 UT WOS:A1997XL68200006 PM 9266632 ER PT J AU Jassoy, C Walker, BD AF Jassoy, C Walker, BD TI HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication SO SPRINGER SEMINARS IN IMMUNOPATHOLOGY LA English DT Review ID SIMIAN IMMUNODEFICIENCY VIRUS; CYTO-TOXIC LYMPHOCYTES; LIMITING DILUTION ANALYSIS; CHORIOMENINGITIS VIRUS; CEREBROSPINAL-FLUID; PERIPHERAL-BLOOD; RHESUS-MONKEYS; CLASS-I; SEROPOSITIVE INDIVIDUALS; TYPE-1 INFECTION C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CTR AIDS RES,BOSTON,MA 02114. RP Jassoy, C (reprint author), UNIV WURZBURG,INST VIROL & IMMUNOBIOL,VERSBACHER STR 7,D-8700 WURZBURG,GERMANY. FU NIAID NIH HHS [R37 AI28568, R01 AI30914] NR 104 TC 21 Z9 22 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0344-4325 J9 SPRINGER SEMIN IMMUN JI Springer Semin. Immunopathol. PY 1997 VL 18 IS 3 BP 341 EP 354 DI 10.1007/BF00813502 PG 14 WC Immunology; Pathology SC Immunology; Pathology GA WN668 UT WOS:A1997WN66800007 PM 9089953 ER PT J AU Ogawa, M Yonemura, Y Ku, H AF Ogawa, M Yonemura, Y Ku, H TI In vitro expansion of hematopoietic stem cells SO STEM CELLS LA English DT Article; Proceedings Paper CT Symposium on Hematopoietic Stem Cells CY 1996 CL HOHENZOLLERN CASTLE, MOUNT ZOLLERN, GERMANY SP AMGEN HO HOHENZOLLERN CASTLE DE stem cells; hematopoiesis; interleukins; growth factors ID MURINE MARROW-CELLS; EX-VIVO EXPANSION; BLOOD CD34+ CELLS; PROGENITOR CELLS; EXVIVO EXPANSION; GROWTH-FACTORS; BONE-MARROW; KIT-LIGAND; RECONSTITUTION; CULTURE AB We have investigated the effects of interleukin 3 (IL-3) and IL-1 on in vitro expansion of murine hematopoietic progenitors and stem cells using a highly purified progenitor population. Lineage negative, Ly-6A/E+, c-kit(+) bone marrow cells from male mice were cultured in suspension in the presence of stem cell factor, IL-6, IL-11 and erythropoietin with or without IL-3 or IL-1. An exponential increase in total nucleated cell counts and about a 10-fold enhancement of nucleated cells by IL-3 were observed during the initial 10 days. Addition of IL-3 hastened the development but significantly suppressed the peak production of colony-forming cells. Addition of IL-1 also significantly suppressed the numbers of progenitors. We then tested the reconstituting ability of the cultured cells by transplanting cells together with ''compromised'' marrow cells into lethally irradiated mice. The cells expanded from enriched cells in the absence of IL-3 or IL-1 revealed engraftment at two, six and 10 months, while addition of IL-3 or IL-1 to the cultures significantly reduced the reconstituting ability. IL-3 and IL-1 may have negative modulatory effects on the self-renewal of stem cells. C1 MED UNIV S CAROLINA, DEPT MED, RALPH H JOHNSON DEPT VET AFFAIRS MED CTR, CHARLESTON, SC 29425 USA. FU NIDDK NIH HHS [DK32294, DK/HL48714] NR 20 TC 11 Z9 11 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 EI 1549-4918 J9 STEM CELLS JI Stem Cells PY 1997 VL 15 SU 2 BP 7 EP 11 PG 5 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA YF081 UT WOS:A1997YF08100004 PM 9368319 ER PT J AU Spangrude, GJ Orlic, D Griffin, JD Moore, MAS AF Spangrude, GJ Orlic, D Griffin, JD Moore, MAS TI Transduction efficiency of cell lines and hematopoietic stem cells correlates with retrovirus receptor mRNA levels - Discussion SO STEM CELLS LA English DT Editorial Material C1 NIH, LAB GENE TRANSFER, NCHGR, BETHESDA, MD 20892 USA. DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA. SLOAN KETTERING INST CANC RES, NEW YORK, NY 10021 USA. RP UNIV UTAH, SALT LAKE CITY, UT 84132 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 EI 1549-4918 J9 STEM CELLS JI Stem Cells PY 1997 VL 15 SU 2 BP 28 EP 29 PG 2 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA YF081 UT WOS:A1997YF08100009 ER PT J AU Spangarde, GJ Adamson, JW TorokStorb, B Broxmeyer, HE Griffin, JD Quesenberry, PJ Fibbe, WE Kanz, L Sharkis, SJ Hoffman, R Papayannopoulou, T AF Spangarde, GJ Adamson, JW TorokStorb, B Broxmeyer, HE Griffin, JD Quesenberry, PJ Fibbe, WE Kanz, L Sharkis, SJ Hoffman, R Papayannopoulou, T TI Cord blood stem cell banking and transplantation - Discussion SO STEM CELLS LA English DT Editorial Material C1 NEW YORK BLOOD CTR, NEW YORK, NY 10021 USA. FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA. JOHNS HOPKINS UNIV, CTR ONCOL, DEPT ONCOL, BALTIMORE, MD 21287 USA. INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, DEPT MICROBIOL & IMMUNOL, INDIANAPOLIS, IN 46202 USA. DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA. LEIDEN UNIV, MED CTR, DEPT HEMATOL, NL-2300 RC LEIDEN, NETHERLANDS. UNIV ILLINOIS, COLL MED, HEMATOL ONCOL SECT, CHICAGO, IL 60607 USA. UNIV TUBINGEN, DEPT HEMATOL, D-72076 TUBINGEN, GERMANY. UNIV MASSACHUSETTS, MED CTR, CTR CANC, WORCESTER, MA 01605 USA. UNIV WASHINGTON, SEATTLE, WA 98195 USA. RP UNIV UTAH, SALT LAKE CITY, UT 84132 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 EI 1549-4918 J9 STEM CELLS JI Stem Cells PY 1997 VL 15 SU 2 BP 59 EP 61 PG 3 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA YF081 UT WOS:A1997YF08100017 ER PT J AU Kaushansky Broxmeyer Griffin Fibbe AF Kaushansky Broxmeyer Griffin Fibbe TI Biology and mechanisms of action of synergistically stimulated myeloid progenitor cell proliferation and suppression by chemokines - Discussion SO STEM CELLS LA English DT Editorial Material C1 INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, DEPT MICROBIOL & IMMUNOL, INDIANAPOLIS, IN 46202 USA. DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA. LEIDEN UNIV, MED CTR, DEPT HEMATOL, NL-2300 RC LEIDEN, NETHERLANDS. RP UNIV WASHINGTON, SCH MED, DIV HEMATOL, BOX 357710, SEATTLE, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 EI 1549-4918 J9 STEM CELLS JI Stem Cells PY 1997 VL 15 SU 2 BP 78 EP 78 PG 1 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA YF081 UT WOS:A1997YF08100021 ER PT J AU Griffin, JD Lowenberg, B TorokStorb, B AF Griffin, JD Lowenberg, B TorokStorb, B TI Peripheral blood progenitor cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia - Discussion SO STEM CELLS LA English DT Editorial Material C1 DR DANIEL DEN HOED CANC CTR, NL-3008 AE ROTTERDAM, NETHERLANDS. FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA. RP DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, 44 BINNEY ST, BOSTON, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 EI 1549-4918 J9 STEM CELLS JI Stem Cells PY 1997 VL 15 SU 2 BP 181 EP 181 PG 1 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA YF081 UT WOS:A1997YF08100044 ER PT J AU Dick, JE Spangrude, GJ Quesenberry, PJ Hoffman, R Broxmeyer, HE Eaves, C Ogawa, M Fibbe, WE TorokStorb, B Griffin, JD AF Dick, JE Spangrude, GJ Quesenberry, PJ Hoffman, R Broxmeyer, HE Eaves, C Ogawa, M Fibbe, WE TorokStorb, B Griffin, JD TI Assay of human stem cells by repopulation of NOD/SCID mice - Discussion SO STEM CELLS LA English DT Editorial Material C1 UNIV UTAH, SALT LAKE CITY, UT 84132 USA. UNIV MASSACHUSETTS, MED CTR, CTR CANC, WORCESTER, MA 01605 USA. UNIV ILLINOIS, COLL MED, HEMATOL ONCOL SECT, CHICAGO, IL 60607 USA. INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, DEPT IMMUNOL & MICROBIOL, INDIANAPOLIS, IN 46202 USA. BRITISH COLUMBIA CANC RES CTR, TERRY FOX LAB, VANCOUVER, BC V5Z 1L3, CANADA. VET ADM MED CTR, CHARLESTON, SC 29401 USA. LEIDEN UNIV, MED CTR, DEPT HEMATOL, NL-2300 RC LEIDEN, NETHERLANDS. FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA. DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA. RP UNIV TORONTO, HOSP SICK CHILDREN, RES INST, DEPT GENET, 555 UNIV AVE, TORONTO, ON M5G 1X8, CANADA. NR 0 TC 33 Z9 34 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 EI 1549-4918 J9 STEM CELLS JI Stem Cells PY 1997 VL 15 SU 2 BP 204 EP 207 PG 4 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA YF081 UT WOS:A1997YF08100048 ER PT J AU Lemischka, IR Lansdorp, PM Dick, JE Spangrude, GJ Kaushansky, K Kanz, L Zanjani, ED TorokStorb, B Griffin, JD Ogawa, M Eaves, C Quesenberry, PJ AF Lemischka, IR Lansdorp, PM Dick, JE Spangrude, GJ Kaushansky, K Kanz, L Zanjani, ED TorokStorb, B Griffin, JD Ogawa, M Eaves, C Quesenberry, PJ TI Intrinsic control of stem cell fate - Discussion SO STEM CELLS LA English DT Editorial Material C1 TERRY FOX LAB, VANCOUVER, BC V5Z 1L3, CANADA. UNIV WASHINGTON, SCH MED, DIV HEMATOL, SEATTLE, WA 98195 USA. UNIV TUBINGEN, DEPT HEMATOL, D-72076 TUBINGEN, GERMANY. VET ADM MED CTR, CHARLESTON, SC 29401 USA. UNIV MASSACHUSETTS, MED CTR, CTR CANC, WORCESTER, MA 01605 USA. UNIV TORONTO, HOSP SICK CHILDREN, RES INST, DEPT GENET, TORONTO, ON M5G 1X8, CANADA. CHILDRENS HOSP, DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA. UNIV UTAH, SALT LAKE CITY, UT 84132 USA. FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA. VET ADM MED CTR, RENO, NV 89520 USA. RP PRINCETON UNIV, DEPT MOL BIOL, LEWIS THOMAS LAB 229, PRINCETON, NJ 08544 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 EI 1549-4918 J9 STEM CELLS JI Stem Cells PY 1997 VL 15 SU 2 BP 225 EP 227 PG 3 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA YF081 UT WOS:A1997YF08100053 ER PT J AU Sharkis, SJ Moore, MAS Lansdorp, PM Eaves, C TorokStorb, B Broxmeyer, HE Adamson, JW Spangrude, GJ Griffin, JD Papayannopoulou, T Ogawa, M Orlic, D Kanz, L AF Sharkis, SJ Moore, MAS Lansdorp, PM Eaves, C TorokStorb, B Broxmeyer, HE Adamson, JW Spangrude, GJ Griffin, JD Papayannopoulou, T Ogawa, M Orlic, D Kanz, L TI Stem cell proliferation: Ex vivo and in vivo observations - Discussion SO STEM CELLS LA English DT Editorial Material C1 SLOAN KETTERING INST CANC RES, NEW YORK, NY 10021 USA. TERRY FOX LAB, VANCOUVER, BC V5Z 1L3, CANADA. FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA. INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, DEPT IMMUNOL & MICROBIOL, INDIANAPOLIS, IN 46202 USA. NEW YORK BLOOD CTR, NEW YORK, NY 10021 USA. UNIV UTAH, SALT LAKE CITY, UT USA. DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA. UNIV WASHINGTON, SEATTLE, WA 98195 USA. VET ADM MED CTR, CHARLESTON, SC 29401 USA. NIH, NCHGR, LAB GENE TRANSFER, BETHESDA, MD 20892 USA. UNIV TUBINGEN, DEPT HEMATOL, D-72076 TUBINGEN, GERMANY. RP JOHNS HOPKINS UNIV, CTR ONCOL, 600 N WOLFE ST, BALTIMORE, MD 21287 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 EI 1549-4918 J9 STEM CELLS JI Stem Cells PY 1997 VL 15 SU 2 BP 248 EP 251 PG 4 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA YF081 UT WOS:A1997YF08100057 ER PT J AU Alexander, E Moriarty, TM Kikinis, R Black, P Jolesz, FM AF Alexander, E Moriarty, TM Kikinis, R Black, P Jolesz, FM TI The present and future role of intraoperative MRI in neurosurgical procedures SO STEREOTACTIC AND FUNCTIONAL NEUROSURGERY LA English DT Article; Proceedings Paper CT XIIth Meeting of the World Society for Stereotactic and Functional Neurosurgery CY JUL 01-04, 1997 CL LYON, FRANCE SP World Soc Stereotact & Funct Neurosurg DE magnetic resonance imaging; intraoperative MR; intraoperative imaging; surgical guidance AB Objective: We have worked in conjunction with scientists from the General Electric Corporation over 6 years to develop an open-bore MR imaging system (0.5 T) enabling optimal vertical access of surgeon and assistant to the patient, and real-time imaging during major neurosurgical procedures. Methods: The intraoperative MR system (MRT) is located in a specially modified operative suite that combines the features of an MR-imaging suite with a fully functional operating room. An MR-compatible anesthesia machine and patient-monitoring device are located next to the magnet. The position of instruments, platforms and supports may be mapped in the operative Field using 3 charge-coupled device video cameras mounted in the overhead support truncheon that follow various light-emitting diodes on the devices (Pixsys). The MR image plane can be defined as the axial, coronal or sagittal views through a point along the vector beneath the Pixsys tripod. A variety of surface coils were designed to take full advantage of full open patient access. The software, implemented by a technologist located outside the MR room, is now equivalent to that available on the commercial 0.5-tesla Sigma Advantage system. Development of very robust 3-dimensional software in conjunction with the Surgical Planning Laboratory (SPL) at the Brigham & Women's Hospital is the subject of significant effort. The MRT system has been shown to possess imaging capabilities comparable, or even slightly superior(by 10%), to a conventional 0.5-tesla MR scanner. Two modified liquid-crystal display screens are mounted on the magnet housing for the surgeon to monitor the images during the procedures. Projection into larger screens or the operating microscope is under development. Results: We have performed 110 neurosurgical cases in MRT as of January 29, 1997, including 47 biopsies, 6 catheter placements, 4 cyst drainages, 47 craniotomies for resection, 3 spinal cases (1 syrinx drainage), and 3 laser tumor ablations. Conclusions: MRT is especially useful in guiding biopsies and resections near cysts, ventricles and critical vascular structures where preoperative images with framed/frameless techniques would be inadequate to show anatomic changes during the procedure. Real-time images of a biopsy needle within the abnormal area are very useful in cases of subtle pathologic change. More complete resection of infiltrative tumor is readily accomplished. SPL image fusion of SPECT and neurofunctional data (e.g. from magnetic stimulation preoperatively) into the imaging space enables the surgeon to better visualize tumor invasion or neural function in real-time imaging during resection. Imaging of thermal gradients for cryoprobe or laser ablation, and combination with endoscopy and robotics will offer additional benefit in the performance of difficult neurosurgical procedures. C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Surg Neurosurg, Boston, MA 02115 USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiol, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. RP Alexander, E (reprint author), Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA. FU NCI NIH HHS [P01CA67165] NR 6 TC 39 Z9 38 U1 0 U2 5 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1011-6125 J9 STEREOT FUNCT NEUROS JI Stereotact. Funct. Neurosurg. PY 1997 VL 68 IS 1-4 BP 10 EP 17 DI 10.1159/000099896 PG 8 WC Neurosciences; Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA ZZ207 UT WOS:000074706300002 PM 9711689 ER PT J AU Schwamm, L Cramer, SC Rordorf, G Kaufman, J Koroshetz, WJ Buonanno, F AF Schwamm, L Cramer, SC Rordorf, G Kaufman, J Koroshetz, WJ Buonanno, F TI Magnetic resonance venography (MRV) detection of pelvic thrombus in stroke patients with patent foramen ovale (PFO) SO STROKE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 1997 VL 28 IS 1 BP 57 EP 57 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA WB814 UT WOS:A1997WB81400108 ER PT J AU Gonzalez, G Schaefer, P Buonanno, F Schwamm, L Budzik, R Rordorf, G Wang, B Sorensen, G Koroshetz, W AF Gonzalez, G Schaefer, P Buonanno, F Schwamm, L Budzik, R Rordorf, G Wang, B Sorensen, G Koroshetz, W TI Clinical sensitivity and specificity of diffusion weighted MRI hyperacute stroke SO STROKE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 1997 VL 28 IS 1 BP 61 EP 61 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA WB814 UT WOS:A1997WB81400112 ER PT J AU ShimizuSasamata, M Kano, T Pierce, AR Rogowska, J Trocha, M Shore, MT Hara, H Moskowitz, MA Lo, EH AF ShimizuSasamata, M Kano, T Pierce, AR Rogowska, J Trocha, M Shore, MT Hara, H Moskowitz, MA Lo, EH TI Early functional computed tomography predicts later brain damage after focal ischemia in rats. SO STROKE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CTR IMAGING & PHARMACEUT RES,CHARLESTOWN,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 1997 VL 28 IS 1 BP 64 EP 64 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA WB814 UT WOS:A1997WB81400115 ER PT J AU Hara, H Ayata, C Friedlander, RM Gagliardini, V Huang, Z ShimizuSasamata, M Yuan, J Moskowitz, MA AF Hara, H Ayata, C Friedlander, RM Gagliardini, V Huang, Z ShimizuSasamata, M Yuan, J Moskowitz, MA TI Inhibition of interleukin-1 beta converting enzyme (ICE)/ced-3 family proteases and ischemic neuronal damage SO STROKE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,STROKE & NEUROVASC REGULAT LAB,CHARLESTOWN,MA. HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,CHARLESTOWN,MA. RI Friedlander, Robert/A-2845-2016 OI Friedlander, Robert/0000-0003-4423-9219 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 1997 VL 28 IS 1 BP 73 EP 73 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA WB814 UT WOS:A1997WB81400124 ER PT J AU Polidori, MC Frei, B Koroshetz, WJ Rordorf, G Ogilvy, CS Beal, MF AF Polidori, MC Frei, B Koroshetz, WJ Rordorf, G Ogilvy, CS Beal, MF TI Levels of plasma lipid hydroperoxides and antioxidants in patients with subarachnoid hemorrhage SO STROKE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,NEUROL SERV,BOSTON,MA. BOSTON UNIV,SCH MED,WHITAKER CARDIOVASC INST,BOSTON,MA 02118. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 1997 VL 28 IS 1 BP 82 EP 82 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA WB814 UT WOS:A1997WB81400133 ER PT J AU Kawamata, T Schallert, TJ Dietrich, WD Benowitz, LI Gotts, JE Cocke, RR Finklestein, SP AF Kawamata, T Schallert, TJ Dietrich, WD Benowitz, LI Gotts, JE Cocke, RR Finklestein, SP TI Intracisternal basic fibroblast growth factor (bFGF) enhances functional recovery and upregulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction SO STROKE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT NEUROL,CNS,GROWTH FACTOR RES LAB,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA. NR 0 TC 3 Z9 3 U1 0 U2 1 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 1997 VL 28 IS 1 BP 90 EP 90 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA WB814 UT WOS:A1997WB81400141 ER PT J AU Cramer, SC Benson, RR Kwong, KK Nelles, G Parker, RA Kennedy, DN Kaplan, JD Finklestein, SP Rosen, BR AF Cramer, SC Benson, RR Kwong, KK Nelles, G Parker, RA Kennedy, DN Kaplan, JD Finklestein, SP Rosen, BR TI A functional MRI study of subjects recovered from hemiparetic stroke SO STROKE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. SPAULDING REHAB HOSP,BOSTON,MA. BETH ISRAEL BIOMET CTR,BOSTON,MA. HARVARD UNIV,SCH MED,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 1997 VL 28 IS 1 BP 91 EP 91 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA WB814 UT WOS:A1997WB81400142 ER PT J AU Koroshetz, WJ Schwamm, L Sorensen, G Copen, W Rordorf, G Buonanno, F Gonzalez, G AF Koroshetz, WJ Schwamm, L Sorensen, G Copen, W Rordorf, G Buonanno, F Gonzalez, G TI The evolution of human brain ischemia: A serial study of diffusion (DW) and hemodynamic weighted (HW) MR imaging in acute stroke SO STROKE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 1997 VL 28 IS 1 BP 103 EP 103 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA WB814 UT WOS:A1997WB81400154 ER PT J AU Sorensen, AG Gonzalez, RG Copen, WA Schwamm, L Rordorf, G Ostergaard, L Weisskoff, RM Rosen, BR Koroshetz, WJ AF Sorensen, AG Gonzalez, RG Copen, WA Schwamm, L Rordorf, G Ostergaard, L Weisskoff, RM Rosen, BR Koroshetz, WJ TI Quantitation of diffusion/perfusion MRI mismatch in acute human cerebral infarction SO STROKE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 1997 VL 28 IS 1 BP 104 EP 104 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA WB814 UT WOS:A1997WB81400155 ER PT J AU Greenberg, SM Vonsattel, JPG AF Greenberg, SM Vonsattel, JPG TI Sensitivity nd specificity of cortical biopsy for diagnosis of cerebral amyloid angiopathy SO STROKE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 1997 VL 28 IS 1 BP 171 EP 171 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA WB814 UT WOS:A1997WB81400221 ER PT J AU Nelles, G Cramer, SC Schaechter, JD Kaplan, JD Finklestein, SP AF Nelles, G Cramer, SC Schaechter, JD Kaplan, JD Finklestein, SP TI Computerized analysis of motor recovery after stroke SO STROKE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. HARVARD UNIV,SCH MED,SPAULDING REHAB HOSP,BOSTON,MA. NORTHEASTERN UNIV,DEPT PHYS THERAPY,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 1997 VL 28 IS 1 BP 194 EP 194 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA WB814 UT WOS:A1997WB81400244 ER PT J AU Rordorf, G Cramer, SC Buonanno, F Koroshetz, WJ AF Rordorf, G Cramer, SC Buonanno, F Koroshetz, WJ TI Induced hypertension in stroke: Safety and efficacy SO STROKE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 1997 VL 28 IS 1 BP 216 EP 216 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA WB814 UT WOS:A1997WB81400266 ER PT J AU Werner, J Rivera, J FernandezdelCastillo, C Lewandrowski, K Adrie, C Rattner, DW Warshaw, AL AF Werner, J Rivera, J FernandezdelCastillo, C Lewandrowski, K Adrie, C Rattner, DW Warshaw, AL TI Differing roles of nitric oxide in the pathogenesis of acute edematous versus necrotizing pancreatitis SO SURGERY LA English DT Article ID TRYPSINOGEN-ACTIVATION PEPTIDES; L-ARGININE; RAT; SUPEROXIDE; ADHESION; PATHWAY; AGGREGATION; ENDOTHELIUM; NEUTROPHILS; PROGRESSION AB Background. Microcirculatory changes and leukocyte-endothelial interaction are both central to the pathogenesis of acute pancreatitis. We studied the effects of nitric oxide (NO) donors (intravenous or inhaled) and NO inhibitors, which affect each of these processes, on markers of experimental mild (edematous) and severe (necrotizing) pancreatitis in rats. Methods. Mild pancreatitis was induced with intravenous cerulein (n = 100) and severe pancreatitis with intravenous cerulein and intraductal glycodeoxycholic acid (n = 100). Each group was randomly divided into five equal treatment subgroups: control, NO-synthase substrate L-arginine, NO donor sodium nitroprusside, NO-synthase inhibitor N-nitro-L-arginine methyl ester (L-NAME), and NO-inhalation. After 6 hours edema was measured by a wet/dry weight ratio, and pancreatic injury was quantified by tissue levels of trypsinogen activation peptides (TAPs) and by histologic analysis of inflammation and necrosis. Results. In mild pancreatitis (1) both NO donors reduced edema formation (p < 0.001) and also reduced intrapancreatic TAPs (p < 0.03); (2) L-NAME significantly increased tissue TAPs (p < 0.03); and (3) inhaled NO had no effect. In severe pancreatitis (1) both intravenous NO donors reduced edema formation (p < 0.005) and both markedly reduced intrapancreatic TAPs (p < 0.001); (2) L-NAME did not further increase the already high tissue TAPs; and (3) inhaled NO decreased tissue TAPs (p = 0.01). Evaluation of inflammation and necrosis by histologic scoring confirmed the reduction of pancreatic injury by NO donors and worsening with NO-synthase inhibitor. Conclusions. NO donors have a beneficial effect on edema formation in acute pancreatitis but confer more important protection against ectopic trypsinogen activation, which correlates with mortality, inflammation and nemesis. Although direct microcirculatory action is likely, the salutary effect of inhaled NO in severe pancreatitis may suggest indirect action on circulating leukocytes, which are thought to potentiate tissue injury. C1 MASSACHUSETTS GEN HOSP,DEPT SURG,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT ANESTHESIOL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA. HARVARD UNIV,SCH MED,BOSTON,MA 02114. NR 47 TC 60 Z9 67 U1 0 U2 2 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0039-6060 J9 SURGERY JI Surgery PD JAN PY 1997 VL 121 IS 1 BP 23 EP 30 DI 10.1016/S0039-6060(97)90178-1 PG 8 WC Surgery SC Surgery GA WC212 UT WOS:A1997WC21200004 PM 9001547 ER PT J AU Rivera, JA Rall, CJN GraemeCook, F FernandezdelCastillo, C Shu, P Lakey, N Tepper, R Rattner, DW Warshaw, AL Rustgi, AK AF Rivera, JA Rall, CJN GraemeCook, F FernandezdelCastillo, C Shu, P Lakey, N Tepper, R Rattner, DW Warshaw, AL Rustgi, AK TI Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia SO SURGERY LA English DT Article ID GROWTH-FACTOR-ALPHA; FACTOR RECEPTOR; CANCER; CARCINOMA; ADENOCARCINOMA; ACTIVATION; RISK; MELANOMA; LESIONS; GENE AB Background. K-ras oncogene mutations have been identified in up to 95% of pancreatic cancers, implying their critical role in their molecular pathogenesis. However, the earliest stage in which K-ras mutations can be detected in potential precursor lesions of pancreatic cancer remains unclear. This study evaluates pancreatic ductal hyperplasia in the setting of chronic pancreatitis, which predisposes to pancreatic cancer development, for K-ras codon 12 and 13 mutations. Methods. Paraffin-embedded surgical specimens from 42 patients with chronic pancreatitis were examined microscopically for the presence of ductal hyperplasia. Both hyperplastic and nonhyperplastic ducts were microdissected from the specimens that contained hyperplasia (11 of 42). Four of the remaining specimens without hyperplasia served as controls. Genomic DNA was extracted, and polymerase chain reaction and amplification of the K-ras oncogene was performed. Polymerase chain reaction products were evaluated by means of hybridization to mutant specific oligonucleotide probes and by means of automated DNA sequencing. Results. K-ras codon 12 mutations representative glycine to valine substitutions were present in 2 of (18%) 11 patients with ductal hyperplasia. No mutations were found in the controls without ductal hyperplasia. Conclusions. Our study supports the premise that K-ras mutations develop in a subset of chronic pancreatitis associated hyperplasia and provides a genetic basis for the potential progression of chronic pancreatitis to pancreatic cancer. C1 MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,DEPT SURG,HEMATOL ONCOL UNIT,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02114. MILLENNIUM PHARMACEUT INC,CAMBRIDGE,MA. FU NIDDK NIH HHS [DK4351] NR 36 TC 63 Z9 66 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0039-6060 J9 SURGERY JI Surgery PD JAN PY 1997 VL 121 IS 1 BP 42 EP 49 DI 10.1016/S0039-6060(97)90181-1 PG 8 WC Surgery SC Surgery GA WC212 UT WOS:A1997WC21200007 PM 9001550 ER PT J AU Tanabe, KK AF Tanabe, KK TI Lymphatic mapping and epitrochlear lymph node dissection for melanoma SO SURGERY LA English DT Article RP Tanabe, KK (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIV SURG ONCOL,DEPT SURG,COX 626,BOSTON,MA 02114, USA. NR 6 TC 16 Z9 16 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0039-6060 J9 SURGERY JI Surgery PD JAN PY 1997 VL 121 IS 1 BP 102 EP 104 DI 10.1016/S0039-6060(97)90189-6 PG 3 WC Surgery SC Surgery GA WC212 UT WOS:A1997WC21200015 PM 9001558 ER PT J AU Wagoner, MD AF Wagoner, MD TI Chemical injuries of the eye: Current concepts in pathophysiology and therapy SO SURVEY OF OPHTHALMOLOGY LA English DT Review DE acid; alkali; chemical injury; conjunctival transplantation; corneal epithelium; corneal limbus; corneal stroma; inflammation; limbal autograft; limbal allograft; mucous membrane transplantation; ocular surface; penetrating keratoplasty; tenoplasty ID EPIDERMAL GROWTH-FACTOR; BURNED RABBIT CORNEAS; CONJUNCTIVAL AUTOGRAFT TRANSPLANTATION; KETOROLAC TROMETHAMINE SOLUTION; EXPERIMENTAL ALKALI BURNS; COLLAGENOLYTIC GELATINOLYTIC METALLOPROTEINASES; REDUCING POSTOPERATIVE INFLAMMATION; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; EPITHELIAL BASEMENT-MEMBRANE; NASAL-MUCOSA TRANSPLANTATION AB Chemical injuries of the eye may produce extensive damage to the ocular surface epithelium, cornea, and anterior segment, resulting in permanent unilateral or bilateral visual impairment. Pathophysiological events which may influence the final visual prognosis and which are amenable to therapeutic modulation include 1) ocular surface injury, repair, and differentiation, 2) corneal stromal matrix injury, repair and/or ulceration, and 3) corneal and stromal inflammation. Immediately following chemical injury, it is important to estimate and clinically grade the severity of limbal stem cell injury (by assessing the degree of limbal, conjunctival, and scleral ischemia and necrosis) and intraocular penetration of the noxious agent (by assessing clarity of the corneal stroma and anterior segment abnormalities). Immediate therapy is directed toward prompt irrigation and removal of any remaining reservoir of chemical contact with the eye. Initial medical therapy is directed toward promoting re-epithelialization and transdifferentiation of the ocular surface, augmenting corneal repair by supporting keratocyte collagen production and minimizing ulceration related to collagenase activity, and controlling inflammation. Early surgical therapy, if indicated, is directed toward removal of necrotic corneal epithelium and conjunctiva, prompt re-establishment of an adequate limbal vascularity, and re-establishment of limbal stem cell populations early in the clinical course, if sufficient evidence exists of complete limbal stem cell loss. Re-establishment of limbal stem cells by limbal autograft or allograft transplantation, or by transfer in conjunction with large diameter penetrating keratoplasty may facilitate development of an intact, phenotypically correct corneal epithelium. Limbal stem cell transplantation may prevent the development of fibrovascular pannus or sterile corneal corneal ulceration, simplify visual rehabilitation, and improve the visual prognosis. Advances in ocular surface transplantation techniques which allow late attempts at visual rehabilitation of a scarred and vascularized cornea include limbal stem cell transplantation for incomplete transdifferentiation and persistent corneal epithelial dysfunction, and conjunctival and/or mucosal membrane transplantation for ocular surface mechanical dysfunction. Rehabilitation of the ocular surface may be followed, if necessary by standard penetrating keratoplasty if all aspects of ocular surface rehabilitation are complete, or by large diameter penetrating keratoplasty if successful limbal stem cell transplantation cannot be achieved but other ocular surface rehabilitation is complete. (C) 1997 by Elsevier Science Inc. C1 MASSACHUSETTS EYE & EAR INFIRM, CORNEA SERV, BOSTON, MA 02114 USA. HARVARD UNIV, SCH MED, DEPT OPHTHALMOL, BOSTON, MA USA. RP Wagoner, MD (reprint author), KING KHALID EYE SPECIALIST HOSP, MED LIB, ANTERIOR SEGMENT EXTERNAL DIS DIV, POB 7191, RIYADH 11462, SAUDI ARABIA. NR 428 TC 209 Z9 224 U1 0 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6257 J9 SURV OPHTHALMOL JI Surv. Ophthalmol. PD JAN-FEB PY 1997 VL 41 IS 4 BP 275 EP 313 DI 10.1016/S0039-6257(96)00007-0 PG 39 WC Ophthalmology SC Ophthalmology GA WQ488 UT WOS:A1997WQ48800001 PM 9104767 ER PT J AU Benjamin, RJ Linsley, L Fountain, D Churchill, WH Sieff, C Cannon, ME Uhl, L Gaynes, L Antin, JH Wheeler, C AF Benjamin, RJ Linsley, L Fountain, D Churchill, WH Sieff, C Cannon, ME Uhl, L Gaynes, L Antin, JH Wheeler, C TI Preapheresis peripheral blood CD34+ mononuclear cell counts as predictors of progenitor cell yield SO TRANSFUSION LA English DT Article ID COLONY-STIMULATING FACTOR; HIGH-DOSE CHEMOTHERAPY; NON-HODGKINS-LYMPHOMA; LARGE-VOLUME LEUKAPHERESIS; GRANULOCYTE-MACROPHAGE; STEM-CELLS; AUTOLOGOUS TRANSPLANTATION; MARROW TRANSPLANTATION; COLLECTION; CYCLOPHOSPHAMIDE AB BACKGROUND: Peripheral blood progenitor cells, harvested by apheresis after mobilization, provide rapid hematologic recovery after high-dose chemotherapy. However, because harvesting these cells is expensive and time-consuming, there has been much interest in optimizing collection protocols. An investigation was made to determine whether, in this clinical setting, peripheral blood progenitor cell yields may be predicted from preapheresis progenitor cell counts, allowing the length of each procedure to be ''fine tuned'' to achieve specific target goals. STUDY DESIGN AND METHODS: Preapheresis peripheral blood CD34+ cell and total colony-forming cell counts were assessed before 78 peripheral blood progenitor cell collections from 13 consecutive patients were performed. Preapheresis counts were correlated with actual progenitor cell yields. Factors affecting this correlation were analyzed. RESULTS: With the use of linear regression analysis, preapheresis progenitor cell counts were found to correlate significantly but weakly with actual yields per kg of body weight per liter of blood processed (CD34+ cells: r = 0.43; colony-forming cells: r = 0.56). Further analysis revealed two possible causes: 1) circulating progenitor cell concentrations fluctuate widely during harvest, which implies that preapheresis counts are not representative of actual concentrations during apheresis, and 2) the efficiency with which apheresis machines extract mononuclear cells varies greatly between procedures. CONCLUSION: Preapheresis CD34+ and colony-forming cell counts correlated poorly with subsequent yields in this clinical setting, which suggests that it is not practical to use such counts to predict with certainty the length of apheresis needed to achieve a target yield. C1 HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. DANA FARBER CANC INST,DEPT PEDIAT ONCOL,BOSTON,MA 02115. BETH ISRAEL HOSP,BLOOD BANK,BOSTON,MA 02215. BETH ISRAEL HOSP,DEPT HEMATOL ONCOL,BOSTON,MA 02215. RP Benjamin, RJ (reprint author), BRIGHAM & WOMENS HOSP,BLOOD BANK,DEPT HEMATOL ONCOL,75 FRANCIS ST,BOSTON,MA 02115, USA. FU NCI NIH HHS [CA 39542, CA 58661] NR 30 TC 45 Z9 45 U1 0 U2 0 PU AMER ASSOC BLOOD BANKS PI BETHESDA PA 8101 GLENBROOK RD, BETHESDA, MD 20814-2749 SN 0041-1132 J9 TRANSFUSION JI Transfusion PD JAN PY 1997 VL 37 IS 1 BP 79 EP 85 DI 10.1046/j.1537-2995.1997.37197176955.x PG 7 WC Hematology SC Hematology GA WF548 UT WOS:A1997WF54800014 PM 9024494 ER PT J AU Hammerschmidt, M Brook, A McMahon, AP AF Hammerschmidt, M Brook, A McMahon, AP TI The world according to Hedgehog SO TRENDS IN GENETICS LA English DT Review ID MOTOR-NEURON INDUCTION; FLOOR PLATE DIFFERENTIATION; TERMINAL CLEAVAGE PRODUCT; LIMB-PATTERNING ACTIVITY; CELL-CELL COMMUNICATION; DROSOPHILA PATCHED GENE; DEVELOPING CHICK LIMB; SONIC-HEDGEHOG; AUTOPROTEOLYTIC CLEAVAGE; MOLECULAR-ORGANIZATION AB Members of the Hedgebog family of signaling molecules mediate many important short- and long-range patterning processes during invertebrate and vertebrate development. In the fly, a single hedgebog gene regulates segmental and imaginal disc patterning. In contrast, in vertebrates a hedgebog gene family is involved in the control of left-right asymmetry, polarity in the central nervous system (CNS), somites and limb, organogenesis, chondrogenesis and spermatogenesis. Here, we review experiments addressing the function of the various Hedgebog members during invertebrate and vertebrate development. C1 MASSACHUSETTS GEN HOSP,CTR CANC,MOL ONCOL LAB,CHARLESTOWN,MA 02129. HARVARD UNIV,DEPT MOL & CELLULAR BIOL,BIOLABS,CAMBRIDGE,MA 02138. RP Hammerschmidt, M (reprint author), MAX PLANCK INST IMMUNBIOL,SPEMANN LABS,STUEBEWEG 51,D-79108 FREIBURG,GERMANY. NR 99 TC 438 Z9 452 U1 0 U2 14 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB SN 0168-9525 J9 TRENDS GENET JI Trends Genet. PD JAN PY 1997 VL 13 IS 1 BP 14 EP 21 DI 10.1016/S0168-9525(96)10051-2 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA WC223 UT WOS:A1997WC22300006 PM 9009843 ER PT B AU Podolsky, DK AF Podolsky, DK BE McLeod, RS Martin, F Sutherland, LR Wallace, JL Williams, CN TI Animal models of inflammatory bowel disease SO TRENDS IN INFLAMMATORY BOWEL DISEASE THERAPY 1996 LA English DT Proceedings Paper CT 1996 Trends in Inflammatory Bowel Therapy Symposium CY JUN 12-15, 1996 CL OTTAWA, CANADA SP Axcan Pharma AB Over the past few years, application of targeted gene deletion and transgenic approaches has led to the often unanticipated development of rodent lines which develop inflammatory bowel disease. While none of these lines recapitulate the histopathological and clinical features usually associated with human inflammatory bowel disease in their entirety, many exhibit key features including the development of 'spontaneous' chronic and acute inflammation. These models include targeted gene deletion of the IL-4, IL-10, TGF beta, T-cell receptor alpha/beta, keratin 8, and the Gi2 alpha genes. In addition, animals bearing transgenes for the human HLA B27 (with beta-2 microglobulin) as well as a dominant negative construct which functionally blocks E-cadherin have also been observed to develop chronic inflammatory bowel disease. Most of the mutant murine lines experience a diffuse colitis, although some (HLA B27 and IL-10-deficient) also experience a small bowel inflammation. Although the development of chronic intestinal inflammation following genetic manipulation of a wide variety of loci makes it unlikely that any one of these genetic sites is necessarily causally related to the human disorders. the variety of manipulations provide some important broad insights. Most importantly, it is apparent that inflammatory bowel disease can result from either impairment of epithelial barrier function or dysregulation of mucosal immune responses. Further, it is evident that the natural history of the inflammation resulting from mutation at a single genetic loci is substantially modulated by other genetic factors with the demonstration that the onset and severity of disease varies substantially depending on the background murine strain. Further study of a number of models has demonstrated the important interaction between environmental factors and genetic predisposition. Thus, in at least some of the lines (IL-2 deficient and HLA B27), the inflammatory bowel disease is not observed when the mutant mice are maintained in a germ-foe environment but does develop after reconstitution with a pathogen-free flora. This suggests that the microflora play a pivotal role ill driving inflammatory responses through mechanisms distinct from typical tissue invasion or toxin production. In other models, inflammation may not occur without some challenge by an exogenous external agent. These models offer great promise to permit further dissection of the various constituents of the intestinal epithelium and mucosal immune response systems which are necessary for maintaining normal homeostasis and which can contribute to the development of inflammatory bowel disease. Further, they offer powerful tools for exploring the interaction between genetic and environmental factors to explicate the pathogenesis of inflammatory bowel disease and to develop new therapeutic intervention strategies. RP Podolsky, DK (reprint author), MASSACHUSETTS GEN HOSP,GI UNIT JACKSON 7,32 FRUIT ST,BOSTON,MA 02114, USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 0-7923-8718-X PY 1997 BP 8 EP 13 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA BJ40D UT WOS:A1997BJ40D00002 ER PT J AU Lee, S McAuliffe, DJ Zhang, H Xu, Z Taitelbaum, J Flotte, TJ Doukas, AG AF Lee, S McAuliffe, DJ Zhang, H Xu, Z Taitelbaum, J Flotte, TJ Doukas, AG TI Stress-wave-induced membrane permeation of red blood cells is facilitated by aquaporins SO ULTRASOUND IN MEDICINE AND BIOLOGY LA English DT Article DE aquaporins; membrane permeability; molecular delivery; photoacoustics; phonophoresis; red blood cells; shock waves; water channels ID LITHOTRIPTER SHOCK-WAVES; WATER PERMEABILITY; IN-VITRO; ERYTHROCYTES; INVITRO; PATHWAYS; EXPOSURE; VESICLES; CHANNEL; INJURY AB Stress waves generated by lasers and extracorporeal lithotripters have been shown to transiently increase the permeability of the plasma membrane, without affecting cell viability, Molecules present in the medium can diffuse into the cytoplasm under the concentration gradient, Molecular uptake under stress waves correlates with the presence of functioning aquaporins in the plasma membrane, (C) 1997 World Federation for Ultrasound in Medicine & Biology. RP Lee, S (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,WELLMAN LABS PHOTOMED,DEPT DERMATOL,BOSTON,MA 02114, USA. NR 33 TC 44 Z9 46 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0301-5629 J9 ULTRASOUND MED BIOL JI Ultrasound Med. Biol. PY 1997 VL 23 IS 7 BP 1089 EP 1094 DI 10.1016/S0301-5629(97)00083-5 PG 6 WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging GA XV860 UT WOS:A1997XV86000012 PM 9330452 ER PT J AU Dreyer, EB AF Dreyer, EB TI Amino acid abnormalities in the vitreous of the buphthalmic rabbit SO VETERINARY & COMPARATIVE OPHTHALMOLOGY LA English DT Article DE glaucoma; glutamate; buphthalmic rabbit; intraocular pressure; amino acids; vitreous ID RETINAL GANGLION-CELLS; VISUAL-FIELD LOSS; GLUTAMATE NEUROTOXICITY; NMDA RECEPTORS; GLAUCOMA; ASPARTATE; CULTURE; NERVE; RISK AB Glutamate excitotoxicity may play a role in the retinal ganglion cell loss seen in human and experimental monkey glaucoma. The buphthalmic rabbit is an example of an inherited form of developmental glaucoma. We therefore sought to establish whether glutamate levels were elevated in the vitreous of these eyes. New Zealand White (NZW) rabbits were employed as controls. Animals were sacrificed at 1 year of age, and the vitreous assayed for amino acid concentrations by high performance liquid chromatography (HPLC). The glutamate levels in the buphthalmic rabbit eye were 135 +/- 13 mu M/L, compared to 23 +/- 13 mu M/L in control eyes (P < 0.001). It is not possible to establish whether these variations in amino acid concentrations are a direct consequence of the elevated pressure in these eyes, or a secondary result of buphthalmia. However, in a fashion similar to that seen in primates with either acquired or experimental glaucoma, the rabbit buphthalmic eye has a potentially toxic level of glutamate in its vitreous. RP Dreyer, EB (reprint author), MASSACHUSETTS EYE & EAR INFIRM,RETINAL GANGL CELL BIOL LAB,GLAUCOMA CONSULTAT SERV,BOSTON,MA 02114, USA. NR 45 TC 5 Z9 5 U1 0 U2 0 PU VETERINARY PRACTICE PUBL CO PI IRVINE PA 3 BURROUGHSDR, IRVINE, CA 92618-2804 SN 1061-5768 J9 VET COMP OPHTHALMOL JI Vet. Comp. Ophthalmol. PY 1997 VL 7 IS 3 BP 192 EP 195 PG 4 WC Ophthalmology; Veterinary Sciences SC Ophthalmology; Veterinary Sciences GA YC008 UT WOS:A1997YC00800010 ER PT J AU Deutsch, JC AF Deutsch, JC TI Gas chromatographic mass spectrometric measurement of ascorbic acid and analysis of ascorbic acid degradation in solution SO VITAMINS AND COENZYMES, PT I SE METHODS IN ENZYMOLOGY LA English DT Review C1 UNIV COLORADO,HLTH SCI CTR,DIV HEMATOL,DENVER,CO 80220. DENVER VA HOSP,DENVER,CO 80220. RP Deutsch, JC (reprint author), UNIV COLORADO,HLTH SCI CTR,DIV GASTROENTEROL,DEPT MED,DENVER,CO 80220, USA. NR 10 TC 9 Z9 9 U1 1 U2 9 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0076-6879 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1997 VL 279 BP 13 EP 24 PG 12 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BJ25G UT WOS:A1997BJ25G00002 PM 9211252 ER PT J AU Read, JP Stern, AL Wolfe, J Ouimette, PC AF Read, JP Stern, AL Wolfe, J Ouimette, PC TI Use of a screening instrument in women's health care: Detecting relationships among victimization history, psychological distress, and medical complaints SO WOMEN & HEALTH LA English DT Article ID SEXUAL ASSAULT HISTORY; EATING DISORDERS; PSYCHIATRIC-DISORDERS; ANOREXIA-NERVOSA; SOCIAL SUPPORT; ABUSE; PREVALENCE; ALCOHOLISM; STRESS; HARASSMENT AB The interactive relationship between psychological distress and physical health is a particularly salient one for women. Routine screening for abuse history and current psychological disturbance is essential in providing comprehensive patient care. The present study examines the utility of a brief screening measure in detecting psychological factors in female patients at a primary care facility. Sixty-nine percent of 108 women screened at a women's health clinic reported a history of trauma and almost half (49%) reported having been sexually harassed. Women presenting to treatment for gynecological problems were more likely to be victims of sexual assault and were more likely to report a history of childhood sexual abuse. In addition, women seeking specialized health care also reported increased rates of stress. Relationships among victimization histories, substance use, and eating disturbances were also found. These data suggest the importance of assessing psychological disturbances and trauma histories as part of a comprehensive medical evaluation. C1 DEPT VET AFFAIRS MED CTR,NATL CTR POSTTRAUMAT STRESS DISORDER 116B3,WOMENS HLTH SCI DIV,BOSTON,MA 02130. UNIV RHODE ISL,DEPT PSYCHOL,KINGSTON,RI 02881. VA PALO ALTO HLTH CARE SYST,CTR HLTH CARE EVALUAT,PROGRAM EVALUAT & RES CTR,PALO ALTO,CA. VA PALO ALTO HLTH CARE SYST,CTR HLTH CARE EVALUAT,HSR&D,PALO ALTO,CA. NR 49 TC 13 Z9 13 U1 2 U2 2 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 SN 0363-0242 J9 WOMEN HEALTH JI Women Health PY 1997 VL 25 IS 3 BP 1 EP 17 DI 10.1300/J013v25n03_01 PG 17 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA XR944 UT WOS:A1997XR94400001 PM 9273980 ER PT J AU Silverman, PR AF Silverman, PR TI The stranger who bore me: Adoptee birth mother relations - March,K SO WOMEN & HEALTH LA English DT Book Review C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PSYCHIAT,BOSTON,MA. RP Silverman, PR (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,MGH INST HLTH PROFESS,BOSTON,MA 02114, USA. NR 10 TC 0 Z9 0 U1 0 U2 1 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 SN 0363-0242 J9 WOMEN HEALTH JI Women Health PY 1997 VL 25 IS 3 BP 87 EP 90 PG 4 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA XR944 UT WOS:A1997XR94400007 ER PT J AU Kocher, MS AF Kocher, MS TI Early limb salvage: Open tibia fractures of Ambroise Pare (1510-1590) and Percivall Pott (1714-1789) SO WORLD JOURNAL OF SURGERY LA English DT Article AB Ambroise Pare and Percivall Pott were preeminent clinicians, writers, and educators who advanced the cause of surgery through their independent thinking and insightful observations. In addition to their legacies and numerous enduring contributions, both men sustained open tibial fractures that were successfully managed during times when most often amputation was prescribed for such injuries. This article explores their lives and their fractures. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT ORTHOPED SURG,BOSTON,MA 02114. NR 16 TC 10 Z9 10 U1 1 U2 1 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0364-2313 J9 WORLD J SURG JI World J.Surg. PD JAN PY 1997 VL 21 IS 1 BP 116 EP 122 PG 7 WC Surgery SC Surgery GA VZ670 UT WOS:A1997VZ67000020 PM 8943188 ER PT J AU Johnston, JA Norgren, S Anneren, G Cowburn, RF Lannfelt, L AF Johnston, JA Norgren, S Anneren, G Cowburn, RF Lannfelt, L TI A new quantitative solution hybridisation-RNase protection assay for APP and APLP2 mRNA SO MOLECULAR BRAIN RESEARCH LA English DT Article DE solution hybridisation RNase protection assay; mRNA; amyloid precursor protein; amyloid precursor-like protein 2 ID AMYLOID PRECURSOR PROTEIN; NORMAL HUMAN-BRAIN; ALZHEIMERS-DISEASE; MESSENGER-RNA; MOLECULAR-CLONING; GENE-EXPRESSION; RECEPTOR; CELLS; CDNA; LOCALIZATION AB Amyloid precursor protein (APP) and amyloid precursor-like protein 2 (APLP2) are members of a multigene family of proteins implicated in the pathogenesis of Alzheimer's disease. We describe the development of an RNA-RNA solution hybridisation-RNase protection assay to quantify APP mRNA, APP mRNA splice forms containing the Kunitz-type protease inhibitor (KPI) insert, and APLP2 mRNA in total nucleic acid extracts from a range of tissue types. Solution hybridisation-RNase protection assay enables absolute quantification of target mRNA, by conversion of the hybridisation signal to pg mRNA using a standard curve. The assay is sensitive, capable of detecting 1 pg target mRNA, and reproducible, with an inter-assay variability of less than 10% and an intra-assay variability of 3-4%. We quantified APP and APLP2 mRNA in cell lines and post-mortem human brain tissue samples. To test whether we could detect physiological differences in APP mRNA levels, a fibroblast cell line with a paternal chromosome 21 deletion of the region including the APP gene was analysed and found to express half as much APP mRNA as control fibroblasts. In addition, a reversible, approx. 30% increase in APP mRNA levels was detected in human lymphoblastoid cell lines following heat shock, a physical stimulus previously shown to increase APP expression. Regional differences in the expression of APP and APLP2 were seen in human post-mortem cerebral cortex and cerebellum. Levels of APP and APLP2 mRNA were highest in the temporal cortex, slightly lower in frontal and occipital cortices, and lowest in the cerebellum. The highest proportion of KPI-containing APP was seen in the frontal and temporal cortices. The ratio of APP:APLP2 mRNA was 1:0.3 in the cortical tissue and 1:0.8 in the cerebellum. In conclusion, quantitative solution hybridisation-RNase protection assay of total APP, APP KPI and APLP2 mRNA provides a new tool to improve the resolution of studies of potentially subtle alterations in the expression of these genes in both cell culture model systems and Alzheimer's disease post-mortem human brain tissue. C1 KAROLINSKA HOSP,ROLF LUFT CTR DIABET RES,DEPT MOL MED,S-10401 STOCKHOLM,SWEDEN. HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02215. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215. UNIV UPPSALA HOSP,DEPT CLIN GENET,S-75185 UPPSALA,SWEDEN. RP Johnston, JA (reprint author), KAROLINSKA INST,NOVUM KFC,DEPT CLIN NEUROSCI & FAMILY MED,GERIATR SECT,S-14186 HUDDINGE,SWEDEN. RI Johnston, Janet/C-4890-2009 NR 33 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0169-328X J9 MOL BRAIN RES JI Mol. Brain Res. PD DEC 31 PY 1996 VL 43 IS 1-2 BP 77 EP 84 DI 10.1016/S0169-328X(96)00160-X PG 8 WC Neurosciences SC Neurosciences & Neurology GA WD744 UT WOS:A1996WD74400009 ER PT J AU Johnston, JA Norgren, S Ravid, R Wasco, W Winblad, B Lannfelt, L Cowburn, RF AF Johnston, JA Norgren, S Ravid, R Wasco, W Winblad, B Lannfelt, L Cowburn, RF TI Quantification of APP and APLP2 mRNA in APOE genotyped Alzheimer's disease brains SO MOLECULAR BRAIN RESEARCH LA English DT Article DE amyloid precursor protein; amyloid precursor-like protein 2; Alzheimer's disease; solution hybridisation RNase protection; mRNA; post-mortem human brain ID AMYLOID-BETA-PROTEIN; PRECURSOR MESSENGER-RNA; GENE-EXPRESSION; DIFFERENTIAL EXPRESSION; INSITU HYBRIDIZATION; MOLECULAR-CLONING; INSULIN-RECEPTOR; CDNA; CORTEX; TISSUE AB Amyloid precursor protein (APP) is metabolised to produce A beta, a peptide found aggregated in Alzheimer's disease neuritic plaques. APP is a member of a multigene protein family which includes amyloid precursor-like protein 2 (APLP2). Since A beta accumulation can be triggered by factors acting up- or downstream of APP processing, we investigated whether APP mRNA expression was altered in Alzheimer's disease post-mortem cerebral cortex. In addition, we characterised cortical APLP2 mRNA levels. Quantitative RNA-RNA solution hybridisation-RNase protection was used to assay total APP, APP containing the Kunitz-type protease inhibitor (KPI) insert and APLP2 mRNA in mid-temporal and superior frontal cortices from apolipoprotein E-genotyped subjects with Alzheimer's disease, other neurological diseases and non-demented controls. Approximately 3 times more APP than APLP2 mRNA was detected and about 70% of total APP mRNA contained the KPI insert in the control subjects. Total APP and APLP2 mRNA levels were significantly reduced in Alzheimer's disease mid-temporal, but not superior frontal cortex, suggesting that regional reductions in these mRNAs correlate with severity of disease pathology. A small significant increase in the proportion of APP KPI mRNA was seen in both cortical regions in Alzheimer's disease. Apolipoprotein E genotype did not: influence cortical levels of total APP, APP KPI or APLP2 mRNA. Alzheimer's disease-related increases in tissue DNA content were seen in both regions studied, while tissue RNA levels were reduced in the positive disease controls. In summary, these results indicate that Alzheimer's disease is not associated with over-expression of either APP or APLP2 mRNA. Our findings reveal a disease-associated increase in the proportion of APP KPI-containing isoforms, and further investigation should clarify whether this predisposes affected individuals to A beta production and aggregation, or reflects later events such as gliosis and neuronal cell death. C1 KAROLINSKA HOSP,ROLF LUFT CTR DIABET RES,DEPT MOL MED,S-10401 STOCKHOLM,SWEDEN. HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02215. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215. NETHERLANDS BRAIN BANK,NL-1105 AZ AMSTERDAM,NETHERLANDS. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GENET & AGING LAB,NEUROSCI CTR,CHARLESTOWN,MA 02129. RP Johnston, JA (reprint author), KAROLINSKA INST,NOVUM KFC,DEPT CLIN NEUROSCI & FAMILY MED,GERIATR SECT,S-14186 HUDDINGE,SWEDEN. RI Johnston, Janet/C-4890-2009 NR 67 TC 8 Z9 8 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0169-328X J9 MOL BRAIN RES JI Mol. Brain Res. PD DEC 31 PY 1996 VL 43 IS 1-2 BP 85 EP 95 DI 10.1016/S0169-328X(96)00161-1 PG 11 WC Neurosciences SC Neurosciences & Neurology GA WD744 UT WOS:A1996WD74400010 ER PT J AU Suri, C Jones, PF Patan, S Bartunkova, S Maisonpierre, PC Davis, S Sato, TN Yancopoulos, GD AF Suri, C Jones, PF Patan, S Bartunkova, S Maisonpierre, PC Davis, S Sato, TN Yancopoulos, GD TI Requisite role of Angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis SO CELL LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE GENES; NEUREGULIN RECEPTOR; CARDIAC DEVELOPMENT; MOLECULAR-CLONING; VASCULAR SYSTEM; MICE LACKING; CELL LINEAGE; EXPRESSION; TEK AB Vascular endothelial growth factor (VEGF), which acts via members of a family of endothelial-specific receptor tyrosine kinases, is the only factor that has been shown definitively to play a role in the formation of the embryonic vasculature. Only one other family of receptor tyrosine kinases, comprising TIE1 and TIE2, is largely endothelial cell specific. We have recently cloned a ligand for TIE2, termed Angiopoietin-1. Here we show that mice engineered to lack Angiopoietin-1 display angiogenic deficits reminiscent of those previously seen in mice lacking TIE2, demonstrating that Angiopoietin-1 is a primary physiologic ligand for TIE2 and that it has critical in vivo angiogenic actions that are distinct from VEGF and that are not reflected in the classic in vitro assays used to characterize VEGF. Angiopoietin-1 seems to play a crucial role in mediating reciprocal interactions between the endothelium and surrounding matrix and mesenchyme. C1 BETH ISRAEL HOSP,BOSTON,MA 02215. HARVARD UNIV,SCH MED,BOSTON,MA 02215. MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114. RP Suri, C (reprint author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA. NR 37 TC 1854 Z9 1930 U1 2 U2 36 PU CELL PRESS PI CAMBRIDGE PA 1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 SN 0092-8674 J9 CELL JI Cell PD DEC 27 PY 1996 VL 87 IS 7 BP 1171 EP 1180 DI 10.1016/S0092-8674(00)81813-9 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA WA541 UT WOS:A1996WA54100006 PM 8980224 ER PT J AU deNooij, JC Letendre, MA Hariharan, IK AF deNooij, JC Letendre, MA Hariharan, IK TI A cyclin-dependent kinase inhibitor, dacapo, is necessary for timely exit from the cell cycle during Drosophila embryogenesis SO CELL LA English DT Article ID S-PHASE; NERVOUS-SYSTEM; GENE; MELANOGASTER; EXPRESSION; EMBRYOS; CLONING; DOMAIN; EYE; P57(KIP2) AB In a screen for genes that interact with the Rap1 GTPase, we have identified a Drosophila gene, dacapo (dap), which is a member of the p21/p27 family of cdk inhibitors. Unlike mammalian cdk inhibitors studied to dale, dap is essential for normal embryonic development. Dacapo inhibits cyclin-cdk activity in vitro. Overexpressing dap during eye development interferes with cell cycle progression and interacts genetically with the retinoblastoma homolog (Rbf) and cyclin E. dap expression in embryos parallels the exit of cells from the cell cycle. dap mutant embryos delay the normal cell cycle exit during development; many cells complete an additional cycle and subsequently become quiescent. Thus, dap functions during embryogenesis to achieve a precisely timed exit from the cell cycle. RP deNooij, JC (reprint author), MASSACHUSETTS GEN HOSP,CTR CANC,BLDG 149,13TH ST,CHARLESTOWN,MA 02129, USA. NR 47 TC 246 Z9 247 U1 0 U2 4 PU CELL PRESS PI CAMBRIDGE PA 1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 SN 0092-8674 J9 CELL JI Cell PD DEC 27 PY 1996 VL 87 IS 7 BP 1237 EP 1247 DI 10.1016/S0092-8674(00)81819-X PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA WA541 UT WOS:A1996WA54100012 PM 8980230 ER PT J AU Liu, J Tse, AGD Chang, HC Liu, JH Wang, JH Hussey, RE Chishti, Y Rheinhold, B Spoerl, R Nathenson, SG Sacchettini, JC Reinherz, EL AF Liu, J Tse, AGD Chang, HC Liu, JH Wang, JH Hussey, RE Chishti, Y Rheinhold, B Spoerl, R Nathenson, SG Sacchettini, JC Reinherz, EL TI Crystallization of a deglycosylated T cell receptor (TCR) complexed with an anti-TCR Fab fragment SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; HETERODIMERS; RECOGNITION; EXPRESSION; PROTEINS; CHAIN; OLIGOSACCHARIDES; GLYCOSYLATION AB A strategy to overexpress T cell receptors (TCRs) in Lec3.2.8.1 cells has been developed using the ''Velcro'' leucine zipper sequence to facilitate alpha-beta pairing. Upon secretion in culture media, the VSV-8-specific/H2-K-b-restricted N15 TCR could be readily immunopurified using the anti-leucine zipper monoclonal antibody 2H11, with a yield of 5-10 mg/liter. Mass spectrometry analysis revealed that all attached glycans were GlcNAc(2)-Man(5). Following Superdex 200 gel filtration to remove aggregates, wild-type N15 or N15(s), a C183S variant lacking the unpaired cysteine at amino acid residue 183 in the C beta domain, was thrombin-cleaved and endoglycosidase H-digested, and the two derivatives were termed iN15 Delta(H) and N15(s) Delta(H), respectively, and sized by Superdex 75 chromatography to high purity. N-terminal and C-terminal microsequencing analysis showed the expected unique termini of N15 alpha and beta subunits. Nevertheless, neither protein crystallized under a wide range of conditions. Subsequently, we produced a Fab fragment of the murine TCR C beta-specific hamster monoclonal antibody H57 and complexed the Fab fragment with iN15 Delta(H) and N15(s) Delta(H). Both N15(s) Delta(H)-Fab[H57] and iN15 Delta(H)-Fab[H57] complexes crystallize, with the former diffracting to 2.8-Angstrom resolution. These findings show that neither intact glycans nor the conserved and partially exposed Cys-183 is required for protein stability. Furthermore, our results suggest that the H57 Fab fragment aids in the crystallization of TCRs by altering their molecular surface and/or stabilizing inherent conformational mobility. C1 DANA FARBER CANC INST,IMMUNOBIOL LAB,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02118. YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461. YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461. FU NIAID NIH HHS [AI19807, AI39098]; NIGMS NIH HHS [GM45859] NR 38 TC 28 Z9 28 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 27 PY 1996 VL 271 IS 52 BP 33639 EP 33646 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA WA713 UT WOS:A1996WA71300067 PM 8969233 ER PT J AU McNaughton, M Barry, MJ AF McNaughton, M Barry, MJ TI Controversies in prostate cancer screening - Analogies to the early lung cancer screening debate SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID MEDICARE PROVIDE REIMBURSEMENT; DIGITAL RECTAL EXAMINATION; DETECTION PROGRAM; BREAST-CANCER; ANTIGEN; PREVALENCE; TRIAL; SERUM; MANAGEMENT; DIAGNOSIS AB The current debate regarding early detection and aggressive treatment of prostate cancer is fueled by the absence of controlled studies defining the risks and benefits of prostate cancer screening, and by the lack of adequately powered trials demonstrating the benefit of curative treatment for early-stage prostate cancer. Pending the results of clinical trials in 10 to 15 years, advocates of early detection of prostate cancer with digital rectal examination and prostate-specific antigen have compared prostate cancer screening with the effective strategy of breast cancer screening, implying that prostate cancer screening should similarly reduce cancer mortality. They have also cited the high burden of disease, the acceptable operating characteristics of digital rectal examination and prostate-specific antigen, a stage shift among cases detected by screening, and the theoretical curability of early-stage disease as sufficient reasons to proceed with screening. These arguments, however, are reminiscent of earlier arguments in favor of lung cancer screening with chest x-ray examination and sputum cytology, a practice ultimately proven ineffective in clinical trials. We reviewed published articles on lung and prostate cancer screening and identified many parallels. While prostate cancer screening may one day prove effective, analogies between the current prostate cancer screening controversy and the older lung cancer screening debate should inject some caution regarding widespread dissemination of prostate cancer screening without experimental evidence that such screening does more good than harm. C1 MASSACHUSETTS GEN HOSP,MED PRACTICES EVALUAT CTR,DIV GEN MED,MED SERV,BOSTON,MA 02114. NR 72 TC 4 Z9 4 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 25 PY 1996 VL 276 IS 24 BP 1976 EP 1979 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA VY689 UT WOS:A1996VY68900031 ER EF